activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	512201	CHEMBL679504	Inhibition of FAK kinase	B	Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1		CHEMBL131577	>	IC50	nM	25000.0	CHEMBL2695	Homo sapiens	IC50	uM	25.0
	512201	CHEMBL679504	Inhibition of FAK kinase	B	Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1		CHEMBL131577	>	IC50	nM	25000.0	CHEMBL2695	Homo sapiens	IC50	uM	25.0
	512209	CHEMBL679503	Selectivity against FAK kinase	B	Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1		CHEMBL131577	>	Fold selectivity		7000.0	CHEMBL2695	Homo sapiens	Fold selectivity		7000.0
	586958	CHEMBL873609	Inhibition of FAK, focal adhesion kinase	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	IC50	nM	40000.0	CHEMBL2695	Homo sapiens	IC50	uM	40.0
	1601166	CHEMBL880633	Inhibitory concentration against FAK cytoplasmic sequence; Reported as mean (variability <15%)	B	CCc1c(NC(=O)OCCn2ccnc2)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12		CHEMBL412367	>	IC50	nM	25000.0	CHEMBL2695	Homo sapiens	IC50	uM	25.0
	1605409	CHEMBL880630	In vitro inhibitory concentration against FAK with ATP concentration at 1/2Km	B	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL401930	=	IC50	nM	150.0	CHEMBL2695	Homo sapiens	IC50	nM	150.0
Not Active	1650783	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554		Kd			CHEMBL2695	Homo sapiens	Kd		
	1650784	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	4400.0	CHEMBL2695	Homo sapiens	Kd	uM	4.4
Not Active	1650785	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253		Kd			CHEMBL2695	Homo sapiens	Kd		
	1650786	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	610.0	CHEMBL2695	Homo sapiens	Kd	uM	0.61
Not Active	1650787	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1650788	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1650789	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1650790	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1650791	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Kd			CHEMBL2695	Homo sapiens	Kd		
	1652149	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	68.0	CHEMBL2695	Homo sapiens	Kd	uM	0.068
Not Active	1652150	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652151	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652152	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652153	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652154	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652155	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652156	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652157	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652158	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828		Kd			CHEMBL2695	Homo sapiens	Kd		
Not Active	1652159	CHEMBL860898	Average Binding Constant for PTK2; NA=Not Active at 10 uM	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965		Kd			CHEMBL2695	Homo sapiens	Kd		
	1653650	CHEMBL861599	Inhibitory activity against FAK	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	1678205	CHEMBL862053	Inhibitory activity against FAK	B	COc1cc2c(Nc3ncc(CC(=O)Nc4cccc(F)c4)s3)ncnc2cc1OCCCN1CCC(CO)CC1		CHEMBL201307	=	IC50	nM	4000.0	CHEMBL2695	Homo sapiens	IC50	uM	4.0
	1706656	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc(Br)c(Nc3ccccn3)n2)cc(OC)c1OC		CHEMBL382608	=	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	uM	0.1
	1706657	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccc(=O)n(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL381282	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706658	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3c(n2)N(c2ccccn2)CCC3)cc(OC)c1OC		CHEMBL426311	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	uM	0.2
	1706659	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(O)CC3)cc(OC)c1OC		CHEMBL383300	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	uM	0.2
	1706660	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(=O)CC3)cc(OC)c1OC		CHEMBL207736	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706661	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3c(n2)N(c2ccccn2)CC3)cc(OC)c1OC		CHEMBL383241	=	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	uM	0.1
	1706662	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3c(n2)N(c2ccccn2)C(=O)C3)cc(OC)c1OC		CHEMBL205368	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706663	CHEMBL865637	Inhibitory activity against FAK	B	CCOC(=O)Cc1cnc(Nc2cc(OC)c(OC)c(OC)c2)nc1Nc1ccccn1		CHEMBL204933	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	uM	0.2
	1706664	CHEMBL865637	Inhibitory activity against FAK	B	CCOC(=O)Cc1cnc(Nc2cc(OC)c(OC)c(OC)c2)nc1Cl		CHEMBL206796	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706665	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(C)cn4)c3n2)cc(OC)c1OC		CHEMBL206504	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706666	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4ccnc(Cl)c4)c3n2)cc(OC)c1OC		CHEMBL207147	=	IC50	nM	800.0	CHEMBL2695	Homo sapiens	IC50	uM	0.8
	1706667	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4ccnc(Cl)n4)c3n2)cc(OC)c1OC		CHEMBL383672	=	IC50	nM	800.0	CHEMBL2695	Homo sapiens	IC50	uM	0.8
	1706668	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4nccc(Cl)n4)c3n2)cc(OC)c1OC		CHEMBL207032	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706669	CHEMBL865637	Inhibitory activity against FAK	B	COc1ccncc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21		CHEMBL205316	=	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	uM	0.3
	1706670	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4cnccc4Cl)c3n2)cc(OC)c1OC		CHEMBL383006	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	1706671	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4cnccc4F)c3n2)cc(OC)c1OC		CHEMBL207820	=	IC50	nM	800.0	CHEMBL2695	Homo sapiens	IC50	uM	0.8
	1706672	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4nccs4)c3n2)cc(OC)c1OC		CHEMBL205588	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	1706673	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4cccs4)c3n2)cc(OC)c1OC		CHEMBL205587	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706674	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4ccncc4)c3n2)cc(OC)c1OC		CHEMBL381161	=	IC50	nM	9000.0	CHEMBL2695	Homo sapiens	IC50	uM	9.0
	1706675	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4cccnc4)c3n2)cc(OC)c1OC		CHEMBL378811	=	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	uM	0.1
	1706676	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL205098	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	uM	0.2
	1706677	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(CCc4ccncc4)c3n2)cc(OC)c1OC		CHEMBL425599	=	IC50	nM	7500.0	CHEMBL2695	Homo sapiens	IC50	uM	7.5
	1706678	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(CCc4cccnc4)c3n2)cc(OC)c1OC		CHEMBL205911	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706679	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(Nc2ncc3ccn(Cc4cccnc4)c3n2)cc(OC)c1OC		CHEMBL426131	=	IC50	nM	7900.0	CHEMBL2695	Homo sapiens	IC50	uM	7.9
	1706680	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc(-c2cnc3ccccc3n2)cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL206853	=	IC50	nM	600.0	CHEMBL2695	Homo sapiens	IC50	uM	0.6
	1706681	CHEMBL865637	Inhibitory activity against FAK	B	c1ccc(-n2ccc3cnc(Nc4ccc5cc[nH]c5c4)nc32)nc1		CHEMBL208169	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706682	CHEMBL865637	Inhibitory activity against FAK	B	c1ccc(-n2ccc3cnc(Nc4ccc5c(c4)OCO5)nc32)nc1		CHEMBL426673	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706683	CHEMBL865637	Inhibitory activity against FAK	B	c1ccc(-n2ccc3cnc(Nc4cccc5c4CCCC5)nc32)nc1		CHEMBL382809	=	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	uM	0.3
	1706684	CHEMBL865637	Inhibitory activity against FAK	B	Cc1cc(I)ccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL203676	=	IC50	nM	8000.0	CHEMBL2695	Homo sapiens	IC50	uM	8.0
	1706685	CHEMBL865637	Inhibitory activity against FAK	B	COc1ccc(C)c(Nc2ncc3ccn(-c4ccccn4)c3n2)c1		CHEMBL377957	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	uM	0.2
	1706686	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc(C(N)=O)cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL379118	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	uM	0.4
	1706687	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc([N+](=O)[O-])cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL205943	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706688	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc(CO)cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL205034	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706689	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc(I)cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL383834	=	IC50	nM	3000.0	CHEMBL2695	Homo sapiens	IC50	uM	3.0
	1706690	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccc(Br)cc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL203675	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706691	CHEMBL865637	Inhibitory activity against FAK	B	O=C1CCCN1CCCNc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL208054	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706692	CHEMBL865637	Inhibitory activity against FAK	B	FC(F)(F)c1ccc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc1		CHEMBL207312	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706693	CHEMBL865637	Inhibitory activity against FAK	B	Oc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1		CHEMBL438623	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706694	CHEMBL865637	Inhibitory activity against FAK	B	CSc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1		CHEMBL381609	=	IC50	nM	2000.0	CHEMBL2695	Homo sapiens	IC50	uM	2.0
	1706695	CHEMBL865637	Inhibitory activity against FAK	B	COc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1		CHEMBL208042	=	IC50	nM	600.0	CHEMBL2695	Homo sapiens	IC50	uM	0.6
	1706696	CHEMBL865637	Inhibitory activity against FAK	B	Cc1cccc(Nc2ncc3ccn(-c4ccccn4)c3n2)c1		CHEMBL205942	=	IC50	nM	700.0	CHEMBL2695	Homo sapiens	IC50	uM	0.7
	1706697	CHEMBL865637	Inhibitory activity against FAK	B	FC(F)(F)c1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL203178	=	IC50	nM	7000.0	CHEMBL2695	Homo sapiens	IC50	uM	7.0
	1706698	CHEMBL865637	Inhibitory activity against FAK	B	Brc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL203020	=	IC50	nM	1500.0	CHEMBL2695	Homo sapiens	IC50	uM	1.5
	1706699	CHEMBL865637	Inhibitory activity against FAK	B	Clc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL207935	=	IC50	nM	700.0	CHEMBL2695	Homo sapiens	IC50	uM	0.7
	1706700	CHEMBL865637	Inhibitory activity against FAK	B	Fc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL378596	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	1706701	CHEMBL865637	Inhibitory activity against FAK	B	CSc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL381308	=	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	uM	1.0
	1706702	CHEMBL865637	Inhibitory activity against FAK	B	COc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL206322	=	IC50	nM	700.0	CHEMBL2695	Homo sapiens	IC50	uM	0.7
	1706703	CHEMBL865637	Inhibitory activity against FAK	B	CC(C)c1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL380116	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706704	CHEMBL865637	Inhibitory activity against FAK	B	CCc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL382637	=	IC50	nM	900.0	CHEMBL2695	Homo sapiens	IC50	uM	0.9
	1706705	CHEMBL865637	Inhibitory activity against FAK	B	Cc1ccccc1Nc1ncc2ccn(-c3ccccn3)c2n1		CHEMBL206797	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	1706706	CHEMBL865637	Inhibitory activity against FAK	B	c1ccc(-n2ccc3cnc(N4CCOCC4)nc32)nc1		CHEMBL206506	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706707	CHEMBL865637	Inhibitory activity against FAK	B	CN1CCN(c2ncc3ccn(-c4ccccn4)c3n2)CC1		CHEMBL205642	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706708	CHEMBL865637	Inhibitory activity against FAK	B	COc1cc(CNc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL381998	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1706709	CHEMBL865637	Inhibitory activity against FAK	B	c1ccc(CNc2ncc3ccn(-c4ccccn4)c3n2)cc1		CHEMBL204982	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717301	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL205098	=	IC50	nM	212.0	CHEMBL2695	Homo sapiens	IC50	uM	0.212
	1717302	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)O)n4)c3n2)cc(OC)c1OC		CHEMBL207491	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	uM	0.004
	1717303	CHEMBL870124	Inhibition of FAK	B	COC(=O)CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)n1		CHEMBL206927	=	IC50	nM	544.0	CHEMBL2695	Homo sapiens	IC50	uM	0.544
	1717304	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCC#N)n4)c3n2)cc(OC)c1OC		CHEMBL380312	=	IC50	nM	242.0	CHEMBL2695	Homo sapiens	IC50	uM	0.242
	1717305	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC#N)n4)c3n2)cc(OC)c1OC		CHEMBL380226	=	IC50	nM	278.0	CHEMBL2695	Homo sapiens	IC50	uM	0.278
	1717306	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCN)n4)c3n2)cc(OC)c1OC		CHEMBL208384	=	IC50	nM	397.0	CHEMBL2695	Homo sapiens	IC50	uM	0.397
	1717307	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN(C)C)n4)c3n2)cc(OC)c1OC		CHEMBL425418	=	IC50	nM	634.0	CHEMBL2695	Homo sapiens	IC50	uM	0.634
	1717308	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN)n4)c3n2)cc(OC)c1OC		CHEMBL208370	=	IC50	nM	182.0	CHEMBL2695	Homo sapiens	IC50	uM	0.182
	1717309	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC(C)C)n4)c3n2)cc(OC)c1OC		CHEMBL204613	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717310	CHEMBL870124	Inhibition of FAK	B	CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)n1		CHEMBL205584	=	IC50	nM	7550.0	CHEMBL2695	Homo sapiens	IC50	uM	7.55
	1717311	CHEMBL870124	Inhibition of FAK	B	COC(=O)CNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL382192	=	IC50	nM	339.0	CHEMBL2695	Homo sapiens	IC50	uM	0.339
	1717312	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCCN(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL204686	=	IC50	nM	236.0	CHEMBL2695	Homo sapiens	IC50	uM	0.236
	1717313	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)NCC(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL207499	=	IC50	nM	63.0	CHEMBL2695	Homo sapiens	IC50	uM	0.063
	1717314	CHEMBL870124	Inhibition of FAK	B	CCNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL207259	=	IC50	nM	345.0	CHEMBL2695	Homo sapiens	IC50	uM	0.345
	1717315	CHEMBL870124	Inhibition of FAK	B	CNC(=O)CCc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL207126	=	IC50	nM	331.0	CHEMBL2695	Homo sapiens	IC50	uM	0.331
	1717317	CHEMBL870124	Inhibition of FAK	B	COC(=O)CNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL207232	=	IC50	nM	635.0	CHEMBL2695	Homo sapiens	IC50	uM	0.635
	1717318	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCCN(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL208392	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717319	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCCN)c4)c3n2)cc(OC)c1OC		CHEMBL379969	=	IC50	nM	1330.0	CHEMBL2695	Homo sapiens	IC50	uM	1.33
	1717320	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NCCN)c4)c3n2)cc(OC)c1OC		CHEMBL207834	=	IC50	nM	727.0	CHEMBL2695	Homo sapiens	IC50	uM	0.727
	1717321	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CCCC5)c4)c3n2)cc(OC)c1OC		CHEMBL205095	=	IC50	nM	5800.0	CHEMBL2695	Homo sapiens	IC50	uM	5.8
	1717322	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)NC5CC5)c4)c3n2)cc(OC)c1OC		CHEMBL439154	=	IC50	nM	117.0	CHEMBL2695	Homo sapiens	IC50	uM	0.117
	1717323	CHEMBL870124	Inhibition of FAK	B	CCNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL207721	=	IC50	nM	421.0	CHEMBL2695	Homo sapiens	IC50	uM	0.421
	1717324	CHEMBL870124	Inhibition of FAK	B	CNC(=O)Cc1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL383263	=	IC50	nM	1810.0	CHEMBL2695	Homo sapiens	IC50	uM	1.81
	1717325	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCO)c4)c3n2)cc(OC)c1OC		CHEMBL380424	=	IC50	nM	882.0	CHEMBL2695	Homo sapiens	IC50	uM	0.882
	1717326	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCO)c4)c3n2)cc(OC)c1OC		CHEMBL379279	=	IC50	nM	434.0	CHEMBL2695	Homo sapiens	IC50	uM	0.434
	1717327	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCCN(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL208000	=	IC50	nM	983.0	CHEMBL2695	Homo sapiens	IC50	uM	0.983
	1717328	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCCN(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL207961	=	IC50	nM	54.0	CHEMBL2695	Homo sapiens	IC50	uM	0.054
	1717329	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCNC(C)=O)c4)c3n2)cc(OC)c1OC		CHEMBL207444	=	IC50	nM	298.0	CHEMBL2695	Homo sapiens	IC50	uM	0.298
	1717330	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN5CCCC5)c4)c3n2)cc(OC)c1OC		CHEMBL377708	=	IC50	nM	73.0	CHEMBL2695	Homo sapiens	IC50	uM	0.073
	1717331	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL379837	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	uM	0.038
	1717332	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCCN)c4)c3n2)cc(OC)c1OC		CHEMBL207084	=	IC50	nM	29.0	CHEMBL2695	Homo sapiens	IC50	uM	0.029
	1717333	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CCCC5)c4)c3n2)cc(OC)c1OC		CHEMBL206978	=	IC50	nM	4110.0	CHEMBL2695	Homo sapiens	IC50	uM	4.11
	1717334	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NCC(C)C)c4)c3n2)cc(OC)c1OC		CHEMBL206977	=	IC50	nM	5060.0	CHEMBL2695	Homo sapiens	IC50	uM	5.06
	1717335	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)NC5CC5)c4)c3n2)cc(OC)c1OC		CHEMBL208468	=	IC50	nM	322.0	CHEMBL2695	Homo sapiens	IC50	uM	0.322
	1717336	CHEMBL870124	Inhibition of FAK	B	CCNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL378661	=	IC50	nM	365.0	CHEMBL2695	Homo sapiens	IC50	uM	0.365
	1717337	CHEMBL870124	Inhibition of FAK	B	CNC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL380515	=	IC50	nM	262.0	CHEMBL2695	Homo sapiens	IC50	uM	0.262
	1717338	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(N)=O)c4)c3n2)cc(OC)c1OC		CHEMBL206417	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717339	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)NCCCN(C)C)c3n2)cc(OC)c1OC		CHEMBL207904	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717340	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)NCCN)c3n2)cc(OC)c1OC		CHEMBL379748	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717341	CHEMBL870124	Inhibition of FAK	B	CNC(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21		CHEMBL208939	=	IC50	nM	342.0	CHEMBL2695	Homo sapiens	IC50	uM	0.342
	1717342	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C(N)=O)c3n2)cc(OC)c1OC		CHEMBL207551	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717343	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCc5nn[nH]n5)c4)c3n2)cc(OC)c1OC		CHEMBL209044	=	IC50	nM	119.0	CHEMBL2695	Homo sapiens	IC50	uM	0.119
	1717344	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(Cc5nn[nH]n5)c4)c3n2)cc(OC)c1OC		CHEMBL206876	=	IC50	nM	232.0	CHEMBL2695	Homo sapiens	IC50	uM	0.232
	1717345	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(-c5nn[nH]n5)c4)c3n2)cc(OC)c1OC		CHEMBL208419	=	IC50	nM	115.0	CHEMBL2695	Homo sapiens	IC50	uM	0.115
	1717346	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(C(=O)O)cc4)c3n2)cc(OC)c1OC		CHEMBL378964	=	IC50	nM	2840.0	CHEMBL2695	Homo sapiens	IC50	uM	2.84
	1717347	CHEMBL870124	Inhibition of FAK	B	COC(=O)c1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL206890	=	IC50	nM	6500.0	CHEMBL2695	Homo sapiens	IC50	uM	6.5
	1717348	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc([N+](=O)[O-])cc4)c3n2)cc(OC)c1OC		CHEMBL382452	=	IC50	nM	3230.0	CHEMBL2695	Homo sapiens	IC50	uM	3.23
	1717349	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(C(F)(F)F)cc4)c3n2)cc(OC)c1OC		CHEMBL207053	=	IC50	nM	1510.0	CHEMBL2695	Homo sapiens	IC50	uM	1.51
	1717350	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(SC)cc4)c3n2)cc(OC)c1OC		CHEMBL379655	=	IC50	nM	831.0	CHEMBL2695	Homo sapiens	IC50	uM	0.831
	1717351	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(C(C)(C)C)cc4)c3n2)cc(OC)c1OC		CHEMBL207787	=	IC50	nM	7320.0	CHEMBL2695	Homo sapiens	IC50	uM	7.32
	1717352	CHEMBL870124	Inhibition of FAK	B	CCCCc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL207161	=	IC50	nM	5120.0	CHEMBL2695	Homo sapiens	IC50	uM	5.12
	1717353	CHEMBL870124	Inhibition of FAK	B	CCc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL381262	=	IC50	nM	1530.0	CHEMBL2695	Homo sapiens	IC50	uM	1.53
	1717354	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccc(C)cc4)c3n2)cc(OC)c1OC		CHEMBL208368	=	IC50	nM	507.0	CHEMBL2695	Homo sapiens	IC50	uM	0.507
	1717355	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CN)c4)c3n2)cc(OC)c1OC		CHEMBL262122	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717356	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(N)c4)c3n2)cc(OC)c1OC		CHEMBL206363	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717357	CHEMBL870124	Inhibition of FAK	B	CNS(=O)(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL207615	=	IC50	nM	2710.0	CHEMBL2695	Homo sapiens	IC50	uM	2.71
	1717358	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)O)c4)c3n2)cc(OC)c1OC		CHEMBL207605	=	IC50	nM	35.0	CHEMBL2695	Homo sapiens	IC50	uM	0.035
	1717359	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC(=O)O)c4)c3n2)cc(OC)c1OC		CHEMBL206255	=	IC50	nM	37.0	CHEMBL2695	Homo sapiens	IC50	uM	0.037
	1717360	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(=O)O)c4)c3n2)cc(OC)c1OC		CHEMBL207131	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	uM	0.038
	1717361	CHEMBL870124	Inhibition of FAK	B	COC(=O)c1cccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)c1		CHEMBL381374	=	IC50	nM	1507.0	CHEMBL2695	Homo sapiens	IC50	uM	1.507
	1717362	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC#N)c4)c3n2)cc(OC)c1OC		CHEMBL206524	=	IC50	nM	93.0	CHEMBL2695	Homo sapiens	IC50	uM	0.093
	1717363	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(CC#N)c4)c3n2)cc(OC)c1OC		CHEMBL382354	=	IC50	nM	63.0	CHEMBL2695	Homo sapiens	IC50	uM	0.063
	1717364	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C#N)c4)c3n2)cc(OC)c1OC		CHEMBL207015	=	IC50	nM	126.0	CHEMBL2695	Homo sapiens	IC50	uM	0.126
	1717365	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C(F)(F)F)c4)c3n2)cc(OC)c1OC		CHEMBL207737	=	IC50	nM	235.0	CHEMBL2695	Homo sapiens	IC50	uM	0.235
	1717366	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4cccc(C)c4)c3n2)cc(OC)c1OC		CHEMBL207614	=	IC50	nM	221.0	CHEMBL2695	Homo sapiens	IC50	uM	0.221
	1717367	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C(=O)O)c3n2)cc(OC)c1OC		CHEMBL207875	=	IC50	nM	2820.0	CHEMBL2695	Homo sapiens	IC50	uM	2.82
	1717368	CHEMBL870124	Inhibition of FAK	B	COC(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21		CHEMBL380683	=	IC50	nM	314.0	CHEMBL2695	Homo sapiens	IC50	uM	0.314
	1717369	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C#N)c3n2)cc(OC)c1OC		CHEMBL206731	=	IC50	nM	504.0	CHEMBL2695	Homo sapiens	IC50	uM	0.504
	1717370	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4NC(C)=O)c3n2)cc(OC)c1OC		CHEMBL378451	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717371	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4CO)c3n2)cc(OC)c1OC		CHEMBL208734	=	IC50	nM	727.0	CHEMBL2695	Homo sapiens	IC50	uM	0.727
	1717372	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4N)c3n2)cc(OC)c1OC		CHEMBL379269	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717373	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4[N+](=O)[O-])c3n2)cc(OC)c1OC		CHEMBL378018	=	IC50	nM	4050.0	CHEMBL2695	Homo sapiens	IC50	uM	4.05
	1717374	CHEMBL870124	Inhibition of FAK	B	CCc1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21		CHEMBL379071	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717375	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3ccn(-c4ccccc4C)c3n2)cc(OC)c1OC		CHEMBL437693	=	IC50	nM	2810.0	CHEMBL2695	Homo sapiens	IC50	uM	2.81
	1717376	CHEMBL870124	Inhibition of FAK	B	CCCNS(=O)(=O)c1ccccc1-n1ccc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc21		CHEMBL208322	=	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	uM	3.5
	1717377	CHEMBL870124	Inhibition of FAK	B	COc1cc(Nc2ncc3cc(C(=O)O)n(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL209189	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1717378	CHEMBL870124	Inhibition of FAK	B	COC(=O)c1cc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc2n1-c1ccccn1		CHEMBL383460	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	1777546	CHEMBL908848	Inhibition of FAK	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Ki	nM	5000.0	CHEMBL2695	Homo sapiens	Ki	uM	5.0
	1790445	CHEMBL912733	Inhibition of human FAK	B	COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC		CHEMBL201511	=	IC50	nM	970.0	CHEMBL2695	Homo sapiens	IC50	M	9.7E-7
	1790571	CHEMBL856428	Inhibition of human recombinant FAK	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Ki	nM	10000.0	CHEMBL2695	Homo sapiens	Ki	uM	10.0
	1841824	CHEMBL913896	Inhibition of FAK	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	nM	50000.0
	1996183	CHEMBL899843	Inhibition of FAK at 10 uM	B	CSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(Cl)c3ccccc3)c2n1		CHEMBL400211	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	Inhibition	%	30.0
	2000773	CHEMBL900484	Inhibition of FAK at 10 nM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCF)CC2)n1	Outside typical range	CHEMBL240158	=	Inhibition	%	-18.3	CHEMBL2695	Homo sapiens	Inhibition	%	-18.3
	2000794	CHEMBL900484	Inhibition of FAK at 10 nM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	81.7	CHEMBL2695	Homo sapiens	Inhibition	%	81.7
	2029832	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccccc3)c2-c2ccccc2N1		CHEMBL250583	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029880	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccc([N+](=O)[O-])cc3)c2-c2ccccc2N1		CHEMBL400310	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029881	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccc(F)cc3F)c2-c2ccccc2N1		CHEMBL248954	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029882	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccccc3Br)c2-c2ccccc2N1		CHEMBL400113	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029883	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccccc3F)c2-c2ccccc2N1		CHEMBL399076	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029884	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3cccc(Cl)c3)c2-c2ccccc2N1		CHEMBL248760	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029885	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccccc3Cl)c2-c2ccccc2N1		CHEMBL248759	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029886	CHEMBL886298	Inhibition of FAK at 10 uM	B	CC(C)(C)c1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL398877	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029887	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3cc(Cl)cc(Cl)c3)c2-c2ccccc2N1		CHEMBL248758	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029888	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccc(C(F)(F)F)cc3)c2-c2ccccc2N1		CHEMBL398876	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029889	CHEMBL886298	Inhibition of FAK at 10 uM	B	Cc1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL400898	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029890	CHEMBL886298	Inhibition of FAK at 10 uM	B	COc1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL248558	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029891	CHEMBL886298	Inhibition of FAK at 10 uM	B	Cc1ccccc1-n1ncc2c1-c1ccccc1NC(=O)C2		CHEMBL400897	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029892	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccc(Cl)cc3)c2-c2ccccc2N1		CHEMBL248557	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2029893	CHEMBL886298	Inhibition of FAK at 10 uM	B	O=C1Cc2cnn(-c3ccc(Br)cc3)c2-c2ccccc2N1		CHEMBL398288	<=	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	Inhibition	%	40.0
	2132657	CHEMBL921281	Inhibition of FAK	B	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL410659	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	2147258	CHEMBL921848	Activity of human FAK kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	110.0	CHEMBL2695	Homo sapiens	Activity	%	110.0
Not Evaluated	2149617	CHEMBL931314	Inhibition of human FAK	B	NC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2		CHEMBL379367		Activity			CHEMBL2695	Homo sapiens	Activity		
	2167621	CHEMBL932341	Inhibition of FAK	B	CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1		CHEMBL445162	=	IC50	nM	19700.0	CHEMBL2695	Homo sapiens	IC50	uM	19.7
	2182381	CHEMBL950802	Inhibition of FAK Tyr397 phosphorylation in human A431 cells by ELISA	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
	2182383	CHEMBL950804	Inhibition of FAK Tyr397 phosphorylation in human PC3 cells after 60 mins by Western blot analysis	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
	2182384	CHEMBL950805	Inhibition of FAK Tyr397 phosphorylation in human SKOV3 cells after 60 mins by Western blot analysis	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
	2182385	CHEMBL950806	Inhibition of FAK Tyr397 phosphorylation in human L3.6pl cells after 60 mins by Western blot analysis	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	nM	300.0
	2182386	CHEMBL950807	Inhibition of FAK Tyr397 phosphorylation in human FG cells after 60 mins by Western blot analysis	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
	2182402	CHEMBL941301	Inhibition of FAK	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	2206862	CHEMBL990537	Inhibition of PTK2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	610.0	CHEMBL2695	Homo sapiens	Kd	nM	610.0
	2270538	CHEMBL964952	Inhibition of FAK by virtual HTS assay	B	O=C(NC(=S)Nc1ccc(O)c(-c2nc3ccccc3s2)c1)c1ccc([N+](=O)[O-])cc1		CHEMBL460746	=	IC50	nM	900.0	CHEMBL2695	Homo sapiens	IC50	uM	0.9
	2279708	CHEMBL960116	Inhibition of PTK2	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1		CHEMBL493937	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
Not Active	2301944	CHEMBL949882	Inhibition of FAK up to 100 uM	B	COc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL483271		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2301968	CHEMBL949882	Inhibition of FAK up to 100 uM	B	COc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL519976		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2301992	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1cccnc1		CHEMBL501256		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302016	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1ccccn1		CHEMBL504135		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302040	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL485444		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302064	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL520515		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302088	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302112	CHEMBL949882	Inhibition of FAK up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL521155		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	2302128	CHEMBL949882	Inhibition of FAK up to 100 uM	B	CN(C)c1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL519977		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	2341440	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1		CHEMBL524898	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	2341481	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL501459	=	Inhibition	%	97.0	CHEMBL2695	Homo sapiens	INH	%	97.0
	2341522	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1		CHEMBL501728	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2341563	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL499617	=	Inhibition	%	78.0	CHEMBL2695	Homo sapiens	INH	%	78.0
	2341605	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1		CHEMBL501200	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	2341645	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1		CHEMBL525070	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	2341686	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1		CHEMBL501463	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2341727	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1		CHEMBL499624	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2341768	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1		CHEMBL502826	=	Inhibition	%	9.0	CHEMBL2695	Homo sapiens	INH	%	9.0
	2341809	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1		CHEMBL502827	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	2341850	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1		CHEMBL526914	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	2341891	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1		CHEMBL501471	=	Inhibition	%	17.0	CHEMBL2695	Homo sapiens	INH	%	17.0
	2341932	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1		CHEMBL501182	=	Inhibition	%	67.0	CHEMBL2695	Homo sapiens	INH	%	67.0
	2341973	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1		CHEMBL499606	=	Inhibition	%	8.0	CHEMBL2695	Homo sapiens	INH	%	8.0
	2342014	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1		CHEMBL499865	=	Inhibition	%	11.0	CHEMBL2695	Homo sapiens	INH	%	11.0
	2342055	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1		CHEMBL499866	=	Inhibition	%	99.0	CHEMBL2695	Homo sapiens	INH	%	99.0
	2342096	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F		CHEMBL520451	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342137	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1		CHEMBL482513	=	Inhibition	%	12.0	CHEMBL2695	Homo sapiens	INH	%	12.0
	2342178	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1		CHEMBL483318	=	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
	2342213	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1		CHEMBL520971	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	2342251	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1		CHEMBL521469	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	2342301	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1		CHEMBL521478	=	Inhibition	%	17.0	CHEMBL2695	Homo sapiens	INH	%	17.0
	2342342	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1		CHEMBL483506	=	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
	2342383	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL483507	=	Inhibition	%	78.0	CHEMBL2695	Homo sapiens	INH	%	78.0
	2342424	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1		CHEMBL520980	=	Inhibition	%	10.0	CHEMBL2695	Homo sapiens	INH	%	10.0
	2342465	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1		CHEMBL519962	=	Inhibition	%	2.0	CHEMBL2695	Homo sapiens	INH	%	2.0
	2342506	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1		CHEMBL526526	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2342547	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1		CHEMBL482488	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	2342608	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1		CHEMBL521002	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	2342609	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1		CHEMBL483710	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	2342610	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1		CHEMBL484707	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	2342611	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1		CHEMBL519146	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	2342612	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1		CHEMBL484713	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2342613	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1		CHEMBL446087	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2342614	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521000	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2342615	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1		CHEMBL482722	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	2342616	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1		CHEMBL483715	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342617	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1		CHEMBL521145	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342618	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1		CHEMBL519311	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342619	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1		CHEMBL483518	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342620	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1		CHEMBL482910	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342621	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1		CHEMBL485524	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	2342622	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1		CHEMBL520512	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342623	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1		CHEMBL484706	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342624	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519349	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342625	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12		CHEMBL520331	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342626	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1		CHEMBL446637	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342627	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1		CHEMBL482721	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342628	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1		CHEMBL482717	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342629	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C		CHEMBL482710	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	2342630	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1		CHEMBL519534	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	2342631	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1		CHEMBL484521	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	2342632	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1		CHEMBL519310	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	2342633	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1		CHEMBL484324	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	2342634	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521479	=	Inhibition	%	2.0	CHEMBL2695	Homo sapiens	INH	%	2.0
	2342635	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519658	=	Inhibition	%	10.0	CHEMBL2695	Homo sapiens	INH	%	10.0
	2342636	CHEMBL953401	Inhibition of FAK at 10 uM by HTRF assay relative to control	B	O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL500661	=	Inhibition	%	99.0	CHEMBL2695	Homo sapiens	INH	%	99.0
	2361590	CHEMBL971635	Inhibition of FAK	B	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12		CHEMBL459729	=	IC50	nM	165.0	CHEMBL2695	Homo sapiens	IC50	uM	0.165
Active	2381823	CHEMBL939552	Inhibition of FAK-Y397 phosphorylation in human BT474 cells at 100 uM after 24 hrs by Western blotting	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	2381828	CHEMBL939556	Inhibition of FAK-Y397 phosphorylation in human BT474 cells at 100 uM after 24 hrs by immunostaining	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	2381829	CHEMBL939557	Inhibition of total FAK autophosphorylation in human BT474 cells at 100 uM after 24 hrs by Western blotting	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	2381830	CHEMBL939558	Inhibition of FAK-Y397 phosphorylation in human BT474 cells after 24 hrs by Western blotting	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
tde	2381832	CHEMBL939560	Inhibition of FAK-Y397 phosphorylation in human BT474 cells at 100 uM by Western blotting	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
tde	2381833	CHEMBL939560	Inhibition of FAK-Y397 phosphorylation in human BT474 cells at 100 uM by Western blotting	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Activity			CHEMBL2695	Homo sapiens	Activity		
tde	2381834	CHEMBL939561	Inhibition of total FAK phosphorylation in human BT474 cells at 100 uM by Western blotting	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	2381853	CHEMBL939562	Inhibition of recombinant full length FAK autophosphorylation expressed in baculovirus by SDS-PAGE	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	2381856	CHEMBL939565	Inhibition of recombinant FAK domain (411 to 686 amino acids) without N terminal domain containing Y397 site at 1 uM	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	2381866	CHEMBL939564	Inhibition of recombinant full length FAK-mediated GST-paxillin autophosphorylation expressed in baculovirus by SDS-PAGE	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL2695	Homo sapiens	Activity		
	2419149	CHEMBL1019637	Inhibition of PTK2 at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	12.0	CHEMBL2695	Homo sapiens	INH	%	12.0
	2461685	CHEMBL962869	Inhibition of recombinant FAK	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12		CHEMBL519982	=	IC50	ug.mL-1	2.4	CHEMBL2695	Homo sapiens	IC50	10'-6g/ml	2.4
	2461765	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1		CHEMBL520144	=	IC50	ug.mL-1	4.9	CHEMBL2695	Homo sapiens	IC50	10'-6g/ml	4.9
	2461766	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1		CHEMBL483526	=	IC50	ug.mL-1	8.9	CHEMBL2695	Homo sapiens	IC50	10'-6g/ml	8.9
	2461767	CHEMBL962869	Inhibition of recombinant FAK	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12		CHEMBL483525	=	IC50	ug.mL-1	2.1	CHEMBL2695	Homo sapiens	IC50	10'-6g/ml	2.1
	2461777	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1		CHEMBL483531	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	10'-5g/ml	1.0
	2461783	CHEMBL962869	Inhibition of recombinant FAK	B	O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O		CHEMBL521470	=	IC50	ug.mL-1	7.3	CHEMBL2695	Homo sapiens	IC50	10'-6g/ml	7.3
	2461784	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1		CHEMBL519395	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	10'-5g/ml	1.0
	2461785	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c2c(c1)C1(OC2=O)C(C)=CC(=O)C1O		CHEMBL408995	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	10'-5g/ml	1.0
	2461786	CHEMBL962869	Inhibition of recombinant FAK	B	COc1cc(O)c2c(c1)-c1cc(O)c(O)cc1COC2=O		CHEMBL507058	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	10'-5g/ml	1.0
	2461787	CHEMBL962869	Inhibition of recombinant FAK	B	Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O		CHEMBL483532	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	10'-5g/ml	1.0
	2464998	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC		CHEMBL201511	=	IC50	nM	650.0	CHEMBL2695	Homo sapiens	IC50	uM	0.65
	2465049	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3cn(C)c4ccccc34)C(=O)NC2)cc(OC)c1OC		CHEMBL509435	=	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	2465050	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3cn(COCc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL453336	=	IC50	nM	40000.0	CHEMBL2695	Homo sapiens	IC50	uM	40.0
	2465051	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3cn(COc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL488811	=	IC50	nM	43000.0	CHEMBL2695	Homo sapiens	IC50	uM	43.0
	2465052	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3cn(COC(C)(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL488646	=	IC50	nM	28000.0	CHEMBL2695	Homo sapiens	IC50	uM	28.0
	2465053	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3cn(COC(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL488645	=	IC50	nM	27000.0	CHEMBL2695	Homo sapiens	IC50	uM	27.0
	2465054	CHEMBL957975	Inhibition of human recombinant FAK	B	CCOCn1cc(C2=C(c3cc(OC)c(OC)c(OC)c3)C(=O)NC2)c2ccccc21		CHEMBL529217	=	IC50	nM	28000.0	CHEMBL2695	Homo sapiens	IC50	uM	28.0
	2465055	CHEMBL957975	Inhibition of human recombinant FAK	B	COCn1cc(C2=C(c3cc(OC)c(OC)c(OC)c3)C(=O)NC2)c2ccccc21		CHEMBL519590	=	IC50	nM	35000.0	CHEMBL2695	Homo sapiens	IC50	uM	35.0
	2465056	CHEMBL957975	Inhibition of human recombinant FAK	B	COc1cc(C2=C(c3c[nH]c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL529663	=	IC50	nM	9500.0	CHEMBL2695	Homo sapiens	IC50	uM	9.5
	2470329	CHEMBL992506	Inhibition of PTK2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL2695	Homo sapiens	INH	%	10.0
	2472141	CHEMBL982664	Inhibition of human FAK at 30 uM	B	C=CCOC(=O)N1c2ccc(OCCCOC3CCCCO3)cc2C[C@H]1[C@@H](CC=C)OC(C)=O		CHEMBL456813	=	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
Active	2472143	CHEMBL982666	Inhibition of FAK in human MDA-MB-231M cells assessed as phosphorylated tyrosine 397 levels at 25 uM after 1 hr by Western blot	B	C=CCOC(=O)N1c2ccc(OCCCOC3CCCCO3)cc2C[C@H]1[C@@H](CC=C)OC(C)=O		CHEMBL456813		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2476667	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2476870	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2478709	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL2695	Homo sapiens	Activity		
	2479521	CHEMBL988915	Binding affinity to human FAK	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409	=	Kd	nM	33.0	CHEMBL2695	Homo sapiens	Kd	nM	33.0
Not Evaluated	2479767	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL2695	Homo sapiens	Activity		
	2480564	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	25.7	CHEMBL2695	Homo sapiens	Activity	%	25.7
Active	2480766	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL2695	Homo sapiens	Activity		
	2507053	CHEMBL947774	Inhibition of PTK2	B	Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cc1Cl		CHEMBL475817	=	IC50	nM	478.0	CHEMBL2695	Homo sapiens	IC50	uM	0.478
	2526451	CHEMBL981420	Inhibition of FAK	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	nM	55.0
Not Active	2527091	CHEMBL984165	Inhibition of PTK2 at => 3 ug/mL	B	COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL451523		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2577388	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL2695	Homo sapiens	Activity		
	2582028	CHEMBL962246	Inhibition of human FAK	B	N=C(N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31		CHEMBL489083	=	IC50	nM	4400.0	CHEMBL2695	Homo sapiens	IC50	uM	4.4
	2588047	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	2588049	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	Cn1ccc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc21		CHEMBL470314	=	IC50	nM	160.0	CHEMBL2695	Homo sapiens	IC50	nM	160.0
	2588052	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	FC(F)(F)c1cnc(Nc2ccc3[nH]ncc3c2)nc1NCc1ccccn1		CHEMBL471526	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
	2588055	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3nccc(NCc4ccccn4)n3)ccc2N1		CHEMBL471697	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	2588058	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	Cc1cnc(Nc2ccc3c(c2)CC(=O)N3)nc1NCc1ccccn1		CHEMBL471698	=	IC50	nM	2200.0	CHEMBL2695	Homo sapiens	IC50	nM	2200.0
	2588061	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(Cl)c(NCc4ccccn4)n3)ccc2N1		CHEMBL511152	=	IC50	nM	77.0	CHEMBL2695	Homo sapiens	IC50	nM	77.0
	2588064	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(Br)c(NCc4ccccn4)n3)ccc2N1		CHEMBL470316	=	IC50	nM	46.0	CHEMBL2695	Homo sapiens	IC50	nM	46.0
	2588067	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	N#Cc1cnc(Nc2ccc3c(c2)CC(=O)N3)nc1NCc1ccccn1		CHEMBL470317	=	IC50	nM	190.0	CHEMBL2695	Homo sapiens	IC50	nM	190.0
	2588070	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc2N1		CHEMBL471357	=	IC50	nM	19.0	CHEMBL2695	Homo sapiens	IC50	nM	19.0
	2588073	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccc4)n3)ccc2N1		CHEMBL471520	=	IC50	nM	34.0	CHEMBL2695	Homo sapiens	IC50	nM	34.0
	2588076	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1)S(C)(=O)=O		CHEMBL513744	=	IC50	nM	1.9	CHEMBL2695	Homo sapiens	IC50	nM	1.9
	2588079	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL487246	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
	2588082	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CS(=O)(=O)c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F		CHEMBL488089	=	IC50	nM	59.0	CHEMBL2695	Homo sapiens	IC50	nM	59.0
	2588085	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccc4S(=O)(=O)N4CCCC4)n3)ccc2N1		CHEMBL529889	=	IC50	nM	170.0	CHEMBL2695	Homo sapiens	IC50	nM	170.0
	2588088	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(N[C@@H]4CCCCNC4=O)n3)ccc2N1		CHEMBL488446	=	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	nM	300.0
	2588091	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F		CHEMBL487227	=	IC50	nM	810.0	CHEMBL2695	Homo sapiens	IC50	nM	810.0
	2588094	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1CCc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc2N1		CHEMBL520059	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	nM	38.0
Not Determined	2588097	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1CCCc2cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc2N1		CHEMBL487228		IC50			CHEMBL2695	Homo sapiens	IC50		
	2588100	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CNC3=O)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL487229	=	IC50	nM	0.5	CHEMBL2695	Homo sapiens	IC50	nM	0.5
	2588103	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CCCNC3=O)ncc1C(F)(F)F		CHEMBL518905	=	IC50	nM	880.0	CHEMBL2695	Homo sapiens	IC50	nM	880.0
	2588106	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CCS3(=O)=O)ncc1C(F)(F)F		CHEMBL472211	=	IC50	nM	623.0	CHEMBL2695	Homo sapiens	IC50	nM	623.0
	2588109	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CN(C)S3(=O)=O)ncc1C(F)(F)F		CHEMBL487057	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	nM	3200.0
	2588112	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL519418	=	IC50	nM	1300.0	CHEMBL2695	Homo sapiens	IC50	nM	1300.0
	2588115	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL488247	=	IC50	nM	0.94	CHEMBL2695	Homo sapiens	IC50	nM	0.94
	2588118	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	3800.0	CHEMBL2695	Homo sapiens	IC50	nM	3800.0
	2588121	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CCN(CC)C(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL455677	=	IC50	nM	3300.0	CHEMBL2695	Homo sapiens	IC50	nM	3300.0
	2588123	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)C(=O)c1cccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)c1		CHEMBL453649	=	IC50	nM	3900.0	CHEMBL2695	Homo sapiens	IC50	nM	3900.0
	2588125	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(N[C@@H]4CCC[C@H]4N(C)C)n3)ccc12		CHEMBL455680	=	IC50	nM	72.0	CHEMBL2695	Homo sapiens	IC50	nM	72.0
	2588128	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccncc2)ncc1C(F)(F)F		CHEMBL452340	=	IC50	nM	4100.0	CHEMBL2695	Homo sapiens	IC50	nM	4100.0
Not Determined	2588130	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccn3ccnc3c2)ncc1C(F)(F)F		CHEMBL507488		IC50			CHEMBL2695	Homo sapiens	IC50		
	2588132	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CS(=O)(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL452341	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
	2588135	CHEMBL962347	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CS(=O)(=O)N3)ncc1C(F)(F)F		CHEMBL452342	>	IC50	nM	650.0	CHEMBL2695	Homo sapiens	IC50	nM	650.0
	2588138	CHEMBL960615	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation by fluorescence polarization assay	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	4500.0	CHEMBL2695	Homo sapiens	IC50	nM	4500.0
	2588139	CHEMBL960615	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation by fluorescence polarization assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccncc2)ncc1C(F)(F)F		CHEMBL452340	=	IC50	nM	6900.0	CHEMBL2695	Homo sapiens	IC50	nM	6900.0
	2588140	CHEMBL960615	Inhibition of GST-tagged FAK assessed as inhibition of poly-Glu-Tyr phosphorylation by fluorescence polarization assay	B	CN(C)C(=O)c1cccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)c1		CHEMBL453649	=	IC50	nM	4000.0	CHEMBL2695	Homo sapiens	IC50	nM	4000.0
Not Evaluated	2593593	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2593796	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2593859	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2594062	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2595005	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2595274	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2596202	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL2695	Homo sapiens	Activity		
	2596405	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342	=	Activity	%	5.9	CHEMBL2695	Homo sapiens	Activity	%	5.9
Not Evaluated	2597674	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Evaluated	2597877	CHEMBL1024919	Binding affinity to human FAK at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	2645024	CHEMBL1036239	Inhibition of FAK phosphorylation in human BT474 cells assessed as decrease in total phosphorylation at 10 uM after 24 hrs by immunoprecipitation technique	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1.Cl		CHEMBL550011		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	2645025	CHEMBL1032148	Inhibition of FAK phosphorylation in human MCF7 cells expressing VEGFR3 cells assessed as decrease in total phosphorylation at 10 uM after 24 hrs by immunoprecipitation technique	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1.Cl		CHEMBL550011		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	2645038	CHEMBL1036238	Inhibition of FAK phosphorylation in human BT474 cells assessed as partial dephosphorylation at 1 uM after 24 hrs by Western blotting	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1.Cl		CHEMBL550011		Activity			CHEMBL2695	Homo sapiens	Activity		
	2671890	CHEMBL1026229	Inhibition of recombinant FAK	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O		CHEMBL556684	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	ug ml-1	10.0
	2671891	CHEMBL1026229	Inhibition of recombinant FAK	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O		CHEMBL463054	>	IC50	ug.mL-1	10.0	CHEMBL2695	Homo sapiens	IC50	ug ml-1	10.0
	2672255	CHEMBL1026229	Inhibition of recombinant FAK	B	COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O		CHEMBL554993	=	IC50	ug.mL-1	5.5	CHEMBL2695	Homo sapiens	IC50	ug ml-1	5.5
	2672298	CHEMBL1026229	Inhibition of recombinant FAK	B	COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O		CHEMBL512054	=	IC50	ug.mL-1	1.5	CHEMBL2695	Homo sapiens	IC50	ug ml-1	1.5
	2709825	CHEMBL1055728	Inhibition of FAK	B	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL401930	=	IC50	nM	150.0	CHEMBL2695	Homo sapiens	IC50	nM	150.0
	2709834	CHEMBL1055728	Inhibition of FAK	B	Cc1cc(N2CCN(CCC#N)CC2)cc2nc(-c3c(NC[C@@H](O)c4ccccc4Cl)cc[nH]c3=O)[nH]c12		CHEMBL564417	=	IC50	nM	94.0	CHEMBL2695	Homo sapiens	IC50	nM	94.0
	2906509	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906510	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906511	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906512	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906513	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	7100.0	CHEMBL2695	Homo sapiens	Kd	nM	7100.0
	2906514	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906515	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906516	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906517	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906518	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906519	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906520	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906521	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906522	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906523	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906524	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906525	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906526	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906527	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906528	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906529	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906530	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906531	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906532	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906533	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906534	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906535	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906536	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906537	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906538	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906539	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906540	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906541	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	64.0	CHEMBL2695	Homo sapiens	Kd	nM	64.0
	2906542	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1200.0	CHEMBL2695	Homo sapiens	Kd	nM	1200.0
	2906543	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	440.0	CHEMBL2695	Homo sapiens	Kd	nM	440.0
	2906544	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906545	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2906546	CHEMBL1061093	Binding constant for PTK2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	2921968	CHEMBL1052936	Inhibition of PTK2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	93.0	CHEMBL2695	Homo sapiens	Activity	%	93.0
	2938399	CHEMBL1040487	Inhibition of FAK	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	>	Ki	nM	10000.0	CHEMBL2695	Homo sapiens	Ki	uM	10.0
	2992495	CHEMBL1040928	Inhibition of human recombinant FAK	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	IC50	nM	8300.0	CHEMBL2695	Homo sapiens	IC50	nM	8300.0
	3021205	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	CNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL585927	=	IC50	nM	17000.0	CHEMBL2695	Homo sapiens	IC50	uM	17.0
	3021206	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(N(C)C)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC	Outside typical range	CHEMBL572237	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021207	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COCCNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL568729	=	IC50	nM	1800.0	CHEMBL2695	Homo sapiens	IC50	uM	1.8
	3021208	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(NC5CCOCC5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570846	=	IC50	nM	1300.0	CHEMBL2695	Homo sapiens	IC50	uM	1.3
	3021209	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(N5CCN(C)CC5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC	Outside typical range	CHEMBL570643	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021210	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(Nc5ccccc5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570647	=	IC50	nM	18000.0	CHEMBL2695	Homo sapiens	IC50	uM	18.0
	3021211	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COCCNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)ccc23)cn1	Outside typical range	CHEMBL570955	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021212	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	CNc1ccn(Cc2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1	Outside typical range	CHEMBL570706	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021213	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(-c5cccs5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC	Outside typical range	CHEMBL570380	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021214	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(-c5cccnc5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC	Outside typical range	CHEMBL570365	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021215	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(Cc5ccccc5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570369	=	IC50	nM	1800.0	CHEMBL2695	Homo sapiens	IC50	uM	1.8
	3021216	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1ccc2c(Oc3ccc(NC(=O)c4cc(-c5cccnc5)cn(-c5ccccc5)c4=O)nc3)ccnc2c1	Outside typical range	CHEMBL570381	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3021217	CHEMBL1037539	Inhibition of human FAK by HTRF assay	B	COc1ccc2c(Oc3ccc(NC(=O)c4cc(-c5cnccn5)cn(-c5ccccc5)c4=O)nc3)ccnc2c1	Outside typical range	CHEMBL570189	>	IC50	nM	125000.0	CHEMBL2695	Homo sapiens	IC50	uM	125.0
	3052605	CHEMBL1037581	Residual activity of FAK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	104.0	CHEMBL2695	Homo sapiens	Residual activity	%	104.0
	3053914	CHEMBL1045124	Residual activity of FAK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	84.0	CHEMBL2695	Homo sapiens	Residual activity	%	84.0
	3054166	CHEMBL1040634	Residual activity of FAK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	94.0	CHEMBL2695	Homo sapiens	Residual activity	%	94.0
	3055453	CHEMBL1037581	Residual activity of FAK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	93.0	CHEMBL2695	Homo sapiens	Residual activity	%	93.0
	3055705	CHEMBL1045124	Residual activity of FAK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	93.0	CHEMBL2695	Homo sapiens	Residual activity	%	93.0
	3057010	CHEMBL1040634	Residual activity of FAK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	99.0	CHEMBL2695	Homo sapiens	Residual activity	%	99.0
	3058330	CHEMBL1037581	Residual activity of FAK at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	98.0	CHEMBL2695	Homo sapiens	Residual activity	%	98.0
	3058582	CHEMBL1045124	Residual activity of FAK at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	93.0	CHEMBL2695	Homo sapiens	Residual activity	%	93.0
	3062465	CHEMBL1037148	Binding affinity to human PTK2 at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	91.0	CHEMBL2695	Homo sapiens	Activity	%	91.0
	3063600	CHEMBL1039797	Binding affinity to human PTK2 at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	65.0	CHEMBL2695	Homo sapiens	Activity	%	65.0
	3063690	CHEMBL1047842	Binding affinity to human PTK2 at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	3065869	CHEMBL1069301	Inhibition of FAK at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	3066935	CHEMBL1069301	Inhibition of FAK at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	3072928	CHEMBL1040634	Residual activity of FAK at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	98.0	CHEMBL2695	Homo sapiens	Residual activity	%	98.0
	3098427	CHEMBL1067990	Inhibition of human FAK at 0.1 uM	B	COc1ccccc1NC(=O)CC(Nc1ccc(Oc2ccnc3cc(-c4cn(C)cn4)sc23)c(F)c1)C(F)(F)F		CHEMBL591924	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	3117923	CHEMBL1072199	Inhibition of FAK	B	CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1		CHEMBL599224	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	3117976	CHEMBL1072199	Inhibition of FAK	B	Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2		CHEMBL599428	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	3118029	CHEMBL1072199	Inhibition of FAK	B	CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2		CHEMBL597754	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	3131739	CHEMBL1065742	Inhibition of PTK2	B	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC		CHEMBL604087	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	3186436	CHEMBL1113283	Inhibition of Fak at 20 uM	B	CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12		CHEMBL1095040	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	3191055	CHEMBL1101922	Inhibition of human FAK at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2-c2cccc(NC(=O)c3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL1082876	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	3213807	CHEMBL1108394	Inhibition of FAK at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-3.0	CHEMBL2695	Homo sapiens	INH	%	-3.0
	3224942	CHEMBL1101495	Inhibition of FAK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	3226321	CHEMBL1101495	Inhibition of FAK at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
Not Active	3293115	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096459		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293131	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccc(F)cc3F)ccc21		CHEMBL1096460		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293147	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096466		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293163	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccccc3)ccc21		CHEMBL1096672		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293179	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccc(Nc2ccc3c(c2)Cc2ccccc2CC3=O)cc1		CHEMBL1096769		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293195	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)C(=O)Cc1ccccc1C2		CHEMBL1096770		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293211	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1096771		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293227	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1097085		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293243	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2ccc(Nc3ccccc3)cc2Cc2ccccc21		CHEMBL1097086		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293259	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097087		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293275	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097088		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293291	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2cc(Nc3ccccc3)ccc2Cc2ccccc21		CHEMBL1096988		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293307	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098461		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293323	CHEMBL1108238	Inhibition of FAK at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098462		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293339	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2ccccc2Cc2cc(-c3ccccc3)ccc21		CHEMBL1096442		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	3293355	CHEMBL1108238	Inhibition of FAK at 10 uM	B	O=C1Cc2ccccc2Cc2cc(NCc3ccccc3)ccc21		CHEMBL1097171		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	3294616	CHEMBL1103928	Inhibition of FAK	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=O)c5cnn(-c6ccccc6)c5C(F)(F)F)cc4F)c3s2)c1		CHEMBL1094718	<	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	INH	%	40.0
	3302305	CHEMBL1117899	Inhibition of FAK	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	3316522	CHEMBL1117899	Inhibition of FAK	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	3327241	CHEMBL1168283	Inhibition of PTK2 at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	3331938	CHEMBL1169228	Inhibition of FAK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	=	Inhibition	%	67.25	CHEMBL2695	Homo sapiens	INH	%	67.25
	3333353	CHEMBL1169228	Inhibition of FAK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Inhibition	%	98.0	CHEMBL2695	Homo sapiens	INH	%	98.0
	3334758	CHEMBL1169228	Inhibition of FAK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	=	Inhibition	%	94.0	CHEMBL2695	Homo sapiens	INH	%	94.0
	3336178	CHEMBL1169228	Inhibition of FAK at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	=	Inhibition	%	83.0	CHEMBL2695	Homo sapiens	INH	%	83.0
	3337775	CHEMBL1169228	Inhibition of FAK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	=	Inhibition	%	84.4	CHEMBL2695	Homo sapiens	INH	%	84.4
	3339109	CHEMBL1169228	Inhibition of FAK at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	=	Inhibition	%	94.0	CHEMBL2695	Homo sapiens	INH	%	94.0
	3340411	CHEMBL1169228	Inhibition of FAK at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	=	Inhibition	%	98.9	CHEMBL2695	Homo sapiens	INH	%	98.9
	3340706	CHEMBL1169228	Inhibition of FAK at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	3342122	CHEMBL1169228	Inhibition of FAK at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	3344683	CHEMBL1168104	Inhibition of FAK assessed as residual activity at 10 uM after 80 mins by microplate scintillation counting	B	CN1CCN(c2ccc(NC(=O)c3ccc4c(c3)/C(=C3/Nc5ccccc5C3=O)C(=O)N4)cc2)CC1		CHEMBL1164526	=	Activity	%	92.0	CHEMBL2695	Homo sapiens	Activity	%	92.0
	3344684	CHEMBL1168105	Inhibition of FAK assessed as residual activity at 1 uM after 80 mins by microplate scintillation counting	B	CN1CCN(c2ccc(NC(=O)c3ccc4c(c3)/C(=C3/Nc5ccccc5C3=O)C(=O)N4)cc2)CC1		CHEMBL1164526	=	Activity	%	103.0	CHEMBL2695	Homo sapiens	Activity	%	103.0
	3358573	CHEMBL1174418	Inhibition of FAK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	75.0	CHEMBL2695	Homo sapiens	INH	%	75.0
	3359015	CHEMBL1174418	Inhibition of FAK at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	59.0	CHEMBL2695	Homo sapiens	INH	%	59.0
Dose-dependent effect	3359770	CHEMBL1177632	Inhibition of FAK phosphorylation in human MDA-MB-231 cells by Western blotting	B	NS(=O)(=O)c1ccc(Nc2nc(N3CCOCC3)nc3[nH]cnc23)cc1		CHEMBL1172957		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	3434684	CHEMBL1246553	Inhibition of FAK at 5 uM	B	c1cc(-c2cc(C3CCNCC3)n[nH]2)ccn1		CHEMBL1241462	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	3445113	CHEMBL1244835	Binding affinity to FAK	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	1100.0	CHEMBL2695	Homo sapiens	Kd	nM	1100.0
	3446210	CHEMBL1244350	Inhibition of PTK2	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	538.0	CHEMBL2695	Homo sapiens	IC50	nM	538.0
	3448431	CHEMBL1244835	Binding affinity to FAK	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	3448754	CHEMBL1244835	Binding affinity to FAK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	3449171	CHEMBL1244835	Binding affinity to FAK	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	440.0	CHEMBL2695	Homo sapiens	Kd	nM	440.0
	3449429	CHEMBL1244835	Binding affinity to FAK	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	=	Kd	nM	6100.0	CHEMBL2695	Homo sapiens	Kd	nM	6100.0
	3449666	CHEMBL1244835	Binding affinity to FAK	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	3450079	CHEMBL1244835	Binding affinity to FAK	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	uM	10.0
	3471614	CHEMBL1250655	Inhibition of FAK	B	Cn1ccc2ncnc(Oc3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c(F)c3)c21		CHEMBL1254007	=	IC50	nM	2600.0	CHEMBL2695	Homo sapiens	IC50	nM	2600.0
	3503187	CHEMBL1261154	Inhibition of FAK	B	Cc1[nH]nc2c1N=C(c1ccccc1Cl)c1cc([N+](=O)[O-])ccc1N2		CHEMBL1258821	=	IC50	nM	6900.0	CHEMBL2695	Homo sapiens	IC50	uM	6.9
	3503188	CHEMBL1261154	Inhibition of FAK	B	N#Cc1ccc2c(c1)C(c1ccccc1F)=Nc1c[nH]nc1N2		CHEMBL1257795	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	3503189	CHEMBL1261154	Inhibition of FAK	B	Nc1ccc2c(c1)C(c1ccccc1Cl)=Nc1c[nH]nc1N2		CHEMBL1257911	=	IC50	nM	150.0	CHEMBL2695	Homo sapiens	IC50	uM	0.15
	3503190	CHEMBL1261154	Inhibition of FAK	B	CC(=O)Nc1ccc2c(c1)C(c1ccccc1Cl)=Nc1c[nH]nc1N2		CHEMBL1257912	=	IC50	nM	180.0	CHEMBL2695	Homo sapiens	IC50	uM	0.18
	3526987	CHEMBL1275106	Inhibition of FAK	B	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1		CHEMBL1270230	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	3590794	CHEMBL1292130	Inhibition of human FAK	B	COc1ccc(CNc2ccnc3oc4ccccc4c23)cc1	Outside typical range	CHEMBL1290072	=	IC50	nM	194000.0	CHEMBL2695	Homo sapiens	IC50	uM	194.0
	3601432	CHEMBL1292406	Inhibition of FAK	B	COc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1		CHEMBL1288582	=	IC50	nM	5490.0	CHEMBL2695	Homo sapiens	IC50	uM	5.49
	5120375	CHEMBL1645959	Inhibition of human FAK at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	106.0	CHEMBL2695	Homo sapiens	INH	%	106.0
	5123816	CHEMBL1645760	Inhibition of PTK2 at 1 uM	B	CCN1C(=O)CCC(C)(C)c2ccc(Nc3ncc(Cl)c(Nc4c(F)cccc4C(=O)NC)n3)cc21		CHEMBL1644812	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	5249819	CHEMBL1687335	Inhibition of FAK at 10 uM	B	COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1		CHEMBL1684800	=	Inhibition	%	1.5	CHEMBL2695	Homo sapiens	INH	%	1.5
	5249831	CHEMBL1687352	Inhibition of FAK	B	COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1		CHEMBL1684800	=	IC50	nM	4.13	CHEMBL2695	Homo sapiens	IC50	nM	4.13
Not Active	6149656	CHEMBL1764704	Inhibition of Fak	B	C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12		CHEMBL1738841		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	6167638	CHEMBL1768904	Inhibition of FAK	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	Ki	uM	1.0
Not Active	6192972	CHEMBL1777217	Inhibition of EGF-induced FAK phosphorylation at Tyr861 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	C/C(=C\C(=O)N[C@H]1CCc2cccc3c2N(C1=O)[C@H](C(=O)N[C@H](C)CCC(N)=O)C3)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1		CHEMBL1774973		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	6192973	CHEMBL1777217	Inhibition of EGF-induced FAK phosphorylation at Tyr861 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	CCCC[C@H](NC(=O)/C=C(\C)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1)C(=O)N1C[C@H]2C[C@H]2[C@H]1C(=O)N[C@@H](CCC(N)=O)C(C)OCc1ccccc1		CHEMBL1774974		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	6192974	CHEMBL1777217	Inhibition of EGF-induced FAK phosphorylation at Tyr861 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	CCCC[C@H](NC(=O)/C=C(\C)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1)C(=O)N1C[C@H]2C[C@H]2[C@H]1C(=O)N[C@H](C)CCC(N)=O		CHEMBL1774976		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	6198118	CHEMBL1776209	Inhibition of FAK assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1		CHEMBL1738758	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	6220266	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
	6220267	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL519418	=	IC50	nM	1300.0	CHEMBL2695	Homo sapiens	IC50	nM	1300.0
	6220268	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	3800.0	CHEMBL2695	Homo sapiens	IC50	nM	3800.0
	6220269	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(=O)(=O)NC3CC3)cc2)ncc1C(F)(F)F		CHEMBL1783837	=	IC50	nM	2100.0	CHEMBL2695	Homo sapiens	IC50	nM	2100.0
	6220270	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	1800.0	CHEMBL2695	Homo sapiens	IC50	nM	1800.0
	6220271	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	1100.0	CHEMBL2695	Homo sapiens	IC50	nM	1100.0
Not Determined	6220272	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CC(C)N=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029182		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	6220273	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc([S+](C)(=N)[O-])cc2)ncc1C(F)(F)F		CHEMBL2029183		IC50			CHEMBL2695	Homo sapiens	IC50		
	6220274	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	1100.0	CHEMBL2695	Homo sapiens	IC50	nM	1100.0
	6220275	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	790.0	CHEMBL2695	Homo sapiens	IC50	nM	790.0
Not Determined	6220276	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CC[S+]([O-])(=NC)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2448536		IC50			CHEMBL2695	Homo sapiens	IC50		
	6220277	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	2300.0	CHEMBL2695	Homo sapiens	IC50	nM	2300.0
	6220278	CHEMBL1787946	Inhibition of purified activated FAK kinase domain (410-689) using ATP and Glu and Tyr random peptide polymer substrate by fluorescence polarization assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	2400.0	CHEMBL2695	Homo sapiens	IC50	nM	2400.0
Not Active	6307619	CHEMBL1816867	Inhibition of recombinant FAK assessed as 33Pi incorporation after 60 mins by scintillation counting	B	C=C[C@]1(C)C=C2[C@@H](O)[C@@H]3OC(=O)[C@@]4(C)CC[C@H]5C[C@]5([C@@H]34)[C@@]2(O)C(=O)C1		CHEMBL1812030		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	6307620	CHEMBL1816867	Inhibition of recombinant FAK assessed as 33Pi incorporation after 60 mins by scintillation counting	B	C=C[C@@]1(C)C=C2C(=O)C(O)=C3[C@](C)(C(=O)O)CC[C@@H]4C[C@]34[C@]2(O)C(=O)C1		CHEMBL516554		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	6307621	CHEMBL1816867	Inhibition of recombinant FAK assessed as 33Pi incorporation after 60 mins by scintillation counting	B	Cc1cc(O)cc2oc3cc(O)cc(O)c3c(=O)c12		CHEMBL466154	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	6307622	CHEMBL1816867	Inhibition of recombinant FAK assessed as 33Pi incorporation after 60 mins by scintillation counting	B	Cc1c(O)c(O)cc2oc3cc(O)cc(O)c3c(=O)c12		CHEMBL454440	=	IC50	nM	15200.0	CHEMBL2695	Homo sapiens	IC50	uM	15.2
	6325311	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	6325340	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1ccc(Nc2ncccn2)cc1		CHEMBL1650061	=	Inhibition	%	10.0	CHEMBL2695	Homo sapiens	INH	%	10.0
	6325372	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	6325404	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	6325436	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Nc1ncccc1OCc1ccccc1		CHEMBL194009	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	6325465	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Nc1[nH]nc2ccccc12		CHEMBL1331627	=	Inhibition	%	13.0	CHEMBL2695	Homo sapiens	INH	%	13.0
	6325495	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Nc1n[nH]c2ncccc12		CHEMBL1817865	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	6325523	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1n[nH]c2c1CCCC2		CHEMBL1817866	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	6325866	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Nc1ccc2ncc(-c3ccccc3)n2n1		CHEMBL1817867	=	Inhibition	%	33.0	CHEMBL2695	Homo sapiens	INH	%	33.0
	6325896	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1ccc(-c2cnc3nccnn23)cc1		CHEMBL1817868	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	6325926	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1		CHEMBL1817869	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	6325955	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1		CHEMBL292785	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	6325984	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1		CHEMBL1817870	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	6326013	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1		CHEMBL1605296	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	6326042	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	6326072	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	Cc1ccc(C(=O)NC2CC2)cc1F		CHEMBL1817871	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	6326100	CHEMBL1819991	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	B	c1ccc(Nc2ccccc2)cc1		CHEMBL38688	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	6341057	CHEMBL1828226	Activity of FAK kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
Not Active	6360103	CHEMBL1832784	Inhibition of FAK in human PC3 cells assessed as decrease in auto-phosphorylation at Tyr-397 by Western blot analysis	B	CNC(=O)CCc1cc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)n(-c2ccc(N3CCNCC3)cc2)n1		CHEMBL1830587		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	6372717	CHEMBL1837745	Inhibition human recombinant FAK using Poly(Glu,Tyr) substrate in presence of [gamma-32P]-ATP	B	CSc1nc(Nc2cccc(Cl)c2)c2cnn(CCc3ccccc3)c2n1		CHEMBL1836673		Ki			CHEMBL2695	Homo sapiens	Ki		
Not Active	6372718	CHEMBL1837745	Inhibition human recombinant FAK using Poly(Glu,Tyr) substrate in presence of [gamma-32P]-ATP	B	CSc1nc(Nc2ccccc2)c2cnn(CC(C)c3ccccc3)c2n1		CHEMBL1836678		Ki			CHEMBL2695	Homo sapiens	Ki		
Not Active	6372719	CHEMBL1837745	Inhibition human recombinant FAK using Poly(Glu,Tyr) substrate in presence of [gamma-32P]-ATP	B	CSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(C)c3ccccc3)c2n1		CHEMBL1836679		Ki			CHEMBL2695	Homo sapiens	Ki		
	6378831	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1ccccc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834689	=	EC50	ug.mL-1	17.74	CHEMBL2695	Homo sapiens	EC50	ug ml-1	17.74
	6378832	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Nc1nnc(-c2ccc3c(c2)OCCO3)s1)c1ccccc1		CHEMBL1834690	=	EC50	ug.mL-1	21.04	CHEMBL2695	Homo sapiens	EC50	ug ml-1	21.04
	6378833	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1cccc(Cl)c1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834693	=	EC50	ug.mL-1	18.11	CHEMBL2695	Homo sapiens	EC50	ug ml-1	18.11
	6378834	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1ccc(Cl)cc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834737	=	EC50	ug.mL-1	12.15	CHEMBL2695	Homo sapiens	EC50	ug ml-1	12.15
	6378835	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1cccc(Br)c1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834738	=	EC50	ug.mL-1	26.15	CHEMBL2695	Homo sapiens	EC50	ug ml-1	26.15
	6378836	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1ccc(Br)cc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834739	=	EC50	ug.mL-1	23.73	CHEMBL2695	Homo sapiens	EC50	ug ml-1	23.73
	6378837	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(CCc1ccccc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834741	=	EC50	ug.mL-1	13.98	CHEMBL2695	Homo sapiens	EC50	ug ml-1	13.98
	6378838	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Cc1ccc(F)cc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834743	=	EC50	ug.mL-1	19.02	CHEMBL2695	Homo sapiens	EC50	ug ml-1	19.02
	6378839	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(Nc1nnc(-c2ccc3c(c2)OCCO3)s1)c1ccc(Cl)nc1		CHEMBL1834746	=	EC50	ug.mL-1	13.69	CHEMBL2695	Homo sapiens	EC50	ug ml-1	13.69
	6378840	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	O=C(/C=C/c1ccccc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834747	=	EC50	ug.mL-1	10.79	CHEMBL2695	Homo sapiens	EC50	ug ml-1	10.79
	6378841	CHEMBL1838972	Inhibition of human recombinant full-length FAK assessed as remaining ATP after 4 hrs by Kinase-Glo-luminescence assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	EC50	ug.mL-1	11.32	CHEMBL2695	Homo sapiens	EC50	ug ml-1	11.32
Active	6378860	CHEMBL1839253	Inhibition of FAK in human HepG2 cells at 2.22 to 20 uM by Western blot analysis	B	O=C(/C=C/c1ccccc1)Nc1nnc(-c2ccc3c(c2)OCCO3)s1		CHEMBL1834747		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	6386340	CHEMBL1839875	Inhibition of recombinant FAK	B	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O		CHEMBL1834657	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	7567135	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7567594	CHEMBL1908426	Binding constant for FAK kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7568065	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	1900.0	CHEMBL2695	Homo sapiens	Kd	nM	1900.0
	7568533	CHEMBL1908426	Binding constant for FAK kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7568965	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1200.0	CHEMBL2695	Homo sapiens	Kd	nM	1200.0
	7569108	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7569568	CHEMBL1908426	Binding constant for FAK kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7570040	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7570503	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	1900.0	CHEMBL2695	Homo sapiens	Kd	nM	1900.0
	7571084	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7571541	CHEMBL1908426	Binding constant for FAK kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	310.0	CHEMBL2695	Homo sapiens	Kd	nM	310.0
	7572017	CHEMBL1908426	Binding constant for FAK kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7572454	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	440.0	CHEMBL2695	Homo sapiens	Kd	nM	440.0
	7573065	CHEMBL1908426	Binding constant for FAK kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	=	Kd	nM	150.0	CHEMBL2695	Homo sapiens	Kd	nM	150.0
	7573522	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7574025	CHEMBL1908426	Binding constant for FAK kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7574433	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	1.1	CHEMBL2695	Homo sapiens	Kd	nM	1.1
	7575043	CHEMBL1908426	Binding constant for FAK kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	210.0	CHEMBL2695	Homo sapiens	Kd	nM	210.0
	7575504	CHEMBL1908426	Binding constant for FAK kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7575533	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	3700.0	CHEMBL2695	Homo sapiens	Kd	nM	3700.0
	7575998	CHEMBL1908426	Binding constant for FAK kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7576406	CHEMBL1908426	Binding constant for FAK kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7577017	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7577512	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7577982	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7578387	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	42.0	CHEMBL2695	Homo sapiens	Kd	nM	42.0
	7579407	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	180.0	CHEMBL2695	Homo sapiens	Kd	nM	180.0
	7579881	CHEMBL1908426	Binding constant for FAK kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	2100.0	CHEMBL2695	Homo sapiens	Kd	nM	2100.0
	7580350	CHEMBL1908426	Binding constant for FAK kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7580753	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7580941	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7581326	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	7100.0	CHEMBL2695	Homo sapiens	Kd	nM	7100.0
	7581771	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7582242	CHEMBL1908426	Binding constant for FAK kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7582706	CHEMBL1908426	Binding constant for FAK kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7583106	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7583287	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7583684	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7584129	CHEMBL1908426	Binding constant for FAK kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7584600	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7585062	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	250.0	CHEMBL2695	Homo sapiens	Kd	nM	250.0
	7585466	CHEMBL1908426	Binding constant for FAK kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7585617	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7586025	CHEMBL1908426	Binding constant for FAK kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7586471	CHEMBL1908426	Binding constant for FAK kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7586942	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7587396	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7587578	CHEMBL1908426	Binding constant for FAK kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7587997	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7588450	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7588921	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7589543	CHEMBL1908426	Binding constant for FAK kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7589967	CHEMBL1908426	Binding constant for FAK kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	1100.0	CHEMBL2695	Homo sapiens	Kd	nM	1100.0
	7590434	CHEMBL1908426	Binding constant for FAK kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	=	Kd	nM	200.0	CHEMBL2695	Homo sapiens	Kd	nM	200.0
	7590917	CHEMBL1908426	Binding constant for FAK kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7591516	CHEMBL1908426	Binding constant for FAK kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7591938	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7592441	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7592894	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7593483	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7593918	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7593948	CHEMBL1908426	Binding constant for FAK kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7594421	CHEMBL1908426	Binding constant for FAK kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7594873	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	570.0	CHEMBL2695	Homo sapiens	Kd	nM	570.0
	7595451	CHEMBL1908426	Binding constant for FAK kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7595927	CHEMBL1908426	Binding constant for FAK kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7596398	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7596845	CHEMBL1908426	Binding constant for FAK kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7597434	CHEMBL1908426	Binding constant for FAK kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7597907	CHEMBL1908426	Binding constant for FAK kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7598377	CHEMBL1908426	Binding constant for FAK kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2695	Homo sapiens	Kd	nM	10000.0
	7598819	CHEMBL1908426	Binding constant for FAK kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	64.0	CHEMBL2695	Homo sapiens	Kd	nM	64.0
	7843037	CHEMBL1913273	Inhibition of human recombinant FAK at 10 uM after 4 hrs by Kinase-Glo luminescent assay	B	O=C(c1c[nH]c2ccccc12)c1nccc2c1[nH]c1ccc(O)cc12		CHEMBL1910715	=	Inhibition	%	11.0	CHEMBL2695	Homo sapiens	INH	%	11.0
	7922666	CHEMBL1918835	Inhibition of human recombinant FAK at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	70.0	CHEMBL2695	Homo sapiens	INH	%	70.0
	7931129	CHEMBL1919466	Inhibition of PTK2 relative to control	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	Inhibition	%	-2.0	CHEMBL2695	Homo sapiens	INH	%	-2.0
Not Active	7933254	CHEMBL1920112	Inhibition of human FAK phosphorylation in MDA-MB-231 cells at 100 uM after 30 mins by Western blot analysis	B	c1ccc(C[C@H](CCNCc2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)cc1		CHEMBL1916396		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	7943732	CHEMBL1921575	Inhibition of FAK	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	17.15	CHEMBL2695	Homo sapiens	IC50	nM	17.15
	7943772	CHEMBL1921429	Inhibition of FAK at 10 uM	B	O=C1CC(c2cccc(NC(=O)c3ccc(Cl)c(C(F)(F)F)c3)c2)=Nc2cnn(Cc3ccccc3)c2N1		CHEMBL1917776	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	7951358	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@@H]1[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/CC(C)C		CHEMBL1922224	=	IC50	nM	16900.0	CHEMBL2695	Homo sapiens	IC50	uM	16.9
	7951359	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/CC(C)C		CHEMBL518060	=	IC50	nM	9920.0	CHEMBL2695	Homo sapiens	IC50	uM	9.92
	7951360	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@H](CCc3cc(O)ccc3C)C(=O)CC[C@@]21C)C(C)C		CHEMBL1922225	=	IC50	nM	10700.0	CHEMBL2695	Homo sapiens	IC50	uM	10.7
	7951361	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C		CHEMBL456936	=	IC50	nM	9630.0	CHEMBL2695	Homo sapiens	IC50	uM	9.63
	7951362	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@H]1[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC[C@H]1O		CHEMBL517956	=	IC50	nM	13200.0	CHEMBL2695	Homo sapiens	IC50	uM	13.2
	7951363	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1C[C@H](O)[C@@H]2[C@H](C)CCCC(C)C		CHEMBL456294	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	7951364	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@H](CCc3cc(O)ccc3C)[C@H](O)CC[C@@]21C)C(C)C		CHEMBL515982	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	7951365	CHEMBL1926224	Inhibition of recombinant human FAK using poly(Glu,Tyr)4:1 as substrate	B	Cc1ccc(O)cc1CC[C@H]1[C@@H]2C[C@H](O)[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC[C@H]1O		CHEMBL464351	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	7956231	CHEMBL1924894	Inhibition of N-terminus flag-tagged FAK expressed in baculovirus infected insect cells using ATP as substrate after 60 mins	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	7959759	CHEMBL1932854	Inhibition of FAK	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	7959760	CHEMBL1932854	Inhibition of FAK	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	IC50	nM	2000.0	CHEMBL2695	Homo sapiens	IC50	uM	2.0
	7991200	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	COc1cc(Nc2ncc3ccc(-c4ccccc4)n3n2)cc(OC)c1OC		CHEMBL1822511	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
	7991201	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	COc1cc(C2CCN(CC(N)=O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1		CHEMBL1934334	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	7991202	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	COc1ccccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12		CHEMBL1934335	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	nM	55.0
	7991203	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CN(c1ccccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934336	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
	7991204	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CC(C)(C)NS(=O)(=O)c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934337	=	IC50	nM	5.7	CHEMBL2695	Homo sapiens	IC50	nM	5.7
	7991205	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	COc1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cn1		CHEMBL1934338	=	IC50	nM	39.0	CHEMBL2695	Homo sapiens	IC50	nM	39.0
	7991206	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CS(=O)(=O)Nc1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934339	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	7991207	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CN(c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1)S(C)(=O)=O		CHEMBL1934340	=	IC50	nM	48.0	CHEMBL2695	Homo sapiens	IC50	nM	48.0
	7991208	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc(CO)c5)n4n3)cc2)CC1		CHEMBL1934341	=	IC50	nM	33.0	CHEMBL2695	Homo sapiens	IC50	nM	33.0
	7991209	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CS(=O)(=O)c1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cc1		CHEMBL1934342	=	IC50	nM	114.0	CHEMBL2695	Homo sapiens	IC50	nM	114.0
	7991210	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CS(=O)(=O)c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934343	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
	7991211	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CN(c1ncccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934344	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
	7991212	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	COc1cccnc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12		CHEMBL1934345	=	IC50	nM	2040.0	CHEMBL2695	Homo sapiens	IC50	nM	2040.0
	7991213	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5ncccn5)n4n3)cc2)CC1		CHEMBL1934346	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	7991214	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cnccn5)n4n3)cc2)CC1		CHEMBL1934347	=	IC50	nM	551.0	CHEMBL2695	Homo sapiens	IC50	nM	551.0
	7991215	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc6c5OC(F)(F)O6)n4n3)cc2)CC1		CHEMBL1934348	=	IC50	nM	122.0	CHEMBL2695	Homo sapiens	IC50	nM	122.0
	7991216	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CN(C)Cc1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cc1		CHEMBL1934349	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
	7991217	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CS(=O)(=O)N1Cc2cccc(-c3ccc4cnc(Nc5ccc(C6CCN(CC(N)=O)CC6)cc5)nn34)c2C1		CHEMBL1934350	=	IC50	nM	205.0	CHEMBL2695	Homo sapiens	IC50	nM	205.0
	7991218	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc6cccnc56)n4n3)cc2)CC1		CHEMBL1934351	=	IC50	nM	167.0	CHEMBL2695	Homo sapiens	IC50	nM	167.0
	7991219	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	Cc1cc(-c2ccccc2N(C)S(C)(=O)=O)n2nc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)ncc12		CHEMBL1934352	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
	7991220	CHEMBL1936031	Inhibition of human recombinant FAK expressed in baculovirus expression system after 30 mins by time resolved fluorescence assay	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
	7991240	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	COc1ccccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12		CHEMBL1934335	=	IC50	nM	690.0	CHEMBL2695	Homo sapiens	IC50	nM	690.0
	7991241	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CN(c1ccccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934336	=	IC50	nM	610.0	CHEMBL2695	Homo sapiens	IC50	nM	610.0
	7991242	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CC(C)(C)NS(=O)(=O)c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934337	=	IC50	nM	1340.0	CHEMBL2695	Homo sapiens	IC50	nM	1340.0
	7991243	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	COc1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cn1		CHEMBL1934338	=	IC50	nM	1190.0	CHEMBL2695	Homo sapiens	IC50	nM	1190.0
	7991244	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CS(=O)(=O)Nc1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934339	=	IC50	nM	660.0	CHEMBL2695	Homo sapiens	IC50	nM	660.0
	7991245	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CN(c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1)S(C)(=O)=O		CHEMBL1934340	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	7991246	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc(CO)c5)n4n3)cc2)CC1		CHEMBL1934341	=	IC50	nM	1390.0	CHEMBL2695	Homo sapiens	IC50	nM	1390.0
	7991247	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CS(=O)(=O)c1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cc1		CHEMBL1934342	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	7991248	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CS(=O)(=O)c1cccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)c1		CHEMBL1934343	=	IC50	nM	1010.0	CHEMBL2695	Homo sapiens	IC50	nM	1010.0
	7991249	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CN(c1ncccc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934344	=	IC50	nM	750.0	CHEMBL2695	Homo sapiens	IC50	nM	750.0
	7991250	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	COc1cccnc1-c1ccc2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12		CHEMBL1934345	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
Not Determined	7991251	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5ncccn5)n4n3)cc2)CC1		CHEMBL1934346		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	7991252	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cnccn5)n4n3)cc2)CC1		CHEMBL1934347		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	7991253	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc6c5OC(F)(F)O6)n4n3)cc2)CC1		CHEMBL1934348		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	7991254	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CN(C)Cc1ccc(-c2ccc3cnc(Nc4ccc(C5CCN(CC(N)=O)CC5)cc4)nn23)cc1		CHEMBL1934349		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	7991255	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CS(=O)(=O)N1Cc2cccc(-c3ccc4cnc(Nc5ccc(C6CCN(CC(N)=O)CC6)cc5)nn34)c2C1		CHEMBL1934350		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	7991256	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	NC(=O)CN1CCC(c2ccc(Nc3ncc4ccc(-c5cccc6cccnc56)n4n3)cc2)CC1		CHEMBL1934351		IC50			CHEMBL2695	Homo sapiens	IC50		
	7991257	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	Cc1cc(-c2ccccc2N(C)S(C)(=O)=O)n2nc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)ncc12		CHEMBL1934352	=	IC50	nM	1230.0	CHEMBL2695	Homo sapiens	IC50	nM	1230.0
	7991258	CHEMBL1936008	Inhibition of FAK in human 293GT cells after 1 hr by luminescence-based spectrophotometry	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	IC50	nM	420.0	CHEMBL2695	Homo sapiens	IC50	nM	420.0
	7996715	CHEMBL1944367	Inhibition of PTK2 at 1 uM	B	CNC(=O)c1cccc(F)c1Nc1nc(Nc2ccc3c(c2)NC(=O)[C@H](NC(=O)N2CCCC2)CC3(C)C)ncc1Cl		CHEMBL1939491	=	Inhibition	%	98.0	CHEMBL2695	Homo sapiens	INH	%	98.0
	7996757	CHEMBL1944367	Inhibition of PTK2 at 1 uM	B	CNC(=O)c1cccc(F)c1Nc1nc(Nc2ccc3c(c2)NC(=O)[C@@H](NC(=O)N2CCCC2)CC3(C)C)ncc1Cl		CHEMBL1939492	=	Inhibition	%	99.0	CHEMBL2695	Homo sapiens	INH	%	99.0
	8004481	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=c1c2ccccc2[se]n1-c1ccccc1		CHEMBL51085	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
Not Active	8004513	CHEMBL1944089	Inhibition of FAK phosphorylation in EGF-stimulated human MDA231 cells using [gamma32P]ATP as substrate at 50 uM after 2 hrs by scintillation counting	B	O=c1c2ccccc2[se]n1-c1ccccc1		CHEMBL51085		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	8004521	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](n2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940991	=	Inhibition	%	69.3	CHEMBL2695	Homo sapiens	INH	%	69.3
	8004523	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940992	=	Inhibition	%	54.9	CHEMBL2695	Homo sapiens	INH	%	54.9
	8004525	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993	=	Inhibition	%	80.1	CHEMBL2695	Homo sapiens	INH	%	80.1
	8004558	CHEMBL1944085	Inhibition of human recombinant full-length FAK using ATP and Poly Glu:Tyr as substrate after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993	=	IC50	nM	420.0	CHEMBL2695	Homo sapiens	IC50	uM	0.42
Active	8004560	CHEMBL1944087	Inhibition of FAK phosphorylation at Tyr-397 in EGF-stimulated human MDA231 cells at 10 uM after 2 hrs by Western blot analysis	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	8004561	CHEMBL1944088	Inhibition of FAK phosphorylation in EGF-stimulated human MDA231 cells using [gamma32P]ATP as substrate at 10 to 50 uM after 2 hrs by scintillation counting	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	8004573	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=c1c2ccccc2[se]n1[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O		CHEMBL1940994	=	Inhibition	%	7.4	CHEMBL2695	Homo sapiens	INH	%	7.4
	8004575	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=c1c2ccccc2[se]n1[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O		CHEMBL1940995	=	Inhibition	%	9.9	CHEMBL2695	Homo sapiens	INH	%	9.9
	8004577	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=c1c2ccccc2[se]n1[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O		CHEMBL1940996	=	Inhibition	%	1.3	CHEMBL2695	Homo sapiens	INH	%	1.3
	8004579	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](NC(=O)CCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940997	=	Inhibition	%	69.0	CHEMBL2695	Homo sapiens	INH	%	69.0
	8005222	CHEMBL1944085	Inhibition of human recombinant full-length FAK using ATP and Poly Glu:Tyr as substrate after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](NC(=O)CCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940997	=	IC50	nM	920.0	CHEMBL2695	Homo sapiens	IC50	uM	0.92
	8005230	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC(=O)CCCn3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940998	=	Inhibition	%	55.9	CHEMBL2695	Homo sapiens	INH	%	55.9
	8005232	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1940999	=	Inhibition	%	51.9	CHEMBL2695	Homo sapiens	INH	%	51.9
	8005265	CHEMBL1944085	Inhibition of human recombinant full-length FAK using ATP and Poly Glu:Tyr as substrate after 4 hrs by luminescence analysis	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1940999	=	IC50	nM	960.0	CHEMBL2695	Homo sapiens	IC50	uM	0.96
	8005273	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O		CHEMBL1941000	=	Inhibition	%	13.9	CHEMBL2695	Homo sapiens	INH	%	13.9
	8005275	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	CC(=O)OC[C@H]1O[C@@H](OCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1941001	=	Inhibition	%	51.9	CHEMBL2695	Homo sapiens	INH	%	51.9
	8005277	CHEMBL1943616	Inhibition of human recombinant full-length FAK using Poly Glu:Tyr as substrate at 1 uM after 4 hrs by luminescence analysis	B	O=c1c2ccccc2[se]n1CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1941002	=	Inhibition	%	50.9	CHEMBL2695	Homo sapiens	INH	%	50.9
	8013065	CHEMBL1947852	Inhibition of FAK using ATP as substrate	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O		CHEMBL1945559	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	8039302	CHEMBL1953280	Inhibition of FAK	B	COc1ccc(C(=O)NC[C@@H](O)CO)cc1/C=C/c1ccc(Cl)cc1		CHEMBL1949788	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	8039303	CHEMBL1953280	Inhibition of FAK	B	COc1ccc(C(=O)NC[C@H](O)CO)cc1/C=C/c1ccc(Cl)cc1		CHEMBL1949789	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	8047162	CHEMBL1959387	Inhibition of PTK2 at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8048877	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957497	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8048878	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cccc5[nH]ncc45)cn3c2Br)CC1		CHEMBL1957498	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8048879	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(C#N)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957499	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8048880	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957500	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8049762	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957502	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8049763	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	O=C(NCCN1CCOCC1)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957504	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8049764	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	CN(C)CCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957505	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8049765	CHEMBL1959606	Inhibition of FAK at 5 to 10 uM	B	COCCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957508	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	8060117	CHEMBL1961283	Inhibition of human recombinant FAK expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting	B	CC(C)n1c2c(c3c1-c1ccccc1C3=O)C(=O)CCC2		CHEMBL1957190	>	IC50	nM	35000.0	CHEMBL2695	Homo sapiens	IC50	uM	35.0
	8060118	CHEMBL1961283	Inhibition of human recombinant FAK expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting	B	O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23		CHEMBL6246	=	IC50	nM	3110.0	CHEMBL2695	Homo sapiens	IC50	uM	3.11
inactive	9589042	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)CCOc1cc(-c2ccc(C(N)=O)cc2)cc2[nH]nc(N)c12		CHEMBL2001398	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9589043	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9589044	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589045	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9589046	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
active	9589047	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	100.0	CHEMBL2695	Homo sapiens	pKi		7.0
active	9589048	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9589049	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589050	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	125.89	CHEMBL2695	Homo sapiens	pKi		6.9
inactive	9589051	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589052	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589053	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9589054	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589055	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589056	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589057	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589058	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589059	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589060	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	31622.78	CHEMBL2695	Homo sapiens	pKi		4.5
inactive	9589061	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589062	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589063	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589064	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589065	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589066	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589067	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589068	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589069	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589070	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589071	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589072	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589073	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9589074	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589075	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9589076	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589077	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589078	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589079	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589080	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589081	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	19952.62	CHEMBL2695	Homo sapiens	pKi		4.7
active	9589082	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
active	9589083	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
active	9589084	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9589085	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2000934	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9589086	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	15848.93	CHEMBL2695	Homo sapiens	pKi		4.8
inactive	9589087	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589088	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589089	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589090	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589091	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589092	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	=	Ki	nM	63095.73	CHEMBL2695	Homo sapiens	pKi		4.2
active	9589093	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9589094	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9589095	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9589096	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9589097	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9589098	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	79.43	CHEMBL2695	Homo sapiens	pKi		7.1
active	9589099	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9589100	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589101	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589102	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	50118.72	CHEMBL2695	Homo sapiens	pKi		4.3
active	9589103	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
active	9589104	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9589105	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589106	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589107	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589108	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589109	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589110	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589111	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1966842	<	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9589112	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589113	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589114	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	158.49	CHEMBL2695	Homo sapiens	pKi		6.8
inactive	9589115	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589116	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	79.43	CHEMBL2695	Homo sapiens	pKi		7.1
inactive	9589117	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9589118	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	251.19	CHEMBL2695	Homo sapiens	pKi		6.6
inactive	9589119	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9589120	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9589121	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592691	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592692	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1c2cc([N+](=O)[O-])ccc2-n2c1nc1cccc(Br)c1c2=O		CHEMBL1976158	<	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
active	9592693	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	=	Ki	nM	39.81	CHEMBL2695	Homo sapiens	pKi		7.4
inactive	9592694	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592695	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9592696	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
active	9592697	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2cccc(-c3ccc(F)cc3)c12		CHEMBL1971519	=	Ki	nM	19952.62	CHEMBL2695	Homo sapiens	pKi		4.7
active	9592698	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592699	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592700	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592701	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592702	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592703	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C1		CHEMBL1971132	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592704	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592705	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592706	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592707	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(=O)[nH]c2[nH]nc(-c3cccc(C(F)(F)F)c3)c12		CHEMBL1991377	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592708	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592709	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	79.43	CHEMBL2695	Homo sapiens	pKi		7.1
inactive	9592710	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592711	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592712	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592713	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	79.43	CHEMBL2695	Homo sapiens	pKi		7.1
inactive	9592714	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592715	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592716	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	63.1	CHEMBL2695	Homo sapiens	pKi		7.2
inactive	9592717	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592718	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592719	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592720	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592721	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9592722	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592723	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592724	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592725	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592726	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592727	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592728	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	398.11	CHEMBL2695	Homo sapiens	pKi		6.4
inactive	9592729	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592730	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9592731	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592732	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592733	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592734	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
active	9592735	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
inactive	9592736	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592737	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592738	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592739	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
active	9592740	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9592741	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592742	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1Cl)c1ccccc1F		CHEMBL2001228	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592743	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	39810.72	CHEMBL2695	Homo sapiens	pKi		4.4
inactive	9592744	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592745	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592746	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592747	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOC(=O)Cc1nc2c(N)cccc2[nH]1		CHEMBL1981671	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592748	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592749	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592750	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592751	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592752	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592753	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592754	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592755	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9592756	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592757	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592758	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592759	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592760	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(CNc2nc(Nc3cc(C4CC4)[nH]n3)c3sccc3n2)cc1		CHEMBL1997924	=	Ki	nM	5.012	CHEMBL2695	Homo sapiens	pKi		8.3
inactive	9592761	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592762	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592763	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)c1ccccc1		CHEMBL1978267	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9592764	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1c(NC(=O)Cc2ccccc2)cccc1-c1nc2sccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1		CHEMBL1971485	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592765	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592766	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592767	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592768	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592769	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)CC(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1992334	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592770	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592771	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592772	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592773	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592774	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592775	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	=	Ki	nM	199.53	CHEMBL2695	Homo sapiens	pKi		6.7
active	9592776	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	31622.78	CHEMBL2695	Homo sapiens	pKi		4.5
inactive	9592777	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592778	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592779	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
active	9592780	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9592781	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592782	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4ccccc4)cc[nH]c3=O)nc12		CHEMBL1992527	=	Ki	nM	31.62	CHEMBL2695	Homo sapiens	pKi		7.5
inactive	9592783	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592784	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc2ccncc2s1		CHEMBL1971534	=	Ki	nM	100000.0	CHEMBL2695	Homo sapiens	pKi		4.0
inactive	9592785	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592786	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccccc1N1CCCC1)c1ccc2ccccc2n1		CHEMBL2002799	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592787	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	125.89	CHEMBL2695	Homo sapiens	pKi		6.9
active	9592788	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nc2ncc(-c3ccccc3)cn2n1		CHEMBL2002480	=	Ki	nM	100000.0	CHEMBL2695	Homo sapiens	pKi		4.0
inactive	9592789	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592790	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592791	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592792	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592793	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592794	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
inactive	9592795	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592796	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592797	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	39.81	CHEMBL2695	Homo sapiens	pKi		7.4
inactive	9592798	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592799	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592800	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
active	9592801	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	63095.73	CHEMBL2695	Homo sapiens	pKi		4.2
inactive	9592802	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592803	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592804	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9592805	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592806	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592807	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592808	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NS(=O)(=O)c2ccc(Cl)cc21		CHEMBL1967612	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
inactive	9592809	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592810	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592811	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592812	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	100.0	CHEMBL2695	Homo sapiens	pKi		7.0
inactive	9592813	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592814	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592815	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592816	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	251.19	CHEMBL2695	Homo sapiens	pKi		6.6
inactive	9592817	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592818	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592819	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592820	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(F)cc12		CHEMBL2007603	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592821	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592822	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592823	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592824	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nnc2cncc(Cl)n12		CHEMBL1968130	=	Ki	nM	25118.86	CHEMBL2695	Homo sapiens	pKi		4.6
inactive	9592825	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592826	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592827	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592828	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592829	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	<	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592830	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592831	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592832	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL1972466	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9592833	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCNc1ccc(O)c2ccccc12		CHEMBL576113	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592834	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592835	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592836	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592837	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592838	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	12589.25	CHEMBL2695	Homo sapiens	pKi		4.9
inactive	9592839	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592840	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592841	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592842	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	39810.72	CHEMBL2695	Homo sapiens	pKi		4.4
inactive	9592843	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592844	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)NCCO)cc2)n1		CHEMBL2006149	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592845	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592846	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592847	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592848	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592849	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592850	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592851	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592852	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	158.49	CHEMBL2695	Homo sapiens	pKi		6.8
inactive	9592853	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592854	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592855	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592856	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	398.11	CHEMBL2695	Homo sapiens	pKi		6.4
inactive	9592857	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592858	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	199.53	CHEMBL2695	Homo sapiens	pKi		6.7
active	9592859	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
active	9592860	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
active	9592861	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592862	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9592863	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592864	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592865	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9592866	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592867	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	100.0	CHEMBL2695	Homo sapiens	pKi		7.0
inactive	9592868	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592869	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592870	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592871	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592872	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccccc3Cl)n2)c1		CHEMBL1995428	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9592873	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592874	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592875	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	39810.72	CHEMBL2695	Homo sapiens	pKi		4.4
inactive	9592876	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592877	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9592878	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592879	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592880	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	1.585	CHEMBL2695	Homo sapiens	pKi		8.8
inactive	9592881	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592882	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592883	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592884	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592885	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592886	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592887	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592888	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592889	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592890	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9592891	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592892	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9592893	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592894	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592895	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592896	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592897	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9592898	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592899	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	7.943	CHEMBL2695	Homo sapiens	pKi		8.1
inactive	9592900	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592901	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592902	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9592903	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592904	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592905	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592906	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592907	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9592908	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
active	9592909	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
active	9592910	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	31622.78	CHEMBL2695	Homo sapiens	pKi		4.5
inactive	9592911	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592912	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592913	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592914	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592915	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592916	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592917	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592918	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592919	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592920	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592921	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592922	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592923	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592924	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9592925	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9592926	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9592927	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
active	9592928	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	=	Ki	nM	1.995	CHEMBL2695	Homo sapiens	pKi		8.7
active	9596493	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	=	Ki	nM	31.62	CHEMBL2695	Homo sapiens	pKi		7.5
inactive	9596494	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596495	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596496	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596497	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596498	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Ki	nM	100.0	CHEMBL2695	Homo sapiens	pKi		7.0
inactive	9596499	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596500	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596501	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COC(=O)c1c(N)nc2ccccn12		CHEMBL1981492	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
active	9596502	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596503	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596504	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596505	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596506	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596507	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596508	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596509	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596510	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596511	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596512	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596513	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596514	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
inactive	9596515	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596516	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596517	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596518	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOCC(C)Oc1cccc2[nH]nc(N)c12		CHEMBL2002736	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596519	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9596520	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596521	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596522	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596523	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596524	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
active	9596525	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	251.19	CHEMBL2695	Homo sapiens	pKi		6.6
active	9596526	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	39.81	CHEMBL2695	Homo sapiens	pKi		7.4
inactive	9596527	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4c(F)cccc4F)c3)nc3sccn23)n1		CHEMBL1997051	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
active	9596528	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
inactive	9596529	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596530	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596531	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596532	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596533	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596534	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596535	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596536	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596537	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596538	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(-c2ccnc3[nH]ccc23)cc1		CHEMBL482538	=	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596539	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596540	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9596541	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596542	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC1=CN2CC(=O)NN=C2C=C1		CHEMBL1964718	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
inactive	9596543	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596544	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9596545	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596546	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596547	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596548	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596549	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596550	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596551	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596552	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9596553	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(NC(=O)CC2Nc3ccccc3NC2=O)cc1		CHEMBL1985469	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596554	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596555	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596556	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CCc1cccc(Nc2nccc(-c3c(-c4cccc(NC(=O)Cc5ccccc5)c4)nc4sccn34)n2)c1		CHEMBL1090363	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596557	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	0.631	CHEMBL2695	Homo sapiens	pKi		9.2
inactive	9596558	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596559	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
active	9596560	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	251.19	CHEMBL2695	Homo sapiens	pKi		6.6
inactive	9596561	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596562	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596563	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596564	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596565	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596566	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596567	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596568	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	=	Ki	nM	199.53	CHEMBL2695	Homo sapiens	pKi		6.7
inactive	9596569	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596570	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596571	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
active	9596572	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9596573	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9596574	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596575	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596576	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	125.89	CHEMBL2695	Homo sapiens	pKi		6.9
active	9596577	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	6.31	CHEMBL2695	Homo sapiens	pKi		8.2
active	9596578	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(C2CCc3[nH]ncc3C2)cc1		CHEMBL2000879	=	Ki	nM	50118.72	CHEMBL2695	Homo sapiens	pKi		4.3
inactive	9596579	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596580	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL1969483	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596581	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
active	9596582	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	=	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596583	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596584	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596585	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596586	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9596587	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596588	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596589	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
active	9596590	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9596591	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ccc2c(C(=O)O)n(-c3ccccc3)nc2c1		CHEMBL1974574	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596592	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596593	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596594	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596595	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
active	9596596	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9596597	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596598	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596599	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	63.1	CHEMBL2695	Homo sapiens	pKi		7.2
inactive	9596600	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596601	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596602	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(N)c2ccccc12		CHEMBL1998253	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596603	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596604	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596605	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596606	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596607	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
active	9596608	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
inactive	9596609	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596610	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596611	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9596612	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596613	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL2000078	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596614	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596615	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596616	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596617	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596618	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596619	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596620	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccccc1)Nc1cc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)ccc1Cl		CHEMBL2005482	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
active	9596621	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596622	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596623	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1997909	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596624	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596625	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596626	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
active	9596627	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596628	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	=	Ki	nM	398.11	CHEMBL2695	Homo sapiens	pKi		6.4
inactive	9596629	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2002660	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596630	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
active	9596631	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
active	9596632	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596633	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596634	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9596635	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596636	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596637	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1cc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)cc2)ccc1NC1CCCCC1		CHEMBL1996795	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596638	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596639	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596640	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596641	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596642	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
active	9596643	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
active	9596644	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
active	9596645	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	=	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9596646	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596647	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9596648	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596649	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1c2cc(N)ccc2-c2ccc(N)cc2C1(O)c1ccccc1		CHEMBL1991818	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596650	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9596651	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596652	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596653	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596654	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1ccc2c(c1)nnc1nnnn12		CHEMBL1986503	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596655	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9596656	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596657	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
inactive	9596658	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596659	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	50118.72	CHEMBL2695	Homo sapiens	pKi		4.3
inactive	9596660	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596661	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596662	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596663	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596664	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596665	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	251.19	CHEMBL2695	Homo sapiens	pKi		6.6
inactive	9596666	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596667	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596668	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596669	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596670	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596671	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596672	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596673	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596674	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596675	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596676	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596677	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596678	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9596679	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596680	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)c1ccccc1-c1ncnc2[nH]ccc12		CHEMBL1977931	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
inactive	9596681	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596682	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596683	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596684	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596685	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596686	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596687	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	63.1	CHEMBL2695	Homo sapiens	pKi		7.2
inactive	9596688	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596689	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596690	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	79432.82	CHEMBL2695	Homo sapiens	pKi		4.1
inactive	9596691	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596692	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596693	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596694	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596695	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596696	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596697	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596698	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596699	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596700	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596701	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596702	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1CN2C(=NN1)COc1ccccc12		CHEMBL1968515	=	Ki	nM	100000.0	CHEMBL2695	Homo sapiens	pKi		4.0
active	9596703	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Ki	nM	12.59	CHEMBL2695	Homo sapiens	pKi		7.9
inactive	9596704	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596705	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596706	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596707	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596708	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596709	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(=O)Nc2cccc(-c3nc4sccn4c3-c3ccnc(Nc4ccc(N5CCOCC5)cc4)n3)c2)c1		CHEMBL1987104	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
active	9596710	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9596711	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596712	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596713	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9596714	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)Nc1ccc(-n2nc3ccc(N)nc3n2)cc1		CHEMBL2002723	=	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
inactive	9596715	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596716	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596717	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596718	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596719	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596720	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596721	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596722	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596723	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596724	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9596725	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	=	Ki	nM	100.0	CHEMBL2695	Homo sapiens	pKi		7.0
inactive	9596726	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	<	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9596727	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9596728	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9596729	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9596730	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600295	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600296	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600297	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600298	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9600299	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600300	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9600301	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600302	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600303	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	=	Ki	nM	630.96	CHEMBL2695	Homo sapiens	pKi		6.2
inactive	9600304	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600305	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600306	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9600307	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600308	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4ccccc4)c3)nc3sccn23)n1		CHEMBL1988076	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600309	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600310	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600311	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600312	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600313	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9600314	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600315	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600316	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600317	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600318	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600319	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600320	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600321	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600322	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600323	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600324	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600325	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600326	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
inactive	9600327	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600328	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(OCc2cccc(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1966501	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600329	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	2.512	CHEMBL2695	Homo sapiens	pKi		8.6
inactive	9600330	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600331	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CCCCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2001451	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600332	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600333	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600334	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600335	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600336	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600337	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600338	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600339	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600340	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600341	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600342	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	=	Ki	nM	25118.86	CHEMBL2695	Homo sapiens	pKi		4.6
active	9600343	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	12589.25	CHEMBL2695	Homo sapiens	pKi		4.9
inactive	9600344	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600345	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600346	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600347	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600348	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600349	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
inactive	9600350	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600351	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	1258.93	CHEMBL2695	Homo sapiens	pKi		5.9
inactive	9600352	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600353	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1		CHEMBL2003689	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600354	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600355	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600356	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600357	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600358	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Ki	nM	125.89	CHEMBL2695	Homo sapiens	pKi		6.9
inactive	9600359	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600360	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600361	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9600362	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600363	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(CCC#N)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1974998	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600364	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600365	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600366	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600367	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	<	Ki	nM	3981.07	CHEMBL2695	Homo sapiens	pKi		5.4
active	9600368	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	25.12	CHEMBL2695	Homo sapiens	pKi		7.6
inactive	9600369	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600370	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600371	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	316.23	CHEMBL2695	Homo sapiens	pKi		6.5
inactive	9600372	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600373	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600374	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	63.1	CHEMBL2695	Homo sapiens	pKi		7.2
inactive	9600375	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600376	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600377	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600378	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ccccc4)cc[nH]c3=O)nc12		CHEMBL2005714	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600379	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600380	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600381	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600382	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600383	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600384	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	25.12	CHEMBL2695	Homo sapiens	pKi		7.6
inactive	9600385	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600386	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600387	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600388	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600389	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600390	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600391	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600392	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600393	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600394	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600395	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9600396	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600397	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	398.11	CHEMBL2695	Homo sapiens	pKi		6.4
inactive	9600398	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600399	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	39810.72	CHEMBL2695	Homo sapiens	pKi		4.4
inactive	9600400	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600401	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	=	Ki	nM	1995.26	CHEMBL2695	Homo sapiens	pKi		5.7
inactive	9600402	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600403	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600404	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600405	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCO)c2)n1		CHEMBL2007073	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600406	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600407	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600408	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	5011.87	CHEMBL2695	Homo sapiens	pKi		5.3
active	9600409	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	=	Ki	nM	25118.86	CHEMBL2695	Homo sapiens	pKi		4.6
inactive	9600410	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600411	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600412	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600413	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600414	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	3162.28	CHEMBL2695	Homo sapiens	pKi		5.5
inactive	9600415	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600416	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600417	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600418	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600419	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600420	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600421	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)Nc1ccc(Nc2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1988872	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600422	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)N(CCN)CCO)c2)n1		CHEMBL1993634	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600423	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600424	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	=	Ki	nM	794.33	CHEMBL2695	Homo sapiens	pKi		6.1
inactive	9600425	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600426	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600427	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600428	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600429	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600430	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600431	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600432	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600433	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600434	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	25118.86	CHEMBL2695	Homo sapiens	pKi		4.6
inactive	9600435	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1c(NC(=O)c2c(F)cccc2F)cccc1-c1nc2sccn2c1-c1ccnc(Nc2cccc(N3CCOCC3)c2)n1		CHEMBL1992473	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600436	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	=	Ki	nM	2511.89	CHEMBL2695	Homo sapiens	pKi		5.6
active	9600437	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	=	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600438	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600439	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600440	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1		CHEMBL1999506	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600441	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	199.53	CHEMBL2695	Homo sapiens	pKi		6.7
inactive	9600442	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600443	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600444	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600445	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600446	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600447	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600448	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Ki	nM	501.19	CHEMBL2695	Homo sapiens	pKi		6.3
inactive	9600449	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600450	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600451	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600452	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600453	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600454	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
inactive	9600455	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600456	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	158.49	CHEMBL2695	Homo sapiens	pKi		6.8
inactive	9600457	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600458	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600459	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600460	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600461	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600462	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600463	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600464	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600465	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600466	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	125.89	CHEMBL2695	Homo sapiens	pKi		6.9
active	9600467	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	79.43	CHEMBL2695	Homo sapiens	pKi		7.1
inactive	9600468	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
inactive	9600469	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600470	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	=	Ki	nM	1000.0	CHEMBL2695	Homo sapiens	pKi		6.0
inactive	9600471	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600472	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	=	Ki	nM	25.12	CHEMBL2695	Homo sapiens	pKi		7.6
inactive	9600473	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cccc(Cl)c2)cc1		CHEMBL1968606	<	Ki	nM	6309.57	CHEMBL2695	Homo sapiens	pKi		5.2
active	9600474	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	3.162	CHEMBL2695	Homo sapiens	pKi		8.5
inactive	9600475	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	<	Ki	nM	1584.89	CHEMBL2695	Homo sapiens	pKi		5.8
active	9600476	CHEMBL1963801	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	12.59	CHEMBL2695	Homo sapiens	pKi		7.9
	10838579	CHEMBL2014152	Inhibition of FAK at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	10850052	CHEMBL2019774	Inhibition of human FAK at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
Active	10857319	CHEMBL2021163	Inhibition of FAK in human MCF7 cells at 2 to 8 uM by Western blot analysis	B	O=C(Nc1nnc(-c2ccc(Cl)cc2)s1)c1cc(Cl)ccc1O		CHEMBL2017910		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10896862	CHEMBL2039236	Inhibition of FAK at 3 uM	B	C=CC(=O)NCc1coc(-c2c(N)ncnc2Nc2ccc(OCc3ccccn3)c(Cl)c2)n1		CHEMBL2035810	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	10896880	CHEMBL2039254	Inhibition of FAK	B	C=CC(=O)NCc1coc(-c2c(N)ncnc2Nc2ccc(OCc3ccccn3)c(Cl)c2)n1		CHEMBL2035810	>	IC50	nM	3000.0	CHEMBL2695	Homo sapiens	IC50	uM	3.0
	10912551	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(=O)c2ccc(-c3nc4ccccc4n3C)nc2n(C)c1=O		CHEMBL2036871	=	IC50	nM	92000.0	CHEMBL2695	Homo sapiens	IC50	uM	92.0
Not Active	10912556	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(=O)c2ccc(-c3nc4ccccc4n3C)nc2n(C)c1=O		CHEMBL2036871		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10912567	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2NC(=O)C3)cc1O		CHEMBL603463	=	IC50	nM	640.0	CHEMBL2695	Homo sapiens	IC50	uM	0.64
	10913461	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccccc3)n2)nc2ccccc21		CHEMBL2036725	=	IC50	nM	38000.0	CHEMBL2695	Homo sapiens	IC50	uM	38.0
Not Active	10913466	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccccc3)n2)nc2ccccc21		CHEMBL2036725		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913477	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036726	=	IC50	nM	58000.0	CHEMBL2695	Homo sapiens	IC50	uM	58.0
Not Active	10913482	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036726		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913493	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(Cl)cc3)n2)nc2ccccc21		CHEMBL2036727	=	IC50	nM	69000.0	CHEMBL2695	Homo sapiens	IC50	uM	69.0
Not Active	10913498	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(Cl)cc3)n2)nc2ccccc21		CHEMBL2036727		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913509	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc2ccccc21		CHEMBL2036728	=	IC50	nM	24000.0	CHEMBL2695	Homo sapiens	IC50	uM	24.0
Not Active	10913514	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc2ccccc21		CHEMBL2036728		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913525	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CCOc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036867	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
Not Active	10913530	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	CCOc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036867		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913541	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036868	=	IC50	nM	27000.0	CHEMBL2695	Homo sapiens	IC50	uM	27.0
Not Active	10913546	CHEMBL2038039	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036868		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	10913557	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(O)cc3)n2)nc2ccccc21		CHEMBL2036869	=	IC50	nM	11400.0	CHEMBL2695	Homo sapiens	IC50	uM	11.4
	10913562	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3cccc(O)c3)n2)nc2ccccc21		CHEMBL2036870	=	IC50	nM	5200.0	CHEMBL2695	Homo sapiens	IC50	uM	5.2
	10913567	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(O)c(Cl)c3)n2)nc2ccccc21		CHEMBL2036865	=	IC50	nM	10400.0	CHEMBL2695	Homo sapiens	IC50	uM	10.4
	10913572	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1O		CHEMBL2036866	=	IC50	nM	3400.0	CHEMBL2695	Homo sapiens	IC50	uM	3.4
	10913587	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1		CHEMBL1200485	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	10913602	CHEMBL2038024	Inhibition of recombinant FAK using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	IC50	nM	1600.0	CHEMBL2695	Homo sapiens	IC50	uM	1.6
	10921358	CHEMBL2046156	Inhibition of FAK at 1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	99.0	CHEMBL2695	Homo sapiens	INH	%	99.0
	10921359	CHEMBL2046157	Inhibition of FAK at 0.1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	72.0	CHEMBL2695	Homo sapiens	INH	%	72.0
	10934986	CHEMBL2051522	Inhibition of PTK2 at 10 uM	B	O=C(Nc1ccc(Oc2ccnc(-c3ncc(C(F)(F)F)[nH]3)c2)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL2047981	=	Inhibition	%	4.9	CHEMBL2695	Homo sapiens	INH	%	4.9
	10949935	CHEMBL2049467	Inhibition of FAK using ATP measured after 60 mins	B	CC(C)(N)C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21		CHEMBL2048912	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	10981542	CHEMBL2067604	Inhibition of human FAK at 1 uM	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	>=	Inhibition	%	90.0	CHEMBL2695	Homo sapiens	INH	%	90.0
	10981557	CHEMBL2067589	Inhibition of human FAK	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	=	IC50	nM	133.0	CHEMBL2695	Homo sapiens	IC50	nM	133.0
	10984741	CHEMBL2072037	Inhibition of human FAK at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	10993511	CHEMBL2073244	Inhibition of FAK at 10 uM	B	ClC(Cn1ncc2c(NCc3ccccc3)ncnc21)c1ccccc1		CHEMBL411043	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
Dose-dependent effect	11014448	CHEMBL2089629	Inhibition of FAK phosphorylation in human MDA-MB-231 cells after 12 hrs by Western blot analysis	B	COc1cc(O)c2c(c1)oc(=O)c1c3cc(O)c(O)cc3oc21		CHEMBL97453		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	11014449	CHEMBL2089629	Inhibition of FAK phosphorylation in human MDA-MB-231 cells after 12 hrs by Western blot analysis	B	O=c1oc2cc(O)cc(O)c2c2oc3cc(O)c(O)cc3c12		CHEMBL2089002		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	11016429	CHEMBL2092103	Inhibition of FAK at 1 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016430	CHEMBL2092103	Inhibition of FAK at 1 uM	B	Cc1nc(N)ncc1-c1cn2cc(CN3CCN(S(C)(=O)=O)CC3)nc2c(N2CCOCC2)n1		CHEMBL2087480	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016431	CHEMBL2092103	Inhibition of FAK at 1 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1		CHEMBL2087491	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016432	CHEMBL2092103	Inhibition of FAK at 1 uM	B	Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12		CHEMBL2087492	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016433	CHEMBL2092103	Inhibition of FAK at 1 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087493	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016978	CHEMBL2092420	Inhibition of FAK at 5 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016979	CHEMBL2092420	Inhibition of FAK at 5 uM	B	Cc1nc(N)ncc1-c1cn2cc(CN3CCN(S(C)(=O)=O)CC3)nc2c(N2CCOCC2)n1		CHEMBL2087480	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016980	CHEMBL2092420	Inhibition of FAK at 5 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1		CHEMBL2087491	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016981	CHEMBL2092420	Inhibition of FAK at 5 uM	B	Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12		CHEMBL2087492	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	11016982	CHEMBL2092420	Inhibition of FAK at 5 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087493	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	12036429	CHEMBL2150264	Inhibition of full length N-terminal FLAG-tagged FAK expressed in baculovirus after 5 mins	B	CC(C)(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(Cl)c4)c(Cl)c3)c21)S(C)(=O)=O.Cc1ccc(S(=O)(=O)O)cc1		CHEMBL2148053	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12046300	CHEMBL2156630	Inhibition of FAK at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
Not Active	12047552	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3Cl)cc1CC2		CHEMBL2152781		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048343	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3C(F)(F)F)cc1CC2		CHEMBL2152782		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048358	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3Cl)cc1CC2		CHEMBL2152785		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048373	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3C)cc1CC2		CHEMBL2152786		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048388	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(C(F)(F)F)cc3N)cc1CC2		CHEMBL2152787		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048403	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)c(C)c3)cc1CC2		CHEMBL2152788		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048418	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3cc(F)cc(F)c3F)cc1CC2		CHEMBL2152789		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048433	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(-c3ccccc3)cc1CC2		CHEMBL2152791		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048448	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1ccc2ccc3cc(Nc4ccc(F)cc4F)ccc3c(=O)c2c1		CHEMBL2152792		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048463	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccccc4N)cc2CC3)O1		CHEMBL2152798		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048478	CHEMBL2155706	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1ccc(OC[C@H](O)CO)cc1C2=O		CHEMBL2152936		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048493	CHEMBL2155706	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(=O)c3cc(OCCN4CCOCC4)ccc3ccc2c1		CHEMBL2152939		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048508	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCO)cc21		CHEMBL2152940		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048523	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCO)cc21		CHEMBL2152941		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048538	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC3CCOCC3)cc21		CHEMBL2152942		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048553	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152943		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048568	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@@H](O)CO)cc21		CHEMBL2152946		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048583	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@@H](CCOc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152947		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048598	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCN3CCOCC3)cc21		CHEMBL2152950		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048613	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152957		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048628	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@H](O)CO)ccc21		CHEMBL2152958		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048643	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152959		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048658	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@@H](O)CO)ccc21		CHEMBL2152960		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12048673	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccc(F)cc3F)ccc1C2=O		CHEMBL2152965		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049617	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(O)cccc21		CHEMBL2152966		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049632	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c1cccc2C1CCOCC1		CHEMBL2152967		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049647	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152968		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049662	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OC[C@H](O)CO)cccc21		CHEMBL2152969		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049677	CHEMBL2155706	Inhibition of FAK at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OCCN3CCOCC3)cccc21		CHEMBL2152970		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049692	CHEMBL2155706	Inhibition of FAK at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccccc3N)ccc1C2=O		CHEMBL2152971		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049707	CHEMBL2155706	Inhibition of FAK at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccccc4N)ccc2C3=O)O1		CHEMBL2152972		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	12049722	CHEMBL2155706	Inhibition of FAK at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1c(OC[C@H](O)CO)cccc1C2=O		CHEMBL2152973		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	12051570	CHEMBL2154710	Inhibition of FAK	B	CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL2151321	=	IC50	nM	17.2	CHEMBL2695	Homo sapiens	IC50	nM	17.2
	12051592	CHEMBL2154971	Inhibition of FAK at 10 uM	B	CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL2151321	>	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	12060924	CHEMBL2157042	Binding affinity to FAK at 1 uM by high throughput binding assay relative to control	B	Nc1cc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)c1		CHEMBL2152288	=	Activity	%	88.0	CHEMBL2695	Homo sapiens	Activity	%	88.0
	12173617	CHEMBL2213993	Inhibition of FAK assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	63.0	CHEMBL2695	Homo sapiens	Activity	%	63.0
	12183824	CHEMBL2214436	Inhibition of PTK2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	pIC50		5.0
	12197189	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)NC(C)C)[nH]c23)cc1		CHEMBL2207427	=	IC50	nM	7860.0	CHEMBL2695	Homo sapiens	IC50	nM	7860.0
	12197191	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)c(C)c1		CHEMBL2207431	=	IC50	nM	4770.0	CHEMBL2695	Homo sapiens	IC50	nM	4770.0
	12197198	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4ncccc4c3)[nH]n2)cc1		CHEMBL2207440	=	IC50	nM	608.0	CHEMBL2695	Homo sapiens	IC50	nM	608.0
	12197203	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4nccnc4c3)[nH]n2)cc1		CHEMBL2207441	=	IC50	nM	473.0	CHEMBL2695	Homo sapiens	IC50	nM	473.0
	12197229	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(COc3cccnc3)n[nH]2)cc1		CHEMBL1084269	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12197230	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)nc1		CHEMBL2207432	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12197231	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	CCOCCCNC(=O)c1cc2cccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)c2[nH]1		CHEMBL2207430	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12197232	CHEMBL2209546	Inhibition of FAK after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)N(C)CCc4ccccn4)[nH]c23)cc1		CHEMBL2207429	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12239359	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	149.0	CHEMBL2695	Homo sapiens	Residual Activity	%	149.0
	12239360	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	122.0	CHEMBL2695	Homo sapiens	Residual Activity	%	122.0
	12239361	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	130.0	CHEMBL2695	Homo sapiens	Residual Activity	%	130.0
	12239362	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	127.0	CHEMBL2695	Homo sapiens	Residual Activity	%	127.0
	12239363	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	107.0	CHEMBL2695	Homo sapiens	Residual Activity	%	107.0
	12239364	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	137.0	CHEMBL2695	Homo sapiens	Residual Activity	%	137.0
	12239365	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	103.0	CHEMBL2695	Homo sapiens	Residual Activity	%	103.0
	12239366	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	146.0	CHEMBL2695	Homo sapiens	Residual Activity	%	146.0
	12239367	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	80.0	CHEMBL2695	Homo sapiens	Residual Activity	%	80.0
	12239368	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	82.0	CHEMBL2695	Homo sapiens	Residual Activity	%	82.0
	12239369	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	133.0	CHEMBL2695	Homo sapiens	Residual Activity	%	133.0
	12239370	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	131.0	CHEMBL2695	Homo sapiens	Residual Activity	%	131.0
	12239371	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	131.0	CHEMBL2695	Homo sapiens	Residual Activity	%	131.0
	12239372	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	122.0	CHEMBL2695	Homo sapiens	Residual Activity	%	122.0
	12239373	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	64.0	CHEMBL2695	Homo sapiens	Residual Activity	%	64.0
	12239374	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	133.0	CHEMBL2695	Homo sapiens	Residual Activity	%	133.0
	12239375	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	144.0	CHEMBL2695	Homo sapiens	Residual Activity	%	144.0
	12239376	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	140.0	CHEMBL2695	Homo sapiens	Residual Activity	%	140.0
	12239377	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	119.0	CHEMBL2695	Homo sapiens	Residual Activity	%	119.0
	12239378	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	51.0	CHEMBL2695	Homo sapiens	Residual Activity	%	51.0
	12239379	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	124.0	CHEMBL2695	Homo sapiens	Residual Activity	%	124.0
	12239380	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	137.0	CHEMBL2695	Homo sapiens	Residual Activity	%	137.0
	12239381	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	141.0	CHEMBL2695	Homo sapiens	Residual Activity	%	141.0
	12239382	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	143.0	CHEMBL2695	Homo sapiens	Residual Activity	%	143.0
	12239383	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	148.0	CHEMBL2695	Homo sapiens	Residual Activity	%	148.0
	12239384	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	139.0	CHEMBL2695	Homo sapiens	Residual Activity	%	139.0
	12239385	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12239386	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	106.0	CHEMBL2695	Homo sapiens	Residual Activity	%	106.0
	12239387	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	108.0	CHEMBL2695	Homo sapiens	Residual Activity	%	108.0
	12239388	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	119.0	CHEMBL2695	Homo sapiens	Residual Activity	%	119.0
	12239389	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	120.0	CHEMBL2695	Homo sapiens	Residual Activity	%	120.0
	12239390	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239391	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	143.0	CHEMBL2695	Homo sapiens	Residual Activity	%	143.0
	12239392	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	132.0	CHEMBL2695	Homo sapiens	Residual Activity	%	132.0
	12239393	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12239394	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239395	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239396	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	118.0	CHEMBL2695	Homo sapiens	Residual Activity	%	118.0
	12239397	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	120.0	CHEMBL2695	Homo sapiens	Residual Activity	%	120.0
	12239398	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	78.0	CHEMBL2695	Homo sapiens	Residual Activity	%	78.0
	12239399	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	144.0	CHEMBL2695	Homo sapiens	Residual Activity	%	144.0
	12239400	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	120.0	CHEMBL2695	Homo sapiens	Residual Activity	%	120.0
	12239401	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	33.0	CHEMBL2695	Homo sapiens	Residual Activity	%	33.0
	12239402	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12239403	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	106.0	CHEMBL2695	Homo sapiens	Residual Activity	%	106.0
	12239404	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	116.0	CHEMBL2695	Homo sapiens	Residual Activity	%	116.0
	12239405	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	124.0	CHEMBL2695	Homo sapiens	Residual Activity	%	124.0
	12239406	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	52.0	CHEMBL2695	Homo sapiens	Residual Activity	%	52.0
	12239407	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12239408	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	144.0	CHEMBL2695	Homo sapiens	Residual Activity	%	144.0
	12239409	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239410	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	116.0	CHEMBL2695	Homo sapiens	Residual Activity	%	116.0
	12239411	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	73.0	CHEMBL2695	Homo sapiens	Residual Activity	%	73.0
	12239412	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12239413	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	127.0	CHEMBL2695	Homo sapiens	Residual Activity	%	127.0
	12239414	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	141.0	CHEMBL2695	Homo sapiens	Residual Activity	%	141.0
	12239415	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	142.0	CHEMBL2695	Homo sapiens	Residual Activity	%	142.0
	12239416	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	135.0	CHEMBL2695	Homo sapiens	Residual Activity	%	135.0
	12239417	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	122.0	CHEMBL2695	Homo sapiens	Residual Activity	%	122.0
	12239418	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	117.0	CHEMBL2695	Homo sapiens	Residual Activity	%	117.0
	12239419	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12239420	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12239421	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	132.0	CHEMBL2695	Homo sapiens	Residual Activity	%	132.0
	12239422	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	139.0	CHEMBL2695	Homo sapiens	Residual Activity	%	139.0
	12239423	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	147.0	CHEMBL2695	Homo sapiens	Residual Activity	%	147.0
	12239424	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	82.0	CHEMBL2695	Homo sapiens	Residual Activity	%	82.0
	12239425	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	110.0	CHEMBL2695	Homo sapiens	Residual Activity	%	110.0
	12239426	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239427	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12239428	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	72.0	CHEMBL2695	Homo sapiens	Residual Activity	%	72.0
	12239429	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	117.0	CHEMBL2695	Homo sapiens	Residual Activity	%	117.0
	12239430	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	51.0	CHEMBL2695	Homo sapiens	Residual Activity	%	51.0
	12239431	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	133.0	CHEMBL2695	Homo sapiens	Residual Activity	%	133.0
	12239432	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	136.0	CHEMBL2695	Homo sapiens	Residual Activity	%	136.0
	12239433	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	132.0	CHEMBL2695	Homo sapiens	Residual Activity	%	132.0
	12239434	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	129.0	CHEMBL2695	Homo sapiens	Residual Activity	%	129.0
	12239435	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12239436	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	15.0	CHEMBL2695	Homo sapiens	Residual Activity	%	15.0
	12239437	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	139.0	CHEMBL2695	Homo sapiens	Residual Activity	%	139.0
	12239438	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	3.0	CHEMBL2695	Homo sapiens	Residual Activity	%	3.0
	12239439	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	119.0	CHEMBL2695	Homo sapiens	Residual Activity	%	119.0
	12239440	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12239441	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12239442	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	104.0	CHEMBL2695	Homo sapiens	Residual Activity	%	104.0
	12239443	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	21.0	CHEMBL2695	Homo sapiens	Residual Activity	%	21.0
	12239444	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239445	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	119.0	CHEMBL2695	Homo sapiens	Residual Activity	%	119.0
	12239446	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	125.0	CHEMBL2695	Homo sapiens	Residual Activity	%	125.0
	12239447	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	109.0	CHEMBL2695	Homo sapiens	Residual Activity	%	109.0
	12239448	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	39.0	CHEMBL2695	Homo sapiens	Residual Activity	%	39.0
	12239449	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12239450	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239451	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	36.0	CHEMBL2695	Homo sapiens	Residual Activity	%	36.0
	12239452	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	73.0	CHEMBL2695	Homo sapiens	Residual Activity	%	73.0
	12239453	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12239454	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	110.0	CHEMBL2695	Homo sapiens	Residual Activity	%	110.0
	12239455	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	111.0	CHEMBL2695	Homo sapiens	Residual Activity	%	111.0
	12239456	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239457	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239458	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12239459	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	57.0	CHEMBL2695	Homo sapiens	Residual Activity	%	57.0
	12239460	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	39.0	CHEMBL2695	Homo sapiens	Residual Activity	%	39.0
	12239461	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12239462	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239463	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	86.0	CHEMBL2695	Homo sapiens	Residual Activity	%	86.0
	12239464	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	97.0	CHEMBL2695	Homo sapiens	Residual Activity	%	97.0
	12239465	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239466	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239467	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12239468	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	82.0	CHEMBL2695	Homo sapiens	Residual Activity	%	82.0
	12239469	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	107.0	CHEMBL2695	Homo sapiens	Residual Activity	%	107.0
	12239470	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	111.0	CHEMBL2695	Homo sapiens	Residual Activity	%	111.0
	12239471	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	50.0	CHEMBL2695	Homo sapiens	Residual Activity	%	50.0
	12239472	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12239473	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12239474	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239475	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	68.0	CHEMBL2695	Homo sapiens	Residual Activity	%	68.0
	12239476	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12239477	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	103.0	CHEMBL2695	Homo sapiens	Residual Activity	%	103.0
	12239478	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	118.0	CHEMBL2695	Homo sapiens	Residual Activity	%	118.0
	12239479	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	76.0	CHEMBL2695	Homo sapiens	Residual Activity	%	76.0
	12239480	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	53.0	CHEMBL2695	Homo sapiens	Residual Activity	%	53.0
	12239481	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	46.0	CHEMBL2695	Homo sapiens	Residual Activity	%	46.0
	12239482	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239483	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	16.0	CHEMBL2695	Homo sapiens	Residual Activity	%	16.0
	12239484	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12239485	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	65.0	CHEMBL2695	Homo sapiens	Residual Activity	%	65.0
	12239486	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	108.0	CHEMBL2695	Homo sapiens	Residual Activity	%	108.0
	12239487	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	67.0	CHEMBL2695	Homo sapiens	Residual Activity	%	67.0
	12239488	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	20.0	CHEMBL2695	Homo sapiens	Residual Activity	%	20.0
	12239489	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12239490	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12239491	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	52.0	CHEMBL2695	Homo sapiens	Residual Activity	%	52.0
	12239492	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12239493	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12239494	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	42.0	CHEMBL2695	Homo sapiens	Residual Activity	%	42.0
	12239495	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	97.0	CHEMBL2695	Homo sapiens	Residual Activity	%	97.0
	12239496	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	72.0	CHEMBL2695	Homo sapiens	Residual Activity	%	72.0
	12239497	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	59.0	CHEMBL2695	Homo sapiens	Residual Activity	%	59.0
	12239498	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239499	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	99.0	CHEMBL2695	Homo sapiens	Residual Activity	%	99.0
	12239500	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12239501	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12239502	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	123.0	CHEMBL2695	Homo sapiens	Residual Activity	%	123.0
	12239503	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12239504	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	109.0	CHEMBL2695	Homo sapiens	Residual Activity	%	109.0
	12239505	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239506	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	100.0	CHEMBL2695	Homo sapiens	Residual Activity	%	100.0
	12239507	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	109.0	CHEMBL2695	Homo sapiens	Residual Activity	%	109.0
	12239508	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12239509	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	99.0	CHEMBL2695	Homo sapiens	Residual Activity	%	99.0
	12239510	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12239511	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	110.0	CHEMBL2695	Homo sapiens	Residual Activity	%	110.0
	12239512	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12239513	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	109.0	CHEMBL2695	Homo sapiens	Residual Activity	%	109.0
	12239514	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	106.0	CHEMBL2695	Homo sapiens	Residual Activity	%	106.0
	12239515	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	117.0	CHEMBL2695	Homo sapiens	Residual Activity	%	117.0
	12239516	CHEMBL2219060	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	111.0	CHEMBL2695	Homo sapiens	Residual Activity	%	111.0
	12239517	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	104.0	CHEMBL2695	Homo sapiens	Residual Activity	%	104.0
	12239518	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	44.0	CHEMBL2695	Homo sapiens	Residual Activity	%	44.0
	12239519	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	79.0	CHEMBL2695	Homo sapiens	Residual Activity	%	79.0
	12239520	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	64.0	CHEMBL2695	Homo sapiens	Residual Activity	%	64.0
	12239521	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	82.0	CHEMBL2695	Homo sapiens	Residual Activity	%	82.0
	12239522	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12239523	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	42.0	CHEMBL2695	Homo sapiens	Residual Activity	%	42.0
	12239524	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	103.0	CHEMBL2695	Homo sapiens	Residual Activity	%	103.0
	12239525	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	105.0	CHEMBL2695	Homo sapiens	Residual Activity	%	105.0
	12239526	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12242122	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	99.0	CHEMBL2695	Homo sapiens	Residual Activity	%	99.0
	12242123	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12242124	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242125	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	81.0	CHEMBL2695	Homo sapiens	Residual Activity	%	81.0
	12242126	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	7.0	CHEMBL2695	Homo sapiens	Residual Activity	%	7.0
	12242127	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	89.0	CHEMBL2695	Homo sapiens	Residual Activity	%	89.0
	12242128	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	80.0	CHEMBL2695	Homo sapiens	Residual Activity	%	80.0
	12242129	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12242130	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	78.0	CHEMBL2695	Homo sapiens	Residual Activity	%	78.0
	12242131	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	9.0	CHEMBL2695	Homo sapiens	Residual Activity	%	9.0
	12242132	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	79.0	CHEMBL2695	Homo sapiens	Residual Activity	%	79.0
	12242133	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	89.0	CHEMBL2695	Homo sapiens	Residual Activity	%	89.0
	12242134	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	72.0	CHEMBL2695	Homo sapiens	Residual Activity	%	72.0
	12242135	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	73.0	CHEMBL2695	Homo sapiens	Residual Activity	%	73.0
	12242136	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12242137	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	79.0	CHEMBL2695	Homo sapiens	Residual Activity	%	79.0
	12242138	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	65.0	CHEMBL2695	Homo sapiens	Residual Activity	%	65.0
	12242139	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	64.0	CHEMBL2695	Homo sapiens	Residual Activity	%	64.0
	12242140	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	76.0	CHEMBL2695	Homo sapiens	Residual Activity	%	76.0
	12242141	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	71.0	CHEMBL2695	Homo sapiens	Residual Activity	%	71.0
	12242142	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	86.0	CHEMBL2695	Homo sapiens	Residual Activity	%	86.0
	12242143	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	35.0	CHEMBL2695	Homo sapiens	Residual Activity	%	35.0
	12242144	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12242145	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12242146	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	86.0	CHEMBL2695	Homo sapiens	Residual Activity	%	86.0
	12242147	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	85.0	CHEMBL2695	Homo sapiens	Residual Activity	%	85.0
	12242148	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	79.0	CHEMBL2695	Homo sapiens	Residual Activity	%	79.0
	12242149	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	83.0	CHEMBL2695	Homo sapiens	Residual Activity	%	83.0
	12242150	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242151	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	58.0	CHEMBL2695	Homo sapiens	Residual Activity	%	58.0
	12242152	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	108.0	CHEMBL2695	Homo sapiens	Residual Activity	%	108.0
	12242153	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	94.0	CHEMBL2695	Homo sapiens	Residual Activity	%	94.0
	12242154	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	17.0	CHEMBL2695	Homo sapiens	Residual Activity	%	17.0
	12242155	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	34.0	CHEMBL2695	Homo sapiens	Residual Activity	%	34.0
	12242156	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	66.0	CHEMBL2695	Homo sapiens	Residual Activity	%	66.0
	12242157	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	65.0	CHEMBL2695	Homo sapiens	Residual Activity	%	65.0
	12242158	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12242159	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	9.0	CHEMBL2695	Homo sapiens	Residual Activity	%	9.0
	12242160	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12242161	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	50.0	CHEMBL2695	Homo sapiens	Residual Activity	%	50.0
	12242162	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	10.0	CHEMBL2695	Homo sapiens	Residual Activity	%	10.0
	12242163	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	46.0	CHEMBL2695	Homo sapiens	Residual Activity	%	46.0
	12242164	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	13.0	CHEMBL2695	Homo sapiens	Residual Activity	%	13.0
	12242165	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	25.0	CHEMBL2695	Homo sapiens	Residual Activity	%	25.0
	12242166	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12242167	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12242168	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	75.0	CHEMBL2695	Homo sapiens	Residual Activity	%	75.0
	12242169	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	81.0	CHEMBL2695	Homo sapiens	Residual Activity	%	81.0
	12242170	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	76.0	CHEMBL2695	Homo sapiens	Residual Activity	%	76.0
	12242171	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	83.0	CHEMBL2695	Homo sapiens	Residual Activity	%	83.0
	12242172	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	58.0	CHEMBL2695	Homo sapiens	Residual Activity	%	58.0
	12242173	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	37.0	CHEMBL2695	Homo sapiens	Residual Activity	%	37.0
	12242174	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	97.0	CHEMBL2695	Homo sapiens	Residual Activity	%	97.0
	12242175	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	85.0	CHEMBL2695	Homo sapiens	Residual Activity	%	85.0
	12242176	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242177	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	62.0	CHEMBL2695	Homo sapiens	Residual Activity	%	62.0
	12242178	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12242179	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	88.0	CHEMBL2695	Homo sapiens	Residual Activity	%	88.0
	12242180	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	83.0	CHEMBL2695	Homo sapiens	Residual Activity	%	83.0
	12242181	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	71.0	CHEMBL2695	Homo sapiens	Residual Activity	%	71.0
	12242182	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12242183	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	10.0	CHEMBL2695	Homo sapiens	Residual Activity	%	10.0
	12242184	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	37.0	CHEMBL2695	Homo sapiens	Residual Activity	%	37.0
	12242185	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	81.0	CHEMBL2695	Homo sapiens	Residual Activity	%	81.0
	12242186	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	46.0	CHEMBL2695	Homo sapiens	Residual Activity	%	46.0
	12242187	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	54.0	CHEMBL2695	Homo sapiens	Residual Activity	%	54.0
	12242188	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242189	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	4.0	CHEMBL2695	Homo sapiens	Residual Activity	%	4.0
	12242190	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242191	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	0.0	CHEMBL2695	Homo sapiens	Residual Activity	%	0.0
	12242192	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	109.0	CHEMBL2695	Homo sapiens	Residual Activity	%	109.0
	12242193	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	52.0	CHEMBL2695	Homo sapiens	Residual Activity	%	52.0
	12242194	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242195	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12242196	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	8.0	CHEMBL2695	Homo sapiens	Residual Activity	%	8.0
	12242197	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12242198	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	110.0	CHEMBL2695	Homo sapiens	Residual Activity	%	110.0
	12242199	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	115.0	CHEMBL2695	Homo sapiens	Residual Activity	%	115.0
	12242200	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	116.0	CHEMBL2695	Homo sapiens	Residual Activity	%	116.0
	12242201	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	2.0	CHEMBL2695	Homo sapiens	Residual Activity	%	2.0
	12242202	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	108.0	CHEMBL2695	Homo sapiens	Residual Activity	%	108.0
	12242203	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	83.0	CHEMBL2695	Homo sapiens	Residual Activity	%	83.0
	12242204	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	7.0	CHEMBL2695	Homo sapiens	Residual Activity	%	7.0
	12242205	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	104.0	CHEMBL2695	Homo sapiens	Residual Activity	%	104.0
	12242206	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	112.0	CHEMBL2695	Homo sapiens	Residual Activity	%	112.0
	12242207	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	111.0	CHEMBL2695	Homo sapiens	Residual Activity	%	111.0
	12242208	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	114.0	CHEMBL2695	Homo sapiens	Residual Activity	%	114.0
	12242209	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12242210	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	99.0	CHEMBL2695	Homo sapiens	Residual Activity	%	99.0
	12242211	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	91.0	CHEMBL2695	Homo sapiens	Residual Activity	%	91.0
	12242212	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	25.0	CHEMBL2695	Homo sapiens	Residual Activity	%	25.0
	12242213	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	5.0	CHEMBL2695	Homo sapiens	Residual Activity	%	5.0
	12242214	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	116.0	CHEMBL2695	Homo sapiens	Residual Activity	%	116.0
	12242215	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	67.0	CHEMBL2695	Homo sapiens	Residual Activity	%	67.0
	12242216	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	60.0	CHEMBL2695	Homo sapiens	Residual Activity	%	60.0
	12242217	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	57.0	CHEMBL2695	Homo sapiens	Residual Activity	%	57.0
	12242218	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242219	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12242220	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	81.0	CHEMBL2695	Homo sapiens	Residual Activity	%	81.0
	12242221	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	28.0	CHEMBL2695	Homo sapiens	Residual Activity	%	28.0
	12242222	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	102.0	CHEMBL2695	Homo sapiens	Residual Activity	%	102.0
	12242223	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12242224	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	22.0	CHEMBL2695	Homo sapiens	Residual Activity	%	22.0
	12242225	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	85.0	CHEMBL2695	Homo sapiens	Residual Activity	%	85.0
	12242226	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	65.0	CHEMBL2695	Homo sapiens	Residual Activity	%	65.0
	12242227	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	61.0	CHEMBL2695	Homo sapiens	Residual Activity	%	61.0
	12242228	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	9.0	CHEMBL2695	Homo sapiens	Residual Activity	%	9.0
	12242229	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	70.0	CHEMBL2695	Homo sapiens	Residual Activity	%	70.0
	12242230	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	71.0	CHEMBL2695	Homo sapiens	Residual Activity	%	71.0
	12242231	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	71.0	CHEMBL2695	Homo sapiens	Residual Activity	%	71.0
	12242232	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	19.0	CHEMBL2695	Homo sapiens	Residual Activity	%	19.0
	12242233	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	12.0	CHEMBL2695	Homo sapiens	Residual Activity	%	12.0
	12242234	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	11.0	CHEMBL2695	Homo sapiens	Residual Activity	%	11.0
	12242235	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12242236	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	1.0	CHEMBL2695	Homo sapiens	Residual Activity	%	1.0
	12242237	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	96.0	CHEMBL2695	Homo sapiens	Residual Activity	%	96.0
	12242238	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	13.0	CHEMBL2695	Homo sapiens	Residual Activity	%	13.0
	12242239	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	94.0	CHEMBL2695	Homo sapiens	Residual Activity	%	94.0
	12242240	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	49.0	CHEMBL2695	Homo sapiens	Residual Activity	%	49.0
	12242241	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	-1.0	CHEMBL2695	Homo sapiens	Residual Activity	%	-1.0
	12242242	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	64.0	CHEMBL2695	Homo sapiens	Residual Activity	%	64.0
	12242243	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	88.0	CHEMBL2695	Homo sapiens	Residual Activity	%	88.0
	12242244	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	9.0	CHEMBL2695	Homo sapiens	Residual Activity	%	9.0
	12242245	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	90.0	CHEMBL2695	Homo sapiens	Residual Activity	%	90.0
	12242246	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	42.0	CHEMBL2695	Homo sapiens	Residual Activity	%	42.0
	12242247	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	3.0	CHEMBL2695	Homo sapiens	Residual Activity	%	3.0
	12242248	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	83.0	CHEMBL2695	Homo sapiens	Residual Activity	%	83.0
	12242249	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	12.0	CHEMBL2695	Homo sapiens	Residual Activity	%	12.0
	12242250	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	15.0	CHEMBL2695	Homo sapiens	Residual Activity	%	15.0
	12242251	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	65.0	CHEMBL2695	Homo sapiens	Residual Activity	%	65.0
	12242252	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	95.0	CHEMBL2695	Homo sapiens	Residual Activity	%	95.0
	12242253	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	30.0	CHEMBL2695	Homo sapiens	Residual Activity	%	30.0
	12242254	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	100.0	CHEMBL2695	Homo sapiens	Residual Activity	%	100.0
	12242255	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	93.0	CHEMBL2695	Homo sapiens	Residual Activity	%	93.0
	12242256	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	73.0	CHEMBL2695	Homo sapiens	Residual Activity	%	73.0
	12242257	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	66.0	CHEMBL2695	Homo sapiens	Residual Activity	%	66.0
	12242258	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	59.0	CHEMBL2695	Homo sapiens	Residual Activity	%	59.0
	12242259	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	60.0	CHEMBL2695	Homo sapiens	Residual Activity	%	60.0
	12242260	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12242261	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	81.0	CHEMBL2695	Homo sapiens	Residual Activity	%	81.0
	12242262	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	25.0	CHEMBL2695	Homo sapiens	Residual Activity	%	25.0
	12242263	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	98.0	CHEMBL2695	Homo sapiens	Residual Activity	%	98.0
	12242264	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12242265	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	92.0	CHEMBL2695	Homo sapiens	Residual Activity	%	92.0
	12242266	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	87.0	CHEMBL2695	Homo sapiens	Residual Activity	%	87.0
	12242267	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	94.0	CHEMBL2695	Homo sapiens	Residual Activity	%	94.0
	12242268	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	113.0	CHEMBL2695	Homo sapiens	Residual Activity	%	113.0
	12242269	CHEMBL2219061	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	100.0	CHEMBL2695	Homo sapiens	Residual Activity	%	100.0
	12590897	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	3120.0	CHEMBL2695	Homo sapiens	IC50	uM	3.12
	12590898	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/C=C/c1ccccc1		CHEMBL2297986	=	IC50	nM	19380.0	CHEMBL2695	Homo sapiens	IC50	uM	19.38
	12590899	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/c1cc(Br)ccc1O		CHEMBL2297859	=	IC50	nM	2410.0	CHEMBL2695	Homo sapiens	IC50	uM	2.41
	12590900	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/c1ccc(F)cc1		CHEMBL475577	=	IC50	nM	17400.0	CHEMBL2695	Homo sapiens	IC50	uM	17.4
	12590901	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/c1ccc(Cl)cc1		CHEMBL2297994	=	IC50	nM	11980.0	CHEMBL2695	Homo sapiens	IC50	uM	11.98
	12590902	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/c1ccc(Br)cc1		CHEMBL2297993	=	IC50	nM	9170.0	CHEMBL2695	Homo sapiens	IC50	uM	9.17
	12590903	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	Fc1ccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)c(F)c1		CHEMBL2298004	=	IC50	nM	17380.0	CHEMBL2695	Homo sapiens	IC50	uM	17.38
	12590904	CHEMBL3069796	Inhibition of full-length Homo sapiens (human) recombinant FAK assessed as remaining ATP content after 4 hr by Kinase-Glo luminescence analysis	B	Brc1cccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)c1		CHEMBL2298000	=	IC50	nM	14640.0	CHEMBL2695	Homo sapiens	IC50	uM	14.64
Active	12611443	CHEMBL3070125	Inhibition of FAK phosphorylation in Homo sapiens (human) HCT116 cells after 0.5 to 8 uM by Western blot analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)N/N=C/c1cc(Br)ccc1O		CHEMBL2297859		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	12611444	CHEMBL3070125	Inhibition of FAK phosphorylation in Homo sapiens (human) HCT116 cells after 0.5 to 8 uM by Western blot analysis	B	Brc1cccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)c1		CHEMBL2298000		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	12617377	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	Cc1cc2c(NCc3cccnc3N(C)S(C)(=O)=O)ncnc2[nH]1		CHEMBL2315558	=	Kd	nM	57000.0	CHEMBL2695	Homo sapiens	Kd	uM	57.0
	12617378	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1ncnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315559	=	IC50	nM	8900.0	CHEMBL2695	Homo sapiens	IC50	uM	8.9
	12617379	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1ncnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315559	=	Kd	nM	3100.0	CHEMBL2695	Homo sapiens	Kd	uM	3.1
	12617380	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	Fc1ccccc1Nc1ncnc2[nH]ncc12		CHEMBL2315560	=	Kd	nM	43000.0	CHEMBL2695	Homo sapiens	Kd	uM	43.0
Not Determined	12617381	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	Fc1ccc(-c2cc3c(NCc4cc(F)ccc4F)c(C(F)(F)F)cnc3[nH]2)cc1		CHEMBL2315570		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617382	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN1Cc2cccc(Nc3c(C(F)(F)F)cnc4[nH]c(-c5ccc(F)cc5)cc34)c2C1=O		CHEMBL2315569		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617383	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	COc1cc(N2CCOCC2)ccc1-c1cc2c(Nc3ccccc3C#N)c(C(F)(F)F)cnc2[nH]1		CHEMBL2315568		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617384	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	Fc1cc(F)cc(Nc2c(C(F)(F)F)cnc3[nH]c(-c4ccc(N5CCOCC5)cc4)cc23)c1		CHEMBL2315567		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617385	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CCCCc1ccc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)cc1		CHEMBL2315582		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617386	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(C3CCCCC3)cc12)S(C)(=O)=O		CHEMBL2315581		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617387	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1ccnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315574		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	12617388	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315562		Kd			CHEMBL2695	Homo sapiens	Kd		
	12617389	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	Cc1cnc2[nH]ccc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315575	=	IC50	nM	8800.0	CHEMBL2695	Homo sapiens	IC50	nM	8800.0
	12617390	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	Cc1cc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)ccn1		CHEMBL2315583	=	IC50	nM	6500.0	CHEMBL2695	Homo sapiens	IC50	nM	6500.0
	12617391	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1ccnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315576	=	Kd	nM	6380.0	CHEMBL2695	Homo sapiens	Kd	nM	6380.0
	12617392	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1ccnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315576	=	IC50	nM	4800.0	CHEMBL2695	Homo sapiens	IC50	nM	4800.0
	12617393	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1ccnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315574	=	Kd	nM	4760.0	CHEMBL2695	Homo sapiens	Kd	nM	4760.0
	12617394	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315561	=	IC50	nM	4500.0	CHEMBL2695	Homo sapiens	IC50	nM	4500.0
	12617395	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315578	=	IC50	nM	2400.0	CHEMBL2695	Homo sapiens	IC50	nM	2400.0
	12617396	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315584	=	IC50	nM	2015.0	CHEMBL2695	Homo sapiens	IC50	nM	2015.0
	12617397	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	Cc1cnc2[nH]ccc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315575	=	Kd	nM	1700.0	CHEMBL2695	Homo sapiens	Kd	nM	1700.0
	12617398	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315580	=	IC50	nM	1300.0	CHEMBL2695	Homo sapiens	IC50	nM	1300.0
	12617399	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	COc1cc(N2CCOCC2)ccc1-c1cc2c(Nc3ccccc3C#N)c(C(F)(F)F)cnc2[nH]1		CHEMBL2315568	=	Kd	nM	1130.0	CHEMBL2695	Homo sapiens	Kd	nM	1130.0
	12617400	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccccc3)cc12)S(C)(=O)=O		CHEMBL2315579	=	IC50	nM	1100.0	CHEMBL2695	Homo sapiens	IC50	nM	1100.0
	12617401	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	Cc1cnc2[nH]c(-c3ccc(F)cc3)cc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315577	=	IC50	nM	910.0	CHEMBL2695	Homo sapiens	IC50	nM	910.0
	12617402	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(Br)cc3)nc12)S(C)(=O)=O		CHEMBL2315573	=	IC50	nM	700.0	CHEMBL2695	Homo sapiens	IC50	nM	700.0
	12617403	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	Fc1cc(F)cc(Nc2c(C(F)(F)F)cnc3[nH]c(-c4ccc(N5CCOCC5)cc4)cc23)c1		CHEMBL2315567	=	IC50	nM	640.0	CHEMBL2695	Homo sapiens	IC50	nM	640.0
	12617404	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315580	=	Kd	nM	603.0	CHEMBL2695	Homo sapiens	Kd	nM	603.0
	12617405	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	Cc1cnc2[nH]c(-c3ccc(F)cc3)cc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315577	=	Kd	nM	554.0	CHEMBL2695	Homo sapiens	Kd	nM	554.0
	12617406	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315562	=	IC50	nM	552.0	CHEMBL2695	Homo sapiens	IC50	nM	552.0
	12617407	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CCCCc1ccc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)cc1		CHEMBL2315582	=	Kd	nM	430.0	CHEMBL2695	Homo sapiens	Kd	nM	430.0
	12617408	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315564	=	IC50	nM	365.0	CHEMBL2695	Homo sapiens	IC50	nM	365.0
	12617409	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315561	=	Kd	nM	335.0	CHEMBL2695	Homo sapiens	Kd	nM	335.0
	12617410	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(C3CCCCC3)cc12)S(C)(=O)=O		CHEMBL2315581	=	Kd	nM	242.0	CHEMBL2695	Homo sapiens	Kd	nM	242.0
	12617411	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN1Cc2cccc(Nc3c(C(F)(F)F)cnc4[nH]c(-c5ccc(F)cc5)cc34)c2C1=O		CHEMBL2315569	=	Kd	nM	238.0	CHEMBL2695	Homo sapiens	Kd	nM	238.0
	12617412	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	Cc1cc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)ccn1		CHEMBL2315583	=	IC50	nM	220.0	CHEMBL2695	Homo sapiens	IC50	nM	220.0
	12617413	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccccc3)cc12)S(C)(=O)=O		CHEMBL2315579	=	IC50	nM	195.0	CHEMBL2695	Homo sapiens	IC50	nM	195.0
	12617414	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(Br)cc3)nc12)S(C)(=O)=O		CHEMBL2315573	=	Kd	nM	189.0	CHEMBL2695	Homo sapiens	Kd	nM	189.0
	12617415	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315580	=	IC50	nM	177.0	CHEMBL2695	Homo sapiens	IC50	nM	177.0
	12617416	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12		CHEMBL2315571	=	IC50	nM	170.0	CHEMBL2695	Homo sapiens	IC50	nM	170.0
	12617417	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315578	=	Kd	nM	147.0	CHEMBL2695	Homo sapiens	Kd	nM	147.0
	12617418	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315572	=	IC50	nM	130.0	CHEMBL2695	Homo sapiens	IC50	nM	130.0
	12617419	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12		CHEMBL2315571	=	Kd	nM	127.0	CHEMBL2695	Homo sapiens	Kd	nM	127.0
	12617420	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)nc3)cc12		CHEMBL2315566	=	IC50	nM	107.0	CHEMBL2695	Homo sapiens	IC50	nM	107.0
	12617421	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)cc3)cc12		CHEMBL2315565	=	IC50	nM	83.0	CHEMBL2695	Homo sapiens	IC50	nM	83.0
	12617422	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3cccnc3)cc12		CHEMBL2315563	=	IC50	nM	57.0	CHEMBL2695	Homo sapiens	IC50	nM	57.0
	12617423	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315562	=	IC50	nM	51.0	CHEMBL2695	Homo sapiens	IC50	nM	51.0
	12617424	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)nc3)cc12		CHEMBL2315566	=	IC50	nM	45.0	CHEMBL2695	Homo sapiens	IC50	nM	45.0
	12617425	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)cc3)cc12		CHEMBL2315565	=	IC50	nM	45.0	CHEMBL2695	Homo sapiens	IC50	nM	45.0
	12617426	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(-c3ccccc3)cc12)S(C)(=O)=O		CHEMBL2315579	=	Kd	nM	44.0	CHEMBL2695	Homo sapiens	Kd	nM	44.0
	12617427	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315564	=	Kd	nM	40.0	CHEMBL2695	Homo sapiens	Kd	nM	40.0
	12617428	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CNC(=O)c1ccccc1Nc1c(C#N)cnc2[nH]c(-c3ccc(F)cc3)cc12		CHEMBL2315564	=	IC50	nM	37.0	CHEMBL2695	Homo sapiens	IC50	nM	37.0
	12617429	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315584	=	IC50	nM	37.0	CHEMBL2695	Homo sapiens	IC50	nM	37.0
	12617430	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)cc3)cc12		CHEMBL2315565	=	Kd	nM	35.0	CHEMBL2695	Homo sapiens	Kd	nM	35.0
	12617431	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315572	=	Kd	nM	33.0	CHEMBL2695	Homo sapiens	Kd	nM	33.0
	12617432	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315584	=	Kd	nM	24.0	CHEMBL2695	Homo sapiens	Kd	nM	24.0
	12617433	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	Cc1cc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)ccn1		CHEMBL2315583	=	Kd	nM	24.0	CHEMBL2695	Homo sapiens	Kd	nM	24.0
	12617434	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3cccnc3)cc12		CHEMBL2315563	=	Kd	nM	12.0	CHEMBL2695	Homo sapiens	Kd	nM	12.0
	12617435	CHEMBL2320502	Binding affinity to FAK (unknown origin) by surface plasmon resonance analysis	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(N4CCOCC4)nc3)cc12		CHEMBL2315566	=	Kd	nM	9.0	CHEMBL2695	Homo sapiens	Kd	nM	9.0
	12617436	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315561	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617437	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(Br)cc3)nc12)S(C)(=O)=O		CHEMBL2315573	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617438	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(Br)cnc2[nH]c(-c3ccc(F)cc3)nc12		CHEMBL2315571	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617439	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	Fc1ccc(-c2cc3c(NCc4cc(F)ccc4F)c(C(F)(F)F)cnc3[nH]2)cc1		CHEMBL2315570	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617440	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN1Cc2cccc(Nc3c(C(F)(F)F)cnc4[nH]c(-c5ccc(F)cc5)cc34)c2C1=O		CHEMBL2315569	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617441	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	COc1cc(N2CCOCC2)ccc1-c1cc2c(Nc3ccccc3C#N)c(C(F)(F)F)cnc2[nH]1		CHEMBL2315568	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617442	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CCCCc1ccc(-c2cc3c(NCc4cccnc4N(C)S(C)(=O)=O)c(C#N)cnc3[nH]2)cc1		CHEMBL2315582	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617443	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]c(C3CCCCC3)cc12)S(C)(=O)=O		CHEMBL2315581	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617444	CHEMBL2320501	Inhibition of FAK (unknown origin) using biotinylated His-TEV-hsFAK(31-686)(K454R) substrate after 2 hrs by scintillation counting analysis	B	CN(c1ncccc1CNc1ccnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315574	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617445	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C(F)(F)F)cnc2[nH]c(-c3ccc(F)cc3)nc12)S(C)(=O)=O		CHEMBL2315572	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617446	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CNC(=O)c1ccccc1Nc1c(C(F)(F)F)cnc2[nH]c(-c3cccnc3)cc12		CHEMBL2315563	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617447	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1c(C#N)cnc2[nH]ccc12)S(C)(=O)=O		CHEMBL2315578	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617448	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	Cc1cnc2[nH]c(-c3ccc(F)cc3)cc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315577	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617449	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	CN(c1ncccc1CNc1ccnc2[nH]c(-c3ccc(F)cc3)cc12)S(C)(=O)=O		CHEMBL2315576	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12617450	CHEMBL2320500	Inhibition of FAK in human HT-29 cells assessed as phosphorylation at tyrosine 397 after 45 mins	B	Cc1cnc2[nH]ccc2c1NCc1cccnc1N(C)S(C)(=O)=O		CHEMBL2315575	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	12626681	CHEMBL2317129	Inhibition of FAK (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	12656059	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	Clc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1Cl		CHEMBL2325101	=	IC50	nM	6200.0	CHEMBL2695	Homo sapiens	IC50	uM	6.2
	12656060	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	Cc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1		CHEMBL2325100	=	IC50	nM	11500.0	CHEMBL2695	Homo sapiens	IC50	uM	11.5
	12656061	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	COc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1		CHEMBL2325092	=	IC50	nM	10300.0	CHEMBL2695	Homo sapiens	IC50	uM	10.3
	12656062	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc2ccccc2c1		CHEMBL2325087	=	IC50	nM	9900.0	CHEMBL2695	Homo sapiens	IC50	uM	9.9
	12656063	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	Cc1ccc(C2=NN(C(N)=S)C(c3ccc4ccccc4c3)C2)cc1		CHEMBL2324873	=	IC50	nM	28700.0	CHEMBL2695	Homo sapiens	IC50	uM	28.7
	12656064	CHEMBL2327209	Inhibition of human-recombinant full-length FAK after 4 hrs by kinase-Glo-luminescence assay	B	COc1ccc(C2=NN(C(N)=S)C(c3cccc4ccccc34)C2)cc1		CHEMBL2325106	=	IC50	nM	13600.0	CHEMBL2695	Homo sapiens	IC50	uM	13.6
	12674082	CHEMBL2344156	Inhibition of FAK (unknown origin)	B	O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(Oc2ccc(CCNC(=O)/C(Cc3cc(Br)c(O)c(-c4cc(C/C(=N\O)C(=O)NCCc5ccc(O)c(Br)c5)cc(Br)c4O)c3)=N/O)cc2Br)c1)=N/O		CHEMBL2333163	=	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	uM	3.5
	12674083	CHEMBL2344156	Inhibition of FAK (unknown origin)	B	O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(-c2cc(C/C(=N/O)C(=O)NCCc3ccc(O)c(Br)c3)cc(Br)c2O)c1)=N\O		CHEMBL505637	=	IC50	nM	2100.0	CHEMBL2695	Homo sapiens	IC50	uM	2.1
	12674084	CHEMBL2344156	Inhibition of FAK (unknown origin)	B	O=C1N/C=C/c2ccc(c(Br)c2)Oc2cc(cc(Br)c2O)CCNC(=O)/C(=N/O)Cc2ccc(c(Br)c2)Oc2cc(cc(Br)c2O)C/C1=N\O		CHEMBL360190	=	IC50	nM	7300.0	CHEMBL2695	Homo sapiens	IC50	uM	7.3
	12693291	CHEMBL2341965	Inhibition of FAK (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	nM	3500.0
	12705273	CHEMBL2345801	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells after 2 hrs	B	CN1c2ccc(NCc3ccc(C(C)(C)C)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333444	=	IC50	nM	7100.0	CHEMBL2695	Homo sapiens	IC50	uM	7.1
	12705274	CHEMBL2345801	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells after 2 hrs	B	CN1c2ccc(NCc3ccc(Br)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333443	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12705275	CHEMBL2345801	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells after 2 hrs	B	CN1c2ccc(Nc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333442	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12705276	CHEMBL2345801	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells after 2 hrs	B	CN1c2ccc(NCc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333441	=	IC50	nM	19000.0	CHEMBL2695	Homo sapiens	IC50	uM	19.0
	12705277	CHEMBL2345802	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells at 30 uM after 2 hrs	B	CN1c2ccc(NCc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333441	=	Inhibition	%	85.0	CHEMBL2695	Homo sapiens	INH	%	85.0
	12705278	CHEMBL2345802	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells at 30 uM after 2 hrs	B	CN1c2ccc(NC(=O)c3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333440	=	Inhibition	%	8.8	CHEMBL2695	Homo sapiens	INH	%	8.8
	12705279	CHEMBL2345802	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells at 30 uM after 2 hrs	B	CN1c2ccc(CNc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333439	=	Inhibition	%	4.8	CHEMBL2695	Homo sapiens	INH	%	4.8
Not Determined	12705280	CHEMBL2345802	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells at 30 uM after 2 hrs	B	CN1c2ccc(C(=O)Nc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333438		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	12705281	CHEMBL2345802	Inhibition of intracellular FAK autophosphorylation in human PC3 M-luc cells at 30 uM after 2 hrs	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2C)S(=O)(=O)N3C)cc1		CHEMBL2333435	=	Inhibition	%	31.0	CHEMBL2695	Homo sapiens	INH	%	31.0
	12705282	CHEMBL2345803	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 1000 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	2900.0	CHEMBL2695	Homo sapiens	IC50	uM	2.9
	12705283	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(NCc3ccc(C(C)(C)C)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333444	=	IC50	nM	640.0	CHEMBL2695	Homo sapiens	IC50	uM	0.64
	12705284	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(NCc3ccc(Br)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333443	=	IC50	nM	1400.0	CHEMBL2695	Homo sapiens	IC50	uM	1.4
	12705285	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(Nc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333442	=	IC50	nM	4300.0	CHEMBL2695	Homo sapiens	IC50	uM	4.3
	12705286	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(NCc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333441	=	IC50	nM	320.0	CHEMBL2695	Homo sapiens	IC50	uM	0.32
	12705287	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(NC(=O)c3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333440	=	IC50	nM	2400.0	CHEMBL2695	Homo sapiens	IC50	uM	2.4
	12705288	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(CNc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333439	=	IC50	nM	2000.0	CHEMBL2695	Homo sapiens	IC50	uM	2.0
	12705289	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(C(=O)Nc3ccc(F)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333438	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12705290	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2nn(C)cc2S(=O)(=O)N3C)cc1		CHEMBL2333437	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12705291	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	2100.0	CHEMBL2695	Homo sapiens	IC50	uM	2.1
	12705292	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2C)S(=O)(=O)N3C)cc1		CHEMBL2333435	=	IC50	nM	77.0	CHEMBL2695	Homo sapiens	IC50	uM	0.077
	12705293	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(-c3ccc(C(=O)N4CCC(CCO)CC4)cc3)cc2-c2[nH]ncc2S1(=O)=O		CHEMBL2333434	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	12705294	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(-c3ccc(C(=O)NCCO)cc3)cc2-c2[nH]ncc2S1(=O)=O		CHEMBL2333433	=	IC50	nM	990.0	CHEMBL2695	Homo sapiens	IC50	uM	0.99
	12705295	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(-c3ccc(C(N)=O)cc3)cc2-c2[nH]ncc2S1(=O)=O		CHEMBL2333432	=	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	uM	3.5
	12705296	CHEMBL2345804	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 60 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	960.0	CHEMBL2695	Homo sapiens	IC50	uM	0.96
	12705297	CHEMBL2345805	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 1000 uM of ATP preincubated for 5 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	6400.0	CHEMBL2695	Homo sapiens	IC50	uM	6.4
	12705298	CHEMBL2345806	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 5 mins measured after 1 hr by HTRF assay	B	CN1c2ccc(NCc3ccc(C(C)(C)C)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333444	=	IC50	nM	2200.0	CHEMBL2695	Homo sapiens	IC50	uM	2.2
	12705299	CHEMBL2345806	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 5 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2C)S(=O)(=O)N3C)cc1		CHEMBL2333435	=	IC50	nM	420.0	CHEMBL2695	Homo sapiens	IC50	uM	0.42
	12705300	CHEMBL2345806	Allosteric inhibition of FAK (unknown origin) using poly-(GT)-biotin and 0.5 uM of ATP preincubated for 5 mins measured after 1 hr by HTRF assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	12721819	CHEMBL2353804	Inhibition of FAK (unknown origin) at 1 uM relative to control	B	CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1		CHEMBL2347710	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	12728837	CHEMBL2352910	Inhibition of FAK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	98.0	CHEMBL2695	Homo sapiens	Activity	%	98.0
	12729740	CHEMBL2349752	Selectivity ratio of IC50 for human GST-tagged phosphorylated full length FAK to IC50 for human FLAG-tagged unphosphorylated full length FAK	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>=	Ratio IC50		9.0	CHEMBL2695	Homo sapiens	Ratio IC50		9.0
	12729741	CHEMBL2349752	Selectivity ratio of IC50 for human GST-tagged phosphorylated full length FAK to IC50 for human FLAG-tagged unphosphorylated full length FAK	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Ratio IC50		4.1	CHEMBL2695	Homo sapiens	Ratio IC50		4.1
	12729766	CHEMBL2349764	Inhibition of human FAK using [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	8700.0	CHEMBL2695	Homo sapiens	IC50	uM	8.7
	12729767	CHEMBL2349764	Inhibition of human FAK using [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	4200.0	CHEMBL2695	Homo sapiens	IC50	uM	4.2
	12729964	CHEMBL2352201	Inhibition of FAK (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	20.0	CHEMBL2695	Homo sapiens	Activity	%	20.0
	12729977	CHEMBL2352260	Inhibition of FAK (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	97.0	CHEMBL2695	Homo sapiens	Activity	%	97.0
	12730225	CHEMBL2352910	Inhibition of FAK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	94.0	CHEMBL2695	Homo sapiens	Activity	%	94.0
	12730944	CHEMBL2350117	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 60 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	uM	3.2
	12730945	CHEMBL2350117	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 60 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	5600.0	CHEMBL2695	Homo sapiens	IC50	uM	5.6
	12730946	CHEMBL2350118	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 5 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	12730947	CHEMBL2350118	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 5 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	12730948	CHEMBL2350119	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 60 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	uM	3.2
	12730949	CHEMBL2350119	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 60 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	2600.0	CHEMBL2695	Homo sapiens	IC50	uM	2.6
	12730950	CHEMBL2350120	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 5 mins prior to 0.5 uM ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	12730951	CHEMBL2350120	Inhibition of human FLAG-tagged unphosphorylated full length FAK expressed in baculovirus expression system incubated for 5 mins prior to 0.5 uM ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	4200.0	CHEMBL2695	Homo sapiens	IC50	uM	4.2
	12730952	CHEMBL2350121	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 60 mins prior to 1000 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730953	CHEMBL2350121	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 60 mins prior to 1000 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730954	CHEMBL2350122	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 5 mins prior to 1000 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730955	CHEMBL2350122	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 5 mins prior to 1000 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730956	CHEMBL2350123	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 60 mins prior to 0.5 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730957	CHEMBL2350123	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 60 mins prior to 0.5 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	10700.0	CHEMBL2695	Homo sapiens	IC50	uM	10.7
	12730958	CHEMBL2350124	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 5 mins prior to 0.5 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL2695	Homo sapiens	IC50	uM	30.0
	12730959	CHEMBL2350124	Inhibition of human GST-tagged phosphorylated full length FAK incubated for 5 mins prior to 0.5 uM of ATP addition by HTRF analysis	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	16300.0	CHEMBL2695	Homo sapiens	IC50	uM	16.3
Active	12730960	CHEMBL2350125	ATP-competitive inhibition of human FAK at 0.1 to 100 uM by Michaelis-Menten equation analysis	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	12730961	CHEMBL2350125	ATP-competitive inhibition of human FAK at 0.1 to 100 uM by Michaelis-Menten equation analysis	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	12730962	CHEMBL2350126	ATP-noncompetitive inhibition of human FAK at 0.1 to 100 uM incubated for 60 mins prior to ATP addition by Michaelis-Menten equation analysis assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	12730963	CHEMBL2350126	ATP-noncompetitive inhibition of human FAK at 0.1 to 100 uM incubated for 60 mins prior to ATP addition by Michaelis-Menten equation analysis assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	12730964	CHEMBL2351928	Ratio of IC50 for human unphosphorylated FAK kinase domain (411 to 686) incubated for 5 mins prior to ATP addition to IC50 for human unphosphorylated FAK kinase domain (411 to 686) incubated for 60 mins prior to ATP addition	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	Ratio IC50		3.0	CHEMBL2695	Homo sapiens	Ratio IC50		3.0
	12730965	CHEMBL2351928	Ratio of IC50 for human unphosphorylated FAK kinase domain (411 to 686) incubated for 5 mins prior to ATP addition to IC50 for human unphosphorylated FAK kinase domain (411 to 686) incubated for 60 mins prior to ATP addition	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Ratio IC50		2.4	CHEMBL2695	Homo sapiens	Ratio IC50		2.4
	12730966	CHEMBL2352215	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 60 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	uM	1.0
	12730967	CHEMBL2352215	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 60 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	880.0	CHEMBL2695	Homo sapiens	IC50	uM	0.88
	12730968	CHEMBL2352216	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 5 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	3000.0	CHEMBL2695	Homo sapiens	IC50	uM	3.0
	12730969	CHEMBL2352216	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 5 mins prior to 1000 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	2100.0	CHEMBL2695	Homo sapiens	IC50	uM	2.1
	12730970	CHEMBL2352217	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 60 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	1300.0	CHEMBL2695	Homo sapiens	IC50	uM	1.3
	12730971	CHEMBL2352217	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 60 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	990.0	CHEMBL2695	Homo sapiens	IC50	uM	0.99
	12730972	CHEMBL2352218	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 5 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	=	IC50	nM	1600.0	CHEMBL2695	Homo sapiens	IC50	uM	1.6
	12730973	CHEMBL2352218	ATP-noncompetitive inhibition of human unphosphorylated FAK kinase domain (411 to 686) using Poly-(GT)-biotin as substrate incubated for 5 mins prior to 0.5 uM of ATP addition by AlphaScreen assay	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	1100.0	CHEMBL2695	Homo sapiens	IC50	uM	1.1
Dose-dependent effect	13333613	CHEMBL2396302	Inhibition of FAK phosphorylation at Tyr397 in human MDA-MB-231 cells after 24 hrs by Western blotting analysis	B	CCCCCCCCCCCCCC(=O)NCCNC(=O)C(C)(C)C(=O)NCCO[C@@H]1O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL2393157		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	13333614	CHEMBL2396302	Inhibition of FAK phosphorylation at Tyr397 in human MDA-MB-231 cells after 24 hrs by Western blotting analysis	B	CCCCCCCCCCCCCC(=O)NCCNC(=O)C(C)(C)C(=O)NCCO[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL2393156		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	13346682	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Fc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1F		CHEMBL2393377	=	IC50	nM	33600.0	CHEMBL2695	Homo sapiens	IC50	uM	33.6
	13346683	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Clc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1Cl		CHEMBL2393376	=	IC50	nM	28500.0	CHEMBL2695	Homo sapiens	IC50	uM	28.5
	13346684	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	O=[N+]([O-])c1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL2393375	=	IC50	nM	9200.0	CHEMBL2695	Homo sapiens	IC50	uM	9.2
	13346685	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	COc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL2393374	=	IC50	nM	8600.0	CHEMBL2695	Homo sapiens	IC50	uM	8.6
	13346686	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Cc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL2393373	=	IC50	nM	33800.0	CHEMBL2695	Homo sapiens	IC50	uM	33.8
	13346687	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Brc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL2393372	=	IC50	nM	23700.0	CHEMBL2695	Homo sapiens	IC50	uM	23.7
	13346688	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Fc1ccc(CSc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL2393371	=	IC50	nM	9100.0	CHEMBL2695	Homo sapiens	IC50	uM	9.1
	13346689	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	O=[N+]([O-])c1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393370	=	IC50	nM	7000.0	CHEMBL2695	Homo sapiens	IC50	uM	7.0
	13346690	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	COc1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393388	=	IC50	nM	7500.0	CHEMBL2695	Homo sapiens	IC50	uM	7.5
	13346691	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Cc1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393387	=	IC50	nM	15800.0	CHEMBL2695	Homo sapiens	IC50	uM	15.8
	13346692	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Brc1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393386	=	IC50	nM	14200.0	CHEMBL2695	Homo sapiens	IC50	uM	14.2
	13346693	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Clc1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393385	=	IC50	nM	8300.0	CHEMBL2695	Homo sapiens	IC50	uM	8.3
	13346694	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Fc1cccc(CSc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL2393384	=	IC50	nM	7100.0	CHEMBL2695	Homo sapiens	IC50	uM	7.1
	13346695	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	O=[N+]([O-])c1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393383	=	IC50	nM	7600.0	CHEMBL2695	Homo sapiens	IC50	uM	7.6
	13346696	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	COc1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393382	=	IC50	nM	7100.0	CHEMBL2695	Homo sapiens	IC50	uM	7.1
	13346697	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Cc1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393381	=	IC50	nM	12100.0	CHEMBL2695	Homo sapiens	IC50	uM	12.1
	13346698	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Brc1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393380	=	IC50	nM	9800.0	CHEMBL2695	Homo sapiens	IC50	uM	9.8
	13346699	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Clc1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393379	=	IC50	nM	9500.0	CHEMBL2695	Homo sapiens	IC50	uM	9.5
	13346700	CHEMBL2395733	Inhibition of FAK assembly (unknown origin) after 20 mins by TRAP-PCR-ELISA	B	Fc1ccccc1CSc1nnc(Cn2nnc3ccccc32)o1		CHEMBL2393378	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	13374368	CHEMBL2406311	Inhibition of PTK2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
Active	13388089	CHEMBL2412198	Inhibition of FAK autophosphorylation in HUVEC at 1 to 8 uM after 48 hrs by FACE-TM FAK ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	13388151	CHEMBL2412197	Inhibition of FAK phosphorylation at Tyr397 in HUVEC at after 48 hrs by FACE-TM FAK ELISA	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409605		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	13388152	CHEMBL2412198	Inhibition of FAK autophosphorylation in HUVEC at 1 to 8 uM after 48 hrs by FACE-TM FAK ELISA	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409605		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	13388153	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CCC(CC)NC(=O)c1ccccc1Nc1ncnc(Nc2ccc(CN)cc2)n1		CHEMBL2409578	=	IC50	nM	1900.0	CHEMBL2695	Homo sapiens	IC50	uM	1.9
	13388154	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CC(C)NC(=O)c1ccccc1Nc1ncnc(Nc2ccc(CN)cc2)n1		CHEMBL2409577	=	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	uM	1.0
	13388155	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CCNC(=O)c1ccccc1Nc1ncnc(Nc2ccc(CN)cc2)n1		CHEMBL2409593	=	IC50	nM	440.0	CHEMBL2695	Homo sapiens	IC50	uM	0.44
	13388156	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2ccc(CN)cc2)n1		CHEMBL2409592	=	IC50	nM	160.0	CHEMBL2695	Homo sapiens	IC50	uM	0.16
	13388157	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CS(=O)(=O)Nc1ccccc1Nc1ncnc(Nc2ccc(CN)cc2)n1		CHEMBL2409591	=	IC50	nM	2300.0	CHEMBL2695	Homo sapiens	IC50	uM	2.3
	13388158	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2cc(CCC(N)=O)c(OC)c(OC)c2)n1		CHEMBL2409590	=	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	uM	0.3
	13388159	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2ccc(N3CCOCC3)cc2OC)n1		CHEMBL2409589	=	IC50	nM	320.0	CHEMBL2695	Homo sapiens	IC50	uM	0.32
	13388160	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1ccc(Nc2ncnc(Nc3ccccc3NC(C)=O)n2)c(OC)c1		CHEMBL2409588	=	IC50	nM	21100.0	CHEMBL2695	Homo sapiens	IC50	uM	21.1
	13388161	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2ccc(OC)cc2OC)n1		CHEMBL2409587	=	IC50	nM	1500.0	CHEMBL2695	Homo sapiens	IC50	uM	1.5
	13388162	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1ccc(Nc2ncnc(Nc3ccccc3NS(C)(=O)=O)n2)c(OC)c1		CHEMBL2409586	=	IC50	nM	6100.0	CHEMBL2695	Homo sapiens	IC50	uM	6.1
	13388163	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	uM	0.007
	13388164	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409585	=	IC50	nM	17900.0	CHEMBL2695	Homo sapiens	IC50	uM	17.9
	13388165	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3C(=O)NCCN(C)C)n2)cc(OC)c1OC		CHEMBL2409584	=	IC50	nM	10200.0	CHEMBL2695	Homo sapiens	IC50	uM	10.2
	13388166	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3C(=O)NCCO)n2)cc(OC)c1OC		CHEMBL2409583	=	IC50	nM	23800.0	CHEMBL2695	Homo sapiens	IC50	uM	23.8
	13388167	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3C(=O)NC3CCCC3)n2)cc(OC)c1OC		CHEMBL2409582	=	IC50	nM	5200.0	CHEMBL2695	Homo sapiens	IC50	uM	5.2
	13388168	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CCC(CC)NC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409581	=	IC50	nM	6000.0	CHEMBL2695	Homo sapiens	IC50	uM	6.0
	13388169	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3C(=O)NC3CC3)n2)cc(OC)c1OC		CHEMBL2409580	=	IC50	nM	6100.0	CHEMBL2695	Homo sapiens	IC50	uM	6.1
	13388170	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3C(=O)NC(C)C)n2)cc(OC)c1OC		CHEMBL2409579	=	IC50	nM	2200.0	CHEMBL2695	Homo sapiens	IC50	uM	2.2
	13388171	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409605	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	uM	0.4
	13388172	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(Nc3ccccc3NC(C)=O)nc(C(F)(F)F)n2)cc(OC)c1OC	Outside typical range	CHEMBL2409604	=	IC50	nM	125600.0	CHEMBL2695	Homo sapiens	IC50	uM	125.6
	13388173	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(C)nc(Nc3ccccc3NC(=O)N(C)C)n2)cc(OC)c1OC		CHEMBL2409603	=	IC50	nM	54300.0	CHEMBL2695	Homo sapiens	IC50	uM	54.3
	13388174	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)Nc1ccccc1Nc1nc(C)nc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409602	=	IC50	nM	35900.0	CHEMBL2695	Homo sapiens	IC50	uM	35.9
	13388175	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(C)nc(Nc3ccccc3NC(C)=O)n2)cc(OC)c1OC		CHEMBL2409601	=	IC50	nM	50800.0	CHEMBL2695	Homo sapiens	IC50	uM	50.8
	13388176	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(C)nc(Nc3ccccc3NS(C)(=O)=O)n2)cc(OC)c1OC		CHEMBL2409600	=	IC50	nM	7900.0	CHEMBL2695	Homo sapiens	IC50	uM	7.9
	13388177	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNc1nc(Nc2cccc(NS(C)(=O)=O)c2)nc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409599	=	IC50	nM	41300.0	CHEMBL2695	Homo sapiens	IC50	uM	41.3
	13388178	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3cccc(NS(C)(=O)=O)c3)n2)cc(OC)c1OC		CHEMBL2409598	=	IC50	nM	9200.0	CHEMBL2695	Homo sapiens	IC50	uM	9.2
	13388179	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(Cl)nc(Nc3cccc(NS(C)(=O)=O)c3)n2)cc(OC)c1OC		CHEMBL2409597	=	IC50	nM	57800.0	CHEMBL2695	Homo sapiens	IC50	uM	57.8
	13388180	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	CNc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc(Nc2ccccc2NS(C)(=O)=O)n1		CHEMBL2409596	=	IC50	nM	65900.0	CHEMBL2695	Homo sapiens	IC50	uM	65.9
	13388181	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2ncnc(Nc3ccccc3NS(C)(=O)=O)n2)cc(OC)c1OC		CHEMBL2409595	=	IC50	nM	5100.0	CHEMBL2695	Homo sapiens	IC50	uM	5.1
	13388182	CHEMBL2412199	Inhibition of pre-activated recombinant full length FAK (unknown origin) using ULight labeled poly(Glu/Tyr) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(Cl)nc(Nc3ccccc3NS(C)(=O)=O)n2)cc(OC)c1OC		CHEMBL2409594	=	IC50	nM	41900.0	CHEMBL2695	Homo sapiens	IC50	uM	41.9
	13389913	CHEMBL2410714	Inhibition of N-terminal FLAG-tagged recombinant FAK (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr as substrate by AlphaScreen assay	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)nn4c3)ccc2F)n(C)n1		CHEMBL2409778	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	13418831	CHEMBL2422662	Inhibition of PTK2 (unknown origin)	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	pIC50		9.0
	13436518	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436519	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436520	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436521	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436522	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436523	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436524	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436525	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436526	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436527	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436528	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13436529	CHEMBL2422433	Inhibition of FAK in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	<	Inhibition	%	35.0	CHEMBL2695	Homo sapiens	INH	%	35.0
	13439935	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
Not Determined	13441107	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1		CHEMBL2425161		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441108	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1		CHEMBL2425160		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441109	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1		CHEMBL2425159		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441110	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1		CHEMBL2425158		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441111	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1		CHEMBL2425157		IC50			CHEMBL2695	Homo sapiens	IC50		
	13441112	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1		CHEMBL2425156	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
Not Determined	13441113	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1		CHEMBL2425155		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441114	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1		CHEMBL2425154		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441115	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1		CHEMBL2425153		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441116	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1		CHEMBL2425152		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441117	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1		CHEMBL2425151		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441118	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1		CHEMBL2425150		IC50			CHEMBL2695	Homo sapiens	IC50		
	13441119	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1		CHEMBL2425149	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
Not Determined	13441120	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1		CHEMBL2425148		IC50			CHEMBL2695	Homo sapiens	IC50		
Not Determined	13441121	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1		CHEMBL2425147		IC50			CHEMBL2695	Homo sapiens	IC50		
	13441122	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1		CHEMBL2425146	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441123	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1		CHEMBL2425145	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441124	CHEMBL2427448	Inhibition of FAK in human HT-29 cells assessed as Tyr397 phosphorylation after 45 mins	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1		CHEMBL2425144	=	IC50	nM	750.0	CHEMBL2695	Homo sapiens	IC50	uM	0.75
	13441126	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1		CHEMBL2425161	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441127	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1		CHEMBL2425160	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441128	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1		CHEMBL2425159	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441129	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1		CHEMBL2425158	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441130	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1		CHEMBL2425157	=	IC50	nM	5000.0	CHEMBL2695	Homo sapiens	IC50	uM	5.0
	13441131	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1		CHEMBL2425156	=	IC50	nM	7000.0	CHEMBL2695	Homo sapiens	IC50	uM	7.0
	13441132	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1		CHEMBL2425155	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441133	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1		CHEMBL2425154	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441134	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1		CHEMBL2425153	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441135	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1		CHEMBL2425152	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441136	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1		CHEMBL2425151	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441137	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1		CHEMBL2425150	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13441138	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1		CHEMBL2425149	=	IC50	nM	8400.0	CHEMBL2695	Homo sapiens	IC50	uM	8.4
	13441139	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1		CHEMBL2425148	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13443844	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1		CHEMBL2425147	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	13443845	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1		CHEMBL2425146	=	IC50	nM	9100.0	CHEMBL2695	Homo sapiens	IC50	uM	9.1
	13443846	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1		CHEMBL2425145	=	IC50	nM	7700.0	CHEMBL2695	Homo sapiens	IC50	uM	7.7
	13443847	CHEMBL2427452	Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1		CHEMBL2425144	=	IC50	nM	266.0	CHEMBL2695	Homo sapiens	IC50	uM	0.266
	13443848	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1		CHEMBL2425161	>	Kd	nM	25000.0	CHEMBL2695	Homo sapiens	Kd	uM	25.0
	13443849	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1		CHEMBL2425160	>	Kd	nM	100000.0	CHEMBL2695	Homo sapiens	Kd	uM	100.0
	13443850	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1		CHEMBL2425159	=	Kd	nM	9630.0	CHEMBL2695	Homo sapiens	Kd	uM	9.63
	13443851	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1		CHEMBL2425158	=	Kd	nM	38800.0	CHEMBL2695	Homo sapiens	Kd	uM	38.8
	13443852	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1		CHEMBL2425157	=	Kd	nM	3100.0	CHEMBL2695	Homo sapiens	Kd	uM	3.1
	13443853	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1		CHEMBL2425156	=	Kd	nM	770.0	CHEMBL2695	Homo sapiens	Kd	uM	0.77
	13443854	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1		CHEMBL2425155	=	Kd	nM	17600.0	CHEMBL2695	Homo sapiens	Kd	uM	17.6
	13443855	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1		CHEMBL2425154	=	Kd	nM	17100.0	CHEMBL2695	Homo sapiens	Kd	uM	17.1
	13443856	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1		CHEMBL2425153	=	Kd	nM	15900.0	CHEMBL2695	Homo sapiens	Kd	uM	15.9
	13443857	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1		CHEMBL2425152	=	Kd	nM	12400.0	CHEMBL2695	Homo sapiens	Kd	uM	12.4
	13443858	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1		CHEMBL2425151	=	Kd	nM	10800.0	CHEMBL2695	Homo sapiens	Kd	uM	10.8
	13443859	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1		CHEMBL2425150	=	Kd	nM	9020.0	CHEMBL2695	Homo sapiens	Kd	uM	9.02
	13443860	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1		CHEMBL2425149	=	Kd	nM	4590.0	CHEMBL2695	Homo sapiens	Kd	uM	4.59
	13443861	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1		CHEMBL2425148	=	Kd	nM	4000.0	CHEMBL2695	Homo sapiens	Kd	uM	4.0
	13443862	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1		CHEMBL2425147	=	Kd	nM	3120.0	CHEMBL2695	Homo sapiens	Kd	uM	3.12
	13443863	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1		CHEMBL2425146	=	Kd	nM	1530.0	CHEMBL2695	Homo sapiens	Kd	uM	1.53
	13443864	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1		CHEMBL2425145	=	Kd	nM	1040.0	CHEMBL2695	Homo sapiens	Kd	uM	1.04
	13443865	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1		CHEMBL2425144	=	Kd	nM	111.0	CHEMBL2695	Homo sapiens	Kd	uM	0.111
	13443866	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1cc(=O)n2nc(C)c(C#N)c2[nH]1		CHEMBL2425143	=	Kd	nM	887000.0	CHEMBL2695	Homo sapiens	Kd	uM	887.0
	13443867	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	CCOc1ccccc1NC(=O)c1ccoc1		CHEMBL2425142	=	Kd	nM	773000.0	CHEMBL2695	Homo sapiens	Kd	uM	773.0
	13443868	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	CC(=O)Nc1sccc1C(N)=O		CHEMBL2425141	=	Kd	nM	233000.0	CHEMBL2695	Homo sapiens	Kd	uM	233.0
	13443869	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1c(C(=O)O)[nH]c2c1C(=O)CCC2		CHEMBL2425140	=	Kd	nM	460000.0	CHEMBL2695	Homo sapiens	Kd	uM	460.0
	13443870	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	c1ccc2c(N3CCOCC3)ncnc2c1		CHEMBL2425139	=	Kd	nM	290000.0	CHEMBL2695	Homo sapiens	Kd	uM	290.0
	13443871	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	O=C(c1cnc2ccccc2n1)N1CCCC1		CHEMBL1269088	=	Kd	nM	2004000.0	CHEMBL2695	Homo sapiens	Kd	uM	2004.0
	13443872	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Cc1n[nH]c2c[nH]nc12		CHEMBL1599242	=	Kd	nM	93000.0	CHEMBL2695	Homo sapiens	Kd	uM	93.0
	13443873	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Fc1ccccc1Nc1ncnc2[nH]ncc12		CHEMBL2315560	=	Kd	nM	43000.0	CHEMBL2695	Homo sapiens	Kd	uM	43.0
	13443874	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	c1cc(-c2cnco2)ccn1		CHEMBL1643353	=	Kd	nM	1350000.0	CHEMBL2695	Homo sapiens	Kd	uM	1350.0
	13443875	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Brc1cncc(-c2nnn[nH]2)c1		CHEMBL2425111	=	Kd	nM	95000.0	CHEMBL2695	Homo sapiens	Kd	uM	95.0
	13443876	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	Nc1nccc(-c2cccnc2)n1		CHEMBL1236798	=	Kd	nM	159000.0	CHEMBL2695	Homo sapiens	Kd	uM	159.0
	13443877	CHEMBL2427451	Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay	B	CC(=O)Nc1ccc(Cl)cn1		CHEMBL2425110	=	Kd	nM	719000.0	CHEMBL2695	Homo sapiens	Kd	uM	719.0
	13443878	CHEMBL2427453	Competitive binding affinity to FAK kinase domain (410 to 689) (unknown origin) assessed as phosphorylation of p(Glu/Tyr) in presence of ATP	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	13445445	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	85.0	CHEMBL2695	Homo sapiens	INH	%	85.0
	13448500	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	13448636	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	13451431	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	13454616	CHEMBL2429478	Competitive binding affinity to PTK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	13464770	CHEMBL2432164	Inhibition of recombinant GST-tagged FAK catalytic domain region (amino acids 411-686) (unknown origin) expressed in Sf9 cells after 5 mins	B	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F.Cl		CHEMBL2430358	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	13464772	CHEMBL2432166	Reversible inhibition of FAK kinase domain (amino acid 410-689) (unknown origin) assessed as inhibition of Phosphorylation of p(Glu/Tyr) by spectrophotometry	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O.O=S(=O)(O)c1ccccc1		CHEMBL2430359	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nmol/L	1.5
	13464773	CHEMBL2432167	Inhibition of FAK (unknown origin)	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM/L	4.0
	13464774	CHEMBL2432167	Inhibition of FAK (unknown origin)	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5.5	CHEMBL2695	Homo sapiens	IC50	nM	5.5
	13507611	CHEMBL2444007	Inhibition of FAK (unknown origin)	B	CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1		CHEMBL2443026	>	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
	13507612	CHEMBL2444007	Inhibition of FAK (unknown origin)	B	CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1		CHEMBL2443139	>	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
	13507613	CHEMBL2444007	Inhibition of FAK (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1		CHEMBL2443138	>	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
	13507614	CHEMBL2444007	Inhibition of FAK (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1		CHEMBL2443044	>	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
	13836292	CHEMBL3090900	Inhibition of FAK (unknown origin) after 90 mins by TR-FRET/IMAP fluorescence polarization assay	B	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3cc(Cl)c(OC(=O)N(C)C)cc3oc2=O)c1		CHEMBL3086065	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	13872150	CHEMBL3101775	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	110.0	CHEMBL2695	Homo sapiens	Activity	%	110.0
	13872228	CHEMBL3102534	Inhibition of FAK fl (unknown origin) assessed as residual activity at 10 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	63.0	CHEMBL2695	Homo sapiens	Activity	%	63.0
	13872258	CHEMBL3100334	Inhibition of FAK fl (unknown origin) assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	94.0	CHEMBL2695	Homo sapiens	Activity	%	94.0
	13878414	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	13878415	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	80.0	CHEMBL2695	Homo sapiens	IC50	uM	0.08
	13878416	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	Cc1c(O)c(O)c(O)c(C=O)c1-c1cc2c(C=O)c(C)c(O)c(O)c2o1		CHEMBL3104855	=	IC50	nM	800.0	CHEMBL2695	Homo sapiens	IC50	uM	0.8
	13878417	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	Cc1c(O)c(O)c(O)c2c1COC2=O		CHEMBL3104854	=	IC50	nM	7520.0	CHEMBL2695	Homo sapiens	IC50	uM	7.52
	13878418	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	COCc1c(C)c(O)c(O)c(O)c1C=O		CHEMBL3104853	=	IC50	nM	20600.0	CHEMBL2695	Homo sapiens	IC50	uM	20.6
	13878419	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	COC1OC(=O)c2c(O)c(O)c(O)c(C)c21		CHEMBL3104852	=	IC50	nM	16300.0	CHEMBL2695	Homo sapiens	IC50	uM	16.3
	13878420	CHEMBL3108325	Inhibition of FAK (unknown origin)	B	Cc1c(O)c(O)c2c(c1C=O)[C@@H]1O[C@H](O2)c2c(C)c(O)c(O)c(O)c2C1=O		CHEMBL3104851	=	IC50	nM	420.0	CHEMBL2695	Homo sapiens	IC50	uM	0.42
	13897463	CHEMBL3111644	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	COC(=O)c1cc(O)c(O)c(C[C@]2(C)[C@@H](C)CC[C@@]3(C)C(C)=CCC[C@H]32)c1		CHEMBL3109404	=	IC50	nM	4560.0	CHEMBL2695	Homo sapiens	IC50	uM	4.56
	13897464	CHEMBL3111644	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	COc1cc2nc(C)oc2c(C[C@]2(C)[C@@H](C)CC[C@@]3(C)C(C)=CCC[C@H]32)c1O		CHEMBL3109402	=	IC50	nM	7780.0	CHEMBL2695	Homo sapiens	IC50	uM	7.78
	13897465	CHEMBL3111644	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O		CHEMBL3109401	=	IC50	nM	3030.0	CHEMBL2695	Homo sapiens	IC50	uM	3.03
Active	13897494	CHEMBL3111653	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate at 10 uM by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)Cc1c2oc(C)nc2cc2nc(C)oc12		CHEMBL3109403		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	13897495	CHEMBL3111653	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate at 10 uM by radiometric assay	B	CSCCCNC1=CC(=O)C(O)=C(C[C@]2(C)[C@@H](C)CC[C@@]3(C)C(C)=CCC[C@H]32)C1=O		CHEMBL3108787		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	13897496	CHEMBL3111653	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate at 10 uM by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)CC1=C(O)C(=O)C=C(NCCc2c[nH]c3ccccc23)C1=O		CHEMBL3109400		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	13897497	CHEMBL3111653	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate at 10 uM by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)CC1=C(O)C(=O)C=C(NCCc2ccccc2)C1=O		CHEMBL3109399		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	13897498	CHEMBL3111653	Inhibition of recombinant FAK (unknown origin) assessed as incorporation of [gamma-33P]-ATP into substrate at 10 uM by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)CC1=C(O)C(=O)C=C(NCCc2ccc(O)cc2)C1=O		CHEMBL3109398		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	13906538	CHEMBL3117700	Inhibition of FAK (unknown origin) at 10 uM after 30 mins relative to control	B	COc1ccc(S(=O)(=O)Nc2cc(Sc3ncnc4nc[nH]c34)c(O)c3ccccc23)cc1OC		CHEMBL3113284	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	13941189	CHEMBL3129254	Inhibition of PTK2 (unknown origin) using Km levels of ATP	B	Cc1nc([C@](C)(O)CO)sc1-c1cnc(N)c(O[C@H](C)c2cc(F)ccc2-n2nccn2)c1		CHEMBL3128069	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
	13953347	CHEMBL3130935	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	90.0	CHEMBL2695	Homo sapiens	Activity	%	90.0
	13954699	CHEMBL3130935	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	91.0	CHEMBL2695	Homo sapiens	Activity	%	91.0
	13954727	CHEMBL3130935	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	80.0	CHEMBL2695	Homo sapiens	Activity	%	80.0
	13955221	CHEMBL3130283	Inhibition of FAK (unknown origin) at 50 uM by radiometric assay	B	O=C(CCc1nc2ccccc2c(=O)[nH]1)Nc1ncc(Cc2ccc(F)c(F)c2)s1		CHEMBL3125863	=	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	13955222	CHEMBL3130283	Inhibition of FAK (unknown origin) at 50 uM by radiometric assay	B	O=c1[nH]c(CSc2nnc(NCC3CCCO3)s2)nc2sc(-c3ccccc3)cc12		CHEMBL3125862	=	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	13955225	CHEMBL3130285	Inhibition of FAK (unknown origin) by radiometric assay	B	O=C(CCc1nc2ccccc2c(=O)[nH]1)Nc1ncc(Cc2ccc(F)c(F)c2)s1		CHEMBL3125863	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	13955226	CHEMBL3130285	Inhibition of FAK (unknown origin) by radiometric assay	B	O=c1[nH]c(CSc2nnc(NCC3CCCO3)s2)nc2sc(-c3ccccc3)cc12		CHEMBL3125862	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	14544030	CHEMBL3226040	Inhibition of PTK2 (unknown origin) at 10 uM	B	CC1(C)C(=O)Nc2cc3nccc(Oc4ccc(NC(=O)Nc5ccc(F)c(C(F)(F)F)c5)cc4Cl)c3cc21		CHEMBL3218350	=	Inhibition	%	3.6	CHEMBL2695	Homo sapiens	INH	%	3.6
	14553648	CHEMBL3226156	Inhibition of FAK (unknown origin) at 10 uM assessed as residual enzyme activity	B	COc1ccc(-c2n[nH]c3ncc(-c4ccc(Cl)cc4N)cc23)cc1		CHEMBL3220823	=	Activity	%	96.8	CHEMBL2695	Homo sapiens	Activity	%	96.8
	14582495	CHEMBL3242347	Inhibition of human FAK assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	102.0	CHEMBL2695	Homo sapiens	Activity	%	102.0
	14661324	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccccc1Cl)c1cccc2c1OCCO2		CHEMBL3260970	=	IC50	nM	6550.0	CHEMBL2695	Homo sapiens	IC50	uM	6.55
	14661325	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1cccc(Cl)c1)c1cccc2c1OCCO2		CHEMBL3261178	=	IC50	nM	3420.0	CHEMBL2695	Homo sapiens	IC50	uM	3.42
	14661326	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccc(Cl)cc1)c1cccc2c1OCCO2		CHEMBL3261179	=	IC50	nM	18420.0	CHEMBL2695	Homo sapiens	IC50	uM	18.42
	14661327	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccccc1Br)c1cccc2c1OCCO2		CHEMBL3261180	=	IC50	nM	12430.0	CHEMBL2695	Homo sapiens	IC50	uM	12.43
	14661328	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1cccc(Br)c1)c1cccc2c1OCCO2		CHEMBL3261181	=	IC50	nM	10340.0	CHEMBL2695	Homo sapiens	IC50	uM	10.34
	14661329	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccc(Br)cc1)c1cccc2c1OCCO2		CHEMBL3261182	=	IC50	nM	1750.0	CHEMBL2695	Homo sapiens	IC50	uM	1.75
	14661330	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccccc1F)c1cccc2c1OCCO2		CHEMBL3261183	=	IC50	nM	4340.0	CHEMBL2695	Homo sapiens	IC50	uM	4.34
	14661331	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1cccc(F)c1)c1cccc2c1OCCO2		CHEMBL3261184	=	IC50	nM	5210.0	CHEMBL2695	Homo sapiens	IC50	uM	5.21
	14661332	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccc(F)cc1)c1cccc2c1OCCO2		CHEMBL3261185	=	IC50	nM	8010.0	CHEMBL2695	Homo sapiens	IC50	uM	8.01
	14661333	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	Cc1ccccc1/C=C\c1ncc([N+](=O)[O-])n1CCOC(=O)c1cccc2c1OCCO2		CHEMBL3261186	=	IC50	nM	23540.0	CHEMBL2695	Homo sapiens	IC50	uM	23.54
	14661334	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	Cc1cccc(/C=C\c2ncc([N+](=O)[O-])n2CCOC(=O)c2cccc3c2OCCO3)c1		CHEMBL3261187	=	IC50	nM	16210.0	CHEMBL2695	Homo sapiens	IC50	uM	16.21
	14661335	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	Cc1ccc(/C=C\c2ncc([N+](=O)[O-])n2CCOC(=O)c2cccc3c2OCCO3)cc1		CHEMBL3261188	=	IC50	nM	26540.0	CHEMBL2695	Homo sapiens	IC50	uM	26.54
	14661336	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	COc1ccccc1/C=C\c1ncc([N+](=O)[O-])n1CCOC(=O)c1cccc2c1OCCO2		CHEMBL3261189	=	IC50	nM	30070.0	CHEMBL2695	Homo sapiens	IC50	uM	30.07
	14661337	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	COc1cccc(/C=C\c2ncc([N+](=O)[O-])n2CCOC(=O)c2cccc3c2OCCO3)c1		CHEMBL3261190	=	IC50	nM	24430.0	CHEMBL2695	Homo sapiens	IC50	uM	24.43
	14661338	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	COc1ccc(/C=C\c2ncc([N+](=O)[O-])n2CCOC(=O)c2cccc3c2OCCO3)cc1		CHEMBL3261191	=	IC50	nM	28670.0	CHEMBL2695	Homo sapiens	IC50	uM	28.67
	14661339	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1c(F)cccc1Cl)c1cccc2c1OCCO2		CHEMBL3261192	=	IC50	nM	450.0	CHEMBL2695	Homo sapiens	IC50	uM	0.45
	14661340	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1cccc2ccccc12)c1cccc2c1OCCO2		CHEMBL3261193	=	IC50	nM	1010.0	CHEMBL2695	Homo sapiens	IC50	uM	1.01
	14661341	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	O=C(OCCn1c([N+](=O)[O-])cnc1/C=C\c1ccccc1)c1cccc2c1OCCO2		CHEMBL3261194	=	IC50	nM	20560.0	CHEMBL2695	Homo sapiens	IC50	uM	20.56
	14661342	CHEMBL3268423	Inhibition of FAK (unknown origin) assembly after 20 mins by turbidimetric method	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	14672869	CHEMBL3267948	Inhibition of PTK2 (unknown origin) at 1 uM by Z'-LYTE assay relative to control	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccc2ccccc2n1		CHEMBL3265344	=	Inhibition	%	13.0	CHEMBL2695	Homo sapiens	INH	%	13.0
	14672872	CHEMBL3268326	Binding affinity to biotinylated human FAK FAT domain by biolayer interoferometry	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1.Cl		CHEMBL550011	=	Kd	nM	570.0	CHEMBL2695	Homo sapiens	Kd	10'-7M	5.7
Not Active	14672873	CHEMBL3268326	Binding affinity to biotinylated human FAK FAT domain by biolayer interoferometry	B	CN(C)CCNc1ccccn1		CHEMBL1489836		Activity			CHEMBL2695	Homo sapiens	Activity		
	14672874	CHEMBL3268326	Binding affinity to biotinylated human FAK FAT domain by biolayer interoferometry	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccc2ccccc2n1		CHEMBL3265344	=	Kd	nM	18.0	CHEMBL2695	Homo sapiens	Kd	10'-8M	1.8
	14713707	CHEMBL3296772	Binding affinity to FAK (unknown origin)	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Ki	nM	530.0	CHEMBL2695	Homo sapiens	Ki	uM	0.53
	14713734	CHEMBL3296861	Inhibition of FAK (unknown origin) at 1 uM relative to control	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Inhibition	%	66.0	CHEMBL2695	Homo sapiens	INH	%	66.0
Not Determined	14713764	CHEMBL3296772	Binding affinity to FAK (unknown origin)	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Ki			CHEMBL2695	Homo sapiens	Ki		
	14722523	CHEMBL3293407	Inhibition of PTK2 (unknown origin) by TR-FRET-based Z'-LYTE assay	B	C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21		CHEMBL3286830	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
	14751753	CHEMBL3301279	Inhibition of FAK (unknown origin)	B	CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21		CHEMBL3298400	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	14751754	CHEMBL3301279	Inhibition of FAK (unknown origin)	B	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1		CHEMBL3297762	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15016151	CHEMBL3362646	Inhibition of FAK (unknown origin) by TR-FRET assay	B	O=C1CN2C(=NN1)COc1ccccc12		CHEMBL1968515	=	IC50	nM	156000.0	CHEMBL2695	Homo sapiens	IC50	uM	156.0
	15018589	CHEMBL3362253	Inhibition of FAK (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	2.3	CHEMBL2695	Homo sapiens	INH	%	2.3
	15019200	CHEMBL3364393	Inhibition of PTK2 (unknown origin) at 1 uM in presence of 100 uM ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298512	=	Inhibition	%	-4.0	CHEMBL2695	Homo sapiens	INH	%	-4.0
Not Active	15035146	CHEMBL3370967	Inhibition of Fak phosphorylation at Tyr397 in human NCI-H460 cells at 0 to 20 uM for 24 hrs by Western blot analysis	B	COc1cc(O)cc(CCc2ccc(O)c(OC)c2)c1		CHEMBL219553		Activity			CHEMBL2695	Homo sapiens	Activity		
	15036783	CHEMBL3381072	Inhibition of FAK (unknown origin)	B	Nc1nc2c3c(F)cccc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309990	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15036784	CHEMBL3381072	Inhibition of FAK (unknown origin)	B	Nc1ccc2c(c1)nc(Cc1ccc3c(c1)OCO3)n1nc(N)nc21		CHEMBL3309995	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15036785	CHEMBL3381072	Inhibition of FAK (unknown origin)	B	OCCCNc1ccc2c(c1)nc(-c1ccc3c(c1)OCO3)n1ncnc21		CHEMBL3309997	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15036786	CHEMBL3381072	Inhibition of FAK (unknown origin)	B	Nc1nc2c3ccc(NCCO)cc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309998	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15036787	CHEMBL3381072	Inhibition of FAK (unknown origin)	B	CN1CCN(c2cc(F)c3c(c2)nc(Cc2ccc4c(c2)OCO4)n2nc(N)nc32)CC1		CHEMBL3310151	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15037208	CHEMBL3368337	Inhibition of FAK (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	88.0	CHEMBL2695	Homo sapiens	INH	%	88.0
	15037209	CHEMBL3368337	Inhibition of FAK (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	92.0	CHEMBL2695	Homo sapiens	INH	%	92.0
	15037210	CHEMBL3368337	Inhibition of FAK (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	88.0	CHEMBL2695	Homo sapiens	INH	%	88.0
	15037211	CHEMBL3368337	Inhibition of FAK (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	92.0	CHEMBL2695	Homo sapiens	INH	%	92.0
	15037212	CHEMBL3368337	Inhibition of FAK (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	93.0	CHEMBL2695	Homo sapiens	INH	%	93.0
	15055283	CHEMBL3380471	Inhibition of human recombinant FAK using poly(Glu,Tyr) substrate	B	COc1cc(-c2nc(-c3c[nH]c4ccccc34)c[nH]c2=O)cc(OC)c1OC		CHEMBL3358966	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
Active	15071569	CHEMBL3390635	Inhibition of EGF-induced FAK phosphorylation at Tyr397 in human MDA-MB-231 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	15071613	CHEMBL3381603	Inhibition of basal level FAK phosphorylation at Tyr397 in human MDA-MB-231 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	15149825	CHEMBL3395104	Inhibition of FAK phosphorylation at tyrosine 397 in human PC3 cells at 0.1 to 10 uM after 48 hrs by FACEFAK ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	15149826	CHEMBL3395103	Inhibition of FAK phosphorylation at tyrosine 397 in human MDA-MB-231 cells at 0.1 to 10 uM after 48 hrs by FACEFAK ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	15149827	CHEMBL3395102	Inhibition of FAK phosphorylation at tyrosine 397 in human HCT116 cells at 0.1 to 10 uM after 48 hrs by FACEFAK ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	15149828	CHEMBL3395101	Inhibition of FAK phosphorylation at tyrosine 397 in human U87MG cells at 0.1 to 10 uM after 48 hrs by FACEFAK ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	15149829	CHEMBL3395100	Inhibition of FAK phosphorylation at tyrosine 397 in human PC3 cells after 48 hrs by FACEFAK ELISA	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	15149830	CHEMBL3395099	Inhibition of FAK phosphorylation at tyrosine 397 in human MDA-MB-231 cells after 48 hrs by FACEFAK ELISA	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	15149831	CHEMBL3395098	Inhibition of FAK phosphorylation at tyrosine 397 in human HCT116 cells after 48 hrs by FACEFAK ELISA	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	15149832	CHEMBL3395097	Inhibition of FAK phosphorylation at tyrosine 397 in human U87MG cells after 48 hrs by FACEFAK ELISA	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	15149835	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	uM	0.007
	15149836	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(NC2=Nc3nccn3C(Cc3ccccc3NC(C)=O)N2)cc(OC)c1OC		CHEMBL3393289	=	IC50	nM	8910.0	CHEMBL2695	Homo sapiens	IC50	uM	8.91
	15149837	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nc(Cc3ccccc3NS(C)(=O)=O)nc3nccn23)cc(OC)c1OC		CHEMBL3393288	=	IC50	nM	840.0	CHEMBL2695	Homo sapiens	IC50	uM	0.84
	15149838	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Cc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2nccn12		CHEMBL3393287	=	IC50	nM	180.0	CHEMBL2695	Homo sapiens	IC50	uM	0.18
	15149839	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Cc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2nccn12		CHEMBL3393286	=	IC50	nM	370.0	CHEMBL2695	Homo sapiens	IC50	uM	0.37
	15149840	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CN)cc2)n2ccnc2n1		CHEMBL3393285	=	IC50	nM	220.0	CHEMBL2695	Homo sapiens	IC50	uM	0.22
	15149841	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CN)cc2)nc2nccn12		CHEMBL3393284	=	IC50	nM	120.0	CHEMBL2695	Homo sapiens	IC50	uM	0.12
	15149842	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2ccc(CN)cc2)n2ccnc2n1		CHEMBL3393283	=	IC50	nM	280.0	CHEMBL2695	Homo sapiens	IC50	uM	0.28
	15149843	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2ccc(CN)cc2)nc2nccn12		CHEMBL3393282	=	IC50	nM	240.0	CHEMBL2695	Homo sapiens	IC50	uM	0.24
	15149844	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)nc3nccn23)cc1		CHEMBL3393281	=	IC50	nM	880.0	CHEMBL2695	Homo sapiens	IC50	uM	0.88
	15149845	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280	=	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	uM	0.05
	15149846	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)OC)nc3nccn23)cc1		CHEMBL3393279	=	IC50	nM	1050.0	CHEMBL2695	Homo sapiens	IC50	uM	1.05
	15149847	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)OC)n3ccnc3n2)cc1		CHEMBL3393278	=	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	uM	0.5
	15149848	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2ccc(C#N)cc2)n2ccnc2n1		CHEMBL3393277	=	IC50	nM	1730.0	CHEMBL2695	Homo sapiens	IC50	uM	1.73
	15149849	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2ccc(C#N)cc2)nc2nccn12		CHEMBL3393276	=	IC50	nM	920.0	CHEMBL2695	Homo sapiens	IC50	uM	0.92
	15149850	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C#N)cc2)n2ccnc2n1		CHEMBL3393275	=	IC50	nM	1120.0	CHEMBL2695	Homo sapiens	IC50	uM	1.12
	15149851	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C#N)cc2)nc2nccn12		CHEMBL3393274	=	IC50	nM	710.0	CHEMBL2695	Homo sapiens	IC50	uM	0.71
	15149852	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)n2ccnc2n1		CHEMBL3393273	=	IC50	nM	510.0	CHEMBL2695	Homo sapiens	IC50	uM	0.51
	15149853	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2nccn12		CHEMBL3393272	=	IC50	nM	330.0	CHEMBL2695	Homo sapiens	IC50	uM	0.33
	15149854	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)n2ccnc2n1		CHEMBL3393271	=	IC50	nM	570.0	CHEMBL2695	Homo sapiens	IC50	uM	0.57
	15150465	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2nccn12		CHEMBL3393270	=	IC50	nM	370.0	CHEMBL2695	Homo sapiens	IC50	uM	0.37
	15150466	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)n2ccnc2n1		CHEMBL3393269	=	IC50	nM	310.0	CHEMBL2695	Homo sapiens	IC50	uM	0.31
	15150467	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2nccn12		CHEMBL3393268	=	IC50	nM	230.0	CHEMBL2695	Homo sapiens	IC50	uM	0.23
	15150468	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1cccc(Nc2nc(Nc3cc(OC)c(OC)c(OC)c3)n3ccnc3n2)c1		CHEMBL3393175	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	15150469	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1cccc(Nc2nc(Nc3cc(OC)c(OC)c(OC)c3)nc3nccn23)c1		CHEMBL3393174	=	IC50	nM	870.0	CHEMBL2695	Homo sapiens	IC50	uM	0.87
	15150470	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)n2ccnc2n1		CHEMBL3393173	=	IC50	nM	570.0	CHEMBL2695	Homo sapiens	IC50	uM	0.57
	15150471	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	COC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2nccn12		CHEMBL3393172	=	IC50	nM	280.0	CHEMBL2695	Homo sapiens	IC50	uM	0.28
	15150568	CHEMBL3395578	Inhibition of FAK (unknown origin) using ULight-poly GT as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1ncnc(Nc2cc(OC)c(OC)c(OC)c2)n1		CHEMBL2409605	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
	15152442	CHEMBL3395871	Inhibition of FAK (unknown origin)	B	O=C1CNCC2=C1C(c1ccccc1F)c1c[nH]nc1N2		CHEMBL3393455	>	IC50	nM	20000.0	CHEMBL2695	Homo sapiens	IC50	uM	20.0
	15253800	CHEMBL3429894	Inhibition of human FAK	B	CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21		CHEMBL3426225	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15649101	CHEMBL3595086	Inhibition of FAK (unknown origin)	B	N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1		CHEMBL3593777	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
	15666942	CHEMBL3603234	Inhibition of FAK (unknown origin) assessed as residual enzyme activity at 1 uM by Z'-Lyte assay relative to control	B	C=CC(=O)Nc1cccc(CNc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1		CHEMBL3601223	=	Activity	%	4.0	CHEMBL2695	Homo sapiens	Activity	%	4.0
	15685884	CHEMBL3607960	Inhibition of human FAK	B	NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2		CHEMBL3606021	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	15723383	CHEMBL3619891	Inhibition of FAK (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccc(NC(=O)c2cc(N3CCN(C)CC3)cc(C(F)(F)F)c2)cc1NC(=O)c1cnoc1C		CHEMBL3616960	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
Not Active	15723384	CHEMBL3619891	Inhibition of FAK (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccccc1C(=O)Nc1cnoc1C		CHEMBL3616990		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	15723434	CHEMBL3620026	Inhibition of FAK (unknown origin) after 40 mins by scintillation counting analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	13.2	CHEMBL2695	Homo sapiens	IC50	nM	13.2
	15753778	CHEMBL3630470	Inhibition of human FAK by kinase inhibition assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	10'-8M	5.5
	15753780	CHEMBL3630460	Inhibition of human FAK at 10 uM by kinase inhibition assay	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1		CHEMBL3628537	=	Inhibition	%	47.3	CHEMBL2695	Homo sapiens	INH	%	47.3
	15753863	CHEMBL3630460	Inhibition of human FAK at 10 uM by kinase inhibition assay	B	COc1ccc2c(c1)SCc1cnc(-c3ccccc3)nc1-2		CHEMBL481789	=	Inhibition	%	11.6	CHEMBL2695	Homo sapiens	INH	%	11.6
	15753917	CHEMBL3630460	Inhibition of human FAK at 10 uM by kinase inhibition assay	B	Clc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1		CHEMBL3628818	=	Inhibition	%	-0.9	CHEMBL2695	Homo sapiens	INH	%	-0.9
	15755879	CHEMBL3630656	Inhibition of FAK (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control	B	O=C1c2ccccc2-c2c1oc1ccccc1c2=O		CHEMBL3629616	=	Activity	%	90.0	CHEMBL2695	Homo sapiens	Activity	%	90.0
	15756990	CHEMBL3630493	Inhibition of FAK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	11.65	CHEMBL2695	Homo sapiens	INH	%	11.65
	15757733	CHEMBL3630493	Inhibition of FAK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	14.96	CHEMBL2695	Homo sapiens	INH	%	14.96
	15758712	CHEMBL3630493	Inhibition of FAK (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	0.5	CHEMBL2695	Homo sapiens	INH	%	0.5
Not Active	15774414	CHEMBL3636788	Inhibition of FAK (unknown origin) after 120 mins by HotSpot assay	B	CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1		CHEMBL3633929		IC50			CHEMBL2695	Homo sapiens	IC50		
216113	16258995	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645033	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216200	16259062	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCN1CCP(=O)(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL3645118	=	IC50	nM	1862.67	CHEMBL2695	Homo sapiens	IC50	nM	1862.67
215985	16259248	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(Cc1ccccc1CNc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642381	=	IC50	nM	276.37	CHEMBL2695	Homo sapiens	IC50	nM	276.37
216094	16259269	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5cnn(-c6ccc(F)cc6)c5)cccn4n3)cc2)CC1		CHEMBL3645015	=	IC50	nM	1374.28	CHEMBL2695	Homo sapiens	IC50	nM	1374.28
216118	16259494	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645038	=	IC50	nM	1783.16	CHEMBL2695	Homo sapiens	IC50	nM	1783.16
215895	16260014	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(N(C)S(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL3642295	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216083	16260363	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncccc1-c1cccn2nc(Nc3ccc(C4CCNCC4)cc3)nc12		CHEMBL3645004	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215906	16260460	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nn23)cc1		CHEMBL3642305	=	IC50	nM	226.9	CHEMBL2695	Homo sapiens	IC50	nM	226.9
216068	16260611	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3cccc(C4CCNCC4)c3)nc12		CHEMBL3644989	=	IC50	nM	481.21	CHEMBL2695	Homo sapiens	IC50	nM	481.21
215979	16260746	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCN(CCO)CC5)c4)nc23)cc1		CHEMBL3642375	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
215965	16261001	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5ccccc5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642361	=	IC50	nM	199.46	CHEMBL2695	Homo sapiens	IC50	nM	199.46
216052	16261517	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccc2nc(Nc3ccc4c(c3)CCNCC4)nn12		CHEMBL3644973	=	IC50	nM	547.04	CHEMBL2695	Homo sapiens	IC50	nM	547.04
215952	16261657	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(Nc5ccccc5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642348	=	IC50	nM	2048.76	CHEMBL2695	Homo sapiens	IC50	nM	2048.76
216020	16262053	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1Cc2ccc(Nc3nc4c(C#Cc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2C1		CHEMBL3642414	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216171	16262392	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cc(Cl)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645089	=	IC50	nM	434.28	CHEMBL2695	Homo sapiens	IC50	nM	434.28
216101	16262570	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1Nc1cccn2nc(Nc3cccc(N4CCN(C)CC4)c3)nc12		CHEMBL3645022	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215966	16262764	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5ccccc5S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642362	=	IC50	nM	200.46	CHEMBL2695	Homo sapiens	IC50	nM	200.46
216051	16263910	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COCc1ccccc1-c1cccc2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nn12		CHEMBL3644972	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
216001	16264208	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(Nc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642395	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215968	16264826	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccccc1CNc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL3642364	=	IC50	nM	98.78	CHEMBL2695	Homo sapiens	IC50	nM	98.78
216017	16265019	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)CCN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642411	=	IC50	nM	580.33	CHEMBL2695	Homo sapiens	IC50	nM	580.33
216072	16265168	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(OCc5cccc(Cl)c5)cccn4n3)c2)CC1		CHEMBL3644993	=	IC50	nM	1592.16	CHEMBL2695	Homo sapiens	IC50	nM	1592.16
2876	16265542	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)N1CCc2ccc(Nc3nc4c(-c5cc(Cl)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645090	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215987	16265897	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5cccc(S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3639412	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216106	16266373	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)Oc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645027	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216032	16266771	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)C(=O)C1		CHEMBL3642425	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216090	16266892	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCN(CC(=O)N(C)C)CC4)cc3)nc12		CHEMBL3645011	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216021	16267100	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(CCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642415	=	IC50	nM	41.73	CHEMBL2695	Homo sapiens	IC50	nM	41.73
215940	16267318	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(S(C)(=O)=O)c4)nc23)cc1		CHEMBL2062800	=	IC50	nM	693.36	CHEMBL2695	Homo sapiens	IC50	nM	693.36
216105	16267801	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cn1ncc2c(-c3cccn4nc(Nc5ccc6c(c5)CCN(C(=O)OC(C)(C)C)CC6)nc34)cccc21		CHEMBL3642250	=	IC50	nM	1033.14	CHEMBL2695	Homo sapiens	IC50	nM	1033.14
215897	16268754	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(C(F)(F)F)cc5)cccn4n3)cc2)CC1		CHEMBL3642297	=	IC50	nM	1247.9	CHEMBL2695	Homo sapiens	IC50	nM	1247.9
215990	16270703	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCC5CCN(C(=O)OC(C)(C)C)C5)cccn4n3)cc2)CC1		CHEMBL3642384	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216199	16270746	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3cccc(C4CCN(CC(=O)N(C)C)CC4)c3)nc12		CHEMBL3645117	=	IC50	nM	658.33	CHEMBL2695	Homo sapiens	IC50	nM	658.33
216125	16271211	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645045	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216107	16271400	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3644979	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216026	16271735	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CP(C)(=O)c1ccc(-c2cccn3nc(N(CCS(C)(=O)=O)c4cccc(C5CCN(CCS(C)(=O)=O)CC5)c4)nc23)cc1		CHEMBL3642419	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216194	16272090	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4ccc(C)nc4)nc23)c1		CHEMBL3645112	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215928	16272593	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1cncc(CNc2cccn3nc(NCCN4CCOCC4)nc23)c1		CHEMBL3642328	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216047	16272918	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COCc1ccccc1-c1cccc2nc(Nc3ccc4c(c3)CCN(C(=O)OC(C)(C)C)CC4)nn12		CHEMBL3644968	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216180	16273132	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(CNc2cccn3nc(Nc4ccc(N5CCN(C)CC5)cc4)nc23)cc1		CHEMBL3645098	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216163	16273225	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c(OCC(F)F)c1		CHEMBL3645081	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216045	16273504	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cnn(CCN5CCCC5)c4)nc23)cc1		CHEMBL3644966	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215888	16273521	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1-c1cccn2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc12		CHEMBL3642291	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215938	16273542	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(Nc5cccnc5N(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642338	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215925	16273740	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2nc3c(NCc4cccc([N+](=O)[O-])c4)cccn3n2)CC1		CHEMBL3642325	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216195	16274018	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(NCCc4ccccn4)nc23)cc1		CHEMBL3645113	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216160	16274426	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(F)cc5)cccn4n3)c2)CC1		CHEMBL2062812	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216161	16274561	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)COc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645079	=	IC50	nM	1905.36	CHEMBL2695	Homo sapiens	IC50	nM	1905.36
215933	16274597	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cc(F)cn4n3)cc2)CC1		CHEMBL3642333	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
3040	16275046	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	C=Cc1nc(NC(=O)Nc2ccc(N3CCNCC3)cc2)nn1C(=C)c1ccc(S(C)(=O)=O)cc1		CHEMBL3642251	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215951	16275328	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ncccc1CNc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642347	=	IC50	nM	59.73	CHEMBL2695	Homo sapiens	IC50	nM	59.73
215949	16275858	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5cccnc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642345	=	IC50	nM	29.99	CHEMBL2695	Homo sapiens	IC50	nM	29.99
216120	16276048	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645040	=	IC50	nM	690.79	CHEMBL2695	Homo sapiens	IC50	nM	690.79
215963	16276487	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5cccnc5N(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642359	=	IC50	nM	71.08	CHEMBL2695	Homo sapiens	IC50	nM	71.08
215914	16276986	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4ccc(CN5CCOCC5)cc4)nn23)cc1		CHEMBL3642314	=	IC50	nM	173.0	CHEMBL2695	Homo sapiens	IC50	nM	173.0
216137	16277033	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(C(F)F)ccc1-c1cccn2nc(Nc3ccc(C4CCNCC4)cc3)nc12		CHEMBL3645056	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215983	16277440	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642379	=	IC50	nM	178.99	CHEMBL2695	Homo sapiens	IC50	nM	178.99
215878	16277772	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)cc4)nc23)cc1		CHEMBL3642283	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216036	16278231	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCn1cc(Nc2nc3c(-c4ccc(S(C)(=O)=O)cc4)cccn3n2)cn1		CHEMBL3644957	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216167	16278729	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)COc1ccc(Cl)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645085	=	IC50	nM	442.65	CHEMBL2695	Homo sapiens	IC50	nM	442.65
215921	16278764	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)c2)CC1		CHEMBL3642321	=	IC50	nM	1268.1	CHEMBL2695	Homo sapiens	IC50	nM	1268.1
216182	16279300	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(CNc2cccn3nc(Nc4cccc(N5CCN(C)CC5)c4)nc23)cc1		CHEMBL3645100	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216112	16279656	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccc(Cl)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645032	=	IC50	nM	1228.96	CHEMBL2695	Homo sapiens	IC50	nM	1228.96
216070	16279804	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL3644991	=	IC50	nM	3392.26	CHEMBL2695	Homo sapiens	IC50	nM	3392.26
216049	16280296	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COCc1ccccc1-c1cccc2nc(Nc3ccc4c(c3)CCNCC4)nn12		CHEMBL3644970	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215976	16280477	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(NCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642372	=	IC50	nM	13.58	CHEMBL2695	Homo sapiens	IC50	nM	13.58
216129	16280547	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(Cl)ccc1-c1cccn2nc(Nc3cccc(C4CCN(CC(=O)N(C)C)CC4)c3)nc12		CHEMBL3645049	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215871	16280579	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(Nc4ccc(S(C)(=O)=O)cc4)cccn3n2)cc1		CHEMBL3642277	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215876	16280783	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(CN5CCOCC5)cc4)nc23)cc1		CHEMBL3642281	=	IC50	nM	1170.8	CHEMBL2695	Homo sapiens	IC50	nM	1170.8
215981	16280830	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1cncc(CNc2cccn3nc(Nc4ccc(OCCN5CCCC5)cc4)nc23)c1		CHEMBL3642377	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216034	16281189	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(P(C)(C)=O)cc5)cccn4n3)c2)C(=O)C1		CHEMBL3644956	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216073	16281471	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(OCc5ccccc5C#N)cccn4n3)cc2)CC1		CHEMBL3644994	=	IC50	nM	2562.89	CHEMBL2695	Homo sapiens	IC50	nM	2562.89
216040	16281675	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cnn(C5CCNCC5)c4)nc23)cc1		CHEMBL3644961	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215917	16281869	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(Cc2ccc(Nc3nc4cccc(-c5cccc(S(C)(=O)=O)c5)n4n3)cc2)CC1		CHEMBL3642317	=	IC50	nM	1031.3	CHEMBL2695	Homo sapiens	IC50	nM	1031.3
216139	16282243	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCC(c2ccc(Nc3nc4c(-c5ccc(F)cc5)cccn4n3)cc2)CC1		CHEMBL3645058	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216025	16282262	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(P(C)(C)=O)cc5)cccn4n3)c2)CC1		CHEMBL2062813	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215908	16282707	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1ccc(-c2cccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nn23)cc1		CHEMBL3642307	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215932	16282772	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(N(c3cccc(N4CCN(C)CC4)c3)c3nc4c(-c5ccc(S(C)(=O)=O)cc5)cc(F)cn4n3)c2)CC1		CHEMBL3642332	=	IC50	nM	1053.0	CHEMBL2695	Homo sapiens	IC50	nM	1053.0
216004	16282818	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(Cc1cccc(-c2cccn3nc(Nc4ccc(OCCN5CCCC5)cc4)nc23)c1)S(C)(=O)=O		CHEMBL3642398	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216193	16282899	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3ccnc(C)c3)nc12		CHEMBL3645111	=	IC50	nM	2584.52	CHEMBL2695	Homo sapiens	IC50	nM	2584.52
215893	16283518	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5cccc(S(C)(=O)=O)c5)cccn4n3)c2)CC1		CHEMBL3642294	=	IC50	nM	1255.1	CHEMBL2695	Homo sapiens	IC50	nM	1255.1
216124	16283711	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5cc(C(F)(F)F)ccc5OCC(F)F)cccn4n3)cc2)CC1		CHEMBL3645044	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216178	16284080	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cncc(Nc3nc4c(NCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)n2)CC1		CHEMBL3645096	=	IC50	nM	1058.8	CHEMBL2695	Homo sapiens	IC50	nM	1058.8
216156	16284111	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)c1cccc(-c2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)c1		CHEMBL3645075	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215877	16284124	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(Cc2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL3642282	=	IC50	nM	1126.1	CHEMBL2695	Homo sapiens	IC50	nM	1126.1
216122	16284148	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(Cl)ccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645042	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215975	16284218	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642371	=	IC50	nM	14.63	CHEMBL2695	Homo sapiens	IC50	nM	14.63
3038	16284272	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cn1ncc2c(-c3cccn4nc(Nc5ccc6c(c5)CCN(C(=O)OC(C)(C)C)CC6)nc34)cccc21		CHEMBL3642250	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215860	16284489	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1cc(-c2ccncc2)c2nc(Nc3ccc(N4CCOCC4)cc3)nn2c1		CHEMBL3642257	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216071	16284540	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(OCc5cccc(Cl)c5)cccn4n3)cc2)CC1		CHEMBL3644992	=	IC50	nM	1104.46	CHEMBL2695	Homo sapiens	IC50	nM	1104.46
215887	16285171	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(S(=O)(=O)N(C)C)cc5)cccn4n3)cc2)CC1		CHEMBL3642290	=	IC50	nM	787.3	CHEMBL2695	Homo sapiens	IC50	nM	787.3
216038	16285428	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCn1cc(Nc2nc3c(Oc4ccc(S(C)(=O)=O)cc4)cccn3n2)cn1		CHEMBL3644959	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216109	16285579	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1ccc(OCC(C)C)c(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c1		CHEMBL3645029	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216128	16285641	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(Cl)ccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)C4)nc12		CHEMBL3645048	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216143	16285649	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)c1		CHEMBL3645062	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216179	16286111	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4ccc(N5CCN(C)CC5)cc4)nc23)c1		CHEMBL3645097	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216133	16286463	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(C(=O)OC(C)(C)C)C4)nc12		CHEMBL3645053	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216187	16286476	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4cccnc4)nc23)c1		CHEMBL3645105	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215882	16286895	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(N5CCC(N6CCOCC6)CC5)cc4)nc23)cc1		CHEMBL3642286	=	IC50	nM	250.7	CHEMBL2695	Homo sapiens	IC50	nM	250.7
216053	16286940	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccc2nc(Nc3ccc4c(c3)CCN(CCSC)CC4)nn12		CHEMBL3644974	=	IC50	nM	135.43	CHEMBL2695	Homo sapiens	IC50	nM	135.43
215977	16287770	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ccccc1CNc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642373	=	IC50	nM	12.96	CHEMBL2695	Homo sapiens	IC50	nM	12.96
216123	16288013	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)Oc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645043	=	IC50	nM	5499.0	CHEMBL2695	Homo sapiens	IC50	nM	5499.0
215982	16288208	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ncccc1CNc1cccn2nc(Nc3ccc(N4CCN(CCO)CC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642378	=	IC50	nM	379.27	CHEMBL2695	Homo sapiens	IC50	nM	379.27
215920	16288389	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3cccc(-c4ccc(S(C)(=O)=O)cc4)n3n2)cc1		CHEMBL3642320	=	IC50	nM	2599.8	CHEMBL2695	Homo sapiens	IC50	nM	2599.8
216058	16288637	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3644979	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215913	16289234	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4cccc(-c5ccc(NS(C)(=O)=O)cc5)n4n3)cc2)CC1		CHEMBL3642313	=	IC50	nM	2284.1	CHEMBL2695	Homo sapiens	IC50	nM	2284.1
216056	16289423	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(C(F)(F)F)ccc1-c1cccc2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nn12		CHEMBL3644977	=	IC50	nM	1947.44	CHEMBL2695	Homo sapiens	IC50	nM	1947.44
216168	16289431	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cc(F)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645086	=	IC50	nM	1249.7	CHEMBL2695	Homo sapiens	IC50	nM	1249.7
215901	16289566	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(Nc5ccccc5S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642300	=	IC50	nM	608.4	CHEMBL2695	Homo sapiens	IC50	nM	608.4
216048	16289626	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1ccc2c(c1)CCCN2c1nc2cccc(N3CCCc4ccccc43)n2n1		CHEMBL3644969	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216103	16290097	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)COc1cccc(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c1		CHEMBL3645024	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216013	16290159	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CC[C@@H](c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)[C@@H](O)C1		CHEMBL3642407	=	IC50	nM	2992.43	CHEMBL2695	Homo sapiens	IC50	nM	2992.43
216155	16290449	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)c(F)c1		CHEMBL3645074	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216029	16290642	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ccccc1CNc1cccn2nc(Nc3ccccc3)nc12)S(C)(=O)=O		CHEMBL3642422	=	IC50	nM	189.47	CHEMBL2695	Homo sapiens	IC50	nM	189.47
215874	16290677	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(NC4CCN(S(C)(=O)=O)CC4)cccn3n2)cc1		CHEMBL3642279	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216006	16290909	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642400	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216014	16290938	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCN(CCCF)CC5)c4)nc23)cc1		CHEMBL3642408	=	IC50	nM	2437.14	CHEMBL2695	Homo sapiens	IC50	nM	2437.14
215856	16291096	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(N5CCOCC5)cc4)nc23)cc1		CHEMBL2062803	=	IC50	nM	461.2	CHEMBL2695	Homo sapiens	IC50	nM	461.2
216198	16291109	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(NCc4ccccn4)nc23)cc1		CHEMBL3645116	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215900	16291597	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccccc5S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642299	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216039	16292108	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCC(n2cc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cn2)CC1		CHEMBL3644960	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216173	16292332	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)COc1ccc(C(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645091	=	IC50	nM	1076.57	CHEMBL2695	Homo sapiens	IC50	nM	1076.57
216005	16292369	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(-c5cccc(CN(C)S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642399	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216186	16292621	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4ccnc(C)c4)nc23)c1		CHEMBL3645104	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216175	16292928	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cncc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)n2)CC1		CHEMBL3645093	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216093	16293284	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Fc1ccc(-n2cc(-c3cccn4nc(Nc5ccc(C6CCNCC6)cc5)nc34)cn2)cc1		CHEMBL3645014	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216080	16294166	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCc2ccc(Nc3nc4c(-c5cc(C(F)(F)F)ccc5F)cccn4n3)cc2CC1		CHEMBL3645001	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215855	16294666	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1-c1cccn2nc(Nc3ccc(N4CCOCC4)cc3)nc12		CHEMBL3642253	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
215899	16294805	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccccc5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642298	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216119	16294998	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nc12		CHEMBL3645039	=	IC50	nM	572.16	CHEMBL2695	Homo sapiens	IC50	nM	572.16
216084	16295024	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncccc1-c1cccn2nc(Nc3ccc(C4CCN(CC(=O)N(C)C)CC4)cc3)nc12		CHEMBL3645005	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216165	16295030	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cc(S(C)(=O)=O)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645083	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216130	16295239	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCN(C(=O)OC(C)(C)C)CC4)cc3)nc12		CHEMBL3645050	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216033	16295824	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(N6CCC(N7CCN(C)CC7)CC6)cc5)cccn4n3)c2)CC1		CHEMBL3644955	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216088	16296220	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCN(C(=O)OC(C)(C)C)CC4)cc3)nc12		CHEMBL3645009	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215960	16296848	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(Nc5cccnc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642356	=	IC50	nM	2065.53	CHEMBL2695	Homo sapiens	IC50	nM	2065.53
216170	16297288	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645088	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215880	16297352	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(Nc4ccccc4S(C)(=O)=O)cccn3n2)cc1		CHEMBL3642284	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216069	16297393	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL3644990	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216097	16297909	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cnc(-c2cccn3nc(Nc4ccc(C5CCN(CC(=O)N(C)C)CC5)cc4)nc23)cn1		CHEMBL3645018	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216095	16298161	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cnc(-c2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)cn1		CHEMBL3645016	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215907	16298496	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)cc2)CC1		CHEMBL3642306	=	IC50	nM	359.4	CHEMBL2695	Homo sapiens	IC50	nM	359.4
216189	16298783	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3cccnc3)nc12		CHEMBL3645107	=	IC50	nM	3115.79	CHEMBL2695	Homo sapiens	IC50	nM	3115.79
216082	16298965	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncccc1-c1cccn2nc(Nc3ccc(C4CCN(C(=O)OC(C)(C)C)CC4)cc3)nc12		CHEMBL3645003	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215867	16299133	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL2062805	=	IC50	nM	410.2	CHEMBL2695	Homo sapiens	IC50	nM	410.2
216141	16299247	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc5c(c4)CNC5)nc23)c1		CHEMBL3645060	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216046	16300470	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Oc1cccn2nc(Nc3ccc(C(F)(F)F)cc3)nc12		CHEMBL3644967	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216164	16300762	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(OCC(F)F)c(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c1		CHEMBL3645082	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
2870	16301187	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cn1ncc2c(-c3cccn4nc(Nc5ccc6c(c5)CCNCC6)nc34)cccc21		CHEMBL3645026	=	IC50	nM	1033.14	CHEMBL2695	Homo sapiens	IC50	nM	1033.14
216022	16301367	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(OCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642416	=	IC50	nM	21.81	CHEMBL2695	Homo sapiens	IC50	nM	21.81
216019	16302024	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(C#Cc5ccccc5N(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642413	=	IC50	nM	2423.72	CHEMBL2695	Homo sapiens	IC50	nM	2423.72
215947	16302186	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(CN5CCS(=O)(=O)CC5)c4)nc23)cc1		CHEMBL2062807	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215894	16302444	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL2062809	=	IC50	nM	265.1	CHEMBL2695	Homo sapiens	IC50	nM	265.1
216177	16302622	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3cccc(N4CCN(C)CC4)c3)nc12		CHEMBL3645095	=	IC50	nM	951.19	CHEMBL2695	Homo sapiens	IC50	nM	951.19
215858	16302666	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(-c2cccn3nc(Nc4ccc(N5CCOCC5)cc4)nc23)cn1		CHEMBL3642255	=	IC50	nM	1477.4	CHEMBL2695	Homo sapiens	IC50	nM	1477.4
216145	16302689	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)c1F		CHEMBL3645064	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216079	16303475	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)CCN1CCc2ccc(Nc3nc4c(-c5cc(C(F)(F)F)ccc5Cl)cccn4n3)cc2CC1		CHEMBL3645000	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
215957	16303867	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2cccc(Nc3nc4c(-c5ccccc5N(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642353	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216010	16304302	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCN(CC(N)=O)CC5)c4)nc23)cc1		CHEMBL3642404	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216115	16304546	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645035	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
216076	16304835	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1cccn2nc(Nc3ccc(S(C)(=O)=O)cc3)nc12		CHEMBL3644997	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216012	16304895	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(N(C)Cc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642406	=	IC50	nM	62.53	CHEMBL2695	Homo sapiens	IC50	nM	62.53
215869	16305217	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2ccc3nc(Nc4ccc(N5CCOCC5)cc4)nn3c2)cc1		CHEMBL3642275	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216197	16305727	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(NCc4cccnc4)nc23)cc1		CHEMBL3645115	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215944	16305807	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4cccc(CN5CCOCC5)c4)nn23)cc1		CHEMBL3642341	=	IC50	nM	1468.32	CHEMBL2695	Homo sapiens	IC50	nM	1468.32
216009	16305890	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(C5CCNCC5)c4)nc23)cc1		CHEMBL3642403	=	IC50	nM	1002.53	CHEMBL2695	Homo sapiens	IC50	nM	1002.53
215942	16306041	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4ccc(CN5CCS(=O)(=O)CC5)cc4)nn23)cc1		CHEMBL3642340	=	IC50	nM	1053.01	CHEMBL2695	Homo sapiens	IC50	nM	1053.01
215857	16306392	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1cncc(-c2cccn3nc(Nc4ccc(N5CCOCC5)cc4)nc23)c1		CHEMBL3642254	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216111	16307105	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCCOc1ccc(Cl)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645031	=	IC50	nM	946.16	CHEMBL2695	Homo sapiens	IC50	nM	946.16
216050	16307853	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COCc1ccccc1-c1cccc2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nn12		CHEMBL3644971	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216149	16308266	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)c1OC		CHEMBL3645068	=	IC50	nM	1906.62	CHEMBL2695	Homo sapiens	IC50	nM	1906.62
215936	16308275	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(Nc5cccc(S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642336	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215903	16308921	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4cccc(-c5ccc(CN6CCS(=O)(=O)CC6)cc5)n4n3)cc2)CC1		CHEMBL3642302	=	IC50	nM	291.0	CHEMBL2695	Homo sapiens	IC50	nM	291.0
216102	16309012	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)COc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645023	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
216146	16309433	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)c1F		CHEMBL3645065	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215994	16309574	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1Cc2ccc(Nc3nc4c(NCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2C1		CHEMBL3642388	=	IC50	nM	17.76	CHEMBL2695	Homo sapiens	IC50	nM	17.76
216015	16309820	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc([C@@H]5CCNC[C@@H]5O)c4)nc23)cc1		CHEMBL3642409	=	IC50	nM	1940.37	CHEMBL2695	Homo sapiens	IC50	nM	1940.37
215861	16310234	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4ccc(N5CCOCC5)cc4)nn23)cc1		CHEMBL3642258	=	IC50	nM	434.0	CHEMBL2695	Homo sapiens	IC50	nM	434.0
216132	16311103	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCN(CC(=O)N(C)C)CC4)cc3)nc12		CHEMBL3645052	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
215924	16311163	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3cccc(-c4ccc(CN5CCS(=O)(=O)CC5)cc4)n3n2)cc1		CHEMBL3642324	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
216166	16311425	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)(F)c1cccc(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c1		CHEMBL3645084	=	IC50	nM	422.01	CHEMBL2695	Homo sapiens	IC50	nM	422.01
215937	16312025	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(Nc5cccc(S(C)(=O)=O)c5)cccn4n3)c2)CC1		CHEMBL3642337	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216110	16312098	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCCOc1ccc(Cl)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645030	=	IC50	nM	1047.75	CHEMBL2695	Homo sapiens	IC50	nM	1047.75
216065	16312120	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc12		CHEMBL3644986	=	IC50	nM	1081.89	CHEMBL2695	Homo sapiens	IC50	nM	1081.89
216191	16312145	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(NCc4ccccc4OC)cccn3n2)cn1		CHEMBL3645109	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216007	16312176	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642401	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215929	16312733	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cc(C(F)(F)F)cn4n3)c2)CC1		CHEMBL3642329	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215967	16313233	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(NCc5ccccc5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642363	=	IC50	nM	123.79	CHEMBL2695	Homo sapiens	IC50	nM	123.79
215859	16313238	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(OCCN5CCCC5)cc4)nc23)cc1		CHEMBL3642256	=	IC50	nM	205.8	CHEMBL2695	Homo sapiens	IC50	nM	205.8
216127	16313573	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(Cl)ccc1-c1cccn2nc(Nc3ccc(C4CCN(CC(=O)N(C)C)CC4)cc3)nc12		CHEMBL3645047	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215964	16313773	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(N2CCN(C)CC2)ccc1Nc1nc2c(NCc3cccnc3N(C)S(C)(=O)=O)cccn2n1		CHEMBL3642360	=	IC50	nM	39.71	CHEMBL2695	Homo sapiens	IC50	nM	39.71
215879	16313953	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(CN5CCOCC5)c4)nc23)cc1		CHEMBL3639411	=	IC50	nM	953.3	CHEMBL2695	Homo sapiens	IC50	nM	953.3
215956	16315001	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2cccc(Nc3nc4c(-c5cccc(N(C)S(C)(=O)=O)c5)cccn4n3)c2)CC1		CHEMBL3642352	=	IC50	nM	759.22	CHEMBL2695	Homo sapiens	IC50	nM	759.22
216016	16315025	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(C#Cc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642410	=	IC50	nM	521.75	CHEMBL2695	Homo sapiens	IC50	nM	521.75
215868	16315065	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL2062804	=	IC50	nM	1056.3	CHEMBL2695	Homo sapiens	IC50	nM	1056.3
216059	16315358	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCc2ccc(Nc3nc4c(-c5cccc6c5OC(F)(F)O6)cccn4n3)cc2CC1		CHEMBL3644980	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215886	16315690	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)S(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCN(C)CC5)c4)nc23)cc1		CHEMBL2062810	=	IC50	nM	865.0	CHEMBL2695	Homo sapiens	IC50	nM	865.0
216104	16316209	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1ccc(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c(OCC(C)C)c1		CHEMBL3645025	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216008	16316290	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCNCC5)c4)nc23)cc1		CHEMBL3642402	=	IC50	nM	1127.21	CHEMBL2695	Homo sapiens	IC50	nM	1127.21
215892	16316399	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5cccc(S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642293	=	IC50	nM	2586.0	CHEMBL2695	Homo sapiens	IC50	nM	2586.0
216018	16316853	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc([C@@H]5CCN(CC(N)=O)C[C@@H]5O)c4)nc23)cc1		CHEMBL3642412	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216144	16316896	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCN(CC(=O)N(C)C)CC5)cc4)nc23)c1		CHEMBL3645063	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216136	16317189	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(C(F)F)ccc1-c1cccn2nc(Nc3ccc(C4CCN(C(=O)OC(C)(C)C)CC4)cc3)nc12		CHEMBL3639439	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215945	16317272	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(Cc2cccc(Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)c2)CC1		CHEMBL3642342	=	IC50	nM	2862.98	CHEMBL2695	Homo sapiens	IC50	nM	2862.98
216147	16317347	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCN(CC(=O)N(C)C)CC5)cc4)nc23)c1F		CHEMBL3645066	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215988	16317530	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5cccc(S(C)(=O)=O)c5)cccn4n3)c2)CC1		CHEMBL3642383	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216131	16317789	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCNCC4)cc3)nc12		CHEMBL3645051	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215996	16317834	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5cccc(N(C)S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642390	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216188	16317851	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4ccncc4)nc23)c1		CHEMBL3645106	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215873	16318048	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(Nc2nc3c(-c4ccc(S(C)(=O)=O)cc4)cccn3n2)c1		CHEMBL2062798	=	IC50	nM	1355.0	CHEMBL2695	Homo sapiens	IC50	nM	1355.0
216077	16318905	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(OCc5ccccc5C(N)=O)cccn4n3)c2)CC1		CHEMBL3644998	=	IC50	nM	1665.67	CHEMBL2695	Homo sapiens	IC50	nM	1665.67
215958	16319350	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(Nc5cccnc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642354	=	IC50	nM	1367.36	CHEMBL2695	Homo sapiens	IC50	nM	1367.36
215891	16320060	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(C2CCN(c3cccc(Nc4nc5c(-c6ccc(S(C)(=O)=O)cc6)cccn5n4)c3)CC2)CC1		CHEMBL2062529	=	IC50	nM	2385.2	CHEMBL2695	Homo sapiens	IC50	nM	2385.2
216043	16320285	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC(F)(F)c1ccc(-c2cccn3nc(Nc4cnn(CCN5CCCC5)c4)nc23)cc1		CHEMBL3644964	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216121	16320618	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(F)ccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3645041	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216031	16320797	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)C(=O)C1		CHEMBL3642424	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215865	16320816	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCOCC5)c4)nc23)cc1		CHEMBL2062802	=	IC50	nM	2022.2	CHEMBL2695	Homo sapiens	IC50	nM	2022.2
215923	16321630	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4cccc(S(C)(=O)=O)c4)nn23)cc1		CHEMBL3642323	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216086	16321949	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5ccc[nH]c5=O)cccn4n3)cc2)CC1		CHEMBL3645007	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
216184	16322065	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5ccccc5F)cccn4n3)c2)CC1		CHEMBL3645102	=	IC50	nM	1482.18	CHEMBL2695	Homo sapiens	IC50	nM	1482.18
215997	16322072	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCC5CCCN5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642391	=	IC50	nM	872.25	CHEMBL2695	Homo sapiens	IC50	nM	872.25
215941	16322867	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(CN5CCS(=O)(=O)CC5)cc4)nc23)cc1		CHEMBL3642339	=	IC50	nM	1477.99	CHEMBL2695	Homo sapiens	IC50	nM	1477.99
216100	16323238	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1ccc(-n2cc(-c3cccn4nc(Nc5ccc(C6CCNCC6)cc5)nc34)cn2)cc1		CHEMBL3645021	=	IC50	nM	2415.34	CHEMBL2695	Homo sapiens	IC50	nM	2415.34
216157	16323599	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(-c2cccn3nc(Nc4ccc(C5CCN(CC(=O)N(C)C)CC5)cc4)nc23)c(F)c1		CHEMBL3645076	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215993	16323725	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1Cc2ccc(Nc3nc4c(NCc5cccnc5N(C)S(C)(=O)=O)cccn4n3)cc2C1		CHEMBL3642387	=	IC50	nM	48.13	CHEMBL2695	Homo sapiens	IC50	nM	48.13
216190	16324436	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3ccncc3)nc12		CHEMBL3645108	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216108	16325450	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	c1ccc(-c2cccn3nc(Nc4ccc5c(c4)CCNCC5)nc23)c(OCC2CC2)c1		CHEMBL3645028	=	IC50	nM	2789.04	CHEMBL2695	Homo sapiens	IC50	nM	2789.04
216061	16326098	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nc12		CHEMBL3644982	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215926	16326176	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	O=[N+]([O-])c1cccc(CNc2cccn3nc(N4CCOCC4)nc23)c1		CHEMBL3642326	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216081	16326339	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Fc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645002	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216060	16326461	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	FC1(F)Oc2cccc(-c3cccn4nc(Nc5ccc6c(c5)CCNCC6)nc34)c2O1		CHEMBL3644981	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216181	16326601	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4cccc(N5CCN(C)CC5)c4)nc23)c1		CHEMBL3645099	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215999	16326674	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(Nc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642393	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215959	16326705	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ncccc1Nc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642355	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216003	16327032	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5cccc(CN(C)S(C)(=O)=O)c5)cccn4n3)c2)CC1		CHEMBL3642397	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215955	16327805	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1cccc(-c2cccn3nc(Nc4ccc(OCCN5CCCC5)cc4)nc23)c1)S(C)(=O)=O		CHEMBL3642351	=	IC50	nM	2306.66	CHEMBL2695	Homo sapiens	IC50	nM	2306.66
215918	16327843	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(NC(=O)Nc3nc4cccc(-c5cccc(S(C)(=O)=O)c5)n4n3)cc2)CC1		CHEMBL3642318	=	IC50	nM	8832.3	CHEMBL2695	Homo sapiens	IC50	nM	8832.3
216150	16328395	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCN(CC(=O)N(C)C)CC5)cc4)nc23)c1OC		CHEMBL3645069	=	IC50	nM	1606.68	CHEMBL2695	Homo sapiens	IC50	nM	1606.68
215862	16328680	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1cccc(-c2cccn3nc(Nc4ccc(OCCN5CCCC5)cc4)nc23)c1		CHEMBL3642259	=	IC50	nM	523.7	CHEMBL2695	Homo sapiens	IC50	nM	523.7
215939	16328697	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(Nc2nc3c(-c4ccc(S(C)(=O)=O)cc4)cccn3n2)cc1		CHEMBL2062801	=	IC50	nM	531.12	CHEMBL2695	Homo sapiens	IC50	nM	531.12
216138	16328893	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(C(F)F)ccc1-c1cccn2nc(Nc3ccc(C4CCN(CC(=O)N(C)C)CC4)cc3)nc12		CHEMBL3645057	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215866	16329248	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1cccc(-c2cccn3nc(Nc4cccc(N5CCOCC5)c4)nc23)c1		CHEMBL3642270	=	IC50	nM	1348.9	CHEMBL2695	Homo sapiens	IC50	nM	1348.9
216035	16329340	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCN1CCN(c2cccc(Nc3nc4c(-c5ccc(P(C)(C)=O)cc5)cccn4n3)c2)C(=O)C1		CHEMBL3639438	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216140	16330233	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Fc1ccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)cc1		CHEMBL3645059	=	IC50	nM	1344.62	CHEMBL2695	Homo sapiens	IC50	nM	1344.62
215969	16330608	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	C[C@H](O)CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642365	=	IC50	nM	935.28	CHEMBL2695	Homo sapiens	IC50	nM	935.28
216176	16330614	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc12		CHEMBL3645094	=	IC50	nM	552.58	CHEMBL2695	Homo sapiens	IC50	nM	552.58
215943	16330667	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(Cc2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL2062806	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215970	16331235	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	C[C@@H](O)CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642366	=	IC50	nM	1986.16	CHEMBL2695	Homo sapiens	IC50	nM	1986.16
215992	16331845	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(Nc5ccccc5CS(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642386	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215995	16332070	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1Cc2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cc2C1		CHEMBL3642389	=	IC50	nM	816.14	CHEMBL2695	Homo sapiens	IC50	nM	816.14
215980	16332175	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5cccnc5)cccn4n3)c2)CC1		CHEMBL3642376	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
215950	16332386	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(NCc5cccnc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642346	=	IC50	nM	77.33	CHEMBL2695	Homo sapiens	IC50	nM	77.33
216196	16332422	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(NCCc4cccnc4)nc23)cc1		CHEMBL3645114	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216074	16332675	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(OCc5ccccc5C#N)cccn4n3)c2)CC1		CHEMBL3644995	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215898	16332869	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(C(F)(F)F)cc5)cccn4n3)c2)CC1		CHEMBL2062811	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216028	16333092	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ccccc1CNc1cccn2nc(Nc3ccc4cnccc4c3)nc12)S(C)(=O)=O		CHEMBL3642421	=	IC50	nM	167.28	CHEMBL2695	Homo sapiens	IC50	nM	167.28
215954	16333205	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5cccc(N(C)S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642350	=	IC50	nM	3134.71	CHEMBL2695	Homo sapiens	IC50	nM	3134.71
215864	16333279	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(OCCN5CCOCC5)cc4)nc23)cc1		CHEMBL3642268	=	IC50	nM	584.9	CHEMBL2695	Homo sapiens	IC50	nM	584.9
216027	16333457	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ccccc1CNc1cccn2nc(Nc3ccc4c(c3)CCC(N3CCOCC3)CC4)nc12)S(C)(=O)=O		CHEMBL3642420	=	IC50	nM	18.18	CHEMBL2695	Homo sapiens	IC50	nM	18.18
215984	16334019	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)c2)CC1		CHEMBL3642380	=	IC50	nM	299.53	CHEMBL2695	Homo sapiens	IC50	nM	299.53
216085	16334606	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncccc1-c1cccn2nc(Nc3ccc4ncccc4c3)nc12		CHEMBL3645006	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215934	16334671	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4cncc(-c5ccc(S(C)(=O)=O)cc5)n4n3)c2)CC1		CHEMBL3642334	=	IC50	nM	854.6	CHEMBL2695	Homo sapiens	IC50	nM	854.6
215971	16334966	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(O)CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642367	=	IC50	nM	2049.42	CHEMBL2695	Homo sapiens	IC50	nM	2049.42
216037	16335259	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1nn(C)c(C)c1Nc1nc2c(-c3ccc(S(C)(=O)=O)cc3)cccn2n1		CHEMBL3644958	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215904	16336047	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4cccc(-c5ccc(CN6CCS(=O)(=O)CC6)cc5)n4n3)c2)CC1		CHEMBL3642303	=	IC50	nM	502.4	CHEMBL2695	Homo sapiens	IC50	nM	502.4
216078	16336096	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(=O)Nc1cccc(Nc2nc3c(-c4ccc(S(C)(=O)=O)cc4)cccn3n2)c1		CHEMBL3644999	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216055	16337183	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccc2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nn12		CHEMBL3644976	=	IC50	nM	714.14	CHEMBL2695	Homo sapiens	IC50	nM	714.14
216092	16337565	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(=O)Nc1ccc(Sc2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)cc1		CHEMBL3645013	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216114	16337579	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nc12		CHEMBL3645034	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216067	16337852	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3cccc(C4CCN(C(=O)OC(C)(C)C)CC4)c3)nc12		CHEMBL3644988	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215931	16337940	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cc(C(F)(F)F)cn4n3)cn2)CC1		CHEMBL3642331	=	IC50	nM	669.3	CHEMBL2695	Homo sapiens	IC50	nM	669.3
215948	16338142	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccc3nc(Nc4cccc(CN5CCS(=O)(=O)CC5)c4)nn23)cc1		CHEMBL3642344	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216057	16338334	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(C(=O)OC(C)(C)C)CC4)nc12		CHEMBL3644978	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215915	16338471	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(Cc2ccc(Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)cc2)CC1		CHEMBL3642315	=	IC50	nM	263.5	CHEMBL2695	Homo sapiens	IC50	nM	263.5
215863	16338555	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(-c4ccc(S(C)(=O)=O)cc4)cccn3n2)cc1		CHEMBL2062799	=	IC50	nM	1580.8	CHEMBL2695	Homo sapiens	IC50	nM	1580.8
216063	16338726	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)CCN1CCc2ccc(Nc3nc4c(-c5cccc6c5OC(F)(F)O6)cccn4n3)cc2CC1		CHEMBL3644984	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215896	16338759	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(N(C)S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3642296	=	IC50	nM	1350.1	CHEMBL2695	Homo sapiens	IC50	nM	1350.1
215922	16338980	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(Nc2nc3cccc(-c4ccc(S(C)(=O)=O)cc4)n3n2)cc1		CHEMBL3642322	=	IC50	nM	531.5	CHEMBL2695	Homo sapiens	IC50	nM	531.5
216098	16339169	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	Cc1ccc(-n2cc(-c3cccn4nc(Nc5ccc(C6CCN(C(=O)OC(C)(C)C)CC6)cc5)nc34)cn2)cc1		CHEMBL3645019	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216116	16340097	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645036	=	IC50	nM	1311.53	CHEMBL2695	Homo sapiens	IC50	nM	1311.53
215870	16340461	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4ccc(-c5ccc(S(C)(=O)=O)cc5)cn4n3)cc2)CC1		CHEMBL3642276	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215912	16340953	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4cccc(-c5cccc(NS(C)(=O)=O)c5)n4n3)cc2)CC1		CHEMBL3642312	=	IC50	nM	552.7	CHEMBL2695	Homo sapiens	IC50	nM	552.7
215885	16341739	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)S(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc(N5CCN(C)CC5)cc4)nc23)cc1		CHEMBL3642289	=	IC50	nM	306.4	CHEMBL2695	Homo sapiens	IC50	nM	306.4
216096	16342068	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cnc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)cn1		CHEMBL3645017	=	IC50	nM	2467.32	CHEMBL2695	Homo sapiens	IC50	nM	2467.32
215905	16342130	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(Nc5ccccc5S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642304	=	IC50	nM	379.8	CHEMBL2695	Homo sapiens	IC50	nM	379.8
216030	16342416	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CP(C)(=O)c1ccc(-c2cccn3nc(Nc4cccc(C5CCN(CCS(C)(=O)=O)CC5)c4)nc23)cc1		CHEMBL3642423	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215911	16342741	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4cccc(-c5cccc(S(C)(=O)=O)c5)n4n3)cc2)CC1		CHEMBL2414545	=	IC50	nM	584.0	CHEMBL2695	Homo sapiens	IC50	nM	584.0
216185	16343370	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(NCc5ccc(F)cc5)cccn4n3)c2)CC1		CHEMBL3645103	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216054	16343877	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cc(C(F)(F)F)ccc1-c1cccc2nc(Nc3ccc4c(c3)CCNCC4)nn12		CHEMBL3644975	=	IC50	nM	1013.31	CHEMBL2695	Homo sapiens	IC50	nM	1013.31
216024	16344019	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(Nc1cccn2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc12)c1ccccc1N(C)S(C)(=O)=O		CHEMBL3642418	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
215872	16344313	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(-c4cn[nH]c4)cccn3n2)cc1		CHEMBL3642278	=	IC50	nM	2357.8	CHEMBL2695	Homo sapiens	IC50	nM	2357.8
215974	16344349	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642370	=	IC50	nM	11.39	CHEMBL2695	Homo sapiens	IC50	nM	11.39
215916	16344572	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1cccc(-c2cccc3nc(Nc4ccc(CN5CCOCC5)cc4)nn23)c1		CHEMBL3642316	=	IC50	nM	341.2	CHEMBL2695	Homo sapiens	IC50	nM	341.2
216135	16344677	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)C4)nc12		CHEMBL3645055	=	IC50	nM	1365.43	CHEMBL2695	Homo sapiens	IC50	nM	1365.43
216064	16344736	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cccc6c5OC(F)(F)O6)cccn4n3)cc2CC1		CHEMBL3644985	=	IC50	nM	1697.77	CHEMBL2695	Homo sapiens	IC50	nM	1697.77
216000	16345775	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(Cc1ccccc1Nc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12)S(C)(=O)=O		CHEMBL3642394	=	IC50	nM	1999.0	CHEMBL2695	Homo sapiens	IC50	nM	1999.0
215902	16345886	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccccc1Nc1nc2c(Nc3ccccc3S(C)(=O)=O)cccn2n1		CHEMBL3642301	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
216011	16345904	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(C5CCN(CC(N)=O)CC5)c4)nc23)cc1		CHEMBL3642405	=	IC50	nM	384.26	CHEMBL2695	Homo sapiens	IC50	nM	384.26
216158	16346142	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)c1cccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)c1		CHEMBL3645077	=	IC50	nM	1748.45	CHEMBL2695	Homo sapiens	IC50	nM	1748.45
216148	16346193	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(-c2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)c1OC		CHEMBL3645067	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216152	16346515	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	N#Cc1ccc(-c2cccn3nc(Nc4ccc(C5CCNCC5)cc4)nc23)cc1		CHEMBL3645071	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215881	16346566	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(CS(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL3642285	=	IC50	nM	1718.5	CHEMBL2695	Homo sapiens	IC50	nM	1718.5
216154	16347172	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(-c2cccn3nc(Nc4ccc(C5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc23)c(F)c1		CHEMBL3645073	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215890	16347246	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1		CHEMBL2062808	=	IC50	nM	1178.1	CHEMBL2695	Homo sapiens	IC50	nM	1178.1
215961	16347508	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ncccc1CNc1cccn2nc(Nc3ccc(S(C)(=O)=O)cc3)nc12)S(C)(=O)=O		CHEMBL3642357	=	IC50	nM	751.66	CHEMBL2695	Homo sapiens	IC50	nM	751.66
215935	16347510	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cncc(Nc3nc4cncc(-c5ccc(S(C)(=O)=O)cc5)n4n3)c2)CC1		CHEMBL3642335	=	IC50	nM	3374.2	CHEMBL2695	Homo sapiens	IC50	nM	3374.2
216087	16347626	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	O=c1[nH]cccc1-c1cccn2nc(Nc3ccc4ncccc4c3)nc12		CHEMBL3645008	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215962	16347858	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ncccc1CNc1cccn2nc(Nc3cccc(S(C)(=O)=O)c3)nc12)S(C)(=O)=O		CHEMBL3642358	=	IC50	nM	215.11	CHEMBL2695	Homo sapiens	IC50	nM	215.11
216183	16348879	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1cccc(CNc2cccn3nc(Nc4ccc(OC)nc4)nc23)c1		CHEMBL3645101	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215972	16348885	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4ccc5c(c4)CCC(N4CCOCC4)CC5)nc23)cc1		CHEMBL3642368	=	IC50	nM	670.93	CHEMBL2695	Homo sapiens	IC50	nM	670.93
216174	16348901	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cc(C(F)F)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645092	=	IC50	nM	1120.97	CHEMBL2695	Homo sapiens	IC50	nM	1120.97
215998	16349014	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(Nc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642392	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
215875	16349033	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(Nc2nc3c(-c4cnn(S(C)(=O)=O)c4)cccn3n2)cc1		CHEMBL3642280	=	IC50	nM	507.4	CHEMBL2695	Homo sapiens	IC50	nM	507.4
215991	16349045	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(Nc5ccccc5CS(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642385	=	IC50	nM	1281.18	CHEMBL2695	Homo sapiens	IC50	nM	1281.18
215973	16349206	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1C(=O)Cc2cc(Nc3nc4c(NCc5cccnc5N(C)S(C)(=O)=O)cccn4n3)ccc21		CHEMBL3642369	=	IC50	nM	105.75	CHEMBL2695	Homo sapiens	IC50	nM	105.75
216134	16349648	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNC4)nc12		CHEMBL3645054	=	IC50	nM	778.47	CHEMBL2695	Homo sapiens	IC50	nM	778.47
216041	16349797	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(Oc5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1		CHEMBL3644962	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216117	16349809	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CCS(C)(=O)=O)CC4)nc12		CHEMBL3645037	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215978	16349812	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(NCc5cccnc5)cccn4n3)cc2)CC1		CHEMBL3642374	=	IC50	nM	6499.0	CHEMBL2695	Homo sapiens	IC50	nM	6499.0
215910	16350963	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)cc2)CC1		CHEMBL2414547	=	IC50	nM	421.2	CHEMBL2695	Homo sapiens	IC50	nM	421.2
216089	16351420	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ncc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc(C4CCNCC4)cc3)nc12		CHEMBL3645010	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216002	16351629	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5cccc(CN(C)S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3642396	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216023	16351630	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(/C=C/c5ccccc5N(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642417	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
216162	16352191	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5ccccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645080	=	IC50	nM	2432.11	CHEMBL2695	Homo sapiens	IC50	nM	2432.11
215884	16352226	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(C2CCN(c3ccc(Nc4nc5c(-c6ccc(S(C)(=O)=O)cc6)cccn5n4)cc3)CC2)CC1		CHEMBL3642288	=	IC50	nM	168.3	CHEMBL2695	Homo sapiens	IC50	nM	168.3
215909	16352877	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1cccc(-c2cccc3nc(Nc4ccc(N5CCOCC5)cc4)nn23)c1		CHEMBL3642309	=	IC50	nM	1531.0	CHEMBL2695	Homo sapiens	IC50	nM	1531.0
215930	16352992	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cc(C(F)(F)F)cn4n3)cc2)CC1		CHEMBL3642330	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215946	16353179	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(c1ccc(-c2cccn3nc(Nc4ccc(CN5CCS(=O)(=O)CC5)cc4)nc23)cc1)S(C)(=O)=O		CHEMBL3642343	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216044	16353201	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccc(Oc2cccn3nc(Nc4cnn(CCN5CCCC5)c4)nc23)cc1		CHEMBL3644965	=	IC50	nM	1223.29	CHEMBL2695	Homo sapiens	IC50	nM	1223.29
216151	16353568	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCC(c2ccc(Nc3nc4c(-c5ccc(C#N)cc5)cccn4n3)cc2)CC1		CHEMBL3645070	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216142	16353644	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5ccc(F)cc5)cccn4n3)cc2)CC1		CHEMBL3645061	=	IC50	nM	1477.52	CHEMBL2695	Homo sapiens	IC50	nM	1477.52
216153	16353720	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5ccc(C#N)cc5)cccn4n3)cc2)CC1		CHEMBL3645072	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
215927	16354052	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	NC1CCN(c2nc3c(NCc4cccnc4)cccn3n2)CC1		CHEMBL3642327	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216066	16354192	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3cccc(N4CCN(C)CC4)c3)nc12		CHEMBL3644987	=	IC50	nM	1215.18	CHEMBL2695	Homo sapiens	IC50	nM	1215.18
215953	16354374	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CS(=O)(=O)c1ccccc1Nc1cccn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL3642349	=	IC50	nM	1297.82	CHEMBL2695	Homo sapiens	IC50	nM	1297.82
216042	16354693	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCn1cc(Nc2nc3c(-c4ccc(C(F)(F)F)cc4)cccn3n2)cn1		CHEMBL3644963	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216075	16354705	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(Nc3nc4c(O)cccn4n3)cc2)CC1		CHEMBL3644996	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215883	16354842	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)cc2)CC1		CHEMBL3642287	=	IC50	nM	568.8	CHEMBL2695	Homo sapiens	IC50	nM	568.8
215919	16355265	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2ccc(NC(=O)Nc3nc4cccc(-c5ccc(S(C)(=O)=O)cc5)n4n3)cc2)CC1		CHEMBL3642319	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
216169	16355356	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)COc1ccc(C(F)(F)F)cc1-c1cccn2nc(Nc3ccc4c(c3)CCNCC4)nc12		CHEMBL3645087	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216099	16355487	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCN(c2cccc(Nc3nc4c(-c5cnn(-c6ccc(F)cc6)c5)cccn4n3)c2)CC1		CHEMBL3645020	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216192	16355493	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1CNc1cccn2nc(Nc3ccc(C)nc3)nc12		CHEMBL3645110	=	IC50	nM	1882.86	CHEMBL2695	Homo sapiens	IC50	nM	1882.86
216159	16355689	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCC(c2ccc(Nc3nc4c(-c5cccc(N(C)C)c5)cccn4n3)cc2)CC1		CHEMBL3645078	=	IC50	nM	862.75	CHEMBL2695	Homo sapiens	IC50	nM	862.75
216091	16356377	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CC(C)(C)OC(=O)N1CCC(c2ccc(Nc3nc4c(-c5cnn(-c6ccc(F)cc6)c5)cccn4n3)cc2)CC1		CHEMBL3645012	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215889	16356700	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	COc1ccccc1-c1cccn2nc(Nc3cccc(N4CCN(C)CC4)c3)nc12		CHEMBL3642292	=	IC50	nM	2999.0	CHEMBL2695	Homo sapiens	IC50	nM	2999.0
216062	16356909	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CCOc1ccccc1-c1cccn2nc(Nc3ccc4c(c3)CCN(CC(=O)N(C)C)CC4)nc12		CHEMBL3644983	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
215986	16357008	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(NCc5ccccc5CN(C)S(C)(=O)=O)cccn4n3)cc2)CC1		CHEMBL3642382	=	IC50	nM	537.99	CHEMBL2695	Homo sapiens	IC50	nM	537.99
216126	16357074	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN(C)C(=O)CN1CCc2ccc(Nc3nc4c(-c5cc(C(F)(F)F)ccc5OCC(F)F)cccn4n3)cc2CC1		CHEMBL3645046	=	IC50	nM	999.0	CHEMBL2695	Homo sapiens	IC50	nM	999.0
	16370660	CHEMBL3734199	Inhibition of Fak (unknown origin)	B	CCCS(=O)(=O)Nc1ccc(Cl)c(C(=O)Nc2ccc(NC(C)=O)nc2)c1F		CHEMBL3732214	<=	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	16421908	CHEMBL3750390	Inhibition of FAK (unknown origin)	B	C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1		CHEMBL3651966	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	16425324	CHEMBL3751371	Inhibition of FAK (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	3.6	CHEMBL2695	Homo sapiens	INH	%	3.6
	16431829	CHEMBL3748183	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	16450839	CHEMBL3762695	Inhibition of FAK (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	7.2	CHEMBL2695	Homo sapiens	INH	%	7.2
	16458625	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccccc3C(N)=O)cc12)c1ccccc1		CHEMBL3759085	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	16458626	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3758800	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16458627	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	CN(C)CCNC(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1		CHEMBL3758376	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16458628	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3759480	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	16458629	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1ccc(C(=O)NCCN(C)C)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3758582	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	16458630	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3759559	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	16458631	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3758682	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	16458632	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1		CHEMBL3758768	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	16458633	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3sc(-c4ccc(CO)cc4OC)cc23)c1		CHEMBL3758802	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	16458634	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1		CHEMBL3758351	=	Inhibition	%	16.0	CHEMBL2695	Homo sapiens	INH	%	16.0
	16458635	CHEMBL3761601	Inhibition of PTK2 (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-3.0	CHEMBL2695	Homo sapiens	INH	%	-3.0
	16465833	CHEMBL3767846	Inhibition of human FAK at 10 uM	B	Cc1cncn1-c1cc(C(=O)Nc2cccc(CNc3ccc4c(C(=O)N[C@@H](C)C(N)=O)[nH]nc4c3)c2)cc(C(F)(F)F)c1		CHEMBL3764798	=	Inhibition	%	8.88	CHEMBL2695	Homo sapiens	INH	%	8.88
	16485724	CHEMBL3771573	Inhibition of human recombinant FAK assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	16495988	CHEMBL3778579	Inhibition of N-terminal His6-tagged recombinant human FAK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-10.0	CHEMBL2695	Homo sapiens	Activity	%	-10.0
	16508175	CHEMBL3778579	Inhibition of N-terminal His6-tagged recombinant human FAK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	4.0	CHEMBL2695	Homo sapiens	Activity	%	4.0
	16509152	CHEMBL3778579	Inhibition of N-terminal His6-tagged recombinant human FAK expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-14.0	CHEMBL2695	Homo sapiens	Activity	%	-14.0
Not Active	16514123	CHEMBL3782171	Inhibition of partial length human FAK expressed in bacterial system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	16515642	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Clc1ccccc1Cc1nnc(Cn2nnc3ccccc32)o1		CHEMBL3780479	=	IC50	nM	3900.0	CHEMBL2695	Homo sapiens	IC50	uM	3.9
	16515643	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1ccc(N(Cc2cc(Br)ccc2O)C(=O)Nc2ccccc2)c(F)c1		CHEMBL3780912	=	IC50	nM	26500.0	CHEMBL2695	Homo sapiens	IC50	uM	26.5
	16515644	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Cc1ccc(N(Cc2cc(Br)ccc2O)C(=O)Nc2ccccc2)c(F)c1		CHEMBL3780468	=	IC50	nM	10630.0	CHEMBL2695	Homo sapiens	IC50	uM	10.63
	16516131	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	c1ccc(Cc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3781975	=	IC50	nM	2200.0	CHEMBL2695	Homo sapiens	IC50	uM	2.2
	16516132	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Brc1cccc(Cc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3780752	=	IC50	nM	2600.0	CHEMBL2695	Homo sapiens	IC50	uM	2.6
	16516133	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Brc1ccc(Cc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3780915	=	IC50	nM	2900.0	CHEMBL2695	Homo sapiens	IC50	uM	2.9
	16516134	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Clc1cccc(Cc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3781990	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	uM	3.2
	16516135	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Fc1cccc(Cc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3781207	=	IC50	nM	3300.0	CHEMBL2695	Homo sapiens	IC50	uM	3.3
	16516136	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1cccc(Cc2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3781134	=	IC50	nM	1100.0	CHEMBL2695	Homo sapiens	IC50	uM	1.1
	16516137	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1ccc(Cc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3781092	=	IC50	nM	1800.0	CHEMBL2695	Homo sapiens	IC50	uM	1.8
	16516138	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1ccccc1Cc1nnc(Cn2nnc3ccccc32)o1		CHEMBL3781620	=	IC50	nM	250.0	CHEMBL2695	Homo sapiens	IC50	uM	0.25
	16516139	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	O=[N+]([O-])c1ccc(Cc2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3780545	=	IC50	nM	1900.0	CHEMBL2695	Homo sapiens	IC50	uM	1.9
	16516140	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Brc1cccc(-c2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3781339	=	IC50	nM	6600.0	CHEMBL2695	Homo sapiens	IC50	uM	6.6
	16516141	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Brc1ccc(-c2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3781937	=	IC50	nM	5700.0	CHEMBL2695	Homo sapiens	IC50	uM	5.7
	16516142	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Clc1cccc(-c2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3780194	=	IC50	nM	3900.0	CHEMBL2695	Homo sapiens	IC50	uM	3.9
	16516143	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Fc1cccc(-c2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3779918	=	IC50	nM	3800.0	CHEMBL2695	Homo sapiens	IC50	uM	3.8
	16516144	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1cccc(-c2nnc(Cn3nnc4ccccc43)o2)c1		CHEMBL3781804	=	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	uM	3.5
	16516145	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1ccc(-c2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3780187	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	uM	3.2
	16516146	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	COc1ccccc1-c1nnc(Cn2nnc3ccccc32)o1		CHEMBL3779977	=	IC50	nM	3200.0	CHEMBL2695	Homo sapiens	IC50	uM	3.2
	16516147	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	O=[N+]([O-])c1ccc(-c2nnc(Cn3nnc4ccccc43)o2)cc1		CHEMBL3781302	=	IC50	nM	3800.0	CHEMBL2695	Homo sapiens	IC50	uM	3.8
	16516156	CHEMBL3784610	Inhibition of human full length recombinant FAK after 4 hrs by Kinase-Glo-luminescence assay	B	Cc1ncc([N+](=O)[O-])n1CCOc1ncnc2ccc([N+](=O)[O-])cc12		CHEMBL3780567	=	IC50	nM	10400.0	CHEMBL2695	Homo sapiens	IC50	uM	10.4
	16534390	CHEMBL3789040	Inhibition of human FAK at 1 uM after 30 mins by fluorescence assay in presence of ATP	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C		CHEMBL3786892	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
Active	16535713	CHEMBL3788863	Inhibition of FAK signaling pathway in human A549 cells assessed as decrease in OPN-induced FAK phosphorylation at 5 to 10 uM after 15 mins by Western blot analysis	B	C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/CC1		CHEMBL245412		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	16565458	CHEMBL3802855	Inhibition of N-terminal FLAG-tagged FAK cytoplasmic domain (unknown origin) expressed in baculovirus preincubated for 5 mins measured after 20 mins in presence of ATP by AlphaScreen assay	B	C[C@H](c1ccccc1)N1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798011	>	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
	16565632	CHEMBL3803246	Inhibition of human recombinant FAK expressed in baculovirus infected sf9 cells using KVEKIGEGTYGVVYK as substrate at 100 uM incubated for 10 mins by scintillation counting method relative to control	B	COc1ccc(/C=N/Nc2cc(C)c3ccccc3n2)cc1		CHEMBL3798597	=	Inhibition	%	11.0	CHEMBL2695	Homo sapiens	INH	%	11.0
	16565633	CHEMBL3803246	Inhibition of human recombinant FAK expressed in baculovirus infected sf9 cells using KVEKIGEGTYGVVYK as substrate at 100 uM incubated for 10 mins by scintillation counting method relative to control	B	C/C(=N\Nc1ccc2ccccc2n1)c1ccccc1O		CHEMBL1892026	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	16565634	CHEMBL3803246	Inhibition of human recombinant FAK expressed in baculovirus infected sf9 cells using KVEKIGEGTYGVVYK as substrate at 100 uM incubated for 10 mins by scintillation counting method relative to control	B	Cc1cc(N/N=C/c2ccc(O)cc2)nc2ccccc12		CHEMBL3799359	=	Inhibition	%	13.0	CHEMBL2695	Homo sapiens	INH	%	13.0
	16565635	CHEMBL3803246	Inhibition of human recombinant FAK expressed in baculovirus infected sf9 cells using KVEKIGEGTYGVVYK as substrate at 100 uM incubated for 10 mins by scintillation counting method relative to control	B	COc1ccc(-c2nnc3c(NCCN4CCOCC4)cccn23)cc1OC		CHEMBL3798991	=	Inhibition	%	8.0	CHEMBL2695	Homo sapiens	INH	%	8.0
	16565691	CHEMBL3801098	Inhibition of FAK (unknown origin)	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	570.0	CHEMBL2695	Homo sapiens	Kd	nM	570.0
Not Active	16565692	CHEMBL3801098	Inhibition of FAK (unknown origin)	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Kd			CHEMBL2695	Homo sapiens	Kd		
	16580638	CHEMBL3802866	Inhibition of N-terminal FLAG-tagged FAK cytoplasmic domain (unknown origin) expressed in baculovirus preincubated for 5 mins at 1 uM measured after 20 mins in presence of ATP by AlphaScreen assay	B	CCN1c2cc(-c3c[nH]c4ncccc34)ccc2C(=O)NC1(C)C		CHEMBL3798713	=	Inhibition	%	73.0	CHEMBL2695	Homo sapiens	INH	%	73.0
	16580639	CHEMBL3802866	Inhibition of N-terminal FLAG-tagged FAK cytoplasmic domain (unknown origin) expressed in baculovirus preincubated for 5 mins at 1 uM measured after 20 mins in presence of ATP by AlphaScreen assay	B	CCN1c2cc(-n3c(=O)[nH]c4ncccc43)ccc2C(=O)NC1(C)C		CHEMBL3798933	=	Inhibition	%	2.0	CHEMBL2695	Homo sapiens	INH	%	2.0
	16586978	CHEMBL3807415	Inhibition of FAK (unknown origin) in presence of gamma33-ATP	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	IC50	nM	140.0	CHEMBL2695	Homo sapiens	IC50	uM	0.14
	16593488	CHEMBL3812171	Inhibition of full length GST-tagged human recombinant FAK expressed in baculovirus using Fluorescein-Poly GT as substrate at 100 nM	B	COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1		CHEMBL3808884	<	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	INH	%	40.0
	16594891	CHEMBL3812248	Inhibition of human FAK (402 to 696 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	95.0	CHEMBL2695	Homo sapiens	Activity	%	95.0
	16614472	CHEMBL3816602	Inhibition of human FAK at 1 uM using poly[Glu:Tyr] (4:1) as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-5.0	CHEMBL2695	Homo sapiens	INH	%	-5.0
	16618222	CHEMBL3816332	Inhibition of recombinant human GST-tagged FAK expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
Active	16640088	CHEMBL3824536	Inhibition of FAK phosphorylation at tyrosine 861 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis	B	COc1cc(-c2nn(CCN3CCC(N(C)C)CC3)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C		CHEMBL3824089		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	16640089	CHEMBL3824536	Inhibition of FAK phosphorylation at tyrosine 861 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	16739531	CHEMBL3857076	Inhibition of GST tagged recombinant full length human PTK2 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3901622	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16739532	CHEMBL3857076	Inhibition of GST tagged recombinant full length human PTK2 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCCCC4)cc3)cc12)c1ccccc1		CHEMBL3891846	=	Inhibition	%	16.0	CHEMBL2695	Homo sapiens	INH	%	16.0
	16739533	CHEMBL3857076	Inhibition of GST tagged recombinant full length human PTK2 expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-3.0	CHEMBL2695	Homo sapiens	INH	%	-3.0
	16744133	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
	16744134	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@H](N1CCN(C)CC1)C2		CHEMBL3936443	=	IC50	nM	8.5	CHEMBL2695	Homo sapiens	IC50	nM	8.5
	16744135	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@@H](N1CCN(C)CC1)C2		CHEMBL3980825	=	IC50	nM	6.5	CHEMBL2695	Homo sapiens	IC50	nM	6.5
	16744136	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3N(C)S(C)(=O)=O)n2)ccc2c1CCCC(N1CCN(C)CC1)C2		CHEMBL3961771	=	IC50	nM	2.2	CHEMBL2695	Homo sapiens	IC50	nM	2.2
	16744137	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3N(C)S(C)(=O)=O)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2		CHEMBL3934268	=	IC50	nM	2.4	CHEMBL2695	Homo sapiens	IC50	nM	2.4
	16744138	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3NS(C)(=O)=O)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2		CHEMBL3953048	=	IC50	nM	9.3	CHEMBL2695	Homo sapiens	IC50	nM	9.3
	16744139	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3N3CCCS3(=O)=O)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2		CHEMBL3925372	=	IC50	nM	3.8	CHEMBL2695	Homo sapiens	IC50	nM	3.8
	16744140	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCCC(N2CCN(CCO)CC2)C3)ncc1Cl		CHEMBL3890564	=	IC50	nM	3.1	CHEMBL2695	Homo sapiens	IC50	nM	3.1
	16744141	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3-n3cccn3)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2		CHEMBL3934099	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
	16744142	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1c(Nc2ncc(Cl)c(Nc3ccccc3-c3nccn3C)n2)ccc2c1CCCC(N1CCN(CCO)CC1)C2		CHEMBL3961598	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	16744143	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	COc1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCCC(N2CCN(CCO)CC2)C3)ncc1Cl		CHEMBL3943066	=	IC50	nM	42.0	CHEMBL2695	Homo sapiens	IC50	nM	42.0
	16744144	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@@H](N2CCN(CCO)CC2)C3)ncc1Cl		CHEMBL3972653	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
	16744145	CHEMBL3858244	Inhibition of human FAK expressed in baculovirus after 30 mins using biotinyl-amino-hexanoyl-EQEDEPEGDYFEWLE-amide as substrate by TRF assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl		CHEMBL3951811	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
	16744214	CHEMBL3858261	Inhibition of FAK phosphorylation in human HCC827 cells after 2 to 2.5 hrs by immunoblot analysis	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	=	IC50	nM	944.0	CHEMBL2695	Homo sapiens	IC50	nM	944.0
	16744215	CHEMBL3858261	Inhibition of FAK phosphorylation in human HCC827 cells after 2 to 2.5 hrs by immunoblot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl		CHEMBL3951811	=	IC50	nM	80.0	CHEMBL2695	Homo sapiens	IC50	nM	80.0
	16804190	CHEMBL3869781	Inhibition of human recombinant full length GST-tagged PTK2 cytoplasmic domain expressed in baculovirus expression system at 200 nM by Z'-LYTE assay	B	Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1		CHEMBL3979920	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	16824323	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CN1Cc2ccncc2N(S(C)(=O)=O)C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3977870	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
	16824324	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	C=CCN(c1cnccc1CN(C)c1nc(Nc2ccc(N3CCOCC3)c(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3898282	=	IC50	nM	7496.0	CHEMBL2695	Homo sapiens	IC50	nM	7496.0
	16824325	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CN1Cc2cccnc2N(S(C)(=O)=O)C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3969464	=	IC50	nM	5.75	CHEMBL2695	Homo sapiens	IC50	nM	5.75
	16824326	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1CCCc2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3987106	=	IC50	nM	3.21	CHEMBL2695	Homo sapiens	IC50	nM	3.21
	16824327	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3958414	=	IC50	nM	4.34	CHEMBL2695	Homo sapiens	IC50	nM	4.34
	16824328	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	C=CCN(c1ncccc1CNc1nc(Nc2ccc(N3CCOCC3)c(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3965256	=	IC50	nM	0.51	CHEMBL2695	Homo sapiens	IC50	nM	0.51
	16824329	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1CCCc2cccc(c2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3949755	=	IC50	nM	1.26	CHEMBL2695	Homo sapiens	IC50	nM	1.26
	16824330	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1C/C=C/c2cccc(c2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3961368	=	IC50	nM	10.2	CHEMBL2695	Homo sapiens	IC50	nM	10.2
	16824331	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	C=CCN(c1ncccc1CNc1nc(Nc2cccc(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3892377	=	IC50	nM	0.51	CHEMBL2695	Homo sapiens	IC50	nM	0.51
	16824332	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CN1Cc2ccccc2N(S(C)(=O)=O)CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3899046	=	IC50	nM	8.6	CHEMBL2695	Homo sapiens	IC50	nM	8.6
	16824333	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CN(Cc1ccccc1N(CCCCC(=O)O)S(C)(=O)=O)c1nc(Nc2ccc3c(c2)CCN3)ncc1C(F)(F)F		CHEMBL3927099	=	IC50	nM	177.0	CHEMBL2695	Homo sapiens	IC50	nM	177.0
	16824334	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CCS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2ccccc21		CHEMBL3908093	=	IC50	nM	9.2	CHEMBL2695	Homo sapiens	IC50	nM	9.2
	16824335	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CCS(=O)(=O)N(CCCCC(=O)O)c1ccccc1CNc1nc(Nc2ccc3c(c2)CCN3)ncc1C(F)(F)F		CHEMBL3936048	=	IC50	nM	3.3	CHEMBL2695	Homo sapiens	IC50	nM	3.3
	16824336	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2ccccc21		CHEMBL3956954	=	IC50	nM	3.2	CHEMBL2695	Homo sapiens	IC50	nM	3.2
	16824337	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3889951	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
	16824344	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1CCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3914036	=	IC50	nM	27.0	CHEMBL2695	Homo sapiens	IC50	nM	27.0
	16824347	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	O=C1CCCNS(=O)(=O)c2ncccc2CNc2nc(ncc2C(F)(F)F)Nc2ccc3c(c2)CCN13		CHEMBL3912281	=	IC50	nM	11.4	CHEMBL2695	Homo sapiens	IC50	nM	11.4
	16824350	CHEMBL3873677	Inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CS(=O)(=O)N1Cc2cccc(c2)C(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3939286	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	16824353	CHEMBL3873683	Reversible/competitive inhibition of NH2-terminal His6-tagged FAK kinase domain (410 to 689 residues) (unknown origin) expressed in baculovirus infected sf9 cells using p(Glu/Tyr) as substrate in presence of ATP	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	16883082	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	=	Inhibition	%	12.0	CHEMBL2695	Homo sapiens	INH	%	12.0
	16883083	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCn1nc(C)cc1C(=O)Nc1cccc(C(=O)c2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)c1		CHEMBL3915607	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	16883084	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	Cc1cc(C(=O)Nc2cccc(C(=O)c3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)c2)n(C)n1		CHEMBL3891895	=	Inhibition	%	9.0	CHEMBL2695	Homo sapiens	INH	%	9.0
	16883085	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCn1nc(C)cc1C(=O)Nc1cccc(Oc2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)c1		CHEMBL3953227	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	16883086	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CC(C)ONC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL3955019	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16883087	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCn1nc(C)cc1C(=O)Nc1cc(C(=O)c2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)ccc1C		CHEMBL3930485	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16883088	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCCn1nc(C)cc1C(=O)Nc1cccc(C(=O)c2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)c1		CHEMBL3901827	=	Inhibition	%	5.0	CHEMBL2695	Homo sapiens	INH	%	5.0
	16883089	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	C#CCNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL3965277	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	16883090	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCONC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL3963146	=	Inhibition	%	4.0	CHEMBL2695	Homo sapiens	INH	%	4.0
	16883091	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	CCn1nc(C)cc1C(=O)Nc1cc(Nc2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)c(F)cc1C		CHEMBL3982880	=	Inhibition	%	11.0	CHEMBL2695	Homo sapiens	INH	%	11.0
	16883092	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	O=C(NNc1ccccn1)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL3931953	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	16883093	CHEMBL3881064	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 1 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	C=CCn1nc(C)cc1C(=O)Nc1cccc(C(=O)c2ccc3c(/C=C/c4ccccn4)n[nH]c3c2)c1		CHEMBL3904168	=	Inhibition	%	9.0	CHEMBL2695	Homo sapiens	INH	%	9.0
	16883105	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	COc1cc(-c2ccc3c(/C=C/c4ccc(OC)c(OC)c4)n[nH]c3c2)ccc1O		CHEMBL3923888	=	Inhibition	%	69.0	CHEMBL2695	Homo sapiens	INH	%	69.0
	16883106	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	COc1cc(-c2ccc3c(-c4cc5ccccc5[nH]4)n[nH]c3c2)ccc1O		CHEMBL3891392	=	Inhibition	%	26.0	CHEMBL2695	Homo sapiens	INH	%	26.0
	16883107	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	C(=C/c1n[nH]c2cc(Oc3ccccc3)ccc12)\c1ccccc1		CHEMBL3975092	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	16883108	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	C(=C/c1n[nH]c2cc(Sc3ccccc3)ccc12)\c1ccccc1		CHEMBL3915562	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	16883109	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	Oc1ccc(Oc2ccc3c(/C=C/c4ccccc4)n[nH]c3c2)cc1		CHEMBL3946793		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	16883110	CHEMBL3881109	Inhibition of human FAK P410T mutant expressed in baculovirus expression system at 10 uM using poly Glu-Tyr (4:1) as substrate by fluorescence polarization method	B	C=C(c1ccccc1)c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1		CHEMBL3901866		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
215989	17605127	CHEMBL3705306	In Vitro Enzyme Assay: The ability of compounds to inhibit the kinase activity of baculovirus-expressed human FAK and JAK kinase using the time-resolved fluorescence (TRF) assay system.	B	CN1CCC(c2ccc(Nc3nc4c(NCc5cccc(S(C)(=O)=O)c5)cccn4n3)cc2)CC1		CHEMBL3935745	=	IC50	nM	9999.0	CHEMBL2695	Homo sapiens	IC50	nM	9999.0
225440	17613961	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cn2)CC1		CHEMBL3642818	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
225441	17613962	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	Cc1ccc(Nc2ncc3scc(-c4cccc(NS(C)(=O)=O)c4)c3n2)cn1		CHEMBL3642819	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
225442	17613963	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCOCC5)nc4)nc23)c1		CHEMBL3642820	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
225443	17613964	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	CN(C)CCOc1ccc(Nc2ncc3scc(-c4cccc(NS(C)(=O)=O)c4)c3n2)cn1		CHEMBL3642821	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
225444	17613965	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(C(=O)NC6CC6)c5)c4n3)cn2)CC1		CHEMBL3642822	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
225445	17613966	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	Cc1ccc(Nc2ncc3scc(-c4cccc(C(=O)NC5CC5)c4)c3n2)cn1		CHEMBL3642823	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
225446	17613967	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	O=C(NC1CC1)c1cccc(-c2csc3cnc(Nc4ccc(N5CCOCC5)nc4)nc23)c1		CHEMBL3642824	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
225447	17613968	CHEMBL3705136	Kinase Assay: FAK kinase assay using ulight-LANCE assay purchased from PerkinElmer (catalog # TRF0100-D).	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cnc6ccccc6c5)c4n3)cn2)CC1		CHEMBL3642825	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
256894	17639662	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CCC3C)n1		CHEMBL3665866	=	IC50	nM	88.0	CHEMBL2695	Homo sapiens	IC50	nM	88.0
256895	17639663	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CCC3C)n1		CHEMBL3665867	=	IC50	nM	99.0	CHEMBL2695	Homo sapiens	IC50	nM	99.0
256896	17639664	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2)n1		CHEMBL3665868	=	IC50	nM	48.0	CHEMBL2695	Homo sapiens	IC50	nM	48.0
256897	17639665	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COC(=O)c1ccccc1Oc1nc(Nc2cc(F)c(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F		CHEMBL3665869	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
256898	17639666	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2C(N)=O)n1		CHEMBL3665870	=	IC50	nM	52.0	CHEMBL2695	Homo sapiens	IC50	nM	52.0
256899	17639667	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C(=O)O)cc2)n1		CHEMBL3665871	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
256900	17639668	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C(N)=O)cc2)n1		CHEMBL3665872	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
256901	17639669	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C(C)=O)c2)n1		CHEMBL3665873	=	IC50	nM	47.0	CHEMBL2695	Homo sapiens	IC50	nM	47.0
256902	17639670	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccnc2)n1		CHEMBL3665874	=	IC50	nM	64.0	CHEMBL2695	Homo sapiens	IC50	nM	64.0
256903	17639671	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COC(=O)c1ccccc1Oc1nc(Nc2ccc(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F		CHEMBL3665875	=	IC50	nM	8.0	CHEMBL2695	Homo sapiens	IC50	nM	8.0
256904	17639672	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C(N)=O)c2)n1		CHEMBL3665876	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
256905	17639673	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(CC(N)=O)c2)n1		CHEMBL3665877	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
256906	17639674	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(CC(=O)O)cc2)n1		CHEMBL3665878	=	IC50	nM	89.0	CHEMBL2695	Homo sapiens	IC50	nM	89.0
256907	17639675	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(Cl)c2)n1		CHEMBL3665879	=	IC50	nM	64.0	CHEMBL2695	Homo sapiens	IC50	nM	64.0
256908	17639676	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2Cl)n1		CHEMBL3665880	=	IC50	nM	85.0	CHEMBL2695	Homo sapiens	IC50	nM	85.0
256909	17639677	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2CC(N)=O)n1		CHEMBL3665881	=	IC50	nM	78.0	CHEMBL2695	Homo sapiens	IC50	nM	78.0
256910	17639678	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)Cc1ccccc1Oc1nc(Nc2ccc(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F		CHEMBL3665882	=	IC50	nM	392.0	CHEMBL2695	Homo sapiens	IC50	nM	392.0
256911	17639679	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2CC(=O)N(C)C)n1		CHEMBL3665883	=	IC50	nM	82.0	CHEMBL2695	Homo sapiens	IC50	nM	82.0
256912	17639680	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(S(C)(=O)=O)cc2)n1		CHEMBL3665884	=	IC50	nM	114.0	CHEMBL2695	Homo sapiens	IC50	nM	114.0
256913	17639681	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3[nH]ccc23)n1		CHEMBL3665885	=	IC50	nM	43.0	CHEMBL2695	Homo sapiens	IC50	nM	43.0
256914	17639682	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3nc[nH]c23)n1		CHEMBL3665886	=	IC50	nM	19.0	CHEMBL2695	Homo sapiens	IC50	nM	19.0
256915	17639683	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc3[nH]cnc3c2)n1		CHEMBL3665887	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	nM	38.0
256916	17639684	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C(N)=O)c2)n1		CHEMBL3665876	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
256917	17639685	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)c1cccc(Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3665888	=	IC50	nM	74.0	CHEMBL2695	Homo sapiens	IC50	nM	74.0
256918	17639686	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C(=O)N(C)C)c2)n1		CHEMBL3665889	=	IC50	nM	67.0	CHEMBL2695	Homo sapiens	IC50	nM	67.0
256919	17639687	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)Cc1cccc(Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3665890	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
256920	17639688	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(CC(=O)N(C)C)c2)n1		CHEMBL3665891	=	IC50	nM	41.0	CHEMBL2695	Homo sapiens	IC50	nM	41.0
256921	17639689	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(CC(N)=O)cc2)n1		CHEMBL3665892	=	IC50	nM	39.0	CHEMBL2695	Homo sapiens	IC50	nM	39.0
256922	17639690	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)Cc1ccc(Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)cc1		CHEMBL3665893	=	IC50	nM	49.0	CHEMBL2695	Homo sapiens	IC50	nM	49.0
256923	17639691	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(CC(=O)N(C)C)cc2)n1		CHEMBL3665894	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
256924	17639692	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2C(=O)N(C)C)n1		CHEMBL3665895	=	IC50	nM	238.0	CHEMBL2695	Homo sapiens	IC50	nM	238.0
256925	17639693	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)c1ccc(Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)cc1		CHEMBL3665896	=	IC50	nM	62.0	CHEMBL2695	Homo sapiens	IC50	nM	62.0
256926	17639694	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C(=O)N(C)C)cc2)n1		CHEMBL3665897	=	IC50	nM	65.0	CHEMBL2695	Homo sapiens	IC50	nM	65.0
256927	17639695	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2C(C)=O)n1		CHEMBL3665898	=	IC50	nM	58.0	CHEMBL2695	Homo sapiens	IC50	nM	58.0
256928	17639696	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(F)c2C(C)=O)n1		CHEMBL3665899	=	IC50	nM	139.0	CHEMBL2695	Homo sapiens	IC50	nM	139.0
256929	17639697	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2-c2cc[nH]n2)n1		CHEMBL3665900	=	IC50	nM	81.0	CHEMBL2695	Homo sapiens	IC50	nM	81.0
256930	17639698	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2-c2csnn2)n1		CHEMBL3665901	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
256931	17639699	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(Br)cc2C#N)n1		CHEMBL3665902	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
256932	17639700	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cc(Br)ccc2C#N)n1		CHEMBL3665903	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
256933	17639701	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(Cl)c2C#N)n1		CHEMBL3665904	=	IC50	nM	8.0	CHEMBL2695	Homo sapiens	IC50	nM	8.0
256934	17639702	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(F)c2C#N)n1		CHEMBL3665905	=	IC50	nM	31.0	CHEMBL2695	Homo sapiens	IC50	nM	31.0
256935	17639703	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(C#N)c(Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3665906	=	IC50	nM	47.0	CHEMBL2695	Homo sapiens	IC50	nM	47.0
256936	17639704	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(Cl)cc2C#N)n1		CHEMBL3665907	=	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
256937	17639705	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CC(=O)N3)n1		CHEMBL3665908	=	IC50	nM	69.0	CHEMBL2695	Homo sapiens	IC50	nM	69.0
256938	17639706	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CC(=O)N3)n1		CHEMBL3665909	=	IC50	nM	150.0	CHEMBL2695	Homo sapiens	IC50	nM	150.0
256939	17639707	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2C#N)n1		CHEMBL3665910	=	IC50	nM	6.0	CHEMBL2695	Homo sapiens	IC50	nM	6.0
256940	17639708	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2C#N)n1		CHEMBL3665911	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
256941	17639709	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Sc2ccccc2)n1		CHEMBL3665912	=	IC50	nM	64.0	CHEMBL2695	Homo sapiens	IC50	nM	64.0
256942	17639710	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Sc2ccccc2)n1		CHEMBL3665913	=	IC50	nM	70.0	CHEMBL2695	Homo sapiens	IC50	nM	70.0
256943	17639711	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C(NCc1ccccc1)c1ccc(Nc2ncc(C(F)(F)F)c(OCCN3CCCC3=O)n2)cc1		CHEMBL3665914	=	IC50	nM	7852.0	CHEMBL2695	Homo sapiens	IC50	nM	7852.0
256944	17639712	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C(NCc1ccccc1)c1ccc(Nc2ncc(C(F)(F)F)c(OCCCNC(=O)C(F)(F)F)n2)cc1		CHEMBL3665915	=	IC50	nM	3054.0	CHEMBL2695	Homo sapiens	IC50	nM	3054.0
256945	17639713	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCCNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(OCCCNC(=O)C(F)(F)F)n2)cc1		CHEMBL3665916	=	IC50	nM	3295.0	CHEMBL2695	Homo sapiens	IC50	nM	3295.0
256946	17639714	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cccc(COc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3665917	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
256947	17639715	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCCN2CCCC2=O)n1		CHEMBL3665918	=	IC50	nM	39.0	CHEMBL2695	Homo sapiens	IC50	nM	39.0
256948	17639716	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCC2CCCO2)n1		CHEMBL3665919	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
256949	17639717	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCC2CCCCN2C)n1		CHEMBL3665920	=	IC50	nM	56.0	CHEMBL2695	Homo sapiens	IC50	nM	56.0
256950	17639718	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OC2CCCN(C)C2)n1		CHEMBL3665921	=	IC50	nM	74.0	CHEMBL2695	Homo sapiens	IC50	nM	74.0
256951	17639719	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(OC)c(CCOc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3665922	=	IC50	nM	104.0	CHEMBL2695	Homo sapiens	IC50	nM	104.0
256952	17639720	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCc2cccc(OC)c2OC)n1		CHEMBL3665923	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
256953	17639721	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCC2CCCCO2)n1		CHEMBL3665924	=	IC50	nM	40.0	CHEMBL2695	Homo sapiens	IC50	nM	40.0
256954	17639722	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(OCC2CCCCC2)n1		CHEMBL3665925	=	IC50	nM	225.0	CHEMBL2695	Homo sapiens	IC50	nM	225.0
256955	17639723	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COC(=O)COc1nc(Nc2ccc(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F		CHEMBL3665926	=	IC50	nM	61.0	CHEMBL2695	Homo sapiens	IC50	nM	61.0
256956	17639724	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2-c2cncs2)n1		CHEMBL3665927	=	IC50	nM	222.0	CHEMBL2695	Homo sapiens	IC50	nM	222.0
256957	17639725	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ncc(-c2ccccc2Oc2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc2C(F)(F)F)s1		CHEMBL3665928	=	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
256958	17639726	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2-c2ccon2)n1		CHEMBL3665929	=	IC50	nM	19.0	CHEMBL2695	Homo sapiens	IC50	nM	19.0
256959	17639727	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cc(C)ccc2C#N)n1		CHEMBL3665930	=	IC50	nM	161.0	CHEMBL2695	Homo sapiens	IC50	nM	161.0
256960	17639728	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C)c2C#N)n1		CHEMBL3665931	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
256961	17639729	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)O)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2N(C)C(=O)CC3)n1		CHEMBL3665932	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
256962	17639730	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCCN(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2N(C)C(=O)CC3)n1		CHEMBL3665933	=	IC50	nM	127.0	CHEMBL2695	Homo sapiens	IC50	nM	127.0
256963	17639731	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2NS(C)(=O)=O)n1		CHEMBL3665934	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
256964	17639732	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CS(=O)(=O)N3)n1		CHEMBL3665935	=	IC50	nM	365.0	CHEMBL2695	Homo sapiens	IC50	nM	365.0
256965	17639733	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2N(C)S(C)(=O)=O)n1		CHEMBL3665936	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
256966	17639734	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN(c1ccccc1Oc1nc(Nc2ccc(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3665937	=	IC50	nM	27.0	CHEMBL2695	Homo sapiens	IC50	nM	27.0
256967	17639735	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccccc2N(C)S(C)(=O)=O)n1		CHEMBL3665938	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
256968	17639736	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN(c1ccccc1Oc1nc(Nc2cc(F)c(C(=O)NC3CCN(C)CC3)cc2OC)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3665939	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	nM	38.0
256969	17639737	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2c(Cl)cccc2NS(C)(=O)=O)n1		CHEMBL3665940	=	IC50	nM	6.0	CHEMBL2695	Homo sapiens	IC50	nM	6.0
256970	17639738	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(Cl)cc2NS(C)(=O)=O)n1		CHEMBL3665941	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
256971	17639739	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cc(F)ccc2NS(C)(=O)=O)n1		CHEMBL3665942	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
256972	17639740	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cc(C)ccc2NS(C)(=O)=O)n1		CHEMBL3665943	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
256973	17639741	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2CS(=O)(=O)N3)n1		CHEMBL3665944	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
256974	17639742	CHEMBL3705995	DELFIA Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the Europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038). In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 L of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 L/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc(C)c2N(C)C(C)=O)n1		CHEMBL3639648	=	IC50	nM	245.0	CHEMBL2695	Homo sapiens	IC50	nM	245.0
267390	17649709	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)OC3)n1		CHEMBL3657247	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267391	17649710	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)OC3)n1		CHEMBL3657248	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267392	17649711	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657249	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267393	17649712	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657250	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267394	17649713	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657251	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267395	17649714	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657252	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267396	17649715	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657253	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267397	17649716	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657254	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267398	17649717	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657255	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
267399	17649718	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657256	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267400	17649719	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(Cl)c3c2C(=O)CC3C)n1		CHEMBL3657257	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
267401	17649720	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(Cl)c3c2C(=O)CC3C)n1		CHEMBL3657258	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
267402	17649721	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657259	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267403	17649722	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657260	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267404	17649723	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657261	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267405	17649724	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)CC3)n1		CHEMBL3657262	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267406	17649725	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)CC3)n1		CHEMBL3657263	=	IC50	nM	6.0	CHEMBL2695	Homo sapiens	IC50	nM	6.0
267407	17649726	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)CC3)n1		CHEMBL3657264	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
267408	17649727	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657265	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267409	17649728	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CCOCC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657245	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267410	17649729	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC(C)(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657266	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
267411	17649730	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCOCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657267	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
267412	17649731	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657268	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267413	17649732	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCC(O)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3913867	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267414	17649733	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C1Cc2c(ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)CC5)n3)c2F)N1		CHEMBL3657270	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267415	17649734	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)CC5)n3)ccc2N1		CHEMBL3657271	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
267416	17649735	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(-n2ccnn2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657272	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
267417	17649736	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(CCF)C3C)n1		CHEMBL3657273	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267418	17649737	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCOCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)OC3)n1		CHEMBL3657274	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267419	17649738	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)OC5)n3)ccc2N1		CHEMBL3657275	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267420	17649739	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C1Cc2c(ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)OC5)n3)c2F)N1		CHEMBL3657276	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
267421	17649740	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(CCF)[C@H]3C)n1		CHEMBL3657277	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267422	17649741	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(CCF)[C@@H]3C)n1		CHEMBL3657278	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267423	17649742	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(CCF)[C@H]3C)n1		CHEMBL3657279	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267424	17649743	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(CCF)[C@@H]3C)n1		CHEMBL3657280	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267425	17649744	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657281	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267426	17649745	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657282	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267427	17649746	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)CC3)n1		CHEMBL3657283	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267428	17649747	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)CC3)n1		CHEMBL3657284	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267429	17649748	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CC[C@H]1COc2cccc(Oc3nc(Nc4ccc(C(=O)NC5CCN(C)CC5)cc4OC)ncc3C(F)(F)F)c2C(=O)N1		CHEMBL3657285	=	IC50	nM	309.0	CHEMBL2695	Homo sapiens	IC50	nM	309.0
267430	17649749	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(c3ncccn3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657286	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
267431	17649750	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)C(C)C3C)n1		CHEMBL3657246	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267432	17649751	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NC)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657287	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267433	17649752	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NOC)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657288	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
267434	17649753	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657289	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267435	17649754	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)C(C)(C)O3)n1		CHEMBL3657290	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267436	17649755	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)C(C)(C)O3)n1		CHEMBL3657291	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
267437	17649756	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)O)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657292	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267438	17649757	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	Cc1nc2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)CC5)n3)cc2n1C		CHEMBL3657293	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
267439	17649758	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)N(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657294	=	IC50	nM	51.0	CHEMBL2695	Homo sapiens	IC50	nM	51.0
267440	17649759	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657295	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267441	17649760	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NC2CCN(CC)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657296	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
267442	17649761	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NC2CCN(C(C)C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657297	=	IC50	nM	8.0	CHEMBL2695	Homo sapiens	IC50	nM	8.0
267443	17649762	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)N[C@H]2CC[C@H](N3CCOCC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657298	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
267444	17649763	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCc1cc(C(=O)NC2CCCN(C)C2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657299	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267445	17649764	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN1Cc2cccc(Oc3nc(Nc4ccc(C(=O)NC5CCN(C)CC5)cc4OC)ncc3C(F)(F)F)c2C1=O		CHEMBL3657300	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267446	17649765	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	O=C(O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657301	=	IC50	nM	26.0	CHEMBL2695	Homo sapiens	IC50	nM	26.0
267447	17649766	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN1CCC(NC(=O)c2cc(OC)c(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)cc2Cl)CC1		CHEMBL3657302	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267448	17649767	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN1CCC(NC(=O)c2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)c(OC)c2)CC1		CHEMBL3657303	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267449	17649768	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657304	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267450	17649769	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657305	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267451	17649770	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657306	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267452	17649771	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657307	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267453	17649772	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657308	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267454	17649773	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN1CCC(NC(=O)c2cc(OC)c(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)cc2F)CC1		CHEMBL3657309	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267455	17649774	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657310	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267456	17649775	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657311	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267457	17649776	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657312	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267458	17649777	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1nccc(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657313	=	IC50	nM	75.0	CHEMBL2695	Homo sapiens	IC50	nM	75.0
267459	17649778	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657314	=	IC50	nM	26.0	CHEMBL2695	Homo sapiens	IC50	nM	26.0
267460	17649779	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(F)c(Oc3cccc4c3C(=O)CC4)n2)c(OC)c1		CHEMBL3657315	=	IC50	nM	60.0	CHEMBL2695	Homo sapiens	IC50	nM	60.0
267461	17649780	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(F)c(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657316	=	IC50	nM	196.0	CHEMBL2695	Homo sapiens	IC50	nM	196.0
267462	17649781	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2nccc(Oc3cccc4c3C(=O)CC4)n2)c(OC)c1		CHEMBL3657317	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267463	17649782	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)CC3)n1		CHEMBL3657318	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267464	17649783	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(Br)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657319	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267465	17649784	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657320	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267466	17649785	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2nccc(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657321	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267467	17649786	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(F)ccc1Nc1nccc(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657322	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267468	17649787	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657323	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267469	17649788	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(C)C)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657324	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267470	17649789	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657325	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267471	17649790	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)OCc2ccccc2)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657326	=	IC50	nM	53.0	CHEMBL2695	Homo sapiens	IC50	nM	53.0
267472	17649791	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(C(C)C)c(Oc3cccc4c3C(=O)CC4)n2)c(OC)c1		CHEMBL3657327	=	IC50	nM	29.0	CHEMBL2695	Homo sapiens	IC50	nM	29.0
267473	17649792	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(C(C)C)c(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657328	=	IC50	nM	34.0	CHEMBL2695	Homo sapiens	IC50	nM	34.0
267474	17649793	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(C(C)=O)c(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657329	=	IC50	nM	227.0	CHEMBL2695	Homo sapiens	IC50	nM	227.0
267475	17649794	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3C)n1		CHEMBL3657330	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267476	17649795	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3C)n1		CHEMBL3657331	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267478	17649797	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(O[C@@H]2CO[C@@H]3[C@H](O)CO[C@H]23)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3639561	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267479	17649798	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657332	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267480	17649799	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(CN(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657333	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267481	17649800	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(CN2CCCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657334	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267482	17649801	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657335	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267483	17649802	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657336	=	IC50	nM	29.0	CHEMBL2695	Homo sapiens	IC50	nM	29.0
267484	17649803	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(O[C@H]2CCOC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657337	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267485	17649804	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CN1Cc2cccc(Oc3nc(Nc4ccc(O[C@H]5CCOC5)cc4)ncc3C(F)(F)F)c2C1=O		CHEMBL3657338	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
267486	17649805	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CN1Cc2cccc(Oc3nc(Nc4ccc(OC5CCOCC5)cc4)ncc3C(F)(F)F)c2C1=O		CHEMBL3657339	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
267487	17649806	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(OC2CCOCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657340	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
267488	17649807	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657341	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267489	17649808	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CN1CCC(Nc2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)cc2F)CC1		CHEMBL3657342	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267490	17649809	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)O)ccc1Nc1nccc(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657343	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267491	17649810	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3C)n1		CHEMBL3657344	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267492	17649811	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(O[C@@H]2CO[C@@H]3[C@H](O)CO[C@H]23)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3C)n1		CHEMBL3657345	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267493	17649812	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1ccc(Nc2ncc(C#N)c(Oc3cccc4c3C(=O)CC4)n2)cc1		CHEMBL3657346	=	IC50	nM	35.0	CHEMBL2695	Homo sapiens	IC50	nM	35.0
267494	17649813	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)OCc2ccccc2)ccc1Nc1ncc(Br)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657347	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267495	17649814	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657348	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267496	17649815	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1nccc(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657349	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
267497	17649816	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(F)ccc1Nc1ncc(F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657350	=	IC50	nM	72.0	CHEMBL2695	Homo sapiens	IC50	nM	72.0
267498	17649817	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3C)n1		CHEMBL3657351	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267499	17649818	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(C#N)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657352	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267500	17649819	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C#N)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657353	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267501	17649820	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(C#N)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657354	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267502	17649821	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657355	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267503	17649822	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCCN(C)C2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657356	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267504	17649823	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCCN(C)C2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657357	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267505	17649824	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3657358	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267506	17649825	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657359	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267507	17649826	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3657360	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267508	17649827	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3657361	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267509	17649828	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCC(C)(C)CN(C)C)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657362	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267510	17649829	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCOC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657363	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267511	17649830	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC[C@@H]2CCCO2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657364	=	IC50	nM	6.0	CHEMBL2695	Homo sapiens	IC50	nM	6.0
267512	17649831	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCCN(C)C)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657365	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267513	17649832	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CC[C@H](O)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657366	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267514	17649833	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CC3)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657367	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267515	17649834	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC[C@H](O)CO)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657368	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267516	17649835	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657369	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267517	17649836	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCCN(C)C2)c(Cl)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657370	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267518	17649837	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657371	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267519	17649838	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657372	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267520	17649839	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CCOCC3)CC2)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657373	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267521	17649840	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(CC3CC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657374	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267522	17649841	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(OC2CCN(C)C2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657375	=	IC50	nM	28.0	CHEMBL2695	Homo sapiens	IC50	nM	28.0
267523	17649842	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCCN(C)C2)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657376	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267524	17649843	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCCN(C)C2)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657377	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267525	17649844	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCCN(C)C2)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657378	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267526	17649845	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCCN(C)C)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657379	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267527	17649846	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N(C)C)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657380	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267528	17649847	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)c1cc(OC)c(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)cc1C		CHEMBL3657381	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267529	17649848	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657382	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267530	17649849	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657383	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267531	17649850	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCOCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657384	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267532	17649851	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657385	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267533	17649852	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657386	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267534	17649853	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657387	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267535	17649854	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657388	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267536	17649855	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CCOCC3)CC2)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657389	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267537	17649856	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CC[C@H](N3CCN(CC4CC4)CC3)CC2)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657390	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267538	17649857	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCC2CC2)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657391	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267539	17649858	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2OC)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657392	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267540	17649859	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NCC2CCCO2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657393	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
267541	17649860	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CC[C@H](N3CCN(CC4CC4)CC3)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657394	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267542	17649861	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CCOCC3)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657395	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267543	17649862	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C3CCOCC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657245	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267544	17649863	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657396	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267545	17649864	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657397	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267546	17649865	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657398	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267547	17649866	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(Cl)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657399	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267548	17649867	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657400	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267549	17649868	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657401	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267550	17649869	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@@H]3C)n1		CHEMBL3657402	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267551	17649870	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CCN1CC[C@H](NC(=O)c2cc(OC)c(Nc3ncc(Cl)c(Oc4cccc5c4C(=O)N(C)[C@H]5C)n3)cc2F)[C@H](F)C1		CHEMBL3657403	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267552	17649871	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C(C)C)C[C@H]2F)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657404	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267553	17649872	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)[C@H]3C)n1		CHEMBL3657405	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267554	17649873	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2F)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657406	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267555	17649874	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657407	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267556	17649875	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657408	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267557	17649876	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3657409	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267558	17649877	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCOCC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(OC)C3)n1		CHEMBL3657410	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267559	17649878	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@@H]2OC)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3657411	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267560	17649879	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@H]2F)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3657412	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267561	17649880	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)CCO3)n1		CHEMBL3657413	=	IC50	nM	9.0	CHEMBL2695	Homo sapiens	IC50	nM	9.0
267562	17649881	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)CCO3)n1		CHEMBL3661419	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
267563	17649882	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N[C@@H](C)CO3)n1		CHEMBL3661420	=	IC50	nM	102.0	CHEMBL2695	Homo sapiens	IC50	nM	102.0
267564	17649883	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N[C@@H](C)CO3)n1		CHEMBL3661421	=	IC50	nM	92.0	CHEMBL2695	Homo sapiens	IC50	nM	92.0
267565	17649884	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)NC(C)(C)CO3)n1		CHEMBL3661422	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267566	17649885	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)NC(C)(C)CO3)n1		CHEMBL3661423	=	IC50	nM	400.0	CHEMBL2695	Homo sapiens	IC50	nM	400.0
267567	17649886	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(CCO)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661424	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267568	17649887	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CONC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(OC)c1		CHEMBL3661425	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267569	17649888	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CC(=O)N1CCC(NC(=O)c2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)c(C)c2)CC1		CHEMBL3661426	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267570	17649889	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COCCNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(C)c1		CHEMBL3661427	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267571	17649890	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	Cc1cc(C(=O)NC2CCN(CCO)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661428	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267572	17649891	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	Cc1cc(C(=O)NC2CCC(F)(F)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661429	=	IC50	nM	6.0	CHEMBL2695	Homo sapiens	IC50	nM	6.0
267573	17649892	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COCCN1CCC(NC(=O)c2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)c(C)c2)CC1		CHEMBL3661430	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267574	17649893	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(C)c1		CHEMBL3661431	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267575	17649894	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(OC)c1		CHEMBL3661432	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267576	17649895	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCCCC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661433	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
267577	17649896	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCC(F)(F)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661434	=	IC50	nM	8.0	CHEMBL2695	Homo sapiens	IC50	nM	8.0
267578	17649897	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COCCN1CCC(NC(=O)c2ccc(Nc3ncc(C(F)(F)F)c(Oc4cccc5c4C(=O)N(C)C5)n3)c(OC)c2)CC1		CHEMBL3661435	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267579	17649898	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	Cc1cc(C(=O)NC2CCCN(C)C2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661436	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267580	17649899	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	Cc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661437	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267581	17649900	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	CONC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(C)c1		CHEMBL3661438	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267582	17649901	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COCCNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(OC)c1		CHEMBL3661439	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267583	17649902	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COCCCNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Oc3cccc4c3C(=O)N(C)C4)n2)c(OC)c1		CHEMBL3661440	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
267584	17649903	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(CN(C)C)ccc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661441	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267585	17649904	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C[C@@H](O)CO)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661442	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267586	17649905	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C[C@H](O)CO)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661443	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267587	17649906	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661444	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267588	17649907	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(CC(=O)N(C)C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661445	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267589	17649908	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(CC(=O)N(C)OC)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661446	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267590	17649909	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(N2CCN(C3COC3)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661447	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267591	17649910	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)C[C@H]2OC)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661448	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267592	17649911	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C#CC(=O)N(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661449	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267593	17649912	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2ccc(C)c3c2C(=O)N(C)C3)n1		CHEMBL3661450	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
267594	17649913	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)C[C@H]2OC)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661451	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267595	17649914	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)NC2CCN(C)C[C@H]2OC)c(C)cc1Nc1ncc(Cl)c(Oc2cccc3c2C(=O)N(C)C3(C)C)n1		CHEMBL3661452	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267596	17649915	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@@H]2OC)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661453	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267597	17649916	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@@H]2OC)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661454	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267598	17649917	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C#CCN(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661455	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267599	17649918	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@@H]2CCN(C)C[C@H]2OC)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661456	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267600	17649919	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(C(=O)N[C@H]2CCN(C)C[C@@H]2OC)c(C)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661457	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
267601	17649920	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(/C=C/C(=O)N(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661458	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
267602	17649921	CHEMBL3705417	Enzyme Assay: This test uses active PTK2 enzyme (Invitrogen Code PV3832) and poly-Glu-Tyr (4:1, Sigma P-0275) as the kinase substrate. The kinase activity is detected by means of the phosphorylation of the substrate in a DELFIA assay. The phosphorylated substrate is detected with the europium-labelled phosphotyrosine antibody PY20 (Perkin Elmer, No.: AD0038).In order to determine concentration-activity curves with PTK2-inhibitors the compounds are serially diluted in 10% DMSO/H2O and 10 uL of each dilution are dispensed per well in a 96-well microtitre plate (clear U-shaped base plate, Greiner No. 650101) (the inhibitors are tested in duplicates) and mixed with 10 uL/well of PTK2 kinase (0.01 ug/well). PTK2 kinase is diluted accordingly beforehand with kinase dilution buffer (20 mM TRIS/HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10% glycerol with the addition of freshly prepared BSA (fraction V 1 mg/mL) and DTT (1 mM)).	B	COc1cc(/C(C)=C/C(=O)N(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1		CHEMBL3661459	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
297872	17678702	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692169	=	IC50	nM	2.1	CHEMBL2695	Homo sapiens	IC50	nM	2.1
297873	17678703	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)cc2)CC1		CHEMBL3692170	=	IC50	nM	2.5	CHEMBL2695	Homo sapiens	IC50	nM	2.5
297874	17678704	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692171	=	IC50	nM	1.9	CHEMBL2695	Homo sapiens	IC50	nM	1.9
297875	17678705	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692172	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
297876	17678706	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	IC50	nM	2.4	CHEMBL2695	Homo sapiens	IC50	nM	2.4
297877	17678707	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)c2)CC1		CHEMBL3692174	=	IC50	nM	4.2	CHEMBL2695	Homo sapiens	IC50	nM	4.2
297878	17678708	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	IC50	nM	9.6	CHEMBL2695	Homo sapiens	IC50	nM	9.6
297879	17678709	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCCN3)cc2)ncc1C(F)(F)F		CHEMBL3692175	=	IC50	nM	6.1	CHEMBL2695	Homo sapiens	IC50	nM	6.1
297880	17678710	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCCCC1c1ccc(Nc2ncc(C(F)(F)F)c(CCc3ccccc3CC(N)=O)n2)cc1		CHEMBL3692176	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
297881	17678711	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692177	=	IC50	nM	2.9	CHEMBL2695	Homo sapiens	IC50	nM	2.9
297882	17678712	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692178	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
297883	17678713	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CC(C(N)=O)c1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692179	=	IC50	nM	6.3	CHEMBL2695	Homo sapiens	IC50	nM	6.3
297884	17678714	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3639910	=	IC50	nM	0.6	CHEMBL2695	Homo sapiens	IC50	nM	0.6
297885	17678715	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
297886	17678716	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
297887	17678717	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692181	=	IC50	nM	2.0	CHEMBL2695	Homo sapiens	IC50	nM	2.0
297888	17678718	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c2)CC1		CHEMBL3692182	=	IC50	nM	3.4	CHEMBL2695	Homo sapiens	IC50	nM	3.4
297889	17678719	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2cccc(N3CCN(C)CC3)c2)ncc1C(F)(F)F		CHEMBL3692183	=	IC50	nM	13.0	CHEMBL2695	Homo sapiens	IC50	nM	13.0
297890	17678720	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	Cc1ccc(CCc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2C(F)(F)F)cc1C(N)=O		CHEMBL3692184	=	IC50	nM	7.7	CHEMBL2695	Homo sapiens	IC50	nM	7.7
297891	17678721	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCC(N)CC3)cc2)ncc1C(F)(F)F		CHEMBL3692185	=	IC50	nM	0.81	CHEMBL2695	Homo sapiens	IC50	nM	0.81
297892	17678722	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc3c(c2)CCNC3)ncc1C(F)(F)F		CHEMBL3692186	=	IC50	nM	2.4	CHEMBL2695	Homo sapiens	IC50	nM	2.4
297893	17678723	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CNCCO3)cc2)ncc1C(F)(F)F		CHEMBL3692187	=	IC50	nM	2.8	CHEMBL2695	Homo sapiens	IC50	nM	2.8
297894	17678724	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CC(=O)N1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692188	=	IC50	nM	0.39	CHEMBL2695	Homo sapiens	IC50	nM	0.39
297895	17678725	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CC(=O)C1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692189	=	IC50	nM	0.77	CHEMBL2695	Homo sapiens	IC50	nM	0.77
297896	17678726	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(CN3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692190	=	IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
297897	17678727	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1nccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692191	=	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
297898	17678728	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4nccnc4CC(N)=O)n3)cc2)CC1		CHEMBL3692192	=	IC50	nM	7.2	CHEMBL2695	Homo sapiens	IC50	nM	7.2
297899	17678729	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCc2cc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)ccc2C1		CHEMBL3692193	=	IC50	nM	0.3	CHEMBL2695	Homo sapiens	IC50	nM	0.3
297900	17678730	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1cncnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692194	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
297901	17678731	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncncc4CC(N)=O)n3)cc2)CC1		CHEMBL3692195	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
297902	17678732	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692196	=	IC50	nM	3.6	CHEMBL2695	Homo sapiens	IC50	nM	3.6
297903	17678733	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1cccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692197	=	IC50	nM	3.5	CHEMBL2695	Homo sapiens	IC50	nM	3.5
297904	17678734	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692198	=	IC50	nM	6.2	CHEMBL2695	Homo sapiens	IC50	nM	6.2
297905	17678735	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cc(C(N)=O)ccn4)n3)cc2)CC1		CHEMBL3692199	=	IC50	nM	5.7	CHEMBL2695	Homo sapiens	IC50	nM	5.7
297906	17678736	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692200	=	IC50	nM	7.7	CHEMBL2695	Homo sapiens	IC50	nM	7.7
297907	17678737	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCN(Cc2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692201	=	IC50	nM	2.3	CHEMBL2695	Homo sapiens	IC50	nM	2.3
297908	17678738	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)c1cccc(CCc2nc(Nc3ccc(CN4CCNCC4)cc3)ncc2C(F)(F)F)c1		CHEMBL3692202	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
297909	17678739	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692203	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
297910	17678740	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1cccnc1CCc1nc(Nc2ccc(C3CCCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692204	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
297911	17678741	CHEMBL3705701	Biochemical Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)1SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686)N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCl, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 uM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)C1		CHEMBL3692205	=	IC50	nM	51.0	CHEMBL2695	Homo sapiens	IC50	nM	51.0
297912	17678742	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692169	=	Kd	nM	0.49	CHEMBL2695	Homo sapiens	Kd	nM	0.49
297913	17678743	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)cc2)CC1		CHEMBL3692170	=	Kd	nM	1.5	CHEMBL2695	Homo sapiens	Kd	nM	1.5
297914	17678744	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692171	=	Kd	nM	0.91	CHEMBL2695	Homo sapiens	Kd	nM	0.91
297915	17678745	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692172	=	Kd	nM	0.73	CHEMBL2695	Homo sapiens	Kd	nM	0.73
297916	17678746	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	Kd	nM	0.57	CHEMBL2695	Homo sapiens	Kd	nM	0.57
297917	17678747	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)c2)CC1		CHEMBL3692174	=	Kd	nM	6.3	CHEMBL2695	Homo sapiens	Kd	nM	6.3
297918	17678748	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	Kd	nM	2.3	CHEMBL2695	Homo sapiens	Kd	nM	2.3
297919	17678749	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCCN3)cc2)ncc1C(F)(F)F		CHEMBL3692175	=	Kd	nM	1.0	CHEMBL2695	Homo sapiens	Kd	nM	1.0
297920	17678750	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCCCC1c1ccc(Nc2ncc(C(F)(F)F)c(CCc3ccccc3CC(N)=O)n2)cc1		CHEMBL3692176	=	Kd	nM	7.0	CHEMBL2695	Homo sapiens	Kd	nM	7.0
297921	17678751	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CCN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692177	=	Kd	nM	0.96	CHEMBL2695	Homo sapiens	Kd	nM	0.96
297922	17678752	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692178	=	Kd	nM	0.61	CHEMBL2695	Homo sapiens	Kd	nM	0.61
297923	17678753	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CC(C(N)=O)c1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692179	=	Kd	nM	0.92	CHEMBL2695	Homo sapiens	Kd	nM	0.92
297924	17678754	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3639910	=	Kd	nM	0.47	CHEMBL2695	Homo sapiens	Kd	nM	0.47
297925	17678755	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	Kd	nM	6.1	CHEMBL2695	Homo sapiens	Kd	nM	6.1
297926	17678756	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	Kd	nM	5.0	CHEMBL2695	Homo sapiens	Kd	nM	5.0
297927	17678757	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692181	=	Kd	nM	1.3	CHEMBL2695	Homo sapiens	Kd	nM	1.3
297928	17678758	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c2)CC1		CHEMBL3692182	=	Kd	nM	3.5	CHEMBL2695	Homo sapiens	Kd	nM	3.5
297929	17678759	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2cccc(N3CCN(C)CC3)c2)ncc1C(F)(F)F		CHEMBL3692183	=	Kd	nM	13.0	CHEMBL2695	Homo sapiens	Kd	nM	13.0
297930	17678760	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	Cc1ccc(CCc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2C(F)(F)F)cc1C(N)=O		CHEMBL3692184	=	Kd	nM	7.8	CHEMBL2695	Homo sapiens	Kd	nM	7.8
297931	17678761	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCC(N)CC3)cc2)ncc1C(F)(F)F		CHEMBL3692185	=	Kd	nM	0.63	CHEMBL2695	Homo sapiens	Kd	nM	0.63
297932	17678762	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc3c(c2)CCNC3)ncc1C(F)(F)F		CHEMBL3692186	=	Kd	nM	0.44	CHEMBL2695	Homo sapiens	Kd	nM	0.44
297933	17678763	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CNCCO3)cc2)ncc1C(F)(F)F		CHEMBL3692187	=	Kd	nM	0.99	CHEMBL2695	Homo sapiens	Kd	nM	0.99
297934	17678764	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CC(=O)N1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692188	=	Kd	nM	1.3	CHEMBL2695	Homo sapiens	Kd	nM	1.3
297935	17678765	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CC(=O)C1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692189	=	Kd	nM	0.77	CHEMBL2695	Homo sapiens	Kd	nM	0.77
297936	17678766	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(CN3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692190	=	Kd	nM	1.1	CHEMBL2695	Homo sapiens	Kd	nM	1.1
297937	17678767	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1nccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692191	=	Kd	nM	14.0	CHEMBL2695	Homo sapiens	Kd	nM	14.0
297938	17678768	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4nccnc4CC(N)=O)n3)cc2)CC1		CHEMBL3692192	=	Kd	nM	16.6	CHEMBL2695	Homo sapiens	Kd	nM	16.6
297939	17678769	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCc2cc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)ccc2C1		CHEMBL3692193	=	Kd	nM	0.94	CHEMBL2695	Homo sapiens	Kd	nM	0.94
297940	17678770	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1cncnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692194	=	Kd	nM	12.1	CHEMBL2695	Homo sapiens	Kd	nM	12.1
297941	17678771	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncncc4CC(N)=O)n3)cc2)CC1		CHEMBL3692195	=	Kd	nM	5.7	CHEMBL2695	Homo sapiens	Kd	nM	5.7
297942	17678772	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692196	=	Kd	nM	1.0	CHEMBL2695	Homo sapiens	Kd	nM	1.0
297943	17678773	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1cccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692197	=	Kd	nM	2.5	CHEMBL2695	Homo sapiens	Kd	nM	2.5
297944	17678774	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692198	=	Kd	nM	5.6	CHEMBL2695	Homo sapiens	Kd	nM	5.6
297945	17678775	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cc(C(N)=O)ccn4)n3)cc2)CC1		CHEMBL3692199	=	Kd	nM	5.0	CHEMBL2695	Homo sapiens	Kd	nM	5.0
297946	17678776	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692200	=	Kd	nM	1.6	CHEMBL2695	Homo sapiens	Kd	nM	1.6
297947	17678777	CHEMBL3705700	Biacore SPR Assay: Binding parameters of compounds were determined using a Biacore S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction.	B	CN1CCN(Cc2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692201	=	Kd	nM	0.48	CHEMBL2695	Homo sapiens	Kd	nM	0.48
297948	17678778	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692169	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
297949	17678779	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)cc2)CC1		CHEMBL3692170	=	IC50	nM	120.0	CHEMBL2695	Homo sapiens	IC50	nM	120.0
297950	17678780	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692171	=	IC50	nM	1.1	CHEMBL2695	Homo sapiens	IC50	nM	1.1
297951	17678781	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692172	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
297952	17678782	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
297953	17678783	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4cccc(C(N)=O)c4)n3)c2)CC1		CHEMBL3692174	=	IC50	nM	52.0	CHEMBL2695	Homo sapiens	IC50	nM	52.0
297954	17678784	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	IC50	nM	48.0	CHEMBL2695	Homo sapiens	IC50	nM	48.0
297955	17678785	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCCN3)cc2)ncc1C(F)(F)F		CHEMBL3692175	=	IC50	nM	4.8	CHEMBL2695	Homo sapiens	IC50	nM	4.8
297956	17678786	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCCCC1c1ccc(Nc2ncc(C(F)(F)F)c(CCc3ccccc3CC(N)=O)n2)cc1		CHEMBL3692176	=	IC50	nM	2.5	CHEMBL2695	Homo sapiens	IC50	nM	2.5
297957	17678787	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CCN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692177	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
297958	17678788	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692178	=	IC50	nM	2.5	CHEMBL2695	Homo sapiens	IC50	nM	2.5
297959	17678789	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CC(C(N)=O)c1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692179	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
297960	17678790	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3639910	=	IC50	nM	70.0	CHEMBL2695	Homo sapiens	IC50	nM	70.0
297961	17678791	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	IC50	nM	101.0	CHEMBL2695	Homo sapiens	IC50	nM	101.0
297962	17678792	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692180	=	IC50	nM	37.0	CHEMBL2695	Homo sapiens	IC50	nM	37.0
297963	17678793	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692181	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
297964	17678794	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c2)CC1		CHEMBL3692182	=	IC50	nM	31.0	CHEMBL2695	Homo sapiens	IC50	nM	31.0
297965	17678795	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CNC(=O)Cc1ccccc1CCc1nc(Nc2cccc(N3CCN(C)CC3)c2)ncc1C(F)(F)F		CHEMBL3692183	=	IC50	nM	664.0	CHEMBL2695	Homo sapiens	IC50	nM	664.0
297966	17678796	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	Cc1ccc(CCc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2C(F)(F)F)cc1C(N)=O		CHEMBL3692184	=	IC50	nM	37.0	CHEMBL2695	Homo sapiens	IC50	nM	37.0
297967	17678797	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCC(N)CC3)cc2)ncc1C(F)(F)F		CHEMBL3692185	=	IC50	nM	5.0	CHEMBL2695	Homo sapiens	IC50	nM	5.0
297968	17678798	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc3c(c2)CCNC3)ncc1C(F)(F)F		CHEMBL3692186	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
297969	17678799	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CNCCO3)cc2)ncc1C(F)(F)F		CHEMBL3692187	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
297970	17678800	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CC(=O)N1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692188	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
297971	17678801	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CC(=O)C1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692189	=	IC50	nM	3.9	CHEMBL2695	Homo sapiens	IC50	nM	3.9
297972	17678802	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(CN3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692190	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
297973	17678803	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1nccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692191	=	IC50	nM	51.0	CHEMBL2695	Homo sapiens	IC50	nM	51.0
297974	17678804	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4nccnc4CC(N)=O)n3)cc2)CC1		CHEMBL3692192	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
297975	17678805	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCc2cc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)ccc2C1		CHEMBL3692193	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
297976	17678806	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1cncnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692194	=	IC50	nM	68.0	CHEMBL2695	Homo sapiens	IC50	nM	68.0
297977	17678807	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncncc4CC(N)=O)n3)cc2)CC1		CHEMBL3692195	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
297978	17678808	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692196	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
297979	17678809	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1cccnc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692197	=	IC50	nM	5.1	CHEMBL2695	Homo sapiens	IC50	nM	5.1
297980	17678810	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692198	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
297981	17678811	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4cc(C(N)=O)ccn4)n3)cc2)CC1		CHEMBL3692199	=	IC50	nM	184.0	CHEMBL2695	Homo sapiens	IC50	nM	184.0
297982	17678812	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692200	=	IC50	nM	53.0	CHEMBL2695	Homo sapiens	IC50	nM	53.0
297983	17678813	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CN1CCN(Cc2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692201	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
297984	17678814	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)c1cccc(CCc2nc(Nc3ccc(CN4CCNCC4)cc3)ncc2C(F)(F)F)c1		CHEMBL3692202	=	IC50	nM	254.0	CHEMBL2695	Homo sapiens	IC50	nM	254.0
297985	17678815	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692203	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
297986	17678816	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	NC(=O)Cc1cccnc1CCc1nc(Nc2ccc(C3CCCNC3)cc2)ncc1C(F)(F)F		CHEMBL3692204	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
297987	17678817	CHEMBL3705703	Biochemical Assay: Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) (SEQ ID NO: 1). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (the enzyme). The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7A, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 uM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions receiving the same volume DMSO without compound. The plates were sealed with adhesive seals and incubated for 90 minutes at 30 degree.	B	CCN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)C1		CHEMBL3692205	=	IC50	nM	46.0	CHEMBL2695	Homo sapiens	IC50	nM	46.0
297988	17678818	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692171	=	IC50	nM	80.0	CHEMBL2695	Homo sapiens	IC50	nM	80.0
297989	17678819	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)C1		CHEMBL3692173	=	IC50	nM	240.0	CHEMBL2695	Homo sapiens	IC50	nM	240.0
297990	17678820	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCCCN3)cc2)ncc1C(F)(F)F		CHEMBL3692175	=	IC50	nM	127.0	CHEMBL2695	Homo sapiens	IC50	nM	127.0
297991	17678821	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692178	=	IC50	nM	67.0	CHEMBL2695	Homo sapiens	IC50	nM	67.0
297992	17678822	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CC(C(N)=O)c1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692179	=	IC50	nM	81.0	CHEMBL2695	Homo sapiens	IC50	nM	81.0
297993	17678823	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692181	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
297994	17678824	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCN(c2cccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c2)CC1		CHEMBL3692182	=	IC50	nM	44.0	CHEMBL2695	Homo sapiens	IC50	nM	44.0
297995	17678825	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(N3CCC(N)CC3)cc2)ncc1C(F)(F)F		CHEMBL3692185	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
297996	17678826	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc3c(c2)CCNC3)ncc1C(F)(F)F		CHEMBL3692186	=	IC50	nM	113.0	CHEMBL2695	Homo sapiens	IC50	nM	113.0
297997	17678827	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CNCCO3)cc2)ncc1C(F)(F)F		CHEMBL3692187	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
297998	17678828	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CC(=O)C1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692189	=	IC50	nM	71.0	CHEMBL2695	Homo sapiens	IC50	nM	71.0
297999	17678829	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(CN3CCNCC3)cc2)ncc1C(F)(F)F		CHEMBL3692190	=	IC50	nM	66.0	CHEMBL2695	Homo sapiens	IC50	nM	66.0
298000	17678830	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncncc4CC(N)=O)n3)cc2)CC1		CHEMBL3692195	=	IC50	nM	658.0	CHEMBL2695	Homo sapiens	IC50	nM	658.0
298001	17678831	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692196	=	IC50	nM	67.0	CHEMBL2695	Homo sapiens	IC50	nM	67.0
298002	17678832	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ncccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692198	=	IC50	nM	81.0	CHEMBL2695	Homo sapiens	IC50	nM	81.0
298003	17678833	CHEMBL3705702	Phospho ELISA Assay: Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in Endogro MV complete (Cat#SCME004, Millipore) at 200,000 cells/well (volume 1 mL), and the plates incubated at 37 C. and 5% CO2 for 6 hours. The media was replaced with Endogro Basal (Cat # SCME-BM, Millipore)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37 C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 uL of Total VEGFR2 capture antibody (Part #841888, Human Total VEGFR3/Flt4 ELISA Kit, Cat # DYC3491, R&D Systems), or Phospho VEGF R3Capture antibody (Part #841885, Human Phospho VEGF R3/Flt4 ELISA Kit, Cat# DYC2724, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer.	B	CN1CCN(Cc2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)cc2)CC1		CHEMBL3692201	=	IC50	nM	169.0	CHEMBL2695	Homo sapiens	IC50	nM	169.0
322482	17701519	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	COc1cc(N2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689069	=	IC50	nM	1.9	CHEMBL2695	Homo sapiens	IC50	nM	1.9
322483	17701520	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	COc1cc(C2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689070	=	IC50	nM	7.1	CHEMBL2695	Homo sapiens	IC50	nM	7.1
322484	17701521	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689071	=	IC50	nM	2.2	CHEMBL2695	Homo sapiens	IC50	nM	2.2
322485	17701522	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c(OC)c2)CC1		CHEMBL3689072	=	IC50	nM	3.6	CHEMBL2695	Homo sapiens	IC50	nM	3.6
322486	17701523	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	COc1cc(C2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2cccc(C(N)=O)c2)n1		CHEMBL3689073	=	IC50	nM	7.2	CHEMBL2695	Homo sapiens	IC50	nM	7.2
322487	17701524	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2cccc(C(N)=O)c2)n1		CHEMBL3689074	=	IC50	nM	2.1	CHEMBL2695	Homo sapiens	IC50	nM	2.1
322488	17701525	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(Cc4ccccc4C(N)=O)n3)c(OC)c2)CC1		CHEMBL3689075	=	IC50	nM	9.4	CHEMBL2695	Homo sapiens	IC50	nM	9.4
322489	17701526	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCc1cc(C2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689076	=	IC50	nM	5.2	CHEMBL2695	Homo sapiens	IC50	nM	5.2
322490	17701527	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CCc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689077	=	IC50	nM	3.6	CHEMBL2695	Homo sapiens	IC50	nM	3.6
322491	17701528	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2OC(F)(F)F)ncc1C(F)(F)F		CHEMBL3689078	=	IC50	nM	2.7	CHEMBL2695	Homo sapiens	IC50	nM	2.7
322492	17701529	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c(OC(F)(F)F)c2)CC1		CHEMBL3689079	=	IC50	nM	2.2	CHEMBL2695	Homo sapiens	IC50	nM	2.2
322493	17701530	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	Cc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689080	=	IC50	nM	3.6	CHEMBL2695	Homo sapiens	IC50	nM	3.6
322494	17701531	CHEMBL3705933	Alpha Screen Assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) SEQ ID NO: 1). FAK enzyme was expressed in insect cells as catalytic domain (amino acids 411-686) N-terminally tagged with six histidine amino acids and a Tobacco Etch Virus (TeV) cleavage sequence. After lysing the cells by sonication, the kinase was purified by Ni-Immobilised Metal Affinity Chromatography, TeV cleavage leaving a N-terminal glycine, and gel filtration. The 15 ul assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, 25 mM NaCI, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 uM Na3V04, 0.01% (w/v) albumin from chicken egg white, 111 nM peptide substrate, 80 pM ATP, and 4 ng/reaction FAK enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series made up in DMSO.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c(F)c2)CC1		CHEMBL3689081	=	IC50	nM	5.6	CHEMBL2695	Homo sapiens	IC50	nM	5.6
322507	17701544	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	COc1cc(N2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689069	=	Kd	nM	0.29	CHEMBL2695	Homo sapiens	Kd	nM	0.29
322508	17701545	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	COc1cc(C2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689070	=	Kd	nM	0.74	CHEMBL2695	Homo sapiens	Kd	nM	0.74
322509	17701546	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689071	=	Kd	nM	0.21	CHEMBL2695	Homo sapiens	Kd	nM	0.21
322510	17701547	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	CCN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c(OC)c2)CC1		CHEMBL3689072	=	Kd	nM	1.5	CHEMBL2695	Homo sapiens	Kd	nM	1.5
322511	17701548	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2cccc(C(N)=O)c2)n1		CHEMBL3689074	=	Kd	nM	2.9	CHEMBL2695	Homo sapiens	Kd	nM	2.9
322512	17701549	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	CCc1cc(C2CCNCC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689076	=	Kd	nM	0.81	CHEMBL2695	Homo sapiens	Kd	nM	0.81
322513	17701550	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	CCc1cc(C2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(CCc2ccccc2CC(N)=O)n1		CHEMBL3689077	=	Kd	nM	1.5	CHEMBL2695	Homo sapiens	Kd	nM	1.5
322514	17701551	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	NC(=O)Cc1ccccc1CCc1nc(Nc2ccc(C3CCNCC3)cc2OC(F)(F)F)ncc1C(F)(F)F		CHEMBL3689078	=	Kd	nM	0.79	CHEMBL2695	Homo sapiens	Kd	nM	0.79
322515	17701552	CHEMBL3705934	Biacore SPR Assay: In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl2, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25° C.	B	CN1CCC(c2ccc(Nc3ncc(C(F)(F)F)c(CCc4ccccc4CC(N)=O)n3)c(OC(F)(F)F)c2)CC1		CHEMBL3689079	=	Kd	nM	1.7	CHEMBL2695	Homo sapiens	Kd	nM	1.7
420079	17783322	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CNC(=O)c1cccc(-c2csc3c(N)nc(Nc4ccc(N5CCOCC5)nc4)nc23)c1		CHEMBL3958485	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420080	17783323	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CNC(=O)c1cccc(-c2csc3c(N)nc(Nc4ccc(N5CCC(O)CC5)cc4)nc23)c1		CHEMBL3967317	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420081	17783324	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCN1CCN(c2ccc(Nc3nc(N)c4scc(-c5cccc(C(=O)NC)c5)c4n3)cc2)CC1		CHEMBL3917740	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420082	17783325	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CNC(=O)c1cccc(-c2csc3c(N)nc(Nc4ccc(N5CCC(N6CCCC6)CC5)cc4)nc23)c1		CHEMBL3889738	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420083	17783326	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	COc1cc(Nc2nc(N)c3scc(-c4cccc(NC(=O)C5CC5)c4)c3n2)cc(OC)c1OC		CHEMBL3954479	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420084	17783327	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCS(=O)(=O)Nc1cccc(-c2csc3c(N)nc(Nc4cc(OC)c(OC)c(OC)c4)nc23)c1		CHEMBL3930361	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420085	17783328	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CNS(=O)(=O)c1cccc(-c2csc3c(N)nc(Nc4cc(OC)c(OC)c(OC)c4)nc23)c1		CHEMBL3903303	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420086	17783329	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCN1CCN(c2ccc(Nc3nc(N)c4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cn2)CC1		CHEMBL3974247	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420087	17783330	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCN1CCN(c2ccc(Nc3nc(N)c4scc(-c5cnc6ccccc6c5)c4n3)cn2)CC1		CHEMBL3912314	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420088	17783331	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCN1CCN(c2ccc(Nc3nc(N)c4scc(-c5cnc6ccccc6c5)c4n3)cc2)CC1		CHEMBL3979130	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420089	17783332	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	Nc1nc(Nc2ccc(N3CCOCC3)nc2)nc2c(-c3cnc4ccccc4c3)csc12		CHEMBL3982165	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420090	17783333	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCN1CCN(c2cccc(Nc3nc(N)c4scc(-c5cnc6ccccc6c5)c4n3)c2)CC1		CHEMBL3953444	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420091	17783334	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	C#Cc1csc2c(NCc3ccccc3)nc(NC[C@H](C)O)nc12		CHEMBL3948606	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420092	17783335	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	C#Cc1csc2c(N[C@H](C)c3ccccc3)nc(NC[C@H](C)O)nc12		CHEMBL3977799	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420093	17783336	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	C=Cc1csc2c(NCc3ccccc3)nc(NCCN3CCOCC3)nc12		CHEMBL3953914	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420094	17783337	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	C=Cc1csc2c(N[C@H](C)c3ccccc3)nc(NCCN3CCOCC3)nc12		CHEMBL4110024	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
420095	17783338	CHEMBL3888859	ULight-LANCE Assay: Full sequence FAK was purchased from Cell Signaling (Catalog No.: 7796). ULight-poly GT (PerkinElmer #TRF0100-D), Eu-anti-phospho-Tyr (PT66) (PerkinElmer #AD0068) and Lance detection buffer (PerkinElmer #CR-97-100) were purchased from PerkinElmer. The kinase solution (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Tween-20) was adjusted to a final concentration of 3 nM by adding FAK diluted to 6 nM (2×) in white 384 OptiPlate, and added with an amount of 5 μL. 4× ULight-poly GT was adjusted to a final concentration of 100 nM. ATP (Sigma #A2383) was adjusted to a final concentration of 10 μM and in 2.5 μL aliquots. The test compound was sequentially diluted at 12 concentrations and treated with an amount of 0.5 μL. After shaking well and allowing to react at room temperature for 60 minutes, 5 μL of ethylenediaminetetraacetic acid (EDTA, final concentration 40 mM) diluted in Lance detection buffer (Lance detection buffer) was added and the mixture was left at room temperature for 5 minutes to stop the reaction. After adding 4× Eu-anti-phospho-Tyr (PT66) phosphorylated antibody diluted to a final concentration of 2 nM in detection buffer with an amount of 5 μL, and reaction was performed at room temperature for 60 minutes. After adjusting to detect time-resolved fluorescence energy transfer (TR-FRET) at excitation wavelength 320 nm and emission wavelength 665 nm, signals were detected using EnVision Multilabel Reader.	B	CCc1csc2c(NCc3ccccc3)nc(NCCN3CCOCC3)nc12		CHEMBL3962657	<	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
427988	17789658	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3944283	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
427989	17789659	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc2c(c1Nc1nc(Nc3ccc(N4CCOCC4)cc3OC)nc3c1CCN3)OCO2		CHEMBL3975819	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
427990	17789660	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)CCN2		CHEMBL3972759	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
427991	17789661	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3982124	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
427992	17789662	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3965442	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
427993	17789663	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)CCN2		CHEMBL3896626	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
427994	17789664	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)CCN2		CHEMBL3971472	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
427995	17789665	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)CCN2		CHEMBL3967692	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
427996	17789666	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)CCN2		CHEMBL3897679	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
427997	17789667	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)CCN2		CHEMBL3901273	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
427998	17789668	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(NCc3ccccc3N(C)S(C)(=O)=O)n1)CCN2		CHEMBL3906683	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
427999	17789669	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)CCN2		CHEMBL3975221	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428000	17789670	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)CCN2		CHEMBL3904353	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428001	17789671	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2CO)nc2c1CCN2		CHEMBL3950487	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428002	17789672	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2OCCO3)nc2c1CCN2		CHEMBL3894129	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428003	17789673	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c3c2OCCO3)nc2c1CCN2		CHEMBL3959184	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428004	17789674	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCN1C(=O)CCCc2c1ccc(Nc1nc3c(c(Nc4ccccc4C(=O)NC)n1)CCN3)c2OC		CHEMBL3928192	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428005	17789675	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3ccoc23)nc2c1CCN2		CHEMBL3966923	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428006	17789676	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(C)nn2C)nc2c1CCN2		CHEMBL3937170	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428007	17789677	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1CCN2		CHEMBL3975406	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428008	17789678	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3CCCN2CCOCC2)nc2c1CCN2		CHEMBL3949502	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428009	17789679	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3942938	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428010	17789680	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)C(C)CN2		CHEMBL3914954	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428011	17789681	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3920980	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428012	17789682	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3952170	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428013	17789683	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C(C)CN2		CHEMBL3947913	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428014	17789684	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C(C)CN2		CHEMBL3920974	<	IC50	nM	300.0	CHEMBL2695	Homo sapiens	IC50	nM	300.0
428015	17789685	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C(C)CN2		CHEMBL3942382	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428016	17789686	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C(C)CN2		CHEMBL3968458	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428017	17789687	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C(C)CN2		CHEMBL3937080	<	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
428018	17789688	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc(NCc2ccccc2N(C)S(C)(=O)=O)c2c(n1)NCC2C		CHEMBL3957442	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428019	17789689	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C(C)CN2		CHEMBL3913196	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428020	17789690	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C(C)CN2		CHEMBL3928184	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428021	17789691	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1[C@H](C)CN2		CHEMBL4107431	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428022	17789692	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)[C@H](C)CN2		CHEMBL4112034	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428023	17789693	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3949300	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428024	17789694	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)CCN2		CHEMBL3921504	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428025	17789695	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3943967	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428026	17789696	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912539	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428027	17789697	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(N)(=O)=O)n1)CCN2		CHEMBL3935002	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428028	17789698	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CC3)n1)CCN2		CHEMBL3907045	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428029	17789699	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3967797	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428030	17789700	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3941707	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428031	17789701	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)CCN2		CHEMBL3892176	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428032	17789702	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912539	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428033	17789703	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)CCN2		CHEMBL3897579	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428034	17789704	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3929098	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428035	17789705	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCN(C)C)n1)CCN2		CHEMBL3906581	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428036	17789706	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3934545	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428037	17789707	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)CCN2		CHEMBL3890905	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428038	17789708	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3915406	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428039	17789709	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3899895	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428040	17789710	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CO)cc2)nc2c1CCN2		CHEMBL3927886	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428041	17789711	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2F)nc2c1CCN2		CHEMBL3911069	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428042	17789712	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1nc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3939030	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428043	17789713	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)nc2)nc2c1CCN2		CHEMBL3895395	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428044	17789714	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cn2)nc2c1CCN2		CHEMBL3919894	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428045	17789715	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCOc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3896574	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428046	17789716	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2C(F)(F)F)nc2c1CCN2		CHEMBL3924601	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428047	17789717	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(F)(F)F)cc2)nc2c1CCN2		CHEMBL3902048	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428048	17789718	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N(C)C)cc2)nc2c1CCN2		CHEMBL3933520	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428049	17789719	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(=O)Nc1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3918815	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428050	17789720	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3946639	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428051	17789721	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3974350	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428052	17789722	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	Cc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3941437	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428053	17789723	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3965861	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428054	17789724	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3935969	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428055	17789725	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(C)O)cc2)nc2c1CCN2		CHEMBL3889853	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428056	17789726	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(OCCN2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3962392	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428057	17789727	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC(F)(F)F)cc2)nc2c1CCN2		CHEMBL3979231	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428058	17789728	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NC(C)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3950186	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428059	17789729	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(NS(C)(=O)=O)c2)nc2c1CCN2		CHEMBL3966943	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428060	17789730	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1cccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)c1		CHEMBL3933674	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428061	17789731	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(=O)Nc1cccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)c1		CHEMBL3946772	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428062	17789732	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3980018	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428063	17789733	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ccnc2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3942329	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428064	17789734	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCCC3)cc2)nc2c1CCN2		CHEMBL3971936	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428065	17789735	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(CO)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3906918	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428066	17789736	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(O)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3967319	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428067	17789737	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCC(O)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3956331	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428068	17789738	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(C)N3CCCCC3)cc2)nc2c1CCN2		CHEMBL3932107	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428069	17789739	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ccccc2=O)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3955195	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428070	17789740	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2C(C)COCC2C)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3889594	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428071	17789741	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(NCCN2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3904434	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428072	17789742	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(O)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3975280	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428073	17789743	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCS(=O)(=O)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3913439	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428074	17789744	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ncnn2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3980132	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428075	17789745	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N(C)C)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3918922	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428076	17789746	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2cc(C)nc2C)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3890853	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428077	17789747	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	Cc1csc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)n1		CHEMBL3899700	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428078	17789748	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3901728	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428079	17789749	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3928389	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428080	17789750	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2cccn2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3982199	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428081	17789751	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3970653	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428082	17789752	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3899477	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428083	17789753	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912145	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428084	17789754	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCCC2=O)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3908536	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428085	17789755	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2C(=O)CCc3ccccc32)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3967584	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428086	17789756	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCN2		CHEMBL3898470	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428087	17789757	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C(C)CN2		CHEMBL3943268	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428088	17789758	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1[C@@H](C)CN2		CHEMBL3909548	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428089	17789759	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3899566	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428090	17789760	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C(C)(C)CN2		CHEMBL3935375	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428091	17789761	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C(C)(C)CN2		CHEMBL3932350	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428092	17789762	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3971896	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428093	17789763	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)C(C)(C)CN2		CHEMBL3933115	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428094	17789764	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C(C)(C)CN2		CHEMBL3954762	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428095	17789765	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C(C)(C)CN2		CHEMBL3917972	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428096	17789766	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3896031	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428097	17789767	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)C(C)(C)CN2		CHEMBL3923581	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428098	17789768	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3979330	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428099	17789769	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3940192	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428100	17789770	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3915673	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428101	17789771	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3947737	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428102	17789772	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)C(C)(C)CN2		CHEMBL3899645	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428103	17789773	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)C(C)(C)CN2		CHEMBL3984491	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428104	17789774	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC3CC3)n1)C(C)(C)CN2		CHEMBL3954373	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428105	17789775	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCO)n1)C(C)(C)CN2		CHEMBL3926549	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428106	17789776	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCN(C)C)n1)C(C)(C)CN2		CHEMBL3957554	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428107	17789777	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)C(C)(C)CN2		CHEMBL3981963	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428108	17789778	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C(C)(C)CN2		CHEMBL3948905	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428109	17789779	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C(C)(C)CN2		CHEMBL3912131	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428110	17789780	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C(C)(C)CN2		CHEMBL3936573	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428111	17789781	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C(C)(C)CN2		CHEMBL3892608	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428112	17789782	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc2c(c1Nc1nc(Nc3ccc(N4CCOCC4)cc3OC)nc3c1C(C)(C)CN3)OCO2		CHEMBL3968717	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428113	17789783	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(NC3CCCCC3N(C)S(C)(=O)=O)n1)C(C)(C)CN2		CHEMBL3906560	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428114	17789784	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2OCCO3)nc2c1C(C)(C)CN2		CHEMBL3942677	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428115	17789785	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c3c2OCCO3)nc2c1C(C)(C)CN2		CHEMBL3948194	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428116	17789786	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1C(C)(C)CN2		CHEMBL3964456	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428117	17789787	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3ccoc23)nc2c1C(C)(C)CN2		CHEMBL3942122	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428118	17789788	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(C)nn2C)nc2c1C(C)(C)CN2		CHEMBL3957673	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428119	17789789	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCN1C(=O)CCCc2c1ccc(Nc1nc3c(c(Nc4ccccc4C(=O)NC)n1)C(C)(C)CN3)c2OC		CHEMBL3889834	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428120	17789790	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(ccn3CCCN3CCOCC3)c2)nc2c1C(C)(C)CN2		CHEMBL3958881	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428121	17789791	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3961668	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428122	17789792	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)C1(CC1)CN2		CHEMBL3892670	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428123	17789793	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)C1(CC1)CN2		CHEMBL3975901	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428124	17789794	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C1(CC1)CN2		CHEMBL3901621	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428125	17789795	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3936925	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428126	17789796	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC3CC3)n1)C1(CC1)CN2		CHEMBL3914879	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428127	17789797	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3985139	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428128	17789798	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCO)n1)C1(CC1)CN2		CHEMBL3974734	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428129	17789799	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)C1(CC1)CN2		CHEMBL3954119	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428130	17789800	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	C=CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3982805	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428131	17789801	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C1(CC1)CN2		CHEMBL3932524	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428132	17789802	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CC3)n1)C1(CC1)CN2		CHEMBL3901039	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428133	17789803	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3923580	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428134	17789804	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3895587	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428135	17789805	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C1(CC1)CN2		CHEMBL3915483	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428136	17789806	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C1(CC1)CN2		CHEMBL3908546	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428137	17789807	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)C1(CC1)CN2		CHEMBL3986981	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428138	17789808	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3915096	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428139	17789809	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C1(CC1)CN2		CHEMBL3898958	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428140	17789810	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C1(CC1)CN2		CHEMBL3952455	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428141	17789811	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C1(CC1)CN2		CHEMBL3910134	<	IC50	nM	50.0	CHEMBL2695	Homo sapiens	IC50	nM	50.0
428142	17789812	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C1(CC1)CN2		CHEMBL3908380	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428143	17789813	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1C1(CC1)CN2		CHEMBL3963488	<	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	nM	20.0
428144	17789814	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3971195	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
428145	17789815	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccccc2OC)nc2c1CCN2		CHEMBL3972273	<	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
428146	17789816	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)O)n1)CCN2		CHEMBL3893960	<	IC50	nM	500.0	CHEMBL2695	Homo sapiens	IC50	nM	500.0
428147	17789817	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C=O)n1)CCN2		CHEMBL3980333	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428148	17789818	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3CCO)n1)CCN2		CHEMBL3948742	<	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
428149	17789819	CHEMBL3888995	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100× stock. A 5 μl of 100× stock of each concentration was added to wells containing 95 μl of 1× reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5× stock. Then 2 μl of 5× stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 μl of 2.5 nM FAK, 1 μl of 8 μg/μl BSA and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 33.3 μM ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 μl of 2 nM PYK2 and 1.5 μl of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 μl of 46.6 μM ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 μl of 40 mM EDTA stop buffer prepared in 1×LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 μl of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3P(C)(C)=O)n1)CCN2		CHEMBL3928548	<	IC50	nM	100.0	CHEMBL2695	Homo sapiens	IC50	nM	100.0
Inactive	17932390	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932391	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	=	Kd	nM	601.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	601.0
Inactive	17932392	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932393	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932394	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932395	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932396	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932397	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932398	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932399	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932400	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932401	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932402	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932403	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932404	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932405	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	595.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	595.0
Inactive	17932406	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932407	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932408	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	=	Kd	nM	11.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	11.0
Inactive	17932409	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932410	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	264.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	264.0
Inactive	17932411	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932412	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932413	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932414	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932415	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932416	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932417	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	13039.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	13039.0
Inactive	17932418	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932419	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932420	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	118.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	118.0
Inactive	17932421	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932422	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932423	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932424	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932425	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932426	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	=	Kd	nM	74.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	74.0
Inactive	17932427	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932428	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932429	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932430	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932431	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932432	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932433	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932434	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932435	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932436	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932437	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932438	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932439	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932440	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932441	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	948.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	948.0
Inactive	17932442	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932443	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932444	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932445	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932446	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932447	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932448	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932449	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	58.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	58.0
Inactive	17932450	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932451	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932452	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932453	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932454	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932455	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932456	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932457	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932458	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932459	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932460	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932461	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932462	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932463	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932464	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932465	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932466	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932467	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932468	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932469	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932470	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932471	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932472	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	22.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	22.0
Inactive	17932473	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932474	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932475	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932476	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932477	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932478	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932479	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932480	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932481	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932482	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932483	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932484	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932485	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932486	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932487	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932488	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932489	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932490	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932491	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932492	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932493	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932494	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932495	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932496	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932497	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932498	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932499	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932500	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932501	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932502	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932503	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932504	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932505	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932506	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	172.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	172.0
Inactive	17932507	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932508	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932509	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932510	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932511	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932512	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932513	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932514	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932515	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932516	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Kd	nM	218.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	218.0
Inactive	17932517	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932518	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932519	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932520	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932521	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932522	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932523	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932524	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932525	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932526	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932527	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932528	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932529	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932530	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932531	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932532	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932533	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17932534	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	436.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	436.0
Inactive	17932535	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932536	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932537	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	=	Kd	nM	191.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	191.0
Inactive	17932538	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932539	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932540	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932541	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932542	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932543	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932544	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932545	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932546	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932547	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932548	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932549	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932550	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932551	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932552	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932553	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932554	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932555	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932556	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932557	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932558	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932559	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932560	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932561	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932562	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932563	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	=	Kd	nM	437.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	437.0
Inactive	17932564	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932565	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932566	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932567	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932568	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932569	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932570	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932571	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932572	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932573	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932574	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932575	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932576	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932577	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Kd	nM	1501.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	1501.0
Inactive	17932578	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932579	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932580	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932581	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932582	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932583	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932584	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932585	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932586	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932587	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932588	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932589	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932590	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932591	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932592	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932593	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932594	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	33.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	33.0
Inactive	17932595	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932596	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932597	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	0.5	CHEMBL2695	Homo sapiens	Kd apparent	nM	0.5
Inactive	17932598	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932599	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932600	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932601	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932602	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932603	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932604	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932605	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	=	Kd	nM	433.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	433.0
Inactive	17932606	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932607	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	=	Kd	nM	5400.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	5400.0
Inactive	17932608	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932609	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932610	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932611	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932612	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Active	17932613	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	1.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	1.0
Inactive	17932614	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932615	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932616	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932617	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932618	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932619	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932620	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932621	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932622	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932623	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932624	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932625	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932626	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932627	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932628	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932629	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932630	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932631	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932632	CHEMBL3991855	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL2695	Homo sapiens	Kd apparent	nM	30000.0
	17964901	CHEMBL3995010	Inhibition of human FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	61.0	CHEMBL2695	Homo sapiens	Activity	%	61.0
	17985361	CHEMBL3999015	Inhibition of full-length recombinant human FAK (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as residual activity at 100 uM using poly(Glu,Tyr)4:1 as substrate by ADP-Glo bioluminescence assay relative to control relative to control	B	CC(=O)c1cccc(Nc2nc(-c3sc(NC(=O)OC(C)(C)C)nc3C)cs2)c1		CHEMBL4085374	=	Activity	%	82.0	CHEMBL2695	Homo sapiens	Activity	%	82.0
	17996255	CHEMBL4001404	Inhibition of human wild type partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 10 uM by KinomeScan method relative to control	B	Cc1nc2nc(Sc3ccccc3)cnc2cc1NC(=O)Nc1ccccc1		CHEMBL4083528	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	18012396	CHEMBL4004216	Inhibition of recombinant human N-terminal GST-tagged FAK cytoplasmic domain (376 to 1052 residues) expressed in baculovirus expression system	B	COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12		CHEMBL3822972	>	IC50	nM	50000.0	CHEMBL2695	Homo sapiens	IC50	uM	50.0
	18031688	CHEMBL4007705	Inhibition of FAK (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	136.0	CHEMBL2695	Homo sapiens	IC50	uM	0.136
	18031689	CHEMBL4007705	Inhibition of FAK (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	18031690	CHEMBL4007705	Inhibition of FAK (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	18031691	CHEMBL4007705	Inhibition of FAK (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	5500.0	CHEMBL2695	Homo sapiens	IC50	uM	5.5
	18031692	CHEMBL4007705	Inhibition of FAK (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	=	IC50	nM	4790.0	CHEMBL2695	Homo sapiens	IC50	uM	4.79
Dose-dependent effect	18046532	CHEMBL4010919	Inhibition of FAK phosphorylation at Tyr-397 residue in human HCT116 cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	18046533	CHEMBL4010919	Inhibition of FAK phosphorylation at Tyr-397 residue in human HCT116 cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nnc1Cl		CHEMBL4097578		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	18046534	CHEMBL4010918	Inhibition of FAK phosphorylation at Tyr-397 residue in human U87MG cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	18046535	CHEMBL4010918	Inhibition of FAK phosphorylation at Tyr-397 residue in human U87MG cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nnc1Cl		CHEMBL4097578		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18046536	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	uM	0.007
	18046537	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nnc1Cl		CHEMBL4097578	=	IC50	nM	230.0	CHEMBL2695	Homo sapiens	IC50	uM	0.23
	18046538	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nnc1Cl		CHEMBL4065141	=	IC50	nM	340.0	CHEMBL2695	Homo sapiens	IC50	uM	0.34
	18046539	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(C)c(Cl)cc2OC)nnc1Cl		CHEMBL4092812	=	IC50	nM	870.0	CHEMBL2695	Homo sapiens	IC50	uM	0.87
	18046540	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CN)cc2)nnc1Cl		CHEMBL4098626	=	IC50	nM	560.0	CHEMBL2695	Homo sapiens	IC50	uM	0.56
	18046541	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nnc1Cl		CHEMBL4080590	=	IC50	nM	640.0	CHEMBL2695	Homo sapiens	IC50	uM	0.64
	18046542	CHEMBL4010917	Inhibition of FAK (unknown origin) using Ulight-poly(Glu:Tyr)(4:1) as substrate after 1.6 hrs by TR-FRET assay	B	COc1cc(Nc2nnc(Cl)c(Nc3cccc(NS(C)(=O)=O)c3)n2)cc(OC)c1OC		CHEMBL4060227	=	IC50	nM	2500.0	CHEMBL2695	Homo sapiens	IC50	uM	2.5
Active	18057100	CHEMBL4012475	Inhibition of osteopontin-induced FAK phosphorylation in human A549 cells at 1 to 2 uM after 15 mins by Western blot method	B	CC1=CC(=O)c2c(O)cccc2C1=O		CHEMBL295316		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18081868	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	COc1ccc(N2CCN(Cn3nc(-c4ccc5c(c4)OCCO5)oc3=S)CC2)cc1		CHEMBL4092157	=	IC50	nM	2450.0	CHEMBL2695	Homo sapiens	IC50	uM	2.45
	18081869	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	O=[N+]([O-])c1ccc(N2CCN(Cn3nc(-c4ccc5c(c4)OCCO5)oc3=S)CC2)cc1		CHEMBL4094621	=	IC50	nM	2760.0	CHEMBL2695	Homo sapiens	IC50	uM	2.76
	18081870	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	S=c1oc(-c2ccc3c(c2)OCCO3)nn1CN1CCN(C(c2ccccc2)c2ccccc2)CC1		CHEMBL4068178	=	IC50	nM	1120.0	CHEMBL2695	Homo sapiens	IC50	uM	1.12
	18081871	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	COc1ccccc1N1CCN(Cn2nc(-c3ccc4c(c3)OCCO4)oc2=S)CC1		CHEMBL4095558	=	IC50	nM	1460.0	CHEMBL2695	Homo sapiens	IC50	uM	1.46
	18081872	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	S=c1oc(-c2ccc3c(c2)OCCO3)nn1CN1CCN(c2ccccc2Cl)CC1		CHEMBL4096055	=	IC50	nM	1160.0	CHEMBL2695	Homo sapiens	IC50	uM	1.16
	18081873	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	S=c1oc(-c2ccc3c(c2)OCCO3)nn1CN1CCN(c2ccccn2)CC1		CHEMBL4068745	=	IC50	nM	2450.0	CHEMBL2695	Homo sapiens	IC50	uM	2.45
	18081874	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	FC(F)(F)c1cccc(N2CCN(Cn3nc(-c4ccc5c(c4)OCCO5)oc3=S)CC2)c1		CHEMBL4066053	=	IC50	nM	780.0	CHEMBL2695	Homo sapiens	IC50	uM	0.78
	18081875	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	COc1cccc(N2CCN(Cn3nc(-c4ccc5c(c4)OCCO5)oc3=S)CC2)c1		CHEMBL4074665	=	IC50	nM	2450.0	CHEMBL2695	Homo sapiens	IC50	uM	2.45
	18081876	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	S=c1oc(-c2ccc3c(c2)OCCO3)nn1CN1CCN(c2ccc(Cl)c(Cl)c2)CC1		CHEMBL4095124	=	IC50	nM	3120.0	CHEMBL2695	Homo sapiens	IC50	uM	3.12
	18081877	CHEMBL4017675	Inhibition of FAK (unknown origin) by enzyme immuno assay	B	S=c1oc(-c2ccc3c(c2)OCCO3)nn1CN1CCN(Cc2ccccc2)CC1		CHEMBL4084931	=	IC50	nM	1970.0	CHEMBL2695	Homo sapiens	IC50	uM	1.97
	18083209	CHEMBL4018002	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	=	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
Not Active	18083210	CHEMBL4018002	Inhibition of human FAK at 1 uM relative to control	B	Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)C2CC2)C4)cn1		CHEMBL4098032		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	18083211	CHEMBL4018002	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1		CHEMBL4068727		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18083212	CHEMBL4018002	Inhibition of human FAK at 1 uM relative to control	B	Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(c2ccc(F)cc2)CC4)cn1		CHEMBL4088855	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	18096495	CHEMBL4021282	Reversible inhibition of NH2-terminal 6His-tagged FAK catalytic domain (410 to 689 residues) (unknown origin) expressed in Sf9 insect cells using p(Glu/Tyr) as substrate	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	18114358	CHEMBL4025136	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	96.0	CHEMBL2695	Homo sapiens	Activity	%	96.0
	18117605	CHEMBL4025916	Inhibition of N-terminal 6His-tagged recombinant human FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 3 uM relative to control	B	COc1ccc(-c2nnc(-n3c(-c4ccccc4)nc4cc(Cl)ccc4c3=O)s2)cc1		CHEMBL4103440	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
Not Active	18134442	CHEMBL4029537	Inhibition of FAK (unknown origin) at <1 uM using biotinylated poly[Glu:Tyr] (4:1) as substrate pretreated for 5 mins followed by substrate addition measured after 20 mins by Alphascreen assay	B	COCCNC(=O)c1ccc(Oc2sc(C(N)=O)c3c2-c2sncc2CC3)cn1		CHEMBL4066819		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	18134473	CHEMBL4029537	Inhibition of FAK (unknown origin) at <1 uM using biotinylated poly[Glu:Tyr] (4:1) as substrate pretreated for 5 mins followed by substrate addition measured after 20 mins by Alphascreen assay	B	CSc1sc(C(N)=O)c2c1-c1sncc1CC2		CHEMBL4082469		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18155540	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C		CHEMBL4100075	=	IC50	nM	7000.0	CHEMBL2695	Homo sapiens	IC50	uM	7.0
	18155541	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C		CHEMBL4083642	=	IC50	nM	3500.0	CHEMBL2695	Homo sapiens	IC50	uM	3.5
	18155542	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C		CHEMBL4104427	=	IC50	nM	1200.0	CHEMBL2695	Homo sapiens	IC50	uM	1.2
	18155543	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Br)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC		CHEMBL4081727	=	IC50	nM	9500.0	CHEMBL2695	Homo sapiens	IC50	uM	9.5
	18155544	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Br)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC		CHEMBL4063890	=	IC50	nM	2400.0	CHEMBL2695	Homo sapiens	IC50	uM	2.4
	18155545	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Cl)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC		CHEMBL4075241	=	IC50	nM	2000.0	CHEMBL2695	Homo sapiens	IC50	uM	2.0
	18155546	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C		CHEMBL4094546	=	IC50	nM	5500.0	CHEMBL2695	Homo sapiens	IC50	uM	5.5
	18155547	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C		CHEMBL4078023	=	IC50	nM	2900.0	CHEMBL2695	Homo sapiens	IC50	uM	2.9
	18155548	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	Cc1nc(C)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C		CHEMBL4102284	=	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	uM	1.0
	18155549	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Br)c(/C=C2\CC(C)CC(=C\c3nc(C)c(C)nc3C)/C2=N/O)cc1OC		CHEMBL4085902	=	IC50	nM	7800.0	CHEMBL2695	Homo sapiens	IC50	uM	7.8
	18155550	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Br)c(/C=C2\CN(C)CC(=C\c3nc(C)c(C)nc3C)/C2=N\O)cc1OC		CHEMBL4064361	=	IC50	nM	1900.0	CHEMBL2695	Homo sapiens	IC50	uM	1.9
	18155551	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	COc1cc(Br)c(/C=C2\CN(C(C)C)CC(=C\c3nc(C)c(C)nc3C)/C2=N/O)cc1OC		CHEMBL4093642	=	IC50	nM	1800.0	CHEMBL2695	Homo sapiens	IC50	uM	1.8
	18155552	CHEMBL4034794	Inhibition of FAK (unknown origin) assembly preincubated with enzyme followed by GTP addition measured after 20 mins by spectrophotometric analysis	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	IC50	nM	7400.0	CHEMBL2695	Homo sapiens	IC50	uM	7.4
	18203660	CHEMBL4043947	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	78.0	CHEMBL2695	Homo sapiens	Activity	%	78.0
	18231648	CHEMBL4050188	Inhibition of human FAK/PTK2 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	B	COc1cc(N2CCOCC2)ccc1Nc1nc(NC2CCCCC2)c2cc[nH]c2n1		CHEMBL4076767	=	IC50	nM	891.0	CHEMBL2695	Homo sapiens	IC50	10'-7M	8.91
	18231696	CHEMBL4050188	Inhibition of human FAK/PTK2 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	10'-8M	2.0
Not Determined	18231726	CHEMBL4050188	Inhibition of human FAK/PTK2 using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-32P]ATP	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339		IC50			CHEMBL2695	Homo sapiens	IC50		
	18248618	CHEMBL4053901	Inhibition of PTK2 (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	73.0	CHEMBL2695	Homo sapiens	INH	%	73.0
	18253564	CHEMBL4055066	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	88.0	CHEMBL2695	Homo sapiens	Activity	%	88.0
	18253565	CHEMBL4055066	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	88.0	CHEMBL2695	Homo sapiens	Activity	%	88.0
	18254968	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	6.79	CHEMBL2695	Homo sapiens	IC50	nM	6.79
	18254969	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(Oc3ccc(NS(=O)(=O)C(F)(F)F)cc3)cc2)ncc1Cl		CHEMBL4072182	=	IC50	nM	235.9	CHEMBL2695	Homo sapiens	IC50	nM	235.9
	18254970	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(Oc3ccc(NS(C)(=O)=O)cc3)cc2)ncc1Cl		CHEMBL4077716	=	IC50	nM	108.8	CHEMBL2695	Homo sapiens	IC50	nM	108.8
	18254971	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(OC)cc3)c(C)c2)ncc1Cl		CHEMBL4095740	=	IC50	nM	113.8	CHEMBL2695	Homo sapiens	IC50	nM	113.8
	18254972	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(OC)cc3)cc2)ncc1Cl		CHEMBL4066728	=	IC50	nM	110.0	CHEMBL2695	Homo sapiens	IC50	nM	110.0
	18254973	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(F)cc3)cc2)ncc1Cl		CHEMBL4088025	=	IC50	nM	86.7	CHEMBL2695	Homo sapiens	IC50	nM	86.7
	18254974	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(F)cc3)c(OC)c2)ncc1Cl		CHEMBL4075181	=	IC50	nM	84.7	CHEMBL2695	Homo sapiens	IC50	nM	84.7
	18254975	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(C)cc3)c(OC)c2)ncc1Cl		CHEMBL4101846	=	IC50	nM	109.2	CHEMBL2695	Homo sapiens	IC50	nM	109.2
	18254976	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(C)cc3)cc2)ncc1Cl		CHEMBL4085413	=	IC50	nM	82.5	CHEMBL2695	Homo sapiens	IC50	nM	82.5
	18254977	CHEMBL4055456	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate measured after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(NS(=O)(=O)c3ccc(C)cc3)c(C)c2)ncc1Cl		CHEMBL4063835	=	IC50	nM	84.6	CHEMBL2695	Homo sapiens	IC50	nM	84.6
	18282099	CHEMBL4120054	Inhibition of recombinant full length GST-tagged human FAK expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	11.1	CHEMBL2695	Homo sapiens	INH	%	11.1
	18282418	CHEMBL4120054	Inhibition of recombinant full length GST-tagged human FAK expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	10.4	CHEMBL2695	Homo sapiens	INH	%	10.4
	18339291	CHEMBL4138366	Inhibition of FAK phosphorylation at Y397 in human bone marrow mesenchymal stem cells at 1 uM after 1 hr by immunoblot method relative to control	B	CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL480499	=	Inhibition	%	61.0	CHEMBL2695	Homo sapiens	INH	%	61.0
	18339292	CHEMBL4138367	Inhibition of FAK phosphorylation at Y397 in human bone marrow mesenchymal stem cells at 5 uM after 1 hr by immunoblot method relative to control	B	CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL480499	=	Inhibition	%	78.0	CHEMBL2695	Homo sapiens	INH	%	78.0
	18420733	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1	Outside typical range	CHEMBL941	=	Inhibition	%	-62.0	CHEMBL2695	Homo sapiens	INH	%	-62.0
	18420734	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	COc1ccc(CCN2CCC(Nc3nc4nc5ccc(C)cc5nc4c(=O)[nH]3)CC2)cc1	Outside typical range	CHEMBL4167512	=	Inhibition	%	-21.0	CHEMBL2695	Homo sapiens	INH	%	-21.0
	18420735	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	COc1ccc2nc3nc(NCc4ccc(CN5CCN(C)CC5)cc4)[nH]c(=O)c3nc2c1		CHEMBL4171939	=	Inhibition	%	-10.0	CHEMBL2695	Homo sapiens	INH	%	-10.0
	18420736	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	O=c1[nH]c(NCc2ccc(CN3CCCCC3)cc2)nc2nc3ccccc3cc12	Outside typical range	CHEMBL4160278	=	Inhibition	%	-59.0	CHEMBL2695	Homo sapiens	INH	%	-59.0
	18420737	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	CN1CCN(Cc2ccc(CNc3nc4nc5ccc(Cl)cc5cc4c(=O)[nH]3)cc2)CC1	Outside typical range	CHEMBL4171176	=	Inhibition	%	-42.0	CHEMBL2695	Homo sapiens	INH	%	-42.0
	18420738	CHEMBL4153877	Inhibition of FAK (unknown origin) at 10 uM by [33P]-ATP radiometric assay	B	Cc1ccc2nc3nc(NCc4ccc(CN5CCN(C)CC5)cc4)[nH]c(=O)c3cc2c1	Outside typical range	CHEMBL4163273	=	Inhibition	%	-48.0	CHEMBL2695	Homo sapiens	INH	%	-48.0
	18431080	CHEMBL4155761	Inhibition of recombinant full length GST-tagged human FAK expressed in baculovirus expression system at 1 uM by Z'-Lyte assay relative to control	B	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1		CHEMBL4160587	=	Inhibition	%	23.0	CHEMBL2695	Homo sapiens	INH	%	23.0
	18440202	CHEMBL4157026	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	99.0	CHEMBL2695	Homo sapiens	Activity	%	99.0
	18457566	CHEMBL4179647	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1		CHEMBL4212439	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	18457567	CHEMBL4179647	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1		CHEMBL4217392	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	18457568	CHEMBL4179647	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL4208064	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	18457569	CHEMBL4179647	Inhibition of human FAK at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1		CHEMBL4205584	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	18463747	CHEMBL4181163	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	18464428	CHEMBL4181423	Inhibition of recombinant full length GST-tagged human FAK expressed in baculovirus expression system at 100 nM relative to control	B	CCOP(=O)(CCCOc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)N1CCOCC1		CHEMBL4216755	=	Inhibition	%	92.0	CHEMBL2695	Homo sapiens	INH	%	92.0
	18464436	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(Cc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)N1CCOCC1		CHEMBL4211226	=	IC50	nM	5.69	CHEMBL2695	Homo sapiens	IC50	nM	5.69
	18464437	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(CCCOc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)N1CCOCC1		CHEMBL4216755	=	IC50	nM	4.65	CHEMBL2695	Homo sapiens	IC50	nM	4.65
	18464438	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(CCCOc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)OCC		CHEMBL4218975	=	IC50	nM	6.18	CHEMBL2695	Homo sapiens	IC50	nM	6.18
	18464439	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(Cc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)OCC		CHEMBL4207007	=	IC50	nM	5.01	CHEMBL2695	Homo sapiens	IC50	nM	5.01
	18464440	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(CCCOc1ccc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC)n2)cc1)OCC		CHEMBL4209502	=	IC50	nM	10.69	CHEMBL2695	Homo sapiens	IC50	nM	10.69
	18464441	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CCOP(=O)(Cc1ccc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC)n2)cc1)OCC		CHEMBL4218201	=	IC50	nM	4.25	CHEMBL2695	Homo sapiens	IC50	nM	4.25
	18464454	CHEMBL4181392	Inhibition of recombinant human N-terminal His-tagged FAK cytoplasmic domain (393 to 698 residues) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation after 60 mins by ADP-Glo kinase assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	6.79	CHEMBL2695	Homo sapiens	IC50	nM	6.79
Active	18476841	CHEMBL4183719	Induction of PTK2 degradation in human NCI-H3122 cells at 0.01 to 1 uM after 16 hrs by immunoblot method	B	COc1cc(N2CCN(CCOCCOCCNC(=O)CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4217325		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476842	CHEMBL4183719	Induction of PTK2 degradation in human NCI-H3122 cells at 0.01 to 1 uM after 16 hrs by immunoblot method	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1		CHEMBL4213986		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476847	CHEMBL4183718	Induction of PTK2 degradation in human KARPAS299 cells at 0.01 to 1 uM after 16 hrs by immunoblot method	B	COc1cc(N2CCN(CCOCCOCCNC(=O)CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4217325		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476848	CHEMBL4183718	Induction of PTK2 degradation in human KARPAS299 cells at 0.01 to 1 uM after 16 hrs by immunoblot method	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1		CHEMBL4213986		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476853	CHEMBL4183724	Induction of PTK2 degradation in human Kelly cells at 10 to 160 nM after 16 hrs by immunoblot method	B	COc1cc(N2CCN(CCOCCOCCNC(=O)CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4217325		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476854	CHEMBL4183724	Induction of PTK2 degradation in human Kelly cells at 10 to 160 nM after 16 hrs by immunoblot method	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1		CHEMBL4213986		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476859	CHEMBL4183727	Induction of PTK2 degradation in human NCI-H3122 cells at 250 nM measured over 2 to 16 hrs by immunoblot method	B	COc1cc(N2CCN(CCOCCOCCNC(=O)CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4217325		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476860	CHEMBL4183727	Induction of PTK2 degradation in human NCI-H3122 cells at 250 nM measured over 2 to 16 hrs by immunoblot method	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1		CHEMBL4213986		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476867	CHEMBL4183731	Induction of PTK2 degradation in human Kelly cells at 100 nM measured over 2 to 16 hrs by immunoblot method	B	COc1cc(N2CCN(CCOCCOCCNC(=O)CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL4217325		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	18476868	CHEMBL4183731	Induction of PTK2 degradation in human Kelly cells at 100 nM measured over 2 to 16 hrs by immunoblot method	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1		CHEMBL4213986		Activity			CHEMBL2695	Homo sapiens	Activity		
	18484642	CHEMBL4185805	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	99.0	CHEMBL2695	Homo sapiens	Activity	%	99.0
	18484979	CHEMBL4185805	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	92.0	CHEMBL2695	Homo sapiens	Activity	%	92.0
	18489512	CHEMBL4187253	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	85.0	CHEMBL2695	Homo sapiens	Activity	%	85.0
	18507795	CHEMBL4190967	Inhibition of recombinant human FAK (411 to 686 residues) at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	18653643	CHEMBL4230082	Inhibition of FAK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-8.0	CHEMBL2695	Homo sapiens	INH	%	-8.0
	18653644	CHEMBL4230082	Inhibition of FAK (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	3.0	CHEMBL2695	Homo sapiens	INH	%	3.0
	18655530	CHEMBL4230705	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	90.0	CHEMBL2695	Homo sapiens	Activity	%	90.0
	18656503	CHEMBL4231211	Inhibition of recombinant human FAK expressed in Sf9 insect cells using Ulight-TK peptide as substrate after 60 mins by LANCE method	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	62.0	CHEMBL2695	Homo sapiens	IC50	10'-8M	6.2
	18663908	CHEMBL4232892	Inhibition of human FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	18664005	CHEMBL4232989	Binding affinity to human FAK (D402 to R696 residues) expressed in bacterial expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL2695	Homo sapiens	Kd	uM	5.0
	18665486	CHEMBL4233320	Inhibition of FAK (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	18665532	CHEMBL4233320	Inhibition of FAK (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	9000.0	CHEMBL2695	Homo sapiens	IC50	nM	9000.0
	18674655	CHEMBL4235352	Inhibition of FAK (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	10000.0	CHEMBL2695	Homo sapiens	Ki	nM	10000.0
	18674656	CHEMBL4235352	Inhibition of FAK (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	10000.0	CHEMBL2695	Homo sapiens	Ki	nM	10000.0
	18674657	CHEMBL4235352	Inhibition of FAK (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	10000.0	CHEMBL2695	Homo sapiens	Ki	nM	10000.0
	18697637	CHEMBL4254310	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	76.0	CHEMBL2695	Homo sapiens	Activity	%	76.0
	18706759	CHEMBL4256127	Inhibition of FAK (unknown origin) by Lanthascreen assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
	18706772	CHEMBL4256114	Inhibition of FAK (unknown origin) at 50 ug/ml by Lanthascreen assay relative to control	B	CC(C)c1ccc2c(c1)CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)O		CHEMBL12850	=	Inhibition	%	67.1	CHEMBL2695	Homo sapiens	INH	%	67.1
	18737829	CHEMBL4261410	Inhibition of recombinant human FAK (411 to 686 residues) using EEEEYEEEEEEYY as substrate after 40 mins in presence of [gamma-33P]-ATP by scintillation counting analysis	B	CCn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(OC(F)(F)F)c2)c2c(N)ncnc21		CHEMBL4281823	=	IC50	nM	89.0	CHEMBL2695	Homo sapiens	IC50	nM	89.0
	18751114	CHEMBL4263800	Inhibition of FAK (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	-2.0	CHEMBL2695	Homo sapiens	INH	%	-2.0
	18751609	CHEMBL4264294	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	84.0	CHEMBL2695	Homo sapiens	Activity	%	84.0
	18761481	CHEMBL4266559	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	-4.0	CHEMBL2695	Homo sapiens	INH	%	-4.0
	18761777	CHEMBL4266559	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	9.0	CHEMBL2695	Homo sapiens	INH	%	9.0
	18761940	CHEMBL4266559	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
Not Active	18847319	CHEMBL4304901	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18857963	CHEMBL4307809	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
Active	18859186	CHEMBL4308401	Inhibition of FAK phosphorylation at Y397 residue in human LNCAP cells at 50 uM incubated for 48 hrs by chemiluminescence reagent based autoradiography	B	COc1c2c(c(C)c3c1C(=O)OC3)O[C@@]1(C)C[C@]3(O)OC[C@]4(C)O[C@@]5(OC)CC[C@](C)([C@H]1C2)[C@]43O5		CHEMBL4520516		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	18890064	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4567448	=	IC50	nM	34.5	CHEMBL2695	Homo sapiens	IC50	nM	34.5
	18890065	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccc(Nc2nc(Nc3ccccc3C(=O)NC)c3cc[nH]c3n2)cc1		CHEMBL4445212	=	IC50	nM	91.8	CHEMBL2695	Homo sapiens	IC50	nM	91.8
	18890066	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(N2CCOCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4456459	=	IC50	nM	51.1	CHEMBL2695	Homo sapiens	IC50	nM	51.1
	18890067	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cc1		CHEMBL4466781	=	IC50	nM	15.5	CHEMBL2695	Homo sapiens	IC50	nM	15.5
	18890068	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(N2CCOCC2)ccc1Nc1nc(NCc2ccccc2N(C)S(C)(=O)=O)c2cc[nH]c2n1		CHEMBL4440758	=	IC50	nM	31.9	CHEMBL2695	Homo sapiens	IC50	nM	31.9
	18890069	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccc(Nc2nc(NCc3ccccc3N(C)S(C)(=O)=O)c3cc[nH]c3n2)cc1		CHEMBL4443454	=	IC50	nM	17.1	CHEMBL2695	Homo sapiens	IC50	nM	17.1
	18890070	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(N2CCOCC2)ccc1Nc1nc(Nc2cccn(C)c2=O)c2cc[nH]c2n1		CHEMBL4447427	=	IC50	nM	150.8	CHEMBL2695	Homo sapiens	IC50	nM	150.8
	18890071	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccc(Nc2nc(Nc3cccn(C)c3=O)c3cc[nH]c3n2)cc1		CHEMBL4448618	=	IC50	nM	126.4	CHEMBL2695	Homo sapiens	IC50	nM	126.4
	18890072	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CC(=O)Nc1ccc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cc1		CHEMBL4549746	=	IC50	nM	85.0	CHEMBL2695	Homo sapiens	IC50	nM	85.0
	18890073	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CCNS(=O)(=O)c1ccc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cc1		CHEMBL4475504	=	IC50	nM	38.7	CHEMBL2695	Homo sapiens	IC50	nM	38.7
	18890074	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COP(=O)(Cc1ccc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cc1)OC		CHEMBL4592919	=	IC50	nM	82.0	CHEMBL2695	Homo sapiens	IC50	nM	82.0
	18890075	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)NC3CCNCC3)cc2)nc2[nH]ccc12		CHEMBL4453086	=	IC50	nM	6.8	CHEMBL2695	Homo sapiens	IC50	nM	6.8
	18890076	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)NC3CCOCC3)cc2)nc2[nH]ccc12		CHEMBL4472514	=	IC50	nM	16.7	CHEMBL2695	Homo sapiens	IC50	nM	16.7
	18890077	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CN1CCC(NC(=O)c2ccc(Nc3nc(Nc4ccccc4P(C)(C)=O)c4cc[nH]c4n3)cc2)CC1		CHEMBL4445320	=	IC50	nM	17.2	CHEMBL2695	Homo sapiens	IC50	nM	17.2
	18890078	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N[C@@H]3CCCNC3)cc2)nc2[nH]ccc12		CHEMBL4581127	=	IC50	nM	64.4	CHEMBL2695	Homo sapiens	IC50	nM	64.4
	18890079	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N[C@H]3CCCNC3)cc2)nc2[nH]ccc12		CHEMBL4573707	=	IC50	nM	9.1	CHEMBL2695	Homo sapiens	IC50	nM	9.1
	18890080	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCNCC3)cc2)nc2[nH]ccc12		CHEMBL4589102	=	IC50	nM	38.2	CHEMBL2695	Homo sapiens	IC50	nM	38.2
	18890081	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc2[nH]ccc12		CHEMBL4517847	=	IC50	nM	62.1	CHEMBL2695	Homo sapiens	IC50	nM	62.1
	18890082	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CN1CCN(c2ccc(Nc3nc(Nc4ccccc4P(C)(C)=O)c4cc[nH]c4n3)cc2)CC1		CHEMBL4548762	=	IC50	nM	21.9	CHEMBL2695	Homo sapiens	IC50	nM	21.9
	18890083	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCNCC3)cc2)nc2[nH]ccc12		CHEMBL4514956	=	IC50	nM	9.3	CHEMBL2695	Homo sapiens	IC50	nM	9.3
	18890084	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	Cn1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cn1		CHEMBL4447326	=	IC50	nM	156.1	CHEMBL2695	Homo sapiens	IC50	nM	156.1
	18890085	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2cnn(CC(F)F)c2)nc2[nH]ccc12		CHEMBL4577625	=	IC50	nM	132.6	CHEMBL2695	Homo sapiens	IC50	nM	132.6
	18890086	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COCCn1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cn1		CHEMBL4529571	=	IC50	nM	23.1	CHEMBL2695	Homo sapiens	IC50	nM	23.1
	18890087	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2cnn(C3CCOCC3)c2)nc2[nH]ccc12		CHEMBL4471190	=	IC50	nM	64.1	CHEMBL2695	Homo sapiens	IC50	nM	64.1
	18890088	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2cnn(C3CCNCC3)c2)nc2[nH]ccc12		CHEMBL4468872	=	IC50	nM	26.2	CHEMBL2695	Homo sapiens	IC50	nM	26.2
	18890089	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CN(C)C(=O)Cn1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)cn1		CHEMBL4452193	=	IC50	nM	176.6	CHEMBL2695	Homo sapiens	IC50	nM	176.6
	18890090	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2cnn(CC(=O)N3CCOCC3)c2)nc2[nH]ccc12		CHEMBL4466313	=	IC50	nM	21.1	CHEMBL2695	Homo sapiens	IC50	nM	21.1
	18890091	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)NC3CCNCC3)cc2F)nc2[nH]ccc12		CHEMBL4454761	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
	18890092	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	IC50	nM	5.4	CHEMBL2695	Homo sapiens	IC50	nM	5.4
	18890093	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CCOc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4546732	=	IC50	nM	5.8	CHEMBL2695	Homo sapiens	IC50	nM	5.8
	18890094	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CC(C)Oc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4590854	=	IC50	nM	80.8	CHEMBL2695	Homo sapiens	IC50	nM	80.8
	18890095	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)NC3CCNCC3)cc2C(F)(F)F)nc2[nH]ccc12		CHEMBL4464977	=	IC50	nM	347.5	CHEMBL2695	Homo sapiens	IC50	nM	347.5
	18890096	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(C(=O)NC2CCNCC2)c(F)cc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4550782	=	IC50	nM	9.4	CHEMBL2695	Homo sapiens	IC50	nM	9.4
	18890097	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	Cc1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3cc[nH]c3n2)ccc1C(=O)NC1CCNCC1		CHEMBL4457562	=	IC50	nM	10.3	CHEMBL2695	Homo sapiens	IC50	nM	10.3
	18890098	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CP(C)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)NC3CCNCC3)c(F)c2)nc2[nH]ccc12		CHEMBL4475488	=	IC50	nM	5.1	CHEMBL2695	Homo sapiens	IC50	nM	5.1
	18890099	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COCCn1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3ccsc3n2)cn1		CHEMBL4515607	=	IC50	nM	185.6	CHEMBL2695	Homo sapiens	IC50	nM	185.6
	18890100	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COCCn1cc(Nc2nc(Nc3ccccc3P(C)(C)=O)c3sccc3n2)cn1		CHEMBL4452423	=	IC50	nM	154.2	CHEMBL2695	Homo sapiens	IC50	nM	154.2
	18890101	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2ccsc2n1		CHEMBL4461902	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
	18890102	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2sccc2n1		CHEMBL4483692	=	IC50	nM	20.6	CHEMBL2695	Homo sapiens	IC50	nM	20.6
	18890103	CHEMBL4314077	Inhibition of recombinant N-terminal GST-tagged human FAK (327 to 1052 residues) expressed in baculovirus expression system using TK as substrate incubated for 50 mins in presence of ATP and measured after 1 hr by HTRF assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	6.2	CHEMBL2695	Homo sapiens	IC50	nM	6.2
	18890207	CHEMBL4314018	Inhibition of recombinant full length GST-tagged human FAK cytoplasmic domain expressed in baculovirus expression system at 0.5 uM using tyr 07 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	18892612	CHEMBL4314689	Inhibition of recombinant human FAK (411 to 686 residues) assessed as residual activity at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	103.5	CHEMBL2695	Homo sapiens	Activity	%	103.5
	18919517	CHEMBL4322873	Binding affinity to recombinant human full length N-terminal GST-tagged PTK2 expressed in baculovirus expression system incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	401.0	CHEMBL2695	Homo sapiens	Kd	nM	401.0
	18919705	CHEMBL4322873	Binding affinity to recombinant human full length N-terminal GST-tagged PTK2 expressed in baculovirus expression system incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	308.0	CHEMBL2695	Homo sapiens	Kd	nM	308.0
	18930951	CHEMBL4325609	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 1000 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	10.8	CHEMBL2695	Homo sapiens	INH	%	10.8
	18930975	CHEMBL4325633	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	14.7	CHEMBL2695	Homo sapiens	INH	%	14.7
	18934095	CHEMBL4326627	Inhibition of human FAK at 10 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(N4Cc5cccc(N(C)S(C)(=O)=O)c5C4)n3)cc2)CC1		CHEMBL4476226	=	Inhibition	%	96.4	CHEMBL2695	Homo sapiens	INH	%	96.4
	18934118	CHEMBL4326650	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(N4Cc5cccc(N(C)S(C)(=O)=O)c5C4)n3)cc2)CC1		CHEMBL4476226	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	uM	0.011
	18937923	CHEMBL4327692	Inhibition of human FAK assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	92.55	CHEMBL2695	Homo sapiens	Activity	%	92.55
	18937924	CHEMBL4327692	Inhibition of human FAK assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	98.78	CHEMBL2695	Homo sapiens	Activity	%	98.78
	18938532	CHEMBL4328052	Inhibition of human FAK assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL2695	Homo sapiens	Activity	%	65.0
	18938910	CHEMBL4328416	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	13.0	CHEMBL2695	Homo sapiens	IC50	10'-8M	1.3
	18958880	CHEMBL4333399	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	74.0	CHEMBL2695	Homo sapiens	Activity	%	74.0
	18964283	CHEMBL4335079	Inhibition of recombinant human FAK (411 to 686 residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	105.0	CHEMBL2695	Homo sapiens	Activity	%	105.0
	18964284	CHEMBL4335079	Inhibition of recombinant human FAK (411 to 686 residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	105.0	CHEMBL2695	Homo sapiens	Activity	%	105.0
	18971896	CHEMBL4336906	Inhibition of recombinant human FAK (411 to 686 residues) assessed as residual activity at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	82.0	CHEMBL2695	Homo sapiens	Activity	%	82.0
	18972850	CHEMBL4337349	Inhibition of recombinant full-length GST-tagged human PTK2 expressed in baculovirus expression system at 10 uM using propeptide-27 as substrate after 150 mins by electrophoretic mobility shift assay relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1NC(=O)c1ccc2c(c1)OCCO2		CHEMBL4580637	=	Inhibition	%	6.0	CHEMBL2695	Homo sapiens	INH	%	6.0
	18985709	CHEMBL4340008	Inhibition of FAK (unknown origin)	B	COC[C@@H](C)Nc1cc(NC(=O)N2CCCc3cc(CN4CCCCOC4=O)c(C=O)nc32)ncc1C#N		CHEMBL4475216	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	18989216	CHEMBL4340758	Inhibition of recombinant human N-terminal GST-fused FAK (2 to 1052 residues) expressed in Sf9 insect cells using Poly(Glu/Tyr)4:1 as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
	18989952	CHEMBL4340971	Inhibition of FAK (unknown origin) at 1 uM relative to control	B	COCCN1CCOc2c1cnn1c(-c3ccc4cccc(NCC5CCNCC5)c4n3)nnc21		CHEMBL4556293	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	19021484	CHEMBL4347707	Inhibition of recombinant human FAK1 at 20 nM using Ulight-TK peptide as substrate measured after 60 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	19021485	CHEMBL4347708	Inhibition of recombinant human FAK1 at 200 nM using Ulight-TK peptide as substrate measured after 60 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	38.0	CHEMBL2695	Homo sapiens	INH	%	38.0
	19027317	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4580829	=	IC50	nM	7.28	CHEMBL2695	Homo sapiens	IC50	nM	7.28
	19027318	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	O=C(NC1CC1)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4452825	=	IC50	nM	75.8	CHEMBL2695	Homo sapiens	IC50	nM	75.8
	19027319	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4587135	=	IC50	nM	5.17	CHEMBL2695	Homo sapiens	IC50	nM	5.17
	19027322	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OC(C)C(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4444509	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	nM	38.0
	19027323	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CCC(Oc1ccc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NC)n2)cc1)C(=O)N1CCOCC1		CHEMBL4461676	=	IC50	nM	25.6	CHEMBL2695	Homo sapiens	IC50	nM	25.6
	19027324	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(SCC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4471571	=	IC50	nM	2.58	CHEMBL2695	Homo sapiens	IC50	nM	2.58
	19027325	CHEMBL4348759	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	6.79	CHEMBL2695	Homo sapiens	IC50	nM	6.79
Dose-dependent effect	19027380	CHEMBL4348772	Inhibition of FAK in human AsPC1 cells assessed as reduction in autophosphorylation incubated for 72 hrs by immunoblotting analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4587135		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	19027381	CHEMBL4348773	Inhibition of FAK in human AsPC1 cells assessed as reduction in autophosphorylation at 50 nM incubated for 72 hrs by immunoblotting analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4587135	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	19027382	CHEMBL4348774	Inhibition of FAK in human AsPC1 cells assessed as reduction in autophosphorylation at 100 nM incubated for 72 hrs by immunoblotting analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
Active	19027383	CHEMBL4348775	Inhibition of FAK in human AsPC1 cells assessed as reduction in MEK phosphorylation at 10 to 100 nM incubated for 72 hrs by immunoblotting analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4587135		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	19027384	CHEMBL4348776	Inhibition of FAK in human AsPC1 cells assessed as effect on ERK phosphorylation at 10 to 100 nM incubated for 72 hrs by immunoblotting analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CC(=O)N3CCOCC3)cc2)ncc1Cl		CHEMBL4587135		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	19031584	CHEMBL4349537	Inhibition of FAK (unknown origin) relative to control	B	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2c(n1)n(C1CCCC1)c(=O)n2C		CHEMBL2140523	>	Inhibition	%	40.0	CHEMBL2695	Homo sapiens	INH	%	40.0
Not Active	19039785	CHEMBL4351857	Inhibition of recombinant human FAK (411 to 686 residues) at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	19041108	CHEMBL4352369	Inhibition of human FAK at 10 uM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	19044313	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCC(C)O)CC3)cc2)ncc1Cl		CHEMBL4444594	=	Inhibition	%	71.0	CHEMBL2695	Homo sapiens	INH	%	71.0
	19044314	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCO)CC3)cc2)ncc1Cl		CHEMBL4463158	=	Inhibition	%	53.0	CHEMBL2695	Homo sapiens	INH	%	53.0
	19044315	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCS(C)(=O)=O)CC3)cc2)ncc1Cl		CHEMBL4476614	=	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
	19044316	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CCOC(=O)C(=O)CSC(=S)N1CCN(C(=O)c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)CC1		CHEMBL4450265	=	Inhibition	%	57.0	CHEMBL2695	Homo sapiens	INH	%	57.0
	19044317	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CCOC(=O)CSC(=S)N1CCN(C(=O)c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)CC1		CHEMBL4445960	=	Inhibition	%	55.0	CHEMBL2695	Homo sapiens	INH	%	55.0
	19044318	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCC(=O)OC)CC3)cc2)ncc1Cl		CHEMBL4558022	=	Inhibition	%	73.0	CHEMBL2695	Homo sapiens	INH	%	73.0
	19044319	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCOC)CC3)cc2)ncc1Cl		CHEMBL4476042	=	Inhibition	%	69.0	CHEMBL2695	Homo sapiens	INH	%	69.0
	19044320	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	C=CCSC(=S)N1CCN(C(=O)c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)CC1		CHEMBL4556839	=	Inhibition	%	45.0	CHEMBL2695	Homo sapiens	INH	%	45.0
	19044321	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCC#N)CC3)cc2)ncc1Cl		CHEMBL4538710	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	19044322	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1Cl		CHEMBL4469292	=	Inhibition	%	73.0	CHEMBL2695	Homo sapiens	INH	%	73.0
	19044323	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN4CCCC4)CC3)cc2)ncc1Cl		CHEMBL4453821	=	Inhibition	%	55.0	CHEMBL2695	Homo sapiens	INH	%	55.0
	19044324	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN4CCCCC4)CC3)cc2)ncc1Cl		CHEMBL4559783	=	Inhibition	%	44.0	CHEMBL2695	Homo sapiens	INH	%	44.0
	19044325	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN4CCN(C)CC4)CC3)cc2)ncc1Cl		CHEMBL4514099	=	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	19044326	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN4CCOCC4)CC3)cc2)ncc1Cl		CHEMBL4437276	=	Inhibition	%	62.0	CHEMBL2695	Homo sapiens	INH	%	62.0
	19044327	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCC4OCCO4)CC3)cc2)ncc1Cl		CHEMBL4461409	=	Inhibition	%	63.0	CHEMBL2695	Homo sapiens	INH	%	63.0
	19044328	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCC4CCOCC4)CC3)cc2)ncc1Cl		CHEMBL4455390	=	Inhibition	%	62.0	CHEMBL2695	Homo sapiens	INH	%	62.0
	19044329	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCc4ccccc4)CC3)cc2)ncc1Cl		CHEMBL4440684	=	Inhibition	%	52.0	CHEMBL2695	Homo sapiens	INH	%	52.0
	19044330	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCc4ccccc4)CC3)cc2)ncc1Cl		CHEMBL4468772	=	Inhibition	%	39.0	CHEMBL2695	Homo sapiens	INH	%	39.0
	19044331	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCc4ccncc4)CC3)cc2)ncc1Cl		CHEMBL4476367	=	Inhibition	%	0.0	CHEMBL2695	Homo sapiens	INH	%	0.0
	19044332	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCc4ccccn4)CC3)cc2)ncc1Cl		CHEMBL4454063	=	Inhibition	%	41.0	CHEMBL2695	Homo sapiens	INH	%	41.0
	19044333	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCc4cccnc4)CC3)cc2)ncc1Cl		CHEMBL4525498	=	Inhibition	%	23.0	CHEMBL2695	Homo sapiens	INH	%	23.0
	19044334	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Inhibition	%	65.0	CHEMBL2695	Homo sapiens	INH	%	65.0
	19044335	CHEMBL4353488	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo assay relative to control	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Inhibition	%	89.0	CHEMBL2695	Homo sapiens	INH	%	89.0
	19044503	CHEMBL4353542	Inhibition of recombinant FAK (410 to 689 residues) (unknown origin) using Poly (4:1 Glu, Tyr) peptide as substrate enzyme pretreated with substrate for 15 mins prior to compound addition by ELISA	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	19044505	CHEMBL4353542	Inhibition of recombinant FAK (410 to 689 residues) (unknown origin) using Poly (4:1 Glu, Tyr) peptide as substrate enzyme pretreated with substrate for 15 mins prior to compound addition by ELISA	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	19044506	CHEMBL4353543	Inhibition of FAK (unknown origin)	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5.5	CHEMBL2695	Homo sapiens	IC50	nM	5.5
	19044507	CHEMBL4353544	Inhibition of human recombinant FAK	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	IC50	nM	0.6	CHEMBL2695	Homo sapiens	IC50	nM	0.6
	19044508	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1Cl		CHEMBL4469292	=	IC50	nM	8.57	CHEMBL2695	Homo sapiens	IC50	nM	8.57
	19044509	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1ccnc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)n1		CHEMBL4453262	=	IC50	nM	316.3	CHEMBL2695	Homo sapiens	IC50	nM	316.3
	19044510	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1F		CHEMBL4438250	=	IC50	nM	32.7	CHEMBL2695	Homo sapiens	IC50	nM	32.7
	19044511	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1C		CHEMBL4458861	=	IC50	nM	175.4	CHEMBL2695	Homo sapiens	IC50	nM	175.4
	19044512	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1OC		CHEMBL4590434	=	IC50	nM	506.7	CHEMBL2695	Homo sapiens	IC50	nM	506.7
	19044513	CHEMBL4353545	Inhibition of human recombinant N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 60 mins by ADP-Glo assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCN(C(=S)SCCN(C)C)CC3)cc2)ncc1C(F)(F)F		CHEMBL4554455	=	IC50	nM	0.07	CHEMBL2695	Homo sapiens	IC50	nM	0.07
	19059582	CHEMBL4357883	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	19072945	CHEMBL4362121	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		0.9	CHEMBL2695	Homo sapiens	FC		0.9
	19072984	CHEMBL4362159	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		1.01	CHEMBL2695	Homo sapiens	FC		1.01
	19073023	CHEMBL4362121	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		-0.15	CHEMBL2695	Homo sapiens	log2FC		-0.15
	19073062	CHEMBL4362159	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		0.02	CHEMBL2695	Homo sapiens	log2FC		0.02
	19073124	CHEMBL4362121	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		0.89	CHEMBL2695	Homo sapiens	FC		0.89
	19073163	CHEMBL4362159	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		1.04	CHEMBL2695	Homo sapiens	FC		1.04
	19073202	CHEMBL4362121	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		-0.17	CHEMBL2695	Homo sapiens	log2FC		-0.17
	19073241	CHEMBL4362159	Effect on FAK at Y397 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		0.06	CHEMBL2695	Homo sapiens	log2FC		0.06
	19090153	CHEMBL4365727	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	19091925	CHEMBL4366399	Inhibition of human FAK at 100 nM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	15.89	CHEMBL2695	Homo sapiens	INH	%	15.89
	19114477	CHEMBL4371443	Binding affinity to FAK in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4443828	=	Kd	nM	4445.0	CHEMBL2695	Homo sapiens	Kd(free)	uM	4.445
	19114712	CHEMBL4371443	Binding affinity to FAK in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4462318	=	Kd	nM	2212.0	CHEMBL2695	Homo sapiens	Kd(free)	uM	2.212
	19144795	CHEMBL4377811	Inhibition of recombinant human FAK (411 to 686 residues) at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	22.0	CHEMBL2695	Homo sapiens	INH	%	22.0
	19146912	CHEMBL4378880	Inhibition of recombinant human FAK (411 to 686 residues) at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	-3.0	CHEMBL2695	Homo sapiens	INH	%	-3.0
	19147847	CHEMBL4379321	Inhibition of recombinant human FAK (411 to 686 residues) using EEEEYEEEEEEYY as substrate after 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	19154473	CHEMBL4380708	Inhibition of FAK (unknown origin) using poly (Glu, Tyr) as substrate at 5 uM incubated for 40 mins in presence of 10 uM ATP by kiase-Glo luminescence assay relative to control	B	COc1ccc2c(c1)cc1n2CCN2C(=O)c3cc(F)ccc3N(C)C12		CHEMBL4537640	<	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
	19158889	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	CN(c1cccc(CNc2nc(Nc3ccc(OCCOCCOCCC(=O)NCCOc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)cc3)ncc2C(F)(F)F)c1)S(C)(=O)=O		CHEMBL4586249	=	IC50	nM	4.7	CHEMBL2695	Homo sapiens	IC50	nM	4.7
	19158890	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	CN(c1cccc(CNc2nc(Nc3ccc(OCCOCCOCCOCCOCCC(=O)NCCOc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)cc3)ncc2C(F)(F)F)c1)S(C)(=O)=O		CHEMBL4541275	=	IC50	nM	9.7	CHEMBL2695	Homo sapiens	IC50	nM	9.7
	19158891	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	IC50	nM	3.9	CHEMBL2695	Homo sapiens	IC50	nM	3.9
	19158910	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1		CHEMBL4449796	=	IC50	nM	10.7	CHEMBL2695	Homo sapiens	IC50	nM	10.7
	19158911	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1		CHEMBL4464368	=	IC50	nM	14.7	CHEMBL2695	Homo sapiens	IC50	nM	14.7
	19158912	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCOCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1		CHEMBL4447794	=	IC50	nM	6.5	CHEMBL2695	Homo sapiens	IC50	nM	6.5
	19158913	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCOCCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1		CHEMBL4558994	=	IC50	nM	14.5	CHEMBL2695	Homo sapiens	IC50	nM	14.5
	19158914	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCOCCOCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1		CHEMBL4560289	=	IC50	nM	12.7	CHEMBL2695	Homo sapiens	IC50	nM	12.7
	19158915	CHEMBL4382186	Inhibition of human recombinant FAK using poly[Glu:Tyr] (4:1) substrate in presence of 10 mM ATP and [gamma33P]-ATP	B	CN(c1cccc(CNc2nc(Nc3ccc(OCCCOCCC(=O)NCCOc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)cc3)ncc2C(F)(F)F)c1)S(C)(=O)=O		CHEMBL4567809	=	IC50	nM	11.3	CHEMBL2695	Homo sapiens	IC50	nM	11.3
	19159410	CHEMBL4382514	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	0.0	CHEMBL2695	Homo sapiens	Activity	%	0.0
	19159728	CHEMBL4382832	Inhibition of recombinant full length GST-tagged human FAK expressed in baculovirus expression system by Z-LYTE assay	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
	19181029	CHEMBL4387240	Inhibition of recombinant full length human GST-tagged FAK expressed in baculovirus expression system at 0.1 uM using tyrosine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	15.5	CHEMBL2695	Homo sapiens	INH	%	15.5
	19181255	CHEMBL4387240	Inhibition of recombinant full length human GST-tagged FAK expressed in baculovirus expression system at 0.1 uM using tyrosine-7 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	19.5	CHEMBL2695	Homo sapiens	INH	%	19.5
	19191597	CHEMBL4389233	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	90.0	CHEMBL2695	Homo sapiens	INH	%	90.0
	19191896	CHEMBL4389710	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	90.0	CHEMBL2695	Homo sapiens	INH	%	90.0
Not Active	19197375	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	N#Cc1cccc(/C=C/C(=O)c2ccc(O)cc2)c1		CHEMBL4545330		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	19197376	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	CCCCCN(CCCCC)S(=O)(=O)c1ccc(C(=O)/C=C/c2cccc(C#N)c2)cc1		CHEMBL4459949		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	19197377	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	COC(=O)c1cccc(/C=C/C(=O)c2cccc(O)c2)c1		CHEMBL4483086		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	19197378	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	CCCCCN(CCCCC)S(=O)(=O)c1ccc(C(=O)/C=C/c2cccc(O)c2)cc1		CHEMBL4470548		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	19197379	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	O=C(/C=C/c1ccc(-c2cccnc2)cc1)c1cccc(O)c1		CHEMBL4464788		Activity			CHEMBL2695	Homo sapiens	Activity		
Not Active	19197380	CHEMBL4390783	Effect on FAK phosphorylation in human U87MG cells at 10 uM measured after 24 hrs by Western blot analysis	B	O=C(/C=C/c1ccc(-c2ccncc2)cc1)c1cccc(O)c1		CHEMBL4446669		Activity			CHEMBL2695	Homo sapiens	Activity		
	19199886	CHEMBL4391336	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	87.0	CHEMBL2695	Homo sapiens	Activity	%	87.0
Active	19226125	CHEMBL4396090	Reduction in FAK phosphorylation in HUVEC at 2 to 10 uM after 48 hrs by Western blot analysis	B	COc1cc2c(cc1O)CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)/C(=C/c3ccc(Cl)cc3)C[C@@H]12		CHEMBL4463259		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	19230869	CHEMBL4397152	Inhibition of full-length N-terminal FLAG-tagged FAK (unknown origin) expressed in baculovirus expression system at 100 nM preincubated for 5 mins followed by ATP addition and measured after 60 mins by alphascreen assay relative to control	B	Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL4440381	=	Inhibition	%	83.0	CHEMBL2695	Homo sapiens	INH	%	83.0
	19230871	CHEMBL4397150	Inhibition of human FAK kinase domain (411 to 686 residues) expressed in baculovirus expression system using biotin-poly-GT as substrate pre-incubated for 10 mins followed by ATP addition and measured after 60 mins by HTRF method	B	Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1		CHEMBL4440381	=	IC50	nM	25.0	CHEMBL2695	Homo sapiens	IC50	nM	25.0
	19236760	CHEMBL4398833	Inhibition of FAK (unknown origin) at 100 nM relative to control	B	COc1cc2c(Nc3ccc(NC(=O)C(c4cc(F)ccc4F)N4Cc5ccccc5C4=O)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL4443483	<	Inhibition	%	25.0	CHEMBL2695	Homo sapiens	INH	%	25.0
	19266421	CHEMBL4405371	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
Not Active	19292660	CHEMBL4411700	Effect on FAK phosphorylation in human A549 cells up to 50 uM after 24 hrs by Western blot analysis	B	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)NCC(=O)NCC(=O)O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CNC1=O		CHEMBL4448464		Activity			CHEMBL2695	Homo sapiens	Activity		
	19295875	CHEMBL4412352	Inhibition of FAK (unknown origin) at 1000 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	81.7	CHEMBL2695	Homo sapiens	INH	%	81.7
	19295905	CHEMBL4412382	Inhibition of FAK (unknown origin) at 100 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	8.4	CHEMBL2695	Homo sapiens	INH	%	8.4
	19295935	CHEMBL4412412	Inhibition of FAK (unknown origin) at 10 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	1.1	CHEMBL2695	Homo sapiens	INH	%	1.1
	19312945	CHEMBL4416500	Inhibition of recombinant human N-terminal His6-tagged FAK (411 to 686 residues) expressed by baculovirus infected Sf21 insect cells at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKK peptide as substrate relative to control	B	N#CC[C@H]1CC[C@H](n2c(=O)[nH]c3cnc(Nc4ccc[nH]c4=O)nc32)CC1		CHEMBL4463007	<	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	19432880	CHEMBL4429542	Inhibition of FAK (unknown origin) at 1 uM	B	Cc1nccc(Nc2cc(NC3CCN(c4ccc(C#N)cc4)CC3)c(C(N)=O)cn2)n1		CHEMBL4463436	=	Inhibition	%	18.0	CHEMBL2695	Homo sapiens	INH	%	18.0
	19440250	CHEMBL4431281	Inhibition of FAK (unknown origin) at 20 nM relative to control	B	c1ccc(Nc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1		CHEMBL4448847	=	Inhibition	%	7.4	CHEMBL2695	Homo sapiens	INH	%	7.4
	19440251	CHEMBL4431281	Inhibition of FAK (unknown origin) at 20 nM relative to control	B	Clc1cccc(Nc2nc(Nc3cn[nH]c3)ncc2Cl)c1		CHEMBL4453646	=	Inhibition	%	33.5	CHEMBL2695	Homo sapiens	INH	%	33.5
Active	19442571	CHEMBL4432055	Inhibition of FAK phosphorylation in human A549 cells at 3 to 9 uM after 24 hrs by Western blot analysis	B	C[C@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C		CHEMBL508990		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	19478941	CHEMBL4480184	Inhibition of FAK in human MCF7 cells	B	Cc1ccc(-c2nn(-c3ccccc3)cc2C(=O)NOCc2ccccc2F)cc1		CHEMBL4575118	=	IC50	nM	15600.0	CHEMBL2695	Homo sapiens	IC50	uM	15.6
	20600652	CHEMBL4603604	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system using tyr07 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL2695	Homo sapiens	IC50	uM	100.0
Active	20716897	CHEMBL4630344	Inhibition of FAK phosphorylation at Tyr397 residue in human HCC1806 cells at 50 to 200 nM after 48 hrs by Western blot analysis	B	C=C1C(=O)[C@@]23C(=O)[C@@H]4OC[C@]5(C=CCC(C)(C)[C@@H]45)[C@@H]2CC[C@@H]1[C@H]3OC(=O)/C=C/c1ccncc1		CHEMBL4634156		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	22391659	CHEMBL4666959	Inhibition of recombinant human GST-tagged full length FAK expressed in baculovirus expression system using Tyr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	14.0	CHEMBL2695	Homo sapiens	INH	%	14.0
	22391660	CHEMBL4666959	Inhibition of recombinant human GST-tagged full length FAK expressed in baculovirus expression system using Tyr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	15.0	CHEMBL2695	Homo sapiens	INH	%	15.0
	22391661	CHEMBL4666959	Inhibition of recombinant human GST-tagged full length FAK expressed in baculovirus expression system using Tyr 07 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	20.0	CHEMBL2695	Homo sapiens	INH	%	20.0
	22392053	CHEMBL4667148	Inhibition of recombinant human GST-tagged full length FAK expressed in baculovirus expression system using Tyr 07 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	0.5	CHEMBL2695	Homo sapiens	INH	%	0.5
	22423102	CHEMBL4674117	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate at 0.5 uM by [gamma-33P]-ATP assay relative to control	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Inhibition	%	80.0	CHEMBL2695	Homo sapiens	INH	%	80.0
	22423623	CHEMBL4674387	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	95.02	CHEMBL2695	Homo sapiens	Activity	%	95.02
	22423624	CHEMBL4674387	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	93.93	CHEMBL2695	Homo sapiens	Activity	%	93.93
Not Active	22427481	CHEMBL4675398	Induction of PTK2 degradation in human A549 cells at 10 uM incubated for 18 hrs by protein capillary electrophoresis method	B	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C		CHEMBL160		Activity			CHEMBL2695	Homo sapiens	Activity		
	22427504	CHEMBL4675414	Inhibition of PTK2 (unknown origin) at 1 uM relative to control	B	COc1cc(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4778548	>	Inhibition	%	90.0	CHEMBL2695	Homo sapiens	INH	%	90.0
	22427505	CHEMBL4675414	Inhibition of PTK2 (unknown origin) at 1 uM relative to control	B	COc1cc(C(=O)NCCOCCOCCOCCC(=O)Nc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4781145	>	Inhibition	%	90.0	CHEMBL2695	Homo sapiens	INH	%	90.0
	22427509	CHEMBL4675418	Induction of PTK2 degradation in human A549 cells incubated for 18 hrs by protein capillary electrophoresis method	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657265	>	pDC50		10000.0	CHEMBL2695	Homo sapiens	pDC50		10000.0
	22427514	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4778548	=	IC50	nM	19.0	CHEMBL2695	Homo sapiens	IC50	nM	19.0
	22427515	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NCCOCCOCCOCCC(=O)Nc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4781145	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
	22427516	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4778548	=	IC50	nM	19.95	CHEMBL2695	Homo sapiens	pIC50		7.7
	22427517	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NCCOCCOCCOCCC(=O)Nc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL4781145	=	IC50	nM	19.95	CHEMBL2695	Homo sapiens	pIC50		7.7
	22427518	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657265	=	IC50	nM	15.85	CHEMBL2695	Homo sapiens	pIC50		7.8
	22427519	CHEMBL4675423	Inhibition of human PTK2 (411-689 residues) expressed in Hi-5 cells	B	COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)CC3)n1		CHEMBL3657265	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
	22445678	CHEMBL4679483	Inhibition of FAK (31-686) (unknown origin) using 32P-ATP after 2 hrs incubation measured by scintillation counting	B	COc1cc(Nc2ncc3ccn(-c4cccc(CCC(=O)O)n4)c3n2)cc(OC)c1OC		CHEMBL207491	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	22445680	CHEMBL4679485	Inhibition of Focal adhesion kinase (unknown origin)	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5.5	CHEMBL2695	Homo sapiens	IC50	nM	5.5
	22445685	CHEMBL4679490	Inhibition of GST-FAK domain (410-689) (unknown origin)	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	22445686	CHEMBL4679491	Inhibition of human Focal adhesion kinase	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	<	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
	22445687	CHEMBL4679492	Inhibition of GST-FAK catalytic domain region (411-686) (unknown origin) expressed in baculovirus infected Sf9 cells by spectrophotometry	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	22445688	CHEMBL4679492	Inhibition of GST-FAK catalytic domain region (411-686) (unknown origin) expressed in baculovirus infected Sf9 cells by spectrophotometry	B	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F		CHEMBL3040440	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	22445750	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4752723	=	IC50	nM	20.0	CHEMBL2695	Homo sapiens	IC50	uM	0.02
	22445751	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL1672987	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	22445752	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cn(C)nc1C(=O)N2		CHEMBL4789427	=	IC50	nM	123.0	CHEMBL2695	Homo sapiens	IC50	nM	123.0
	22445753	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ncsc1C(=O)N2		CHEMBL4799289	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	22445754	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2		CHEMBL4749164	=	IC50	nM	62.2	CHEMBL2695	Homo sapiens	IC50	nM	62.2
	22445755	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1oc(C)nc1C(=O)N2C		CHEMBL4754794	=	IC50	nM	525.0	CHEMBL2695	Homo sapiens	IC50	uM	0.525
	22445756	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CCCN1c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc2N(C)C(=O)c2nc(C)sc21		CHEMBL4748282	=	IC50	nM	47.0	CHEMBL2695	Homo sapiens	IC50	uM	0.047
	22445757	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(CC(F)(F)F)c1sc(C)nc1C(=O)N2C		CHEMBL4796049	=	IC50	nM	68.0	CHEMBL2695	Homo sapiens	IC50	uM	0.068
	22445758	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CCN1c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc2N(C)C(=O)c2nc(C)sc21		CHEMBL4749193	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	uM	0.023
	22445759	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CCN1C(=O)c2nc(C)sc2N(C)c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc21		CHEMBL4777901	=	IC50	nM	19.0	CHEMBL2695	Homo sapiens	IC50	uM	0.019
	22445760	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C(F)(F)F)nc1C(=O)N2C		CHEMBL4789375	=	IC50	nM	134.0	CHEMBL2695	Homo sapiens	IC50	uM	0.134
	22445761	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(-c3ccccc3)nc1C(=O)N2C		CHEMBL4784912	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	uM	10.0
	22445762	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C(C)C)nc1C(=O)N2C		CHEMBL4759782	=	IC50	nM	59.0	CHEMBL2695	Homo sapiens	IC50	uM	0.059000000000000004
	22445763	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CCc1nc2c(s1)N(C)c1nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc1N(C)C2=O		CHEMBL4750613	=	IC50	nM	32.0	CHEMBL2695	Homo sapiens	IC50	uM	0.032
	22445764	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1scnc1C(=O)N2		CHEMBL4792962	=	IC50	nM	510.0	CHEMBL2695	Homo sapiens	IC50	uM	0.51
	22445765	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4758463	=	IC50	nM	78.0	CHEMBL2695	Homo sapiens	IC50	uM	0.078
	22445766	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	Cc1nc2c(s1)N(C)c1nc(Nc3cnn(C)c3)ncc1N(C)C2=O		CHEMBL4745575	=	IC50	nM	666.0	CHEMBL2695	Homo sapiens	IC50	uM	0.6659999999999999
	22445767	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	Cc1nc2c(s1)N(C)c1nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc1N(C)C2=O		CHEMBL4750233	=	IC50	nM	196.0	CHEMBL2695	Homo sapiens	IC50	uM	0.196
	22445768	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(CCN(C)C)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4799569	=	IC50	nM	67.0	CHEMBL2695	Homo sapiens	IC50	uM	0.067
	22445769	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(CCO)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4765182	=	IC50	nM	74.0	CHEMBL2695	Homo sapiens	IC50	uM	0.07400000000000001
	22445770	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc2c(cc1Nc1ncc3c(n1)N(C)c1sc(C)nc1C(=O)N3C)CN(C)CC2		CHEMBL4763555	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	uM	0.038
	22445771	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	Cc1nc2c(s1)N(C)c1nc(Nc3ccc4c(c3)CCC(=O)N4)ncc1N(C)C2=O		CHEMBL4776107	=	IC50	nM	670.0	CHEMBL2695	Homo sapiens	IC50	uM	0.67
	22445772	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CNC(=O)c1ccc(Nc2ncc3c(n2)N(C)c2sc(C)nc2C(=O)N3C)c(OC)c1		CHEMBL4762549	=	IC50	nM	45.0	CHEMBL2695	Homo sapiens	IC50	uM	0.045
	22445773	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CNC(=O)c1ccc(Nc2ncc3c(n2)N(C)c2sc(C)nc2C(=O)N3C)cc1		CHEMBL4796700	=	IC50	nM	173.0	CHEMBL2695	Homo sapiens	IC50	uM	0.17300000000000001
	22445774	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	Cc1nc2c(s1)N(C)c1nc(Nc3ccc(N4CCN(C)CC4)cc3OCCO)ncc1N(C)C2=O		CHEMBL4760231	=	IC50	nM	46.5	CHEMBL2695	Homo sapiens	IC50	uM	0.0465
	22445775	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	CCOc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4741192	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	uM	0.055
	22445776	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4763952	=	IC50	nM	52.0	CHEMBL2695	Homo sapiens	IC50	uM	0.052000000000000005
	22445777	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2)c(C)cc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4784924	=	IC50	nM	32.0	CHEMBL2695	Homo sapiens	IC50	uM	0.032
	22445778	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4747113	=	IC50	nM	46.0	CHEMBL2695	Homo sapiens	IC50	uM	0.046
	22445779	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(S(C)(=O)=O)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4756535	=	IC50	nM	47.0	CHEMBL2695	Homo sapiens	IC50	uM	0.047
	22445780	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2=O)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4754414	=	IC50	nM	82.0	CHEMBL2695	Homo sapiens	IC50	uM	0.08199999999999999
	22445781	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCNCC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4791659	=	IC50	nM	44.0	CHEMBL2695	Homo sapiens	IC50	uM	0.044000000000000004
	22445782	CHEMBL4679512	Inhibition of Focal adhesion kinase (unknown origin) using Tyr 07 peptide substrate incubated for 60 mins at room temperature followed by 60 mins development reaction measured fluorescence by Z-LYTE assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1sc(C)nc1C(=O)N2C		CHEMBL4793090	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	uM	0.03
Active	22470073	CHEMBL4684929	Inhibition of PTK2 in human SUIT-2 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22470074	CHEMBL4684929	Inhibition of PTK2 in human SUIT-2 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22470075	CHEMBL4684930	Inhibition of PTK2 in human CAPAN-1 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22470076	CHEMBL4684930	Inhibition of PTK2 in human CAPAN-1 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22470077	CHEMBL4684931	Inhibition of PTK2 in human Panc-1 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22470078	CHEMBL4684931	Inhibition of PTK2 in human Panc-1 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by western blot analysis	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	22470079	CHEMBL4684932	Inhibition of PTK2 in human Panc-1 cells assessed as fold inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470080	CHEMBL4684932	Inhibition of PTK2 in human Panc-1 cells assessed as fold inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470081	CHEMBL4684933	Inhibition of PTK2 in human CAPAN-1 cells assessed as fold inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470082	CHEMBL4684933	Inhibition of PTK2 in human CAPAN-1 cells assessed as fold inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470083	CHEMBL4684934	Inhibition of PTK2 in human SUIT-2 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470084	CHEMBL4684934	Inhibition of PTK2 in human SUIT-2 cells assessed as inhibition of PTK2 phosphorylation at Y397 residue at 5XIC50 incubated for 24 hrs by ELISA relative to control	B	Br.c1ccc2c(-c3nn4cc(-c5ccsc5)nc4s3)c[nH]c2c1		CHEMBL4759358	=	FC		0.4	CHEMBL2695	Homo sapiens	FC		0.4
	22470085	CHEMBL4684935	Inhibition of PTK2 in human SUIT-2 cells at 5XIC50 incubated for 24 hrs by PamChip analysis relative to control	B	Br.Cn1cc(-c2nn3cc(-c4ccsc4)nc3s2)c2ccccc21		CHEMBL4764270	>	FC		2.0	CHEMBL2695	Homo sapiens	FC		2.0
Active	22490289	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4787849		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490290	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C(CNC(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)N(C)C)cc1		CHEMBL4749111		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490291	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccccc1		CHEMBL4763215		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490292	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C2CCCN2C(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)cc1		CHEMBL4787357		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490293	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C2CCCN2C(=O)CC(NC(N)=O)c2ccccc2Cl)cc1OC		CHEMBL4758013		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490294	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1		CHEMBL4761955		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490295	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1cccc(C2CCCN2C(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)c1		CHEMBL4748143		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490296	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	Cc1n[nH]c(C)c1C1CCCN1C(=O)Nc1cc(C(F)(F)F)ccc1N1CCOCC1		CHEMBL4746068		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490297	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(CNC(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)cc1		CHEMBL4748623		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490298	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C2CCCN2C(=O)Nc2cc(Cl)ccc2N2CCOCC2)cc1		CHEMBL4778677		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490299	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C2CCCN2C(=O)Nc2ccccc2N2CCCCC2)cc1		CHEMBL4778134		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490300	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	COc1ccc(C2CCCN2C(=O)Nc2ccc(N(C)C)cc2C(F)(F)F)cc1		CHEMBL4764660		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490301	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	CCC1CCCC(C(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)C1		CHEMBL4746372		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490302	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1C1CCCCC1		CHEMBL4798051		Activity			CHEMBL2695	Homo sapiens	Activity		
Active	22490303	CHEMBL4689539	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccsc1		CHEMBL4800617		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	22490304	CHEMBL4689540	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4787849		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	22490305	CHEMBL4689540	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation incubated for 1 hr by Western blot analysis	B	COc1ccc(C(CNC(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)N(C)C)cc1		CHEMBL4749111		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	22490306	CHEMBL4689540	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccccc1		CHEMBL4763215		Activity			CHEMBL2695	Homo sapiens	Activity		
Dose-dependent effect	22490307	CHEMBL4689540	Activation of FAK in human Caco-2 cells assessed as increase in FAK Tyr397 phosphorylation incubated for 1 hr by Western blot analysis	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1C1CCCCC1		CHEMBL4798051		Activity			CHEMBL2695	Homo sapiens	Activity		
	22490319	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4787849	=	FC		1.5	CHEMBL2695	Homo sapiens	FC		1.5
	22490320	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	COc1ccc(C(CNC(=O)Nc2cc(C(F)(F)F)ccc2N2CCOCC2)N(C)C)cc1		CHEMBL4749111	=	FC		1.4	CHEMBL2695	Homo sapiens	FC		1.4
	22490321	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	Cl.O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4798142	=	FC		1.0	CHEMBL2695	Homo sapiens	FC		1.0
	22490322	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	CN(C)C(CNC(=O)Nc1cc(C(F)(F)F)ccc1N1CCOCC1)c1ccccc1		CHEMBL4760731	=	FC		1.0	CHEMBL2695	Homo sapiens	FC		1.0
	22490323	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	O=C(Nc1ccccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4797397	=	FC		1.1	CHEMBL2695	Homo sapiens	FC		1.1
	22490324	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccccc1		CHEMBL4763215	=	FC		1.4	CHEMBL2695	Homo sapiens	FC		1.4
	22490325	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	Cl.O=C(Nc1ccccc1N1CCOCC1)N1CCCC1c1ccncc1		CHEMBL4777203	=	FC		1.1	CHEMBL2695	Homo sapiens	FC		1.1
	22490326	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCOCC1)N1CCCC1c1ccc(O)cc1		CHEMBL4749424	=	FC		1.1	CHEMBL2695	Homo sapiens	FC		1.1
	22490327	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	CN1CCN(c2ccc(C(F)(F)F)cc2NC(=O)N2CCCC2c2ccncc2)CC1		CHEMBL4763727	=	FC		0.9	CHEMBL2695	Homo sapiens	FC		0.9
	22490328	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	CC1CN(c2ccc(C(F)(F)F)cc2NC(=O)N2CCCC2c2ccncc2)CC(C)O1		CHEMBL4751122	=	FC		1.0	CHEMBL2695	Homo sapiens	FC		1.0
	22490329	CHEMBL4689546	Activation of FAK in human Caco-2 cells assessed as fold increase in FAK Tyr397 phosphorylation at 10 nM incubated for 1 hr by Western blot analysis relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1N1CCS(=O)(=O)CC1)N1CCCC1c1ccncc1		CHEMBL4761065	=	FC		1.0	CHEMBL2695	Homo sapiens	FC		1.0
	22771686	CHEMBL4704546	Inhibition of GST-tagged recombinant FAK (unknown origin) expressed in baculovirus expression system incubated for 15-45 mins in presence of [gamma32P]-ATP by radiometric assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5.4	CHEMBL2695	Homo sapiens	IC50	uM	0.0054
	22771687	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	IC50	nM	0.6	CHEMBL2695	Homo sapiens	IC50	nM	0.6
	22771688	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)CCl)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4764885	=	IC50	nM	5.6	CHEMBL2695	Homo sapiens	IC50	nM	5.6
	22771689	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NOC)n3)cc2)c(=O)c1=O		CHEMBL4788979	=	IC50	nM	3.7	CHEMBL2695	Homo sapiens	IC50	nM	3.7
	22771690	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4ccccc4N(C)S(C)(=O)=O)n3)cc2)c(=O)c1=O		CHEMBL4746264	=	IC50	nM	4.6	CHEMBL2695	Homo sapiens	IC50	nM	4.6
	22771691	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)c(=O)c1=O		CHEMBL4739917	=	IC50	nM	4.9	CHEMBL2695	Homo sapiens	IC50	nM	4.9
	22771692	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccc(S(C)(=O)=O)c4)n3)cc2)c(=O)c1=O		CHEMBL4792798	=	IC50	nM	16.3	CHEMBL2695	Homo sapiens	IC50	nM	16.3
	22771693	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccnc4N(C)S(C)(=O)=O)n3)cc2)c(=O)c1=O		CHEMBL4751164	=	IC50	nM	5.5	CHEMBL2695	Homo sapiens	IC50	nM	5.5
	22771694	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	IC50	nM	6.8	CHEMBL2695	Homo sapiens	IC50	nM	6.8
	22771695	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	CC/C=C(\C#N)C(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4796523	=	IC50	nM	2.5	CHEMBL2695	Homo sapiens	IC50	nM	2.5
	22771696	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	IC50	nM	1.2	CHEMBL2695	Homo sapiens	IC50	nM	1.2
	22771697	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273	=	IC50	nM	1.0	CHEMBL2695	Homo sapiens	IC50	nM	1.0
	22771698	CHEMBL4704547	Inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5.8	CHEMBL2695	Homo sapiens	IC50	nM	5.8
	22771699	CHEMBL4704548	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	Ki	nM	0.23	CHEMBL2695	Homo sapiens	Ki	nM	0.23
	22771700	CHEMBL4704548	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	Ki	nM	2.64	CHEMBL2695	Homo sapiens	Ki	nM	2.64
	22771701	CHEMBL4704548	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	Ki	nM	0.47	CHEMBL2695	Homo sapiens	Ki	nM	0.47
	22771702	CHEMBL4704548	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273	=	Ki	nM	0.4	CHEMBL2695	Homo sapiens	Ki	nM	0.4
	22771703	CHEMBL4704549	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate constant using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	Kinact	/min	0.16	CHEMBL2695	Homo sapiens	Kinact	/min	0.16
	22771704	CHEMBL4704549	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate constant using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	Kinact	/min	0.047	CHEMBL2695	Homo sapiens	Kinact	/min	0.047
	22771705	CHEMBL4704549	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate constant using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	Kinact	/min	0.25	CHEMBL2695	Homo sapiens	Kinact	/min	0.25
	22771706	CHEMBL4704549	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate constant using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273	=	Kinact	/min	0.24	CHEMBL2695	Homo sapiens	Kinact	/min	0.24
	22771707	CHEMBL4704550	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as ratio of Kinact to Ki using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	Ratio	/uM/s	11.6	CHEMBL2695	Homo sapiens	Ratio	/uM/s	11.6
	22771708	CHEMBL4704550	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as ratio of Kinact to Ki using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	Ratio	/uM/s	0.3	CHEMBL2695	Homo sapiens	Ratio	/uM/s	0.3
	22771709	CHEMBL4704550	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as ratio of Kinact to Ki using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	Ratio	/uM/s	8.87	CHEMBL2695	Homo sapiens	Ratio	/uM/s	8.87
	22771710	CHEMBL4704550	Covalent inhibition of recombinant human N-terminal His-tagged FAK (393 to 698 residues) expressed in baculovirus infected Sf9 insect cells assessed as ratio of Kinact to Ki using Poly (4:1 Glu, Tyr) as substrate preincubated for 2 to 60 mins followed by substrate addition and measured after 1 hr by ADP-glo luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273	=	Ratio	/uM/s	10.0	CHEMBL2695	Homo sapiens	Ratio	/uM/s	10.0
	22771750	CHEMBL4704563	Inhibition of human recombinant FAK at 100 nM by [gamma32P]-ATP radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	Inhibition	%	98.1	CHEMBL2695	Homo sapiens	INH	%	98.1
	22771751	CHEMBL4704563	Inhibition of human recombinant FAK at 100 nM by [gamma32P]-ATP radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccnc4N(C)S(C)(=O)=O)n3)cc2)c(=O)c1=O		CHEMBL4751164	=	Inhibition	%	92.2	CHEMBL2695	Homo sapiens	INH	%	92.2
	22771752	CHEMBL4704563	Inhibition of human recombinant FAK at 100 nM by [gamma32P]-ATP radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	Inhibition	%	98.6	CHEMBL2695	Homo sapiens	INH	%	98.6
	22771753	CHEMBL4704563	Inhibition of human recombinant FAK at 100 nM by [gamma32P]-ATP radiometric analysis relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	Inhibition	%	94.1	CHEMBL2695	Homo sapiens	INH	%	94.1
Dose-dependent effect	22771754	CHEMBL4704564	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771755	CHEMBL4704564	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by ELISA	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771756	CHEMBL4704564	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by ELISA	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771757	CHEMBL4704564	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771758	CHEMBL4704564	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by ELISA	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771759	CHEMBL4704565	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by Western blot analysis	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771760	CHEMBL4704565	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771761	CHEMBL4704565	Inhibition of FAK autophosphorylation at Tyr397 residue in human U87MG cells after 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	22771762	CHEMBL4704566	Reversible inhibition of FAK phosphorylation at Tyr397 residue in human U87MG assessed as recovery of FAK autophosphorylation at 0.1 to 5 uM incubated for 48 hrs followed by compound washout with PBS measured by Western blot analysis	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	22771763	CHEMBL4704566	Reversible inhibition of FAK phosphorylation at Tyr397 residue in human U87MG assessed as recovery of FAK autophosphorylation at 0.1 to 5 uM incubated for 48 hrs followed by compound washout with PBS measured by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Not Active	22771764	CHEMBL4704566	Reversible inhibition of FAK phosphorylation at Tyr397 residue in human U87MG assessed as recovery of FAK autophosphorylation at 0.1 to 5 uM incubated for 48 hrs followed by compound washout with PBS measured by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22771765	CHEMBL4704566	Reversible inhibition of FAK phosphorylation at Tyr397 residue in human U87MG assessed as recovery of FAK autophosphorylation at 0.1 to 5 uM incubated for 48 hrs followed by compound washout with PBS measured by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771836	CHEMBL4704581	Inhibition of FAK in human U87MG cells assessed as decrease in Akt phosphorylation incubated for 48 hrs by Western blot analysis	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771837	CHEMBL4704581	Inhibition of FAK in human U87MG cells assessed as decrease in Akt phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771838	CHEMBL4704581	Inhibition of FAK in human U87MG cells assessed as decrease in Akt phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771839	CHEMBL4704581	Inhibition of FAK in human U87MG cells assessed as decrease in Akt phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771840	CHEMBL4704582	Inhibition of FAK in human U87MG cells assessed as decrease in Erk phosphorylation incubated for 48 hrs by Western blot analysis	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771841	CHEMBL4704582	Inhibition of FAK in human U87MG cells assessed as decrease in Erk phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771842	CHEMBL4704582	Inhibition of FAK in human U87MG cells assessed as decrease in Erk phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771843	CHEMBL4704582	Inhibition of FAK in human U87MG cells assessed as decrease in Erk phosphorylation incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771844	CHEMBL4704583	Inhibition of FAK phosphorylation in human U87MG cells assessed as decrease in NF-kappaB level incubated for 48 hrs by Western blot analysis	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771845	CHEMBL4704583	Inhibition of FAK phosphorylation in human U87MG cells assessed as decrease in NF-kappaB level incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771846	CHEMBL4704583	Inhibition of FAK phosphorylation in human U87MG cells assessed as decrease in NF-kappaB level incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C4CC4)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4750273		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Dose-dependent effect	22771847	CHEMBL4704583	Inhibition of FAK phosphorylation in human U87MG cells assessed as decrease in NF-kappaB level incubated for 48 hrs by Western blot analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	22775416	CHEMBL4705525	Inhibition of human FAK	B	COc1cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c(F)c1N1C[C@H](C)N(C)[C@H](C)C1		CHEMBL4764610	>	IC50	nM	3000.0	CHEMBL2695	Homo sapiens	IC50	nM	3000.0
	22820474	CHEMBL4716239	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	6.0	CHEMBL2695	Homo sapiens	Activity	%	6.0
	22820475	CHEMBL4716239	Inhibition of human FAK assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	-1.0	CHEMBL2695	Homo sapiens	Activity	%	-1.0
	22836390	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	-3.0	CHEMBL2695	Homo sapiens	INH	%	-3.0
	22836391	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4786776	=	Inhibition	%	7.0	CHEMBL2695	Homo sapiens	INH	%	7.0
	22836392	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F		CHEMBL4748367	=	Inhibition	%	1.0	CHEMBL2695	Homo sapiens	INH	%	1.0
	22836393	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CCOc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4776396	=	Inhibition	%	9.0	CHEMBL2695	Homo sapiens	INH	%	9.0
	22836394	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4783569	=	Inhibition	%	-2.0	CHEMBL2695	Homo sapiens	INH	%	-2.0
	22836395	CHEMBL4718887	Inhibition of recombinant full length human GST-tagged PTK2 expressed in baculovirus expression system at 500 nM using Tyr 07 as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1	Outside typical range	CHEMBL4780286	=	Inhibition	%	-12.0	CHEMBL2695	Homo sapiens	INH	%	-12.0
	22843748	CHEMBL4720734	Inhibition of human FAK using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	9.12	CHEMBL2695	Homo sapiens	IC50	10^-9M	9.12
	22844100	CHEMBL4721086	Inhibition of human FAK assessed as residual activity using poly[Glu:Tyr] (4:1) as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	94.0	CHEMBL2695	Homo sapiens	Activity	%	94.0
	22844706	CHEMBL4721381	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	39.47	CHEMBL2695	Homo sapiens	Activity	%	39.47
	22853514	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	8.0	CHEMBL2695	Homo sapiens	Activity	%	8.0
	22853515	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	=	Activity	%	-5.0	CHEMBL2695	Homo sapiens	Activity	%	-5.0
	22853516	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	CN1CCN(CCCOc2ccc3ncnc(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)c3c2)CC1		CHEMBL4749477	=	Activity	%	31.0	CHEMBL2695	Homo sapiens	Activity	%	31.0
	22853517	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(Nc1ccc2ncnc(Nc3ccc(Oc4cccc(F)c4)c(Cl)c3)c2c1)c1ccc(CNCCO)cc1		CHEMBL4782561	=	Activity	%	5.0	CHEMBL2695	Homo sapiens	Activity	%	5.0
	22853518	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	Cc1cccc(Oc2ccc(Nc3ncnc4ccc(NC(=O)CNCCO)cc34)cc2Cl)c1		CHEMBL4753194	=	Activity	%	14.0	CHEMBL2695	Homo sapiens	Activity	%	14.0
	22853519	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1		CHEMBL4777529	=	Activity	%	0.0	CHEMBL2695	Homo sapiens	Activity	%	0.0
	22853520	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL4757576	=	Activity	%	6.0	CHEMBL2695	Homo sapiens	Activity	%	6.0
	22853521	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL3637894	=	Activity	%	9.0	CHEMBL2695	Homo sapiens	Activity	%	9.0
	22853522	CHEMBL4724272	Effect on human recombinant N-terminal His-tagged FAK (393 to 698) expressed in Sf9 insect cells in presence of substrate and [gamma-32ATP] at 10 uM incubated for 30 mins by scintillation counting based radiometry assay relative to control	B	O=C(CNCCO)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1		CHEMBL4783947	=	Activity	%	2.0	CHEMBL2695	Homo sapiens	Activity	%	2.0
Not Active	22889509	CHEMBL4729028	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22923366	CHEMBL4737108	Inhibition of FAK phosphorylation in human U2OS cells at 5 to 20 uM incubated for 48 hrs by Western blot analysis	B	O=C(Nc1ccc2c(cnn2C(=O)c2ccccc2)c1)c1cc(Cl)ccc1O		CHEMBL4755314		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22923367	CHEMBL4737109	Inhibition of FAK phosphorylation in human MG-63 cells at 5 to 20 uM incubated for 48 hrs by Western blot analysis	B	O=C(Nc1ccc2c(cnn2C(=O)c2ccccc2)c1)c1cc(Cl)ccc1O		CHEMBL4755314		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	22931012	CHEMBL4738790	Inhibition of Fak phosphorylation in human Huh-7 cells incubated for 12 hrs by Western blot analysis	B	COc1cc(OC)cc(-c2ccc3c(NC(=O)c4cccc(NC(=O)CCl)c4)n[nH]c3c2)c1		CHEMBL4757428		Activity			CHEMBL2695	Homo sapiens	Activity		
	22952835	CHEMBL4766772	Inhibition of recombinant human FAK (411 to 686 residues) assessed as residual activity at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	35.0	CHEMBL2695	Homo sapiens	Activity	%	35.0
	22955417	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(CP(=O)(OC)OC)cc3)nc12		CHEMBL4789753	=	IC50	nM	134.0	CHEMBL2695	Homo sapiens	IC50	nM	134.0
	22955418	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COP(=O)(Cc1ccc(Nc2ncc3scc(-c4ccccc4C(C)=O)c3n2)cc1)OC		CHEMBL4795071	=	IC50	nM	1083.0	CHEMBL2695	Homo sapiens	IC50	nM	1083.0
	22955419	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COP(=O)(Cc1ccc(Nc2ncc3scc(-c4cccc(C(C)=O)c4)c3n2)cc1)OC		CHEMBL4784408	=	IC50	nM	351.0	CHEMBL2695	Homo sapiens	IC50	nM	351.0
	22955420	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COP(=O)(Cc1ccc(Nc2ncc3scc(-c4cccc(S(C)(=O)=O)c4)c3n2)cc1)OC		CHEMBL4798155	=	IC50	nM	140.1	CHEMBL2695	Homo sapiens	IC50	nM	140.1
	22955421	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CNC(=O)c1cccc(-c2csc3cnc(Nc4ccc(CP(=O)(OC)OC)cc4)nc23)c1		CHEMBL4776871	=	IC50	nM	324.5	CHEMBL2695	Homo sapiens	IC50	nM	324.5
	22955422	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COP(=O)(Cc1ccc(Nc2ncc3scc(-c4cccc(NC(C)=O)c4)c3n2)cc1)OC		CHEMBL4800246	=	IC50	nM	377.0	CHEMBL2695	Homo sapiens	IC50	nM	377.0
	22955423	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COP(=O)(Cc1ccc(Nc2ncc3scc(-c4cccc(N(C)S(C)(=O)=O)c4)c3n2)cc1)OC		CHEMBL4797122	=	IC50	nM	638.4	CHEMBL2695	Homo sapiens	IC50	nM	638.4
	22955424	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccc(-c2csc3cnc(Nc4ccc(CP(=O)(OC)OC)cc4)nc23)cc1		CHEMBL4796618	=	IC50	nM	1064.0	CHEMBL2695	Homo sapiens	IC50	nM	1064.0
	22955425	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	6.3	CHEMBL2695	Homo sapiens	IC50	nM	6.3
	22955426	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CCOP(=O)(Cc1ccc(Nc2ncc3scc(-c4ccccc4OC)c3n2)cc1)OCC		CHEMBL4778052	=	IC50	nM	156.8	CHEMBL2695	Homo sapiens	IC50	nM	156.8
	22955427	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CCOP(=O)(Cc1ccc(Nc2ncc3scc(-c4ccccc4OC)c3n2)cc1)NC		CHEMBL4792276	=	IC50	nM	183.6	CHEMBL2695	Homo sapiens	IC50	nM	183.6
	22955428	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CCOP(=O)(OCC)C(O)c1ccc(Nc2ncc3scc(-c4ccccc4OC)c3n2)cc1		CHEMBL4792993	=	IC50	nM	321.5	CHEMBL2695	Homo sapiens	IC50	nM	321.5
	22955429	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CCOP(=O)(Cc1ccc(Nc2ncc3scc(-c4ccccc4OC)c3n2)cc1)N1CCOCC1		CHEMBL4792743	=	IC50	nM	351.5	CHEMBL2695	Homo sapiens	IC50	nM	351.5
	22955430	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CNC(=O)c1ccc(Nc2ncc3scc(-c4ccccc4OC)c3n2)cc1		CHEMBL4791977	=	IC50	nM	79.3	CHEMBL2695	Homo sapiens	IC50	nM	79.3
	22955431	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cc3)nc12		CHEMBL4784230	=	IC50	nM	38.8	CHEMBL2695	Homo sapiens	IC50	nM	38.8
	22955432	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(NC(=O)C4CCNCC4)cc3)nc12		CHEMBL4780493	=	IC50	nM	57.7	CHEMBL2695	Homo sapiens	IC50	nM	57.7
	22955433	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(NC(=O)[C@H]4CCCNC4)cc3)nc12		CHEMBL4779569	=	IC50	nM	167.1	CHEMBL2695	Homo sapiens	IC50	nM	167.1
	22955434	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(NC(=O)[C@@H]4CCCNC4)cc3)nc12		CHEMBL4800645	=	IC50	nM	199.1	CHEMBL2695	Homo sapiens	IC50	nM	199.1
	22955435	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(NC(=O)CN)cc3)nc12		CHEMBL4797985	=	IC50	nM	143.6	CHEMBL2695	Homo sapiens	IC50	nM	143.6
	22955436	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cc3F)nc12		CHEMBL4797411	=	IC50	nM	48.3	CHEMBL2695	Homo sapiens	IC50	nM	48.3
	22955437	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cc3C)nc12		CHEMBL4786967	=	IC50	nM	26.5	CHEMBL2695	Homo sapiens	IC50	nM	26.5
	22955438	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1ncc2scc(-c3ccccc3OC)c2n1		CHEMBL4787717	=	IC50	nM	27.2	CHEMBL2695	Homo sapiens	IC50	nM	27.2
	22955439	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	CCOc1cc(C(=O)NC2CCNCC2)ccc1Nc1ncc2scc(-c3ccccc3OC)c2n1		CHEMBL4788576	=	IC50	nM	165.6	CHEMBL2695	Homo sapiens	IC50	nM	165.6
	22955440	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)cc3C(F)(F)F)nc12		CHEMBL4786229	=	IC50	nM	709.0	CHEMBL2695	Homo sapiens	IC50	nM	709.0
	22955441	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	IC50	nM	28.2	CHEMBL2695	Homo sapiens	IC50	nM	28.2
	22955442	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(C)c3)nc12		CHEMBL4786939	=	IC50	nM	25.7	CHEMBL2695	Homo sapiens	IC50	nM	25.7
	22955443	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1cc(C(=O)NC2CCNCC2)c(F)cc1Nc1ncc2scc(-c3ccccc3OC)c2n1		CHEMBL4789212	=	IC50	nM	38.2	CHEMBL2695	Homo sapiens	IC50	nM	38.2
	22955444	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3cc(F)c(C(=O)NC4CCNCC4)cc3F)nc12		CHEMBL4799952	=	IC50	nM	24.2	CHEMBL2695	Homo sapiens	IC50	nM	24.2
	22955445	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCOCC4)c(F)c3)nc12		CHEMBL4799508	=	IC50	nM	117.7	CHEMBL2695	Homo sapiens	IC50	nM	117.7
	22955446	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)nc12		CHEMBL4797358	=	IC50	nM	47.8	CHEMBL2695	Homo sapiens	IC50	nM	47.8
	22955447	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)N[C@H]4CCNC4)c(F)c3)nc12		CHEMBL4780216	=	IC50	nM	132.3	CHEMBL2695	Homo sapiens	IC50	nM	132.3
	22955448	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)N[C@@H]4CCNC4)c(F)c3)nc12		CHEMBL4799949	=	IC50	nM	71.3	CHEMBL2695	Homo sapiens	IC50	nM	71.3
	22955449	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NCC4CCNCC4)c(F)c3)nc12		CHEMBL4779238	=	IC50	nM	120.2	CHEMBL2695	Homo sapiens	IC50	nM	120.2
	22955450	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC[C@@H]4CCCNC4)c(F)c3)nc12		CHEMBL4780215	=	IC50	nM	111.2	CHEMBL2695	Homo sapiens	IC50	nM	111.2
	22955451	CHEMBL4767590	Inhibition of N-terminal GST-fused human truncated FAK (376 to 1052 residues) expressed in baculovirus expression system using tyrosine kinase peptide as substrate measured after 50 mins in presence of ATP by homogenous time resolved flourescence assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC[C@H]4CCCNC4)c(F)c3)nc12		CHEMBL4784469	=	IC50	nM	148.9	CHEMBL2695	Homo sapiens	IC50	nM	148.9
	22955559	CHEMBL4767616	Inhibition of GST-tagged full length human FAK expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	Inhibition	%	100.0	CHEMBL2695	Homo sapiens	INH	%	100.0
	22979767	CHEMBL4772649	Binding affinity to wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system by Kinomescan method relative to control	B	C[C@@H](Nc1ccc2[nH]nc(/C=C/c3ccccn3)c2c1)c1cc(F)cc(F)c1		CHEMBL4792981	=	Kd	nM	200.0	CHEMBL2695	Homo sapiens	Kd	nM	200.0
	22979801	CHEMBL4772683	Inhibition of wild-type human partial length FAK (D402 to R696 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C[C@@H](Nc1ccc2[nH]nc(/C=C/c3ccccn3)c2c1)c1cc(F)cc(F)c1		CHEMBL4792981	>	Activity	%	90.0	CHEMBL2695	Homo sapiens	Activity	%	90.0
	22989359	CHEMBL4774939	Inhibition of FAK/PTK2 (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2cccc(C#Cc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)c12		CHEMBL4793906	<	Inhibition	%	30.0	CHEMBL2695	Homo sapiens	INH	%	30.0
	23122568	CHEMBL4804919	Inhibition of human FAK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	89.0	CHEMBL2695	Homo sapiens	Activity	%	89.0
	23123263	CHEMBL4805507	Inhibition of human FAK assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	88.0	CHEMBL2695	Homo sapiens	Activity	%	88.0
	23123627	CHEMBL4805871	Inhibition of DNA-tagged human FAK assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	83.0	CHEMBL2695	Homo sapiens	Activity	%	83.0
	23124616	CHEMBL4806524	Inhibition of human FAK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL2695	Homo sapiens	Activity	%	100.0
	23124617	CHEMBL4806524	Inhibition of human FAK assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	96.0	CHEMBL2695	Homo sapiens	Activity	%	96.0
	23128095	CHEMBL4807840	Inhibition of FAK (2 to 1052) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL2695	Homo sapiens	Activity	%	75.0
	23128096	CHEMBL4807840	Inhibition of FAK (2 to 1052) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL2695	Homo sapiens	Activity	%	75.0
	23128097	CHEMBL4807840	Inhibition of FAK (2 to 1052) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL2695	Homo sapiens	Activity	%	75.0
	23150932	CHEMBL4810425	Inhibition of recombinant human FAK (411 to 686 residues) at 1 uM using EEEEYEEEEEEYY as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CCc1cc(Nc2nc(NCc3ccc(Cl)cc3OC)nc3cccc(OC)c23)n[nH]1		CHEMBL4877302	>	Inhibition	%	50.0	CHEMBL2695	Homo sapiens	INH	%	50.0
	23150938	CHEMBL4810431	Inhibition of recombinant human FAK (411 to 686 residues) using EEEEYEEEEEEYY as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay	B	CCc1cc(Nc2nc(NCc3ccc(Cl)cc3OC)nc3cccc(OC)c23)n[nH]1		CHEMBL4877302	=	IC50	nM	220.0	CHEMBL2695	Homo sapiens	IC50	nM	220.0
	23170851	CHEMBL4814446	Inhibition of FAK in human U87MG cells assessed as reduction in phosphorylation at Y397 residue incubated for 30 mins by Western blot analysis	B	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl		CHEMBL4742157	=	IC50	nM	8.5	CHEMBL2695	Homo sapiens	IC50	nM	8.5
	23170852	CHEMBL4814447	Inhibition of FAK in human A549 cells assessed as reduction in phosphorylation at Y397 residue incubated for 30 mins by Western blot analysis	B	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl		CHEMBL4742157	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
	23170853	CHEMBL4814448	Inhibition of FAK in human OVCAR8 cells assessed as reduction in phosphorylation at Y397 residue incubated for 30 mins by Western blot analysis	B	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl		CHEMBL4742157	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
	23170854	CHEMBL4814449	Inhibition of FAK (unknown origin)	B	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl		CHEMBL4742157	=	IC50	nM	0.4	CHEMBL2695	Homo sapiens	IC50	nM	0.4
	23170855	CHEMBL4814449	Inhibition of FAK (unknown origin)	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1Cl		CHEMBL545839	=	IC50	nM	5.5	CHEMBL2695	Homo sapiens	IC50	nM	5.5
	23170856	CHEMBL4814449	Inhibition of FAK (unknown origin)	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	IC50	nM	0.6	CHEMBL2695	Homo sapiens	IC50	nM	0.6
	23170857	CHEMBL4814450	Inhibition of GST-fused FAK (411 to 686 residues) (unknown origin) expressed in sf9 cells using poly(Glu:Tyr) (4:1) copolymer as substrate by spectrophotometric method	B	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F		CHEMBL3040440	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	23170859	CHEMBL4814452	Inhibition of FAK (unknown origin) (410 to 689 residues) assessed as reduction in poly(Glu-Tyr) phosphorylation using poly (Glu,Tyr) as substrate by ELISA-based assay	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL487246	=	IC50	nM	4.0	CHEMBL2695	Homo sapiens	IC50	nM	4.0
	23170869	CHEMBL4814460	Inhibition of human FAK using poly (Glu,Tyr) as substrate by radiometric HotSpot kinase assay	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCOCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCc4cccc(N(C)S(C)(=O)=O)c4)n3)cc2)C(C)(C)C)cc1	Potential transcription error	CHEMBL4447794	=	IC50	nM	6500.0	CHEMBL2695	Homo sapiens	IC50	uM	6.5
	23170872	CHEMBL4814463	Inhibition of FAK (unknown origin) (410 to 689 residues) assessed as reduction in poly(Glu-Tyr) phosphorylation by absorbance method	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	23170873	CHEMBL4814464	Inhibition of human FAK	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3cccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL4862042	=	IC50	nM	0.6	CHEMBL2695	Homo sapiens	IC50	nM	0.6
	23203320	CHEMBL4821211	Inhibition of FAK (unknown origin)	B	CONC(=O)c1ccccc1Nc1nc(Nc2cc(C)nn2C(C)C)ncc1Cl		CHEMBL4853713	=	IC50	nM	22140.0	CHEMBL2695	Homo sapiens	IC50	uM	22.14
	23203321	CHEMBL4821211	Inhibition of FAK (unknown origin)	B	C=CCn1c(SCC(=O)Nc2ccc(C(=O)O)cc2)nnc1-c1ccncc1		CHEMBL4846060	=	IC50	nM	36370.0	CHEMBL2695	Homo sapiens	IC50	uM	36.37
	23203322	CHEMBL4821211	Inhibition of FAK (unknown origin)	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)Nc1ccc(C(=O)O)cc1		CHEMBL1722006	=	IC50	nM	18100.0	CHEMBL2695	Homo sapiens	IC50	uM	18.1
Active	23203323	CHEMBL4821212	Inhibition of human FAK phosphorylation in human HepG2 cells at 4 uM by Western blot analysis	B	C=CCn1c(SCC(=O)Nc2ccc(C(=O)O)cc2)nnc1-c1ccncc1		CHEMBL4846060		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23203324	CHEMBL4821212	Inhibition of human FAK phosphorylation in human HepG2 cells at 4 uM by Western blot analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)Nc1ccc(C(=O)O)cc1		CHEMBL1722006		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	23216099	CHEMBL4823614	Inhibition of human recombinant FAK1 (411 to 686 residues) using EEEEYEEEEEEYY as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CC(C)n1cc(C(=O)Nc2ccc(Oc3ccnc(NC(=O)C4CC4)c3)c(F)c2)c(=O)n(-c2ccc(F)cc2)c1=O		CHEMBL4873571	>	IC50	nM	1000.0	CHEMBL2695	Homo sapiens	IC50	nM	1000.0
	23218512	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3F)n2)cc1		CHEMBL4865567	=	IC50	nM	5.8	CHEMBL2695	Homo sapiens	IC50	nM	5.8
	23218513	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3Cl)n2)cc1		CHEMBL4850588	=	IC50	nM	2.75	CHEMBL2695	Homo sapiens	IC50	nM	2.75
	23218514	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3Br)n2)cc1		CHEMBL4850002	=	IC50	nM	6.29	CHEMBL2695	Homo sapiens	IC50	nM	6.29
	23218515	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3cccc(F)c3)n2)cc1		CHEMBL4873348	=	IC50	nM	4.24	CHEMBL2695	Homo sapiens	IC50	nM	4.24
	23218516	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3cccc(Cl)c3)n2)cc1		CHEMBL4853818	=	IC50	nM	5.71	CHEMBL2695	Homo sapiens	IC50	nM	5.71
	23218517	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3cccc(Br)c3)n2)cc1		CHEMBL4872224	=	IC50	nM	4.02	CHEMBL2695	Homo sapiens	IC50	nM	4.02
	23218518	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccc(F)cc3)n2)cc1		CHEMBL4860092	=	IC50	nM	4.44	CHEMBL2695	Homo sapiens	IC50	nM	4.44
	23218519	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccc(Cl)cc3)n2)cc1		CHEMBL4879100	=	IC50	nM	35.33	CHEMBL2695	Homo sapiens	IC50	nM	35.33
	23218520	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccc(Br)cc3)n2)cc1		CHEMBL4864144	=	IC50	nM	39.66	CHEMBL2695	Homo sapiens	IC50	nM	39.66
	23218521	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3OC)n2)cc1		CHEMBL4874518	=	IC50	nM	5.73	CHEMBL2695	Homo sapiens	IC50	nM	5.73
	23218522	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccc(OC)cc3)n2)cc1		CHEMBL4849923	=	IC50	nM	28.73	CHEMBL2695	Homo sapiens	IC50	nM	28.73
	23218523	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(F)cc3)n2)cc1		CHEMBL4847034	=	IC50	nM	31.25	CHEMBL2695	Homo sapiens	IC50	nM	31.25
	23218524	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3Cl)n2)cc1		CHEMBL4852217	=	IC50	nM	34.37	CHEMBL2695	Homo sapiens	IC50	nM	34.37
	23218525	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3[N+](=O)[O-])n2)cc1		CHEMBL4849851	=	IC50	nM	11.69	CHEMBL2695	Homo sapiens	IC50	nM	11.69
	23218526	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(N)cc3)n2)cc1		CHEMBL4863844	=	IC50	nM	24.19	CHEMBL2695	Homo sapiens	IC50	nM	24.19
	23218527	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3cccc(N)c3)n2)cc1		CHEMBL4864858	=	IC50	nM	30.77	CHEMBL2695	Homo sapiens	IC50	nM	30.77
	23218528	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3OC)n2)cc1		CHEMBL4874046	=	IC50	nM	1.87	CHEMBL2695	Homo sapiens	IC50	nM	1.87
	23218529	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3cccc(OC)c3)n2)cc1		CHEMBL4858762	=	IC50	nM	23.21	CHEMBL2695	Homo sapiens	IC50	nM	23.21
	23218530	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(OC)cc3)n2)cc1		CHEMBL4867150	=	IC50	nM	55.63	CHEMBL2695	Homo sapiens	IC50	nM	55.63
	23218531	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(OC)c(F)c3)n2)cc1		CHEMBL4848228	=	IC50	nM	39.07	CHEMBL2695	Homo sapiens	IC50	nM	39.07
	23218532	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(OC)c(Cl)c3)n2)cc1		CHEMBL4869158	=	IC50	nM	34.74	CHEMBL2695	Homo sapiens	IC50	nM	34.74
	23218533	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(NC(C)=O)cc3)n2)cc1		CHEMBL4877387	=	IC50	nM	21.22	CHEMBL2695	Homo sapiens	IC50	nM	21.22
	23218534	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccc(NS(C)(=O)=O)cc3)n2)cc1		CHEMBL4869055	=	IC50	nM	18.19	CHEMBL2695	Homo sapiens	IC50	nM	18.19
	23218535	CHEMBL4824298	Inhibition of FAK (unknown origin) incubated for 40 mins by HTRF assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	IC50	nM	1.16	CHEMBL2695	Homo sapiens	IC50	nM	1.16
Active	23218807	CHEMBL4824337	Inhibition of FAK activity in human PANC-1 cells assessed as reduction in pFAK/FAK level at 0.5 to 4 uM after 24 hrs by Western blot analysis	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3Cl)n2)cc1		CHEMBL4850588		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23218867	CHEMBL4824366	Inhibition of FAK activity in human PANC-1 cells assessed as reduction in pFAK/FAK level at 0.25 to 4 uM after 24 hrs by Western blot analysis	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3OC)n2)cc1		CHEMBL4874046		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	23219538	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Cn1c(SCCCCCC(=O)O)nnc1-c1ccncc1		CHEMBL4847471	=	IC50	nM	50300.0	CHEMBL2695	Homo sapiens	IC50	uM	50.3
	23219539	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CCn1c(SCCCCCC(=O)O)nnc1-c1ccncc1		CHEMBL4859191	=	IC50	nM	76210.0	CHEMBL2695	Homo sapiens	IC50	uM	76.21
	23219540	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	C=CCn1c(SCCCCCC(=O)O)nnc1-c1ccncc1	Outside typical range	CHEMBL4849217	=	IC50	nM	124300.0	CHEMBL2695	Homo sapiens	IC50	uM	124.3
	23219541	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	O=C(O)CCCCCSc1nnc(-c2ccncc2)n1-c1ccccc1		CHEMBL4862173	=	IC50	nM	36110.0	CHEMBL2695	Homo sapiens	IC50	uM	36.11
	23219542	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Cn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1		CHEMBL4857970	=	IC50	nM	12590.0	CHEMBL2695	Homo sapiens	IC50	uM	12.59
	23219543	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CCn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1	Outside typical range	CHEMBL4863192	=	IC50	nM	124030.0	CHEMBL2695	Homo sapiens	IC50	uM	124.03
	23219544	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	C=CCn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1	Outside typical range	CHEMBL4860240	=	IC50	nM	189360.0	CHEMBL2695	Homo sapiens	IC50	uM	189.36
	23219545	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	O=C(CCCCCSc1nnc(-c2ccncc2)n1-c1ccccc1)NO	Outside typical range	CHEMBL4874813	=	IC50	nM	425310.0	CHEMBL2695	Homo sapiens	IC50	uM	425.31
	23219546	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Cn1c(SCCCCCC(=O)Nc2ccccc2N)nnc1-c1ccncc1		CHEMBL4866619	=	IC50	nM	57080.0	CHEMBL2695	Homo sapiens	IC50	uM	57.08
	23219547	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CCn1c(SCCCCCC(=O)Nc2ccccc2N)nnc1-c1ccncc1	Outside typical range	CHEMBL4849632	=	IC50	nM	140640.0	CHEMBL2695	Homo sapiens	IC50	uM	140.64
	23219548	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	C=CCn1c(SCCCCCC(=O)Nc2ccccc2N)nnc1-c1ccncc1		CHEMBL4868119	=	IC50	nM	14300.0	CHEMBL2695	Homo sapiens	IC50	uM	14.3
	23219549	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Nc1ccccc1NC(=O)CCCCCSc1nnc(-c2ccncc2)n1-c1ccccc1	Outside typical range	CHEMBL4874564	=	IC50	nM	312110.0	CHEMBL2695	Homo sapiens	IC50	uM	312.11
	23219550	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Cn1c(SCc2ccc(C(=O)NO)cc2)nnc1-c1ccncc1		CHEMBL4853791	=	IC50	nM	64350.0	CHEMBL2695	Homo sapiens	IC50	uM	64.35
	23219551	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CCn1c(SCc2ccc(C(=O)NO)cc2)nnc1-c1ccncc1	Outside typical range	CHEMBL4863652	=	IC50	nM	254360.0	CHEMBL2695	Homo sapiens	IC50	uM	254.36
	23219552	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	C=CCn1c(SCc2ccc(C(=O)NO)cc2)nnc1-c1ccncc1		CHEMBL4869232	=	IC50	nM	46120.0	CHEMBL2695	Homo sapiens	IC50	uM	46.12
	23219553	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	O=C(NO)c1ccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)cc1		CHEMBL4845926	=	IC50	nM	22400.0	CHEMBL2695	Homo sapiens	IC50	uM	22.4
	23219554	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Cn1c(SCc2ccc(C(=O)Nc3ccccc3N)cc2)nnc1-c1ccncc1		CHEMBL4857194	=	IC50	nM	53120.0	CHEMBL2695	Homo sapiens	IC50	uM	53.12
	23219555	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CCn1c(SCc2ccc(C(=O)Nc3ccccc3N)cc2)nnc1-c1ccncc1	Outside typical range	CHEMBL4878412	=	IC50	nM	112150.0	CHEMBL2695	Homo sapiens	IC50	uM	112.15
	23219556	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	C=CCn1c(SCc2ccc(C(=O)Nc3ccccc3N)cc2)nnc1-c1ccncc1		CHEMBL4854089	=	IC50	nM	15600.0	CHEMBL2695	Homo sapiens	IC50	uM	15.6
	23219557	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	Nc1ccccc1NC(=O)c1ccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)cc1		CHEMBL4872625	=	IC50	nM	96120.0	CHEMBL2695	Homo sapiens	IC50	uM	96.12
	23219558	CHEMBL4824422	Inhibition of FAK (unknown origin) by FRET-based Z'-Lyte assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	IC50	nM	5200.0	CHEMBL2695	Homo sapiens	IC50	uM	5.2
Active	23219563	CHEMBL4824425	Inhibition of FAK in human A498 cells assessed as reduction in FAK phosphorylation by Western blot analysis	B	Cn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1		CHEMBL4857970		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23219564	CHEMBL4824425	Inhibition of FAK in human A498 cells assessed as reduction in FAK phosphorylation by Western blot analysis	B	C=CCn1c(SCCCCCC(=O)Nc2ccccc2N)nnc1-c1ccncc1		CHEMBL4868119		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23219565	CHEMBL4824426	Inhibition of FAK in human CAKI-1 cells assessed as reduction in FAK phosphorylation by Western blot analysis	B	Cn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1		CHEMBL4857970		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23219566	CHEMBL4824426	Inhibition of FAK in human CAKI-1 cells assessed as reduction in FAK phosphorylation by Western blot analysis	B	C=CCn1c(SCCCCCC(=O)Nc2ccccc2N)nnc1-c1ccncc1		CHEMBL4868119		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23219573	CHEMBL4824433	Inhibition of FAK in human A498 cells assessed as reduction in FAK phosphorylation pretreated for 12 weeks followed by treatment for last 24 hrs by Western blot analysis	B	Cn1c(SCCCCCC(=O)NO)nnc1-c1ccncc1		CHEMBL4857970		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	23256133	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]ccc12)S(C)(=O)=O		CHEMBL4873346	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	nM	55.0
	23256134	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]ncc12)S(C)(=O)=O		CHEMBL4870426	=	IC50	nM	206.0	CHEMBL2695	Homo sapiens	IC50	nM	206.0
	23256135	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.5	CHEMBL2695	Homo sapiens	IC50	nM	1.5
	23256136	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	Cc1c[nH]c2nc(Nc3ccc4c(c3)CC(=O)N4)nc(NCc3cccnc3N(C)S(C)(=O)=O)c12		CHEMBL4846896	=	IC50	nM	64.0	CHEMBL2695	Homo sapiens	IC50	nM	64.0
	23256137	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	Cc1cc2c(NCc3cccnc3N(C)S(C)(=O)=O)nc(Nc3ccc4c(c3)CC(=O)N4)nc2[nH]1		CHEMBL4876183	=	IC50	nM	12000.0	CHEMBL2695	Homo sapiens	IC50	nM	12000.0
	23256138	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4846273	=	IC50	nM	22.0	CHEMBL2695	Homo sapiens	IC50	nM	22.0
	23256139	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]cc(Cl)c12)S(C)(=O)=O		CHEMBL4870488	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	23256140	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]cc(C#N)c12)S(C)(=O)=O		CHEMBL4864580	=	IC50	nM	325.0	CHEMBL2695	Homo sapiens	IC50	nM	325.0
	23256141	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccccc2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4852626	=	IC50	nM	32.0	CHEMBL2695	Homo sapiens	IC50	nM	32.0
	23256142	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc(F)cc2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4879310	=	IC50	nM	38.0	CHEMBL2695	Homo sapiens	IC50	nM	38.0
	23256143	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc(F)c(Cl)c2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4857778	=	IC50	nM	41.0	CHEMBL2695	Homo sapiens	IC50	nM	41.0
	23256144	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2cccc(C#N)c2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4851114	=	IC50	nM	35.0	CHEMBL2695	Homo sapiens	IC50	nM	35.0
	23256145	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	COc1ccc(Nc2nc(NCc3cccnc3N(C)S(C)(=O)=O)c3c(F)c[nH]c3n2)cc1OC		CHEMBL4878089	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
	23256146	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	COc1cc(Nc2nc(NCc3cccnc3N(C)S(C)(=O)=O)c3c(F)c[nH]c3n2)cc(OC)c1OC		CHEMBL4864127	=	IC50	nM	17.0	CHEMBL2695	Homo sapiens	IC50	nM	17.0
	23256147	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	COc1cccc(Nc2nc(NCc3cccnc3N(C)S(C)(=O)=O)c3c(F)c[nH]c3n2)c1C		CHEMBL4874863	=	IC50	nM	76.0	CHEMBL2695	Homo sapiens	IC50	nM	76.0
	23256148	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2cccc(CN)c2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4869688	=	IC50	nM	2098.0	CHEMBL2695	Homo sapiens	IC50	nM	2098.0
	23256149	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CC(=O)NCc1cccc(Nc2nc(NCc3cccnc3N(C)S(C)(=O)=O)c3c(F)c[nH]c3n2)c1		CHEMBL4854959	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
	23256150	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CC(=O)Nc1cccc(Nc2nc(NCc3cccnc3N(C)S(C)(=O)=O)c3c(F)c[nH]c3n2)c1		CHEMBL4850042	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	23256151	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN1CCN(c2ccc(Nc3nc(NCc4cccnc4N(C)S(C)(=O)=O)c4c(F)c[nH]c4n3)cc2)CC1		CHEMBL4847194	=	IC50	nM	13.0	CHEMBL2695	Homo sapiens	IC50	nM	13.0
	23256152	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CN(c1ncccc1CNc1nc(Nc2ccc(N3CCOCC3)cc2)nc2[nH]cc(F)c12)S(C)(=O)=O		CHEMBL4874144	=	IC50	nM	26.0	CHEMBL2695	Homo sapiens	IC50	nM	26.0
	23256153	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	COc1cc(N2CCOCC2)ccc1Nc1nc(NCc2cccnc2N(C)S(C)(=O)=O)c2c(F)c[nH]c2n1		CHEMBL4874516	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
	23256154	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2)CC(=O)N3)nc2[nH]cc(F)c12		CHEMBL4864492	=	IC50	nM	22.0	CHEMBL2695	Homo sapiens	IC50	nM	22.0
	23256155	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(CNC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4874082	=	IC50	nM	14.0	CHEMBL2695	Homo sapiens	IC50	nM	14.0
	23256156	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
	23256157	CHEMBL4832051	Inhibition of FAK (unknown origin) using Poly(Glu,Tyr) and ATP as substrate measured after 40 mins by Kinase-Glo Plus luminescence assay	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2[nH]cc(F)c12		CHEMBL4846781	=	IC50	nM	23.0	CHEMBL2695	Homo sapiens	IC50	nM	23.0
Active	23256236	CHEMBL4832078	Inhibition of FAK phosphorylation in human HCC cells at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256237	CHEMBL4832079	Inhibition of FAK phosphorylation in human HCC cells assessed as reduction in PDK1 phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256238	CHEMBL4832080	Inhibition of FAK phosphorylation in human HCC cells assessed as reduction in Akt phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256239	CHEMBL4832081	Inhibition of FAK phosphorylation in human HCC cells assessed as reduction in mTOR phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256240	CHEMBL4832082	Inhibition of FAK phosphorylation in human HCC cells assessed as reduction in NFkappaB phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256241	CHEMBL4832083	Inhibition of FAK phosphorylation in human HCC cells assessed as upregulation of GSK3 phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256242	CHEMBL4832084	Inhibition of FAK phosphorylation in human HCC cells assessed as upregulation of FOXO phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23256243	CHEMBL4832085	Inhibition of FAK phosphorylation in human HCC cells assessed as upregulation of caspase 9 phosphorylation at 30 uM by KEGG analysis	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc(NC(C)=O)c2)nc2[nH]cc(F)c12		CHEMBL4846334		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	23288942	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	<	IC50	nM	0.5	CHEMBL2695	Homo sapiens	IC50	nM	0.5
	23288943	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL205098	=	IC50	nM	200.0	CHEMBL2695	Homo sapiens	IC50	nM	200.0
	23288944	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4ccccn4)c3n2)cc(OC)c1OC		CHEMBL4861088	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
	23288945	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4cccnc4)c3n2)cc(OC)c1OC		CHEMBL4858365	=	IC50	nM	26.0	CHEMBL2695	Homo sapiens	IC50	nM	26.0
	23288946	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4cccc(C(=O)O)c4)c3n2)cc(OC)c1OC		CHEMBL4876873	=	IC50	nM	49.0	CHEMBL2695	Homo sapiens	IC50	nM	49.0
	23288947	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CNC(=O)c1ccccc1-c1csc2cnc(Nc3cc(OC)c(OC)c(OC)c3)nc12		CHEMBL4879263	=	IC50	nM	55.0	CHEMBL2695	Homo sapiens	IC50	nM	55.0
	23288948	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4ccccc4S(C)(=O)=O)c3n2)cc(OC)c1OC		CHEMBL4850705	=	IC50	nM	668.0	CHEMBL2695	Homo sapiens	IC50	nM	668.0
	23288949	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4cccc(S(C)(=O)=O)c4)c3n2)cc(OC)c1OC		CHEMBL4874892	=	IC50	nM	91.0	CHEMBL2695	Homo sapiens	IC50	nM	91.0
	23288950	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4ccccc4N(C)S(C)(=O)=O)c3n2)cc(OC)c1OC		CHEMBL4846093	=	IC50	nM	15.0	CHEMBL2695	Homo sapiens	IC50	nM	15.0
	23288951	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4cccc(N(C)S(C)(=O)=O)c4)c3n2)cc(OC)c1OC		CHEMBL4877120	=	IC50	nM	35.0	CHEMBL2695	Homo sapiens	IC50	nM	35.0
	23288952	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4ccccc4NS(C)(=O)=O)c3n2)cc(OC)c1OC		CHEMBL4869934	=	IC50	nM	78.0	CHEMBL2695	Homo sapiens	IC50	nM	78.0
	23288953	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	COc1cc(Nc2ncc3scc(-c4cccc(NS(C)(=O)=O)c4)c3n2)cc(OC)c1OC		CHEMBL4851157	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
	23288954	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccccc4)nc23)c1		CHEMBL4871809	=	IC50	nM	30.0	CHEMBL2695	Homo sapiens	IC50	nM	30.0
	23288955	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CN(C)c1ccc(Nc2ncc3scc(-c4cccc(NS(C)(=O)=O)c4)c3n2)cc1		CHEMBL4878656	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
	23288956	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCCCC5)cc4)nc23)c1		CHEMBL4874015	=	IC50	nM	68.0	CHEMBL2695	Homo sapiens	IC50	nM	68.0
	23288957	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCOCC5)cc4)nc23)c1		CHEMBL4873104	=	IC50	nM	8.0	CHEMBL2695	Homo sapiens	IC50	nM	8.0
	23288958	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCNCC5)cc4)nc23)c1		CHEMBL4877875	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
	23288959	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921	=	IC50	nM	7.0	CHEMBL2695	Homo sapiens	IC50	nM	7.0
	23288960	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(Nc4ccc(N5CCC(O)CC5)cc4)nc23)c1		CHEMBL4872520	=	IC50	nM	16.0	CHEMBL2695	Homo sapiens	IC50	nM	16.0
	23288961	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2cccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)c2)CC1		CHEMBL4857298	=	IC50	nM	13.0	CHEMBL2695	Homo sapiens	IC50	nM	13.0
	23288962	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(N)nc23)c1		CHEMBL4858147	=	IC50	nM	4032.0	CHEMBL2695	Homo sapiens	IC50	nM	4032.0
	23288963	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(NC4CC4)nc23)c1		CHEMBL4868316	=	IC50	nM	2355.0	CHEMBL2695	Homo sapiens	IC50	nM	2355.0
	23288964	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(NC4CCCCC4)nc23)c1		CHEMBL4878530	=	IC50	nM	717.0	CHEMBL2695	Homo sapiens	IC50	nM	717.0
	23288965	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(NCCO)nc23)c1		CHEMBL4855302	>	IC50	nM	10000.0	CHEMBL2695	Homo sapiens	IC50	nM	10000.0
	23288966	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccccc5)c4n3)cc2)CC1		CHEMBL4846553	=	IC50	nM	10.0	CHEMBL2695	Homo sapiens	IC50	nM	10.0
	23288967	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccccn5)c4n3)cc2)CC1		CHEMBL4854620	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
	23288968	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccnc5)c4n3)cc2)CC1		CHEMBL4867151	=	IC50	nM	31.0	CHEMBL2695	Homo sapiens	IC50	nM	31.0
	23288969	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccccc5[N+](=O)[O-])c4n3)cc2)CC1		CHEMBL4849868	=	IC50	nM	361.0	CHEMBL2695	Homo sapiens	IC50	nM	361.0
	23288970	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc([N+](=O)[O-])c5)c4n3)cc2)CC1		CHEMBL4861397	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	23288971	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccccc5S(C)(=O)=O)c4n3)cc2)CC1		CHEMBL4878892	=	IC50	nM	194.0	CHEMBL2695	Homo sapiens	IC50	nM	194.0
	23288972	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(S(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4849384	=	IC50	nM	18.0	CHEMBL2695	Homo sapiens	IC50	nM	18.0
	23288973	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCOC(=O)c1ccccc1-c1csc2cnc(Nc3ccc(N4CCN(CC)CC4)cc3)nc12		CHEMBL4878440	=	IC50	nM	1645.0	CHEMBL2695	Homo sapiens	IC50	nM	1645.0
	23288974	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCOC(=O)c1cccc(-c2csc3cnc(Nc4ccc(N5CCN(CC)CC5)cc4)nc23)c1		CHEMBL4867693	=	IC50	nM	321.0	CHEMBL2695	Homo sapiens	IC50	nM	321.0
	23288975	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(C(=O)O)c5)c4n3)cc2)CC1		CHEMBL4873271	=	IC50	nM	59.0	CHEMBL2695	Homo sapiens	IC50	nM	59.0
	23288976	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(C(=O)NC)c5)c4n3)cc2)CC1		CHEMBL4861021	=	IC50	nM	36.0	CHEMBL2695	Homo sapiens	IC50	nM	36.0
	23288977	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(OC)c5)c4n3)cc2)CC1		CHEMBL4853724	=	IC50	nM	12.0	CHEMBL2695	Homo sapiens	IC50	nM	12.0
	23288978	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(S(=O)(=O)NC)c5)c4n3)cc2)CC1		CHEMBL4874196	=	IC50	nM	11.0	CHEMBL2695	Homo sapiens	IC50	nM	11.0
	23288979	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(N(C)S(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4862392	=	IC50	nM	21.0	CHEMBL2695	Homo sapiens	IC50	nM	21.0
	23288980	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(N6CCCS6(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4867910	=	IC50	nM	33.0	CHEMBL2695	Homo sapiens	IC50	nM	33.0
	23288981	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccc6ccccc6c5)c4n3)cc2)CC1		CHEMBL4879025	=	IC50	nM	126.0	CHEMBL2695	Homo sapiens	IC50	nM	126.0
	23288982	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cnc6ccccc6c5)c4n3)cc2)CC1		CHEMBL4860735	=	IC50	nM	29.0	CHEMBL2695	Homo sapiens	IC50	nM	29.0
	23288983	CHEMBL4839006	Inhibition of recombinant FAK (unknown origin) by radiometric kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5ccc6cc[nH]c6c5)c4n3)cc2)CC1		CHEMBL4876098	=	IC50	nM	54.0	CHEMBL2695	Homo sapiens	IC50	nM	54.0
	23288984	CHEMBL4839007	Inhibition of recombinant FAK (unknown origin) at 10 uM by radiometric kinase assay relative to control	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(N)nc23)c1		CHEMBL4858147	<	Inhibition	%	70.0	CHEMBL2695	Homo sapiens	INH	%	70.0
	23288985	CHEMBL4839007	Inhibition of recombinant FAK (unknown origin) at 10 uM by radiometric kinase assay relative to control	B	CS(=O)(=O)Nc1cccc(-c2csc3cnc(NC4CCCCC4)nc23)c1		CHEMBL4878530	<	Inhibition	%	70.0	CHEMBL2695	Homo sapiens	INH	%	70.0
	23289189	CHEMBL4839027	Inhibition of FAK (unknown origin)	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921	=	IC50	nM	9.7	CHEMBL2695	Homo sapiens	IC50	nM	9.7
	23289204	CHEMBL4839042	Inhibition of FAK (unknown origin) at 0.1 uM	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921	=	Inhibition	%	95.6	CHEMBL2695	Homo sapiens	INH	%	95.6
Active	23289345	CHEMBL4839064	Inhibition of FAK autophosphorylation at Y397 in human HCT-116 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289346	CHEMBL4839065	Inhibition of FAK autophosphorylation at Y397 in human MDA-MB-231 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289347	CHEMBL4839066	Inhibition of FAK autophosphorylation at Y576 in human HCT-116 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289348	CHEMBL4839067	Inhibition of FAK autophosphorylation at Y576 in human MDA-MB-231 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289349	CHEMBL4839068	Inhibition of FAK autophosphorylation at Y925 in human HCT-116 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289350	CHEMBL4839069	Inhibition of FAK autophosphorylation at Y925 in human MDA-MB-231 cells at 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289351	CHEMBL4839070	Inhibition of FAK in human HCT-116 cells assessed as inhibition of paxillin phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289352	CHEMBL4839071	Inhibition of FAK in human MDA-MB-231 cells assessed as inhibition of paxillin phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289353	CHEMBL4839071	Inhibition of FAK in human MDA-MB-231 cells assessed as inhibition of paxillin phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289354	CHEMBL4839071	Inhibition of FAK in human MDA-MB-231 cells assessed as inhibition of paxillin phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289355	CHEMBL4839072	Inhibition of FAK in human HCT-116 cells assessed as inhibition of Pyk2 phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
Active	23289356	CHEMBL4839073	Inhibition of FAK in human MDA-MB-231 cells assessed as inhibition of Pyk2 phosphorylation at 0.5 to 5 uM incubated for 24 hrs by Western blot analysis	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921		Inhibition	%		CHEMBL2695	Homo sapiens	INH		
	23295377	CHEMBL4840460	Inhibition of recombinant GST-tagged full length human FAK expressed in baculovirus expression system at 1 uM measured by select screen assay	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(Cc3cc(F)cc(F)c3)C4(C)C)cc2)CC1		CHEMBL4849505	=	Inhibition	%	51.0	CHEMBL2695	Homo sapiens	INH	%	51.0
Not Active	23317403	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	82.0	CHEMBL2695	Homo sapiens	% Control	%	82.0
Not Active	23317871	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23318540	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	77.0	CHEMBL2695	Homo sapiens	% Control	%	77.0
Not Active	23319021	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	97.0	CHEMBL2695	Homo sapiens	% Control	%	97.0
Not Active	23319658	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23320133	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23320811	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	86.0	CHEMBL2695	Homo sapiens	% Control	%	86.0
Not Active	23321279	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23321909	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	86.0	CHEMBL2695	Homo sapiens	% Control	%	86.0
Not Active	23322377	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	88.0	CHEMBL2695	Homo sapiens	% Control	%	88.0
Not Active	23323066	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	94.0	CHEMBL2695	Homo sapiens	% Control	%	94.0
Not Active	23323534	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23324006	CHEMBL4880625	FAK (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	11.0	CHEMBL2695	Homo sapiens	% inhibition	%	11.0
Not Active	23324388	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23325023	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	89.0	CHEMBL2695	Homo sapiens	% Control	%	89.0
Not Active	23325491	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23326138	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	96.0	CHEMBL2695	Homo sapiens	% Control	%	96.0
Not Active	23326606	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	87.0	CHEMBL2695	Homo sapiens	% Control	%	87.0
Not Active	23327306	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23327774	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	95.0	CHEMBL2695	Homo sapiens	% Control	%	95.0
Not Active	23328361	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	96.0	CHEMBL2695	Homo sapiens	% Control	%	96.0
Not Active	23328829	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23329340	CHEMBL4881047	FAK(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	101.0	CHEMBL2695	Homo sapiens	% residual kinase activity	%	101.0
Not Active	23329775	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23330243	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	91.0	CHEMBL2695	Homo sapiens	% Control	%	91.0
Not Active	23330999	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	93.0	CHEMBL2695	Homo sapiens	% Control	%	93.0
Not Active	23331467	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23332054	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23332520	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	96.4	CHEMBL2695	Homo sapiens	% Control	%	96.4
Not Active	23333238	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23333877	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	86.0	CHEMBL2695	Homo sapiens	% Control	%	86.0
Not Active	23334345	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	92.0	CHEMBL2695	Homo sapiens	% Control	%	92.0
Not Active	23335324	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23335792	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23336419	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23336887	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23337750	CHEMBL4882121	PTK2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	87.5	CHEMBL2695	Homo sapiens	% Ctrl	%	87.5
Not Active	23337968	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23338436	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23339048	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	97.0	CHEMBL2695	Homo sapiens	% Control	%	97.0
Not Active	23339516	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23340153	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23340621	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	93.0	CHEMBL2695	Homo sapiens	% Control	%	93.0
Not Active	23341278	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Active	23341746	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	17.0	CHEMBL2695	Homo sapiens	% Control	%	17.0
Not Active	23342362	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23342830	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23343460	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	94.0	CHEMBL2695	Homo sapiens	% Control	%	94.0
Not Active	23343928	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	85.0	CHEMBL2695	Homo sapiens	% Control	%	85.0
Not Active	23344566	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23345139	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	99.0	CHEMBL2695	Homo sapiens	% Control	%	99.0
Not Active	23345607	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	97.0	CHEMBL2695	Homo sapiens	% Control	%	97.0
Not Active	23346184	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	99.9	CHEMBL2695	Homo sapiens	% Control	%	99.9
Not Active	23346653	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	90.2	CHEMBL2695	Homo sapiens	% Control	%	90.2
Not Active	23347258	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	85.7	CHEMBL2695	Homo sapiens	% Control	%	85.7
Not Active	23347744	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23348323	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23348791	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23349378	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	90.0	CHEMBL2695	Homo sapiens	% Control	%	90.0
Not Active	23349996	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23350464	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23351069	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23351537	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	99.0	CHEMBL2695	Homo sapiens	% Control	%	99.0
Not Active	23352203	CHEMBL4882892	PTK2 (FAK) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	14.2	CHEMBL2695	Homo sapiens	% Inhibition	%	14.2004
Not Active	23352561	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	81.0	CHEMBL2695	Homo sapiens	% Control	%	81.0
Not Active	23353029	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	95.0	CHEMBL2695	Homo sapiens	% Control	%	95.0
Not Active	23353911	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23354379	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23355111	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	99.0	CHEMBL2695	Homo sapiens	% Control	%	99.0
Not Active	23355579	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	92.0	CHEMBL2695	Homo sapiens	% Control	%	92.0
Not Active	23356215	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23356683	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23357292	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	93.0	CHEMBL2695	Homo sapiens	% Control	%	93.0
Not Active	23357939	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23358407	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23358993	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23359591	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23360059	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23360644	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	98.0	CHEMBL2695	Homo sapiens	% Control	%	98.0
Not Active	23361112	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	99.0	CHEMBL2695	Homo sapiens	% Control	%	99.0
Not Active	23361685	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	86.0	CHEMBL2695	Homo sapiens	% Control	%	86.0
Not Active	23362221	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23362689	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	95.0	CHEMBL2695	Homo sapiens	% Control	%	95.0
Not Active	23363306	CHEMBL4883269	PTK2 (FAK) Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	-7.353	CHEMBL2695	Homo sapiens	% inhibition	%	-7.3534
Not Active	23363307	CHEMBL4883269	PTK2 (FAK) Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	-9.124	CHEMBL2695	Homo sapiens	% inhibition	%	-9.124
Not Active	23364331	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23364799	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23365538	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23366081	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23366671	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	99.0	CHEMBL2695	Homo sapiens	% Control	%	99.0
Not Active	23367139	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23367567	CHEMBL4883920	FAK ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	113.0	CHEMBL2695	Homo sapiens	% Residual activity with Skepinone-L	%	113.0
Not Active	23368017	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23368485	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23369084	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23369552	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23370062	CHEMBL4884306	FAK(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	84.0	CHEMBL2695	Homo sapiens	% residual kinase activity	%	84.0
Not Active	23370520	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	82.0	CHEMBL2695	Homo sapiens	% Control	%	82.0
Not Active	23370988	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	94.0	CHEMBL2695	Homo sapiens	% Control	%	94.0
Not Active	23371797	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	92.0	CHEMBL2695	Homo sapiens	% Control	%	92.0
Not Active	23372265	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
	23373738	CHEMBL4885515	FAK(PTK2LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL2695	Homo sapiens	pIC50		6.0
Not Active	23374976	CHEMBL4885970	FAK Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	19.5	CHEMBL2695	Homo sapiens	% Inhibition	%	19.5
Not Active	23375361	CHEMBL4886343	PTK2 protein tyrosine kinase 2 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-2.0	CHEMBL2695	Homo sapiens	% inhibition	%	-2.0
Not Active	23375692	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23376160	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23376737	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	90.0	CHEMBL2695	Homo sapiens	% Control	%	90.0
Not Active	23377206	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	79.0	CHEMBL2695	Homo sapiens	% Control	%	79.0
Not Active	23378065	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	94.0	CHEMBL2695	Homo sapiens	% Control	%	94.0
Not Active	23378533	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23379700	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23380168	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	89.0	CHEMBL2695	Homo sapiens	% Control	%	89.0
Not Active	23380862	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23381510	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Not Active	23381978	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL2695	Homo sapiens	% Control	%	100.0
Active	23382439	CHEMBL4887100	Binding assay (PTK2)	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		IC50	nM	0.2	CHEMBL2695	Homo sapiens	IC50	nM	0.2
Active	23382441	CHEMBL4887102	Inhibition of human PTK2 phosphorylation in A431 cells	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		IC50	nM	3.0	CHEMBL2695	Homo sapiens	IC50	nM	3.0
Not Active	23382446	CHEMBL4887100	Binding assay (PTK2)	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		IC50	nM	721.0	CHEMBL2695	Homo sapiens	IC50	nM	721.0
Active	23382602	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	0.2	CHEMBL2695	Homo sapiens	% Control	%	0.2
Active	23383070	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	4.9	CHEMBL2695	Homo sapiens	% Control	%	4.9
Not Active	23383963	CHEMBL4887570	PTK2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	87.0	CHEMBL2695	Homo sapiens	% Ctrl	%	87.0
Not Active	23384271	CHEMBL4887866	FAK(h Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	13.32	CHEMBL2695	Homo sapiens	% inhibition	%	13.32
Not Active	23384704	CHEMBL4888230	PTK2 (FAK) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	4.0	CHEMBL2695	Homo sapiens	% Inhibition	%	4.0
Not Active	23384985	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	85.0	CHEMBL2695	Homo sapiens	% Control	%	85.0
Not Active	23385452	CHEMBL4879709	KinomeScan assay: inhibition of FAK	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	90.0	CHEMBL2695	Homo sapiens	% Control	%	90.0
